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Abstract
An introductory chapter discusses the steric block, RNase H and RNA
interference antisense mechanisms and the application of antisense
nucleic acids as therapeutic agents. Examples of existing chemical
modifications of the sugar and backbone regions of nucleic acids are
given, followed by the introduction of the vinylphosphonate
modification. The vinylphosphonate has previously been examined
in DNA and has been synthesised by either Pd(0) catalysed cross-
coupling of an H-phosphonate with a vinyl bromide, or by the cross-
metathesis of a vinylphosphonate with a terminal olefin.
This thesis details the first examples of the vinylphosphonate
modification in RNA. The initial aim of this project was the synthesis
of a range of nucleosides where the 5-C-O was replaced by a vinyl
bromide carbon-carbon double bond.
Starting from D-D-glucose, acid catalysed formation of the 1,2:5,6-
diisopropylidene D-D-glucofuranose was carried out followed by
protection of the 3-OH as an acetate. The 5,6-isopropylidene was
then subjected to H5IO6 mediated one-pot hydrolysis-oxidative
cleavage to obtain the 5-aldehyde. Wittig olefination using CBr4 and
Ph3P led to the dibromo olefin which was then stereoselectively
reduced using dimethyl phosphite and diisopropylamine to obtain
the pure trans-vinyl bromide. Following hydrolysis of the acetate,
the stereochemistry of the 3-OH was then inverted by sequential
oxidation and reduction. With the correct stereochemistry, the 3-OH
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was protected as the 2-methylnaphthyl ether. The 1,2-
isopropylidene moiety was then hydrolysed and acetylated to the
bis-acetate which was subjected to Vorbrüggen conditions obtaining
the uridine (93%), adenosine (77%), cytidine (30) and guanosine
(63%) vinyl bromide nucleosides. The 2-OAc of the nucleosides
were hydrolysed to the 2-OH in yields of 74-92%. The uridine 2-
OH was protected as the 2-OTBS ether (98%), analogous to the
commercially available phosphoramidites used in automated
oligonucleotide synthesis. Similarly, the adenosine and uridine
nucleosides could also be blocked as the 2-OMe (59% and 73%
respectively). In the case of the uridine vinyl bromide, the 3-O-(2-
methylnaphthyl) protecting group was cleaved using DDQ, this then
enabled the vinylphosphonate-linked uridine dinucleotides to be
functionalised at the 3-OH as the cyanoethyl phosphoramidite using
N,N-diisopropyl-2-cyanoethyl-chlorophosphoramidite, DIPEA and
DMAP in dichloromethane (2-OTBS 74%, 2-OMe 41%). These
could then be used in automated solid phase oligonucleotide
synthesis.
The H-phosphonates were prepared in a single step form the
commercially available phosphoramidites using a tetrazole. These
were then coupled to the vinyl bromide nucleosides using standard
conditions of Pd(OAc)2 (0.2 eq.), dppf (0.4 eq.) and propylene oxide
(20 eq.) in THF at 70 oC in a sealed vial for 6 hours. A range of
vinylphosphonate-linked dinucleotides were accessed in yields of 61-
99%.
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A detailed experimental section at the end of this thesis describes
the procedures used in the synthesis and the analysis of the
structures obtained.
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1. Introduction
1.1 Therapeutic Agents
Starting in 1990, the Human Genome Project saw one of the
greatest landmarks in scientific history realised in 2003 when the
sequence of the 3.7 billion base pairs that make up our human
DNA was reported.1 Previous to this the two groups striving to
unravel the genetic code; the International Human Genome Project
(HGP) and the biotechnology firm Celera both reported outline
sequences of the human genome in 2001.2,3 Identifying the
30,000 to 40,000 genes within human DNA, separated by non-
coding regions also embraced new technologies.2 Building on this
knowledge, it is anticipated that understanding of the proteome
and other molecular machinery will increase, enabling scientists to
better identify, diagnose and treat disease.4
Traditionally, disease is treated by directing small molecule drugs
to target proteins such as enzymes and receptors. Drug discovery
is a lengthy, expensive process; in 1997 it was estimated that
100,000 compounds were screened every day and that several
million compounds screened, identified a few thousand with the
desired characteristic.5 It is estimated that for every 5000-7000
compounds screened, five may progress to clinical trials and only
one of may get approval and be marketed.5,6 The average cost of
developing and taking a drug to market is generally considered to
exceed $800 million dollars.7 Drug molecules may be natural
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products, their analogues or molecules designed and synthesised
using medicinal chemistry.
Protein structure must be carefully considered when designing
molecules which can bind to it. The structure depends on the
unique amino acid sequence and this information is carried in DNA
(deoxyribonucleic acid); the genetic code of an organism. The
process of protein synthesis involves the transcription of DNA to
messenger RNA (mRNA); the information contained in mRNA is
then read during translation and the polypeptide chain is
synthesised to form the protein (Figure 1).
Figure 1.
Knowledge of the human genome however, does not automatically
translate into a more successful programme of drug development.
A gene sequence alone can only be used to predict the primary
structure of a protein (i.e. the amino acid sequence). Predicting
the secondary and tertiary structure, how it folds, is difficult.
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1.2 Targeting the Nucleic Acids
An alternative to targeting a protein is to target the nucleic acids
which contain the information to make the proteins. One of the
advantages of this strategy is the structure of RNA is more highly
conserved and is potentially more accessible than the active sites
of enzymes.8 Many small molecules have been developed to bind
to nucleic acids and the area has been extensively
reviewed.9,10,11,12,13,14,15 One common drug target is the Type 1 HIV
(HIV-1) where the virus has rapidly developed resistance to small
molecules designed to inhibit enzyme function. The RNA
responsible for gene regulation in HIV-1, the trans-activating
region (TAR) has been targeted using small molecules (Figure 2).8
Figure 2. Examples of small molecules which target the HIV-1 TAR RNA: a.
Quinoxaline-2,3-diones; b. CPG40336A (aminoalkyl linked acridines).; c.
Neomycin B (aminoglycoside); d. 2,4-diaminoquinozalines.
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Similar to the targeting proteins, the targeting of DNA or RNA
using small molecules has the downside that a vast number of
molecules must be screened to find a suitable candidate and the
therapeutic agents are often not selective. Direct interaction with
the genetic material can provide an alternative to the random,
expensive and lengthy process of developing small molecule drugs.
1.3 The Antisense Strategy
To target genetic material as a therapeutic strategy requires direct
interaction with the genetic material. This can be achieved using
the antisense principle, where the interaction of complementary
base pairs results in specific binding between the therapeutic agent
and the target genetic material.
DNA is a double helix of two complementary strands; the strand
containing the genetic information is called the sense strand, and
the strand which binds to it is the antisense strand. During
transcription, the antisense strand of DNA is transcribed to a
molecule of messenger RNA (mRNA) in the cell nucleus. Binding of
a complementary antisense oligonucleotide (AON) to the mRNA is
an alternative to using small molecules. A single strand of nucleic
acid can bind to mRNA in a highly specific manner due to the
hydrogen bonding between base pairs; the resulting duplex can
interfere with gene expression. The strength of the interaction
between oligonucleotide strands is characterised by the melting
temperature, Tm of an oligonucleotide; a measure of the
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temperature at which 50% of the duplex structure is dissociated
into its constituent strands.
Nucleic acids can exist in different conformations depending on the
degree of puckering of the sugar moiety. Different puckering is
caused by the presence of the 2-OH in the RNA compared with
DNA results in differences in the helix conformations; RNA exists in
the A-form whereas DNA exists in the B-form (Scheme 1).
Scheme 1. a. A-form (C-2-exo) and b. B form (C-3-exo).
1.3.1 Mechanisms of Antisense Action
There are three main mechanisms through which antisense
mechanisms can be harnessed; (i) steric block, (ii) RNase H and
(iii) RNA interference.
1.3.1.1 Steric Block
Translation involves the reading of the mRNA code and the
subsequent protein synthesis; this process is facilitated by the
movement of a ribosome along the mRNA strand in an ATP
dependent process. Steric block is a none destructive mechanism
of inhibiting protein synthesis; simply involving the binding of an
antisense oligonucleotide fragment to the mRNA to block
progression of the ribosome along the mRNA strand, thus halting
Introduction
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translation and protein synthesis (Figure 3). Translation in
eukaryotic organisms commences with the recognition and binding
on the initiation complex to the 5-cap of the mRNA.16 Translation
then proceeds by the scanning down the mRNA sequence to the
start codon (AUG) where ribosome assembly completes and
translation of the amino acid coding section occurs. Blocking the
complete ribosome assembly is vital to translational arrest.
Figure 3. Mechanism of steric block.
The antisense strand is in equilibrium between the bound and
dissociated state and the ATP driven progression of the ribosome
along the mRNA can be sufficient to dislodge the weakly bound
antisense strand. Targeting the 5-end of the target mRNA
provides more successful steric block.17 Steric block is
stoichiometric; gene knock down is only achieved while the
antisense oligonucleotide is bound to the target mRNA. Therefore
successful steric block requires oligonucleotides with a high Tm.
1.3.1.2 RNase H
An alternative antisense mechanism of involves the RNase H
pathway involved in translation. RNase H is an endogenous
nuclease which recognises DNA-mRNA duplexes and specifically
degrades the mRNA strand of the duplex in a catalytic mechanism
Introduction
- 8 -
(Figure 4). RNases H are found in many diverse organisms e.g.
viruses and humans. Oligonucleotides as short as tetramers can
successfully inhibit RNase H18 however; the oligonucleotides must
possess the DNA-like B-form to achieve activation of the
RNase H.19
Figure 4. Mechanism of the RNase H.
Factors influencing whether a duplex will activate the RNase H
have been extensively studied and reviewed.20 The catalytic
mechanism relies on the presence of Mg2+ and Mn2+ cations as
cofactors.21 The accessibility, size and shape of the minor groove
within the helix are vital to the activation of the RNase H.22,23 The
RNase H mechanism of gene knockdown has been studied for forty
years21 and thus has many candidates being put forward in clinical
trials.
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1.3.1.3 RNA Interference (RNAi)
First observed in 1990 by Jorgensen et al. in the study of the
petunia Neurospora crassa24, RNAi is another method of post-
transcriptional gene silencing. The implications were only fully
realised in the seminal paper published by Fire and Mello in 1998,
which led to a revolution in understanding and application of
RNAi.25 This was recognised by the award of the 2006 Nobel Prize
in Medicine to these two scientists.
Double stranded RNA (dsRNA) is significantly more stable to
nuclease degradation than the lone single strand (ssRNA) RNA, and
this is advantageous in achieving successful gene knockdown.26 In
mammalian cells, short interfering RNA (siRNA) strands, typically
21-23 nucleotides in length has been shown to offer the optimal
compromise between specificity and avoiding an interferon
response.27
The RNA induced silencing complex (RISC) is formed by the duplex
siRNA and a protein aggregate which then triggers an ATP-
dependent process, unwinding the sense strand and leaving the
antisense strand complexed with the protein. This active RISC
binds to the complementary sequence of the target mRNA and the
mRNA within the duplex is then cleaved by endonucleases
contained within the RISC in an ATP independent hydrolysis.28,29 It
is thought that exonucleases then cleave the remaining target
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mRNA. Cleavage of the mRNA releases the active RISC, enabling a
catalytic process (Figure 5).
Figure 5. Mechanism of RNA interference.
The exact structure and make up of the RISC is unknown but some
components and structural domains and their functions have been
identified.30,31,32,33,34 The presence of an protein from the
Argonaute family is a key feature; this is the catalytic component
of the RISC, responsible for binding the siRNA and cleavage of the
mRNA by endonuclease activity.35,36 The Argonaute-2 protein
contains both PAZ and PIWI domains; the PAZ domain is essential
for the nuclease activity of the RISC.35,37 Recently, Hannon et al.
obtained the crystal structure of the Argonaute protein from
achaebacterium Pyrococcus furiosis, showing the PAZ and PIWI
domains (Figure 6).38
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Figure 6. Crystal structure representation of P. furiosus Argonaute. (A) N-
terminal domain (blue), stalk (light blue), PAZ domain (red), middle domain
(green), PIWI domain (purple), and the interdomain connector (yellow). (B)
Schematic diagram of the domain borders.
The 5-end of the siRNA interacts with the PIWI domain of the
Argonaute protein.39,40 The 5-end can exist as the 5-
monophosphate or the 5-OH but does not tolerate chemical
modification. However, capping of the siRNA 3-OH is tolerated
without loss of function.41 RNAi requires an A-form helix, ruling
out the use of antisense DNA.
Short interfering RNAs are already being investigated as
therapeutic agents to target cancers, viral diseases, autoimmune
and inflammatory disorders, neurological conditions, genetic
diseases and other illnesses.42,43 There has also been considerable
investigation of drug delivery and the identification of the most
effective sequences.44,45,46
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1.3.2 Nucleic Acid Structure
Using the antisense strategy is not a problem-free approach;
phosphodiester-linked oligonucleotides are impractical for three
main reasons. The phosphodiester backbone is vulnerable to the
rapid degradation by nucleases. Binding of the antisense strand is
a reversible process; any desired effect of the antisense strategy is
only observed when the duplex is formed. Therapeutic application
requires good delivery and bioavailability of the antisense
oligonucleotide. The anionic phosphodiester linkage has good
aqueous solubility and therefore distribution, however, the
hydrophilic nature results in poor transport across the hydrophobic
cell membrane.
The most effective antisense sequences are those that are least
self-complementary (minimising undesired tertiary structures).
Specificity is important; mismatching reduces the effectiveness and
can cause undesired, potentially toxic interactions.
Native RNA and DNA and modified oligonucleotides have been
developed in antisense applications. There are three types of
modification: backbone, sugar and nucleoside base modification
(Figure 7). Modifications have been designed to increase nuclease
stability and increase the binding affinity between strands.47
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Figure 7. Possible modification of nucleic acids a. sugar (green), b.
nucleoside base (blue) and c. backbone (red).
Modifications can lead to alternative conformations which can
affect the three-dimensional geometry of the structure and lead to
greater or lesser binding. The A-form, adopted by RNA is more
stable than the 2-endo B-form of DNA; hybrid RNA-DNA duplex
stability depends on the extent of A-form characteristics. This
depends on composition and proportion of ribonucleotides present
in the chimera. Duplex stability is also affected by external factors
e.g. base composition, mismatches in base pairs ionic strength,
and the presence of denaturing agents.
Casey and Davidson reported that, depending on the sequence,
RNA-DNA hybrids were typically 10-30 oC more stable than the
analogous DNA-DNA hybrids in 80% formamide solution.48,49 A
comprehensive study by Kankia and Marky, also compared DNA,
RNA and DNA-RNA hybrid duplexes and the effect of cation
concentration and hydration on stability.50 These results show that
there is a wide variation in the relative stability of the hybrid
duplexes.
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The catalytic nature of the RNase H and RNAi mechanisms offer
significant advantages over steric block; in particular lower
concentrations are required to achieve a therapeutic effect. Caplan
et al. reported that siRNA was more effective at gene knockdown
than single stranded DNA.51 However, a comparison of siRNA and
RNaseH using phosphorothioate DNA showed that the potency,
efficacy, specificity and duration of gene knockdown were
equivalent.52 In another comparative study the application of
sequences of antisense DNA and siRNA were compared; 10-20% of
the antisense DNA and 20-40% of the siRNA sequences exhibited
greater than 70% gene knockdown, indicating that the siRNAs
were more efficient.53 Endonucleases such as RNases H also have
limited sequence specificity for single strand DNA which activates
the RNase H pathway and this can cause many off-target effects.
1.4 Nucleic Acid Modifications
1.4.1 Modified DNA
The many examples of modified nucleic acids have been
extensively reviewed.54,55,56,57 Chemical modification of nucleic acid
structure can change the nature of the interactions in the antisense
mechanisms, and this can be exploited to improve the binding
affinity and nuclease resistance; these have been extensively
explored in DNA.
The steric block mechanism, requires a strong binding affinity to
achieve translational arrest. In the steric block mechanism,
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phosphodiester-linked oligonucleotides only weakly inhibit protein
synthesis. Since the mechanism does not involve the interaction of
the antisense oligomer with proteins, highly modified
oligonucleotide structures have been developed. The two most
widely used modifications in the steric block mechanism are the
morpholino oligonucleotides 1 which has the sugar replaced with a
morpholine moiety and peptide nucleic acid (PNA) 2
oligonucleotides, where the sugar-phosphate backbone is
completely replaced with an amide-linked backbone (Figure 8).58
Figure 8. a. Morpholino and b. Peptide Nucleic Acid.
The morpholino modification 1 provides good metabolic stability
and a higher binding affinity due to the absence of electrostatic
interactions in the neutral phosphorodiamidite backbone. This also
increases the lipophilic character however the poor aqueous
solubility leads to the formation of aggregates. Morpholino
oligomers have similar binding affinities to those of DNA-DNA
duplexes and they do not activate the RNase H or siRNA pathways,
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reducing off-target effects.16 They have been extensively studied
and have even progressed to clinical trials.58
Morpholinos are synthesised from the corresponding nucleoside
building blocks in a simple, efficient synthesis from the nucleoside
3, as described by Summerton and Wheeler (Scheme 2).59
Scheme 2.
The monomer morpholino units are coupled together, this is
carried out in the absence of catalysts with high yields and
deprotection of the trityl group is carried out with ease (Scheme 3).
Scheme 3. Synthesis of morpholino oligonucleotides.
Peptide nucleic acid (PNA) 2, is another example of a highly
modified structure that still utilises the Watson-Crick base pairing
of nucleoside bases to create complementary strands.60,61,62 First
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synthesised by Nielsen et al.,63 PNA is resistant to nuclease and
protease degradation and form very stable heteroduplexes with
DNA or RNA.64 As with the morpholinos, PNA does not activate the
RNase H or siRNA pathways. Although the PNA is neutral,
transport across cellular membranes does not readily occur; they
have low solubility and do not readily bind to proteins. Biological
studies have shown that PNA not only inhibits translation,65,66 but
can also activate67 or inhibit68 transcription.
Early synthesis of PNA monomers utilised the standard Boc
protecting group chemistry.69 Oligomer synthesis uses protocols
similar to the Merrifield solid-phase peptide synthesis with solid
support polystyrene beads with 4-methyl benzhydrylamine
functional groups (MBHA). Monomer assembly uses automated
synthesis protocols to obtain the desired oligomer.70 Recently PNA
has utilised milder reagents due to using alternative protecting
groups; fluorenylmethoxycarbonyl (Fmoc) for the nucleoside
primary amines and benzyhydroxycarbonyl (Bhoc) for the peptidic
amines of the monomer units (Scheme 4).71,72
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Scheme 4. Solid-phase synthesis of PNA.
In the RNase H and RNAi pathways, the duplex structure requires
the antisense oligonucleotide to retain characteristics similar to the
natural nucleic acid; thus requiring a more subtle modification than
PNA. For effective response, within the RNA-DNA duplex, the
antisense strand should retain a DNA-like B-form helix (2-endo
sugar) while the target mRNA retains the RNA A-form helix
geometry (3-endo sugar).
In the RNase H pathway, there are many examples of modified
bases and modified backbone antisense oligonucleotides. Two of
the most prevalent backbone modifications are the
phosphorothioate 12 and boranophosphate 13 (Figure 9).73
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Figure 9. RNase H active modifications: a. Phosphorothioate, b.
Boranophosphate.
First investigated by Eckstein, the phosphorothioate 12 is the most
common modification in the RNase H.74 The modification involves
the substitution of one of the phosphate oxygen atoms with a
sulphur atom. The phosphorus is a chiral centre and early
syntheses produced mixtures of diastereoisomers;75,76 early work
used elemental sulphur (S8) to carry out sulphurisation. More
recently the Beaucage reagent (3H-1,2-benzodithole-3-one-1,1-
dioxide)77 has been used (Scheme 5).
Scheme 5.
Stereoselective syntheses of phosphorothioates have recently been
developed by Stec et al.75 and Lesnikowski.76 Oka et al. recently
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reported a stereoselective synthesis of phosphorothioates on a
solid support (Scheme 6).78
Scheme 6. Stereocontrolled synthesis of phosphorothioate DNA.
Phosphorothioates are more resistant to nucleases than the natural
phosphodiester-linked nucleic acids. However, phosphorothioate
oligonucleotides with a mixture of P(R)- and P(S) centres bind
more weakly to the target RNA. Stec et al. showed that R-
phosphorothioates oligonucleotides have stronger, tighter binding
to the target RNA.79
Phosphorothioates have led to the development of many antisense
oligomers. Evidence that antisense therapeutics are a viable
strategy for targeting disease is possible and is highlighted by the
successful marketing and FDA approval of Vitravene®, the first
commercially available antisense drug. Developed by Isis
Pharmaceuticals, Vitravene® is used to treat cytomegalovirus
(CMV) retinitis in AIDS patients via the RNase H mechanism. The
21mer phosphorothioate, 5-GCGTTTGCTCTTCTTCTTGTG-3 is a
mixture of diastereoisomers.
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Synthesis of the boranophosphate as a diastereoisomeric mixture
was first described by Shaw (Scheme 7).80 A non-bridging oxygen
atom is replaced by a borano moiety, the structure is isoelectronic
and isosteric with the natural phosphodiester. The
boranophosphate modification has increased lipophilic character is
resistant to nucleases.
Scheme 7. Synthesis of boranophosphate oligonucleotides.
The boranophosphate, like the phosphorothioate is able to activate
the RNase H mediated cleavage of the complementary RNA.
Analysis of the individual diastereoisomers of the T*T
boranophosphate dimer indicates that both structures have the
DNA-like B-form.81 Studies by Shaw et al.82 using a single
boranophosphate modification in a 14mer and by Matteuci et al.83
of a 15mer containing all boranophosphate linkages showed that
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boranophosphate binding to natural DNA and RNA was weaker
than those of unmodified controls.
The solid-phase synthesis of boranophosphates using H-
phosphonates was recently reported as a more facile method of
oligomer synthesis.84 Using standard protocols, the H-
phosphonate oligomer was synthesised on the solid support then
silylated. The borano moiety introduced using borane-2-
chloropyridine. Deprotection and cleavage of the oligomer from
the solid support used NH4OH (Scheme 8.).
Scheme 8. Solid-phase synthesis of boranophosphates (BSTFA: N,O-
bis(trimethylsilyl)trifluoroacetamide).
In 2000, Shaw et al. reported that the P(S) configuration was
approximately 5 x 102 more stable to snake venom
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phosphodiesterase, than the natural phosphodiester linkage and
the P(R) was completely resistant to enzyme hydrolysis, even after
prolonged incubation.85 Shaw also reported the stereospecific
enzymatic synthesis of the P(S) boranophosphate; synthesis of the
analogous P(R) boranophosphate was not possible due to substrate
specificity of the enzyme.82,86,87
Wada et al. recently reported the synthesis of the P(R) and P(S)
boranophosphates with excellent diastereoselectivity using a chiral
oxazaphospholidine and solid phase synthesis (Scheme 9). This
synthesis has been carried out in solution and on solid support.88
Scheme 9. Stereoselective synthesis of boranophosphates.
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1.4.2 Modified RNA
There are many examples of DNA modifications reported in the
literature. Comparatively fewer have been reported for RNA
although these are well reviewed.26,89,90,91,92
1.4.2.1 Backbone Modifications
Various modified backbone structures and their properties in siRNA
have been investigated (Figure 10.). In comparison to the natural
phosphodiester (A), in general modifications have increased
nuclease resistance.92 The phosphorothioate (B) and the
boranophosphate (C) are two examples of phosphorus containing
backbones. Positional changes of the phosphodiester linkage
connecting to the sugar; the 2,5-phosphodiester linkages (D and
E) are tolerated in the sense strand on siRNAs but not the
antisense strand.93
More diverse structures include capping the 5- and 3-termini with
inverted deoxy sugars without a nucleoside base (F, G); increasing
exonuclease resistance.94 The 2-hydroxyethyl-phosphate (H) is
also a successful end-cap when located at the 3-end of the sense
strand95 and hydrophobic 5-3 and 3-5 amide backbones (I, J)
are being investigated in RNAi.96 Generally, chemical modification
is better tolerated in the sense strand than the antisense strand of
siRNA.97
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Figure 10. Backbone modifications of RNA.
Independent results published by Corey et al.26 and Choi et al.98
show that partial or complete incorporation of the
phosphorothioate modification (B) to RNAi does not increase in
nuclease resistance in human serum. Phosphorothioate
oligonucleotides show slightly reduced binding affinities (i.e. the
duplex is thermodynamically less stable); typically the Tm
decreases by 0.5-0.8 oC per phosphorothioate modification within
an oligomer.99 This reduced binding affinity does not seem to have
a detrimental effect on the potency of the siRNA.
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Phosphorothioates have a tendency to exhibit non-specific binding
to nucleic acids and binding to certain proteins which leads to
cytotoxicity.26 Different syntheses of phosphorothioate RNA have
been reported in the literature; oligomers synthesised by Corey et
al. were made using traditional solid-phase synthesis protocols on
an automated ABI synthesiser, the phosphorothioate linkages were
introduced by using 3H-1,2-benzodithiol-3-one 1,1-dioxide (the
Beaucage reagent) as the oxidiser rather than iodine.26 Similarly,
Ravikumar et al. have used a similar strategy and report a
successful sulfurisation step using phenylacetyl disulfide in
automated synthesis (Scheme 10.).100
Scheme 10.
Studies of boranophosphate siRNA analogues by Shaw et al101,102
have used the same method of synthesis as they reported for the
DNA series, and the P(R) diastereoisomers was isolated by
chromatographic separation.103 Although still negatively charged,
these oligonucleotides have increased lipophilic properties and are
more resistant to nuclease degradation than both the native
phosphodiester and the phosphorothioate RNA.102,104
Boranophosphate analogues show increased siRNA activity
compared to both native siRNA and phosphorothioate siRNA and
increased nuclease resistance unless the modification was present
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in the middles of the antisense strand.102 In addition the
boranophosphate modification is non-toxic to cells.102
1.4.2.2 2-Modifications
Modification at the 2-position provides a solution to the non-
specificity of natural phosphodiester and phosphorothioate
oligonucleotides. The 2-modifications are not tolerated in the
RNase H mechanism because the steric bulk can alter the
conformation of the antisense oligonucleotide, away from the DNA-
like B-form conformation required to activate the RNase H
mechanism. Steric bulk also affects whether an oligonucleotide is
active in the RNAi mechanism if it distorts the structure away from
the A-form conformation.
Research into RNA modifications has found that the 2-OH is not
necessary for RNAi however, the A-form helix is essential.105
Electronegative elements at the 2-position strongly stabilise the
C3-endo conformation of the ring. Complete modification of the
oligonucleotide often leads to complete loss of siRNA activity due to
reduced A-form character caused by steric bulk. Partial
substitution however, can produce siRNA activity and increase
nuclease resistance. Modifications also tend to exhibit positional
effects relating to the siRNA activity of the oligomer.106
Deoxy residues, (K) are commonly used at the 3-termini of siRNA
strands; it is known that they are more resistant to nucleases, and
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this contributes to increased stability of the siRNA (Figure 11).106
As with most modifications however, the deoxy residues also result
in decreased binding affinity.106 The 2-methoxy (L) and the 2-
deoxy-2-fluoro (M) have been partially or wholly incorporated into
siRNA oligomers and show increased stability in the plasma and
increased binding due to stronger base pair interactions.107 They
are most effective when the gapmer strategy is used and
modifications are located at the 3 and 5-ends of the siRNAs and
not in the middle. Fully modified strands of the 2-methoxy (L)
exhibit increased stability but complete loss of siRNA function due
to deviation from the A-form. Partial substitution leads to
comparable increases in stability as fully modified siRNAs but still
active in RNAi pathway.106 The modification is tolerated in both the
sense and the antisense strand but in general the 3-substitutions
result in greater siRNA activity than 5-substitutions.106
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Figure 11. 2-modifications used in RNAi. K. deoxyribose; L. methoxy; M.
fluoro; N. methoxy ethyl (MOE); amino. Y = O or S.
The 2-deoxy-2-fluoro (M) has good thermodynamic stability,
nuclease resistance and gene silencing comparable to non-modified
sequences (both sense and antisense).106 The bulkier the
modification at the 2-position, the less well tolerated it is in terms
of RNAi activity. The 2-methoxyethyl (N) is only tolerated in the
sense strand; when located at 3-end of the antisense strand
significant loss of siRNA activity is observed.106 The 2-deoxy-2-
amino (O) is well tolerated in the sense and the antisense strand
but has reduced siRNA activity.
1.4.2.3 Sugar Modifications and Locked Structures
Three types of sugar modification that have been applied to RNAi;
the 2-deoxy-2-fluoro-arabinonucleotide (2-araF, P) and the 4-
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thioribose (Q) are two examples (Figure 11). In 2-araF (P), the
stereochemistry of the 2-F changes the sugar from being a ribose
to an arabinose. In 4-thioribose (Q) the ring oxygen is replaced
by a sulphur atom. This modification has been incorporated into
phosphodiester-linked RNA oligonucleotides.
Figure 11. Modified sugar structures.
The 2-araF thymidine phosphoramidite 48, was synthesised in six
steps from 1,3,5-tri-O-benzoyl-D-D-ribofuranose 43 (Scheme
11).108 This was then used to make oligomers using the
automated ABI synthesiser protocols.108 The 2-araF, P, has shown
increased RNAi activity and stability in comparison to the
unmodified siRNA. Fully modified 2-araF sense strands and 2-
araF modifications at the 3-end of the antisense strand are
tolerated in the siRNA.109 The 2-fluoro-D-arabinose raises the Tm
of duplexes by ca. +0.5-1.0 °C/nt.108,110
Introduction
- 31 -
Scheme 11. Reagents & conditions: a. DAST, CH2Cl2, 40
oC (71%); b. HBr,
AcOH (97%); c. bis-silylated thymidine, CCl4, reflux (48%); d. concentrated
NH4OH, MeOH (75%); e. MMTCl, pyridine, DMAP (94%); f. Cl-
P(OCH2CH2CN)(N
iPr2), THF (93%).
The 4-thio nucleosides were first reported in 1966 by Whistler et
al.111 Later, Matsuda et al. reported that 4-thioribose RNA was
approximately 600 times more stable than unmodified RNA.112 Egli
et al. obtained X-ray crystallographic data showing that the 4-thio
modification adopted a conformation very similar to the C3-endo
form of natural RNA; thus enabling good interaction with mRNA.113
Mixed oligonucleotides containing combinations of 4-thio, 2-OMe
and the 2-methoxyethyl nucleosides been shown to be effective in
siRNA.114,115 Recently, Dande et al. have improved the synthesis of
the 4-thioribonucleosides and their phosphoramidites (Scheme
12.).114 These oligomers are then assembled using automated
oligonucleotide synthesis protocols.
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Scheme 12. Reagents & conditions: a. diethyl L-tartrate, Ti(OiPr)4, TBHP,
CH2Cl2, -25
oC; b. TMSOTf, Et3N, uracil, toluene/CH2Cl2 (1:1 v/v); c. MeNH2,
MeOH; d. TBSOTf, 2,6-lutidine, CH2Cl2; e. TBAF, AcOH, THF; f. DMT-Cl,
pyridine; g. N,N-diisopropylmethyl-phosphonamidic chloride, DIPEA, CH2Cl2.
TIPDS: tetraisopropyldisiloxane.
The third significant modification is the conformationally locked
oligonucleotides of the one-carbon bridged locked nucleic acid
(LNA), R and the two-carbon bridged ethylene nucleic acid (ENA),
S, which significantly increase the thermodynamic stability of the
duplex (Figure 12.).
Figure 12. Conformationally locked structures: R. LNA; S. ENA.
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Complete modification of the oligonucleotide results in total loss of
siRNA activity but partial substitution results in significant
increases in siRNA activity.116 The LNA, R developed by Wengel is
accepted at both ends of the siRNA, maintaining activity.26
However when ENA residues are located at both ends of the siRNA,
activity in the RNAi pathway is completely lost.116 The application
of modified LNA in the RNase H pathway is comparably efficient at
gene knockdown as siRNA.117
Wengel et al. have achieved the synthesis of the five different
nucleoside base monomers of LNA, 60 (Scheme 13)118 and
oligomers are constructed from these units using automated
synthesis.119
Scheme 13. Reagents & conditions: a. BnBr, NaH, DMF; b. Ac2O, pyridine;
c. 80% AcOH; d. Ac2O, pyridine (55%, steps a-d); e. nucleobase, BSA,
TMSOTf, CH3CN or CH2ClCH2Cl; f. NaOCH3, MeOH (38-74% over steps e-f); g.
TsCl, pyridine; h. NaH, DMF (30-51%, steps g-h); i. Pd(OH)2/C, EtOH, H2; or
1,4-cyclohexadiene, 10% Pd(OH)2/C, MeOH; or BCl3, CH2Cl2, hexane (36-
98%); j. DMTCl, pyridine; k. NCCH2CH2OP(Cl)N(
iPr)2, DIPEA, CH2Cl2, (37-
65%, steps j-k).
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Oligonucleotides containing LNA have increased Tm values of
between 3 oC and 8 oC per LNA unit when binding to both RNA and
DNA.120 LNA adopts the A-type conformation, mimicking RNA in
terms of its helical structure. Further modification of the LNA
oligonucleotides have been made using the phosphorothioate
backbone, the 2-thio, replacing the 2-oxygen with a sulphur121
and the methylphosphonate backbone.122 Other bridged nucleic
acid structures have also been reported.118
1.5 Vinylphosphonate-Linked Nucleic Acids
With the knowledge that modified nucleic acids often have
increased nuclease resistance, one backbone modification of
interest is the vinylphosphonate linkage. This modification
replaces the C5-O5 with a carbon-carbon double bond which has a
similar geometry to that of the native internucleotide
phosphodiester linkage (Figure 13). The torsion angle, E is
restricted to 180o but there is no additional steric bulk which may
affect the conformation.
Figure 13. Vinylphosphonate linkage
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The first vinylphosphonate-linked dinucleotide was reported by
Zhao and Caruthers in 1996; synthesis of a vinylphosphonate-
linked T*T dimer which was incorporated into oligonucleotides
using solid phase synthesis.123 The application of triphenylphos-
phoranylidene methylphosphonate 64, in the synthesis of
vinylphosphonates was first reported by Moffatt et al. in
1968.123,124 The vinylphosphonate was installed using a Wittig
reaction and the dinucleotide was then formed by the condensation
of vinylphosphonate 65 with the 3-OH of thymidine 61 (1.0 eq.)
using triisopropylbenzenesulfonyl chloride (5.0 eq.) and 1-methyl
imidazole (11 eq.). Successful coupling required manipulation of
the protecting groups on the phosphorus to obtain thymidine
dinucleotide 67 as a mixture of diastereoisomers at the
phosphorus centre (Scheme 14.).
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Scheme 14. Reagents & conditions: a. TBSOTf, pyridine (95%); b. 80%
AcOH (82%); c. Pfitzner Moffatt conditions; d. imidazoline protection (93%);
e. pTsOH; f. 64 (64%); g. 2-nitrobenzaldoxime, HN=C(NMe2)2, dioxane aq.
(75%); h. 61, 2,4,6-triisopropylbenzenesulfonyl chloride, 1-methylimidazole
(61%, 1:1 mixture); i. 0.5 M HCl, MeOH (50%); j. DMTCl, Bu4N
+ClO4
-,
pyridine (66%); k. 2-cyanoethylchlorophosphoramidite, DIPEA, THF (56%,
1:1:1:1 mixture).
The T*T dimer, 67 was incorporated into an oligomer, however, to
be compatible with the solid-phase protocols, extensive protecting
group manipulation was once again required. Studies showed that
oligomers containing the vinylphosphonate linkage were readily
soluble, and were sufficiently stable to tolerate storage over
several months in aqueous media at pH 7.0.123 Preliminary
studies of the biological activity showed that the vinylphosphonate-
linkage was considerably more resistant degradation by snake
venom phosphodiesterase, even when only one vinylphosphonate
modification was contained in a 14mer.123 The initial studies also
showed that the presence of the vinylphosphonate modification
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reduced the Tm. An unmodified 14mer of all thymidine residues
had a Tm of 36 oC however, a single modification in the centre of
the oligomer had a Tm of 33 oC and the 14mer containing six
modifications had a Tm of less than 20 oC.
More recently, the vinylphosphonate modification has since
received detailed investigation through the work of Hayes et al.125
It was first found that the presence of a single modification in a
T*T dimer, incorporated into a DNA oligonucleotide was sufficient
to inhibit the activity of PcrA helicase. This enzyme is non-specific
DNA-binding and mostly targets single strand DNA.126 It can also
target double stranded DNA but with a significantly weaker
interaction.127 Studies indicated that rotational flexibility of the
DNA was essential to allow the helicase to interact and process the
single strand DNA. Due to the carbon-carbon double bond, the
vinylphosphonate, while having similar geometry to the natural
phosphodiester, has more limited rotational flexibility. In the
process of translocation, ATP driven helicases unwind double
stranded DNA and move along the single-stranded DNA. A
vinylphosphonate modification on the backbone of the
translocating strand inhibits the translocation. This suggests that
the backbone must have a degree of rotational flexibility of the
backbone to enable efficient unwinding. This finding has helped
confirm that the helicase enzyme operates using an inch-worm
translocation mechanism.
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Hayes et al. also investigated other helicases; the Bloom (BLM)
and Werner (WRN) syndrome proteins.128 Positioning the
vinylphosphonate on the translocating strand, just outside the
duplex region, resulted in partial inhibition of the BLM-mediated
unwinding of the 25 base pair duplex was observed. Positioning
the vinylphosphonate modifications in the duplex region of the
translocating strand the unwinding was more strongly inhibited.
However, location of the vinylphosphonate modifications on the
displaced strand had no inhibitory effect on the helicase. The
human replication protein A (RPA) is known to specifically promote
unwinding of long DNA duplexes by BLM and WRN. Using a 39
base pair forked duplex as the substrate, the presence of four
consecutive modifications located inside the duplex on the
translocating strand were compared to an unmodified version.128
In the absence of the RPA, the BLM helicase could only partially
unwind the duplex in the modified version, however in the
presence of the RPA, both the modified and the unmodified
duplexes were completely unwound, indicating that the RPA
reduced the inhibitory effect of the vinylphosphonate modification
(Figure 14).128
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i. ii.
iii. iv.
Figure 14. Kinetics of unwinding of i. A1 (unmodified), A2 (modified); ii. B1
(unmodified), B2 (modified); iii. D1 (unmodified) and D2 (modified) strands
(1.0 nM concentration) by BLM (20 nM) and iv. C1 (unmodified), C2
(modified) by 20 nM BLM in the presence of 24 nM RPA.
The vinylphosphonate had a similar effect to the BLM on the WRN
helicase. Location of vinylphosphonate modifications in the duplex
region of the oligonucleotide, resulted in translocation inhibition,
however, outside the duplex region, unwinding was observed as
being more facile in the presence of the vinylphosphonate than in
the non-modified version (Figure 15). Once again, the inhibition of
the helicase unwinding activity was removed upon addition of the
RPA. In comparison to the effect of RPA, when the BLM and WRN
were inhibited by the presence of the vinylphosphonate, addition of
the single-stranded DNA binding protein from E. coli (SSB) only
partially restored helicase action.
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Figure 15. Effect of vinylphosphonate internucleotide linkages on WRN
helicase activity in the absence and the presence of RPA. (A) Kinetics of
unwinding of 1 nM A1 and 1 nM A2 by 5 nM WRN. (B) Kinetics of unwinding of
1 nM B1 and 1 nM B2 by 5 nM WRN. (C) Kinetics of unwinding of 1nM C1 and
1nM C2 by 5 nM WRN in the presence of 24nM RPA. (D) Kinetics of unwinding
of 1 nM D1 and 1 nM D2 by 5 nM WRN. (Relative concentration of products
expressed as % of total DNA).
A nuclease resistance study was used to establish whether the
vinylphosphonate modification could be used in antisense
applications.129,130 The nucleases studied were the commercially
availably exonuclease III, a dsDNA specific nuclease and mung
bean nuclease, which acts on ssDNA and as an RNA endonuclease.
The exonuclease cleaves stepwise from the 3-end of dsDNA,
cleaving at the P-O3 position however, the results showed that
when the exonuclease III encountered the vinylphosphonate
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modification, the progress was slowed and cleavage also occurred
at the P-O5 position, altering the pattern of usual cleavage. The
vinylphosphonate-linkage also exhibited partial resistance to the
mung bean nuclease, however only cleavage at the usual P-O3
position was observed.
A single vinylphosphonate modification in an oligonucleotide was
not sufficient to inhibit the action of DNA polymerase I but the
incorporation of four modifications did successfully inhibit the
polymerase.130 DNA polymerase plays an important role in DNA
replication, building new DNA strands alongside the existing
complementary strand. Hence it is possible that DNA polymerase
could be used to introduce vinylphosphonate linkages into DNA.
The above mentioned biological results indicate that the
vinylphosphonate modification can inhibit a range of enzymes
involved in the processing of nucleic acids. There is evidence of
nuclease resistant although, like many modifications discussed, the
binding affinity is slightly weaker than the non-modified version.
In order to investigate this further it is first necessary to
investigate the synthesis of the vinylphosphonates and their
assembly into oligonucleotides.
1.6 The Synthesis of Vinylphosphonates
Within the literature there are many examples of different
synthetic strategies used to make vinylphosphonates. There are
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both catalytic and non-catalytic examples using different synthetic
strategies and these have been extensively reviewed.131,132,133
While exploring the synthesis of vinylphosphonate-linked nucleic
acids 68, the Hayes group has investigated two different catalytic
strategies. Firstly, formation of the carbon-carbon double bond by
the cross metathesis of a vinylphosphonate 69 and a terminal
olefin 70. Secondly, palladium-catalysed carbon-phosphorus bond
formation between an H-phosphonate 71 and a vinyl halide 72.
Both these strategies require the synthesis of the two building
blocks that are then assembled using the appropriate method
(Scheme 15).
Scheme 15. Retrosynthetic analysis of the vinylphosphonate modification.
1.6.1 Carbon-Carbon Bond formation  Metathesis
Recently, cross metathesis has provided a method for the
synthesis of functionalised vinylphosphonates.134 Grubbs et al.
reported that olefin cross-metathesis proceeded with excellent E/Z
selectivity and in high yields.135 Hanson reported the use of the
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first generation Grubbs catalyst I in the synthesis of cyclic
vinylphosphonates (Table 1.).136
Ru
PhCl
Cl
PCy3
PCy3I
Substrate Product(s) Conditions Yield/%
P
O
O
2
P
OHO
O
O
P
O
O 6 mol%,
6 hours
44, 31
P
O
O
2
P
OO
O 3 mol%,
2 hours
79
Table 1.
The second generation Grubbs catalyst II, has been reported to
give superior results compared to the first generation catalyst. A
comparative study reported by van Boom et al. showing that the
second generation catalyst gave significantly higher yields in a
shorter time and at a lower catalyst loading (Table 2).137
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Substrate Product
Grubbs I
Yield/%
Grubbs II
Yield/%
O
P
O
O P
OO
O 44
(6 hours)
100
(30 min)
BnO
P
O
O P
OBnO
O 25
(4 days)
100
(15 min)
BnO
P
O
O P
OBnO
O 65
(2 days)
92
(30 min)
BnO
P
O
O
P
OBnO
O 85
(4 days)
100
(20 min)
Table 2. Comparison of the different Grubbs catalysts. Conditions: 0.01 mol
substrate, CH2Cl2, reflux; catalyst: Grubbs I (2 mol%) or Grubbs II (1 mol%).
Grubbs et al. reported the synthesis of alkyl and aryl
vinylphosphonates 75 using the second generation catalyst II
(Scheme 16, Table 3.).138
Scheme 16.
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Alkene 73 Yield/% Alkene Yield/%
OAc 95 93
Br 82
Br
77
O
6
88 97
90
OMe
97
Table 3.
1.6.1.1 Previous work  Synthesis of the cross-
metathesis building blocks
Using metathesis the synthesis of vinylphosphonate-linked nucleic
acids, vinylphosphonate building blocks, 73 and 74 were
synthesised from the H-phosphonates 71 and 72 respectively as a
mixture of diastereoisomers using a palladium cross-coupling
(Scheme 17).
Scheme 17.
The thymidine terminal olefin nucleoside 85 was accessed from the
commercially available thymidine 80 using a Wittig reaction
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(Scheme 18).139 The disappointing yield of the direct Wittig
reaction (step e) led Solesbury to investigate the synthesis via the
vinyl bromide (f-h).140
Scheme 18. Reagents & conditions: a. TBSCl (1.3 eq.), imidazole (1.5 eq.),
DMF, 0 oC to r.t. (98%); b. TBDPSCl (1.3 eq.), imidazole (1.5 eq.), DMF, 0 oC
to r.t. (98%); c. HF aq. (12 eq.), MeCN, r.t. (90%); d. Dess Martin
periodinane, (1.2 eq.), CH2Cl2, r.t. (83%); e. Ph3PCH3
+Br- (4.0 eq.), nBuLi
(4.0 eq.), THF, 0 oC to r.t. (24%); f. CBr4 (2.0 eq.), Ph3P (4.0 eq.), CH2Cl2, 0
oC to r.t. (51%); g. (MeO)2P(O)H (4.0 eq.), Et3N (4.5 eq.), DMF, r.t. (83%,
E/Z 2.4:1); nBu3SnH (1.6 eq.), Pd(PPh3)4 (0.04 eq.), C6H6, 75
oC (22%).
The disappointing low yield of the Wittig reaction was attributed to
the acidic protons of the thymidine and the 4-H adjacent to the
aldehyde; which can be abstracted in basic conditions.
Investigation of KHMDS and tBuOK bases failed to improve this
yield any further. Lera139 and Solesbury140 both investigated the
methylenation reaction using the Tebbe (Cp2TiCH2ClAl(CH3)2)141
and the Nysted (cyclo-dibromodi-ǋ-methylene[ǋ-(tetrahydro-
furan)]trizinc) reagents. The Tebbe reagent gave a slightly higher
yield of olefin 85 (37%) whereas using the Nysted, the reaction
failed to go to completion. Unfortunately, the purification of these
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reaction mixtures proved problematic so the Wittig strategy was
kept.
Due to the low yield of the terminal olefin obtained, Solesbury
investigated accessing the terminal olefin from a generic sugar. It
was anticipated the starting from 1,2-isopropylidene-D-D-
xylofuranose 86, olefination could be performed prior to addition of
the nucleoside base, of which the acidic NH proton is thought to
interfere with the Wittig reaction. Olefin 90 was obtained in seven
steps, requiring inversion of stereochemistry at the 3-position
(Scheme 19). Wittig olefination of aldehyde 89 using
methyltriphenylphosphonium bromide and butyl lithium produced
olefin 90 in a disappointing yield (27% over 2 steps).
Scheme 19. Reagents & conditions: a. TBSCl (1.4 eq.), imidazole (2.5 eq.),
DMF, 0 oC to r.t. (92%); b. (ClCO)2 (1.1 eq.), DMSO (2.2 eq.), Et3N (3.3 eq.),
-65 oC to r.t. (85%); c. NaBH4 (1.0 eq.), MeOH, 0
oC, (99%); d. NapCH2Br
(1.2 eq.), KOH (1.8 eq.), 18-crown-6 (0.04 eq.), THF, r.t. (82%); e. TBAF,
THF, r.t. (86%); f. Dess Martin periodinane (1.4 eq.), CH2Cl2, r.t.; g.
CH3PPh3Br (4.0 eq.), nBuLi (4.0 eq.), THF, 0
oC to r.t. (27%, 2 steps).
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Due to the low yield observed in the Wittig reaction, the Peterson
reaction and application of the Tebbe, Nysted and Petasis
(Cp2TiMe2)142 reagents were once again explored as alternative
methods of forming the terminal olefin however there was no
improvement in the yield of the olefin.
1.6.1.2 Previous work  Synthesis of
vinylphosphonate-linked nucleic acids by cross-
metathesis
Synthesis of the dinucleotide using cross-metathesis reaction was
first tried using the first generation Grubbs catalyst I; however,
only unreacted starting material was recovered. The more electron
rich second generation Grubbs catalyst II led to the formation of
the desired trans-vinylphosphonate dinucleotides 91 and 92 in
58% and 19% yields respectively with no trace of the cis-
vinylphosphonate (Scheme 20).
Scheme 20.
In the metathesis reaction, it is possible for both olefin components
to undergo self-metathesis to form homo-dimerised products. A
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study by Lera found that terminal olefin 85 underwent self
metathesis, forming the homo-dimer 93 (72%) and the byproduct
of benzylidene transfer from the catalyst 94 (20%); present in a
quantitative amount in relation to the amount of catalyst used
(Scheme 21). Vinylphosphonate 78 did not undergo homo-
dimerisation to form 95 under the same conditions; however the
quantitative byproduct of benzylidine transfer 96 was
observed (20%).
Scheme 21. Reagents & conditions: Grubbs II (0.2 eq.), CH2Cl2, 35
oC.
1.6.2 Carbon-Phosphorus Bond Formation  Pd(0)
The seminal work in carbon-phosphorus bond formation by
palladium catalysed cross-coupling reactions was carried out by
Hirao et al143 and the use of palladium chemistry to form carbon-
phosphorus bonds is well reviewed.144
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The catalytic cycle involved in the carbon-phosphorus bond-
forming reaction involves the oxidative addition of the Pd(0) with
the halide, the nucleophilic phosphorus species then attacks the
organopalladium complex, eliminating the HX which is removed
from the reaction by a scavenger (typically an amine base).
Finally, the cross-coupled product is eliminated by the reductive
elimination which regenerates the Pd(0) species (Scheme 22). The
C-P bond formation occurs with complete retention of
stereochemistry of the vinyl moiety.
Scheme 22. Catalytic cycle for the Pd(0) mediated cross-coupling reaction.
Hirao reported the coupling of arylbromides145 and vinylbromides146
with dialkyl phosphites leading to the dialkyl aryl phosphonates
and dialkyl vinylphosphonates. Reaction of vinyl bromide 97 (1.1
eq.) with dialkylphosphite 98 (1.0 eq.) using catalytic Pd(PPh3)4 (5
mol%) and Et3N (1.1 eq.) at 90 oC, obtained the vinylphosphonate
99 in good yield (Scheme 23, Table 4).146
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Scheme 23.
R1 R2 R3 R4 Yield/%
Ph H H Et 66
H Ph H Et 93
H H Ph Et 91
H H Ph iPr 81
H H Ph nBu 92
H H Me Et 98
H H Me iPr 92
Table 4.
Xu et al. prepared (2-arylvinyl)phosphonate 101 from diethyl
vinylphosphonate 100 and aryl bromides using Pd(OAc)2 (1 mol%)
and a phosphine ligand (2 mol%) to generate the Pd(0) in situ
(Scheme 24, Table 5).147 The products obtained were exclusively
(E)-diethyl 2 arylvinylphosphonates in yields of 60-78%. This work
also shows that simple vinylphosphonates can be further
elaborated to more complex vinylphosphonates using the Heck
reaction.
Scheme 24.
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Ar Yield/% Ar Yield/%
Ph 78 2-Nap 61
p-Me-Ph 72 p-CHO-Ph 60
o-Me-Ph 67 p-NO2-Ph 63
p-MeO-Ph 76 p-CH3CONH-Ph 62
p-Me2N-Ph 74 Ph-Ph 74
Table 5.
Xu et al. also showed that not only is the vinyl moiety
stereochemistry retained, but there is also retention of
stereochemistry (>97% e.e.) at the phosphorus when
enantiomerically pure phosphinates 102 and 104 (>97% e.e.) was
coupled with a vinyl bromide (Scheme 25, Scheme 26).148
Scheme 25.
R1 R2 R3 Yield/%
H H H 64
Me H H 71
H Ph H 98
Scheme 26.
R1 R2 R3 Yield/%
H H H 71
H Ph H 98
H H Ph 98
The stereoselective reaction of trialkylphosphites and
vinylboronates in an oxygen atmosphere can be catalysed to obta
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vinylphosphonates in high yield and excellent selectivity (Scheme
27, Table 6).149
Scheme 27.
R1 R2 Time Yield/%
Ph H 9 78
Ph H 7 75
p-Cl-Ph H 9 79
p-Cl-Ph H 6 60
n-C6H13 H 8 84
n-C6H13 H 6 63
p-F-Ph H 9 81
Ph Me 120 55
Table 6.
Other catalysts were also investigated in this reaction including
PdCl2, NiCl2, Pd(OAc)2-PPh3 and Pd(dppf)Cl2 but the Pd(OAc)2 was
shown to give the highest yields (Scheme 28, Table 7).
Scheme 28.
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Catalyst Time/hours Yield/%
Pd(OAc)2 8 85
PdCl2 8 75
NiCl2 (anhydrous) 6 mol% 25 43
Pd(OAc)2, PPh3 (4.0 eq.) 12 55
Pd(dppf)Cl2 40 incomplete
Table 7.
1.6.2.1 Previous work  Synthesis of the Pd(0)
coupling building blocks
The H-phosphonate building blocks 79, 113, 114 and 115, used
in the palladium catalysed cross-coupling reaction were obtained in
a single step as mixtures of diastereoisomer from the commercially
available phosphoramidites (22, 110, 111 and 112 respectively)
used in solid phase oligonucleotide synthesis (Scheme 29). The
phosphoramidites were also synthesised from the commercially
available 5-ODMT-3-OH nucleosides and the phosphoramidite
using literature procedures.129,150,151,152
Scheme 29.
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Initial studies involved the synthesis of the vinyl bromide
nucleoside from the commercially available nucleoside 116.
Initially focussing on thymidine, aldehyde 118, was obtained in
four steps (Scheme 30).154
Scheme 30. Reagents & conditions: a. TBSCl, imidazole, DMF (86%); b.
TBDPSCl, imidazole, DMF (90%); c. HF, MeCN (88%); d. Dess Martin
periodinane, CH2Cl2 (80%).
The Wittig reaction obtained a mixture of the E- and Z-vinyl
bromides 118 and 119. Bromomethyl(triphenylphosphonium)-
bromide and LiHMDS generates a non-stabilised ylide; leading to
the desired E-isomer forming as the minor product (Scheme
31).154,125
Scheme 31.
Since E-vinyl bromide 118 is the desired isomer, the two-step
synthesis of the vinyl bromide from the aldehyde was investigated
by Abbas.156,154 Dibromo olefin 120 was synthesised using the
procedure of Ramirez et al.153 and was then reduced
stereoselectively using the method of Hirao et al.143 (Scheme 32).
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This two step process obtained the vinyl bromide as a 3:1 mixture
of E- and Z-isomers 118 and 119 respectively in a combined 84%
yield. The E- and Z- isomers were readily separated by
chromatography.
Scheme 32.
Later, Bertram investigated the synthesis of the other nucleoside
vinyl bromides. Adenosine and cytosine dibromo olefins 129 and
130 were synthesised in four steps from the commercially
available nucleosides 121 and 122, using the same methodology.
However, unlike the thymidine, the E- and Z- isomers of the
adenosine and cytosine vinyl bromides 131 and 132 could not be
separated (Scheme 33).
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Scheme 33. Reagents & conditions: a. TBDPSCl, imidazole, DMF; b. 70%
AcOH, THF; c. Dess Martin periodinane, CH2Cl2, r.t.; d. [Ph3P
+CHBr2]Br
-,
KHMDS, CH2Cl2, r.t.; e. (MeO)2P(O)H, Et3N, DMF.
Encouragingly, this work shows that the vinyl bromide nucleosides
can be accessed in five steps from the commercially available
nucleosides.
1.6.2.2 Previous work  Synthesis of
vinylphosphonate-linked nucleic acids by Pd(0) cross-
coupling
Bertram and Abbas have successfully demonstrated the application
of palladium catalysis in the synthesis of the vinylphosphonate-
linked DNA.125,129,139,154,155,157 The synthesis of the vinylphosphonate
using the methodology of Hirao obtained the 5-vinylphosphonate
(Scheme 34).156,139
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Scheme 34. Reagents & conditions: R=TBDPS: Pd(PPh3)4, Et3N, DMF,
70 oC;154,156 R=H: Pd(OAc)2, PPh3, propylene oxide, THF, 70
oC.139
Using the palladium catalysed cross-coupling procedure, the
thymidine vinylphosphonate dinucleotide was synthesised. It was
found that the choice of catalyst, HBr scavenger and solvent had a
strong effect on the reaction but it is seen that the reaction
tolerates different functional groups (Scheme 35, Table 8).157 The
use of the sterically crowded bis(diphenylphosphino)ferrocene
ligand greatly accelerated the reaction and the use of THF as the
solvent removed the requirement of an aqueous work up
procedure.154
Scheme 35.
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R Catalyst Ligand Solvent Scavenger Yield/%
Me Pd(PPh3)4 - DMF Et3N 42
Me Pd(OAc)2 dppf THF Et3N 78
Ph Pd(OAc)2 dppf THF Et3N 21
O2N
Pd(OAc)2 dppf THF Et3N 24
CN Pd(OAc)2 dppf THF
O 72
Me Pd(OAc)2 dppf THF
O 60
Ph Pd(OAc)2 dppf THF
O 53
O2N
Pd(OAc)2 dppf THF
O 65
Table 8. Conditions: Catalyst (0.02 eq.), ligand (0.04 eq.), Et3N (4.5 eq.) or
propylene oxide (1.2 eq.).
The palladium cross-coupling reaction was also applied to a system
containing a thymidine vinyl bromide and the 5-TBS N-6-benzoyl
adenosine H-phosphonate using the same strategy.157 The
formation of the A*T dinucleotide was successfully carried out in a
92% yield indicating that the palladium chemistry is applicable to
purines and pyrimidines. Later, Bertram utilised the
dimethoxytrityl protecting group at the 5-position of the H-
phosphonate, thus being compatible with the protecting groups
used in the automated solid phase synthesis protocols for
oligonucleotides. The four different DNA H-phosphonate
nucleosides were coupled to a thymidine vinyl bromide in good
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yield (Scheme 36, Table 9). Pleasingly the coupling reaction was
also compatible with a free hydroxyl group on the vinyl bromide
and no loss of yield was observed.
Scheme 36.
142 143 144 145 146 147
Base T A(Bz) C(Bz) G(Ac) T A(Bz)
R TBDPS TBDPS TBDPS TBDPS OH OH
Yield/% 73 85 61 67 59 57
Table 9.
Although the adenosine and cytosine vinyl bromides were obtained
as inseparable E/Z mixtures, they successfully underwent cross-
coupling with H-phosphonates although this led to complex
mixtures of isomers, which were also inseparable. Removing the
TBDPS protecting group to obtain the 3-OH did not aid separation,
either at the vinyl bromide stage or the vinylphosphonate
dinucleotide (Scheme 37, Table 10).
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Scheme 37. Reagents & conditions: H-phosphonate 79 or 119 (1.2 eq.),
Pd(OAc)2 (0.2 eq.), dppf (0.4 eq.), propylene oxide (20 eq.), THF.
Base1 Base2 R Yield/%
150 T C(Bz) TBDPS 0
151 A(Bz) C(Bz) TBDPS 35
152 T A(Bz) TBDPS 45
153 A(Bz) A(Bz) TBDPS 53
154 T T H 0
155 A(Bz) A(Bz) H 0
156 T T H 51
157 A(Bz) A(Bz) H 47
Table 10.
These results gave further examples of the successful cross-
coupling of H-phosphonates with vinyl bromides, indicating that it
is tolerant of different protecting groups. Alongside this work, Lera
also found that using the same coupling protocols on a dibromo
olefin gave rise to the alkynylphosphonate compound.139,158
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1.6.3 Comparison of cross-metathesis and Pd(0)
coupling
Throughout most of the previous work on the DNA series, the
building blocks for cross-metathesis or Pd(0) cross-coupling were
accessed from the commercially available nucleosides. Although
the cross-metathesis strategy avoids the problem of obtaining pure
pure E-vinyl bromides, at this time, the palladium-catalysed route
has proven to be the most successful. Unfortunately, the cross
metathesis approach has only given success in the synthesis of the
thymidine and uridine nucleosides. The olefin cross metathesis
route results in not only the desired vinylphosphonate-linked dimer
but also the homo-dimer generated by the competing self-
metathesis of the terminal olefin.140
Vinylphosphonate-linked dinucleotides can be synthesised then
incorporated into oligonucleotides using standard automated solid-
phase synthesis protocols. To date, all biological investigation of
the vinylphosphonate-linked nucleic acids has focussed on the T*T
vinylphosphonate modification.
1.7 Aims of Research
Previous investigation of vinylphosphonate-linked nucleic acids has
focussed on the thymidine DNA nucleotides with the synthesis from
commercially available DNA nucleosides and the application to
RNase H mediated antisense strategies. Further exploration of the
biology of vinylphosphonate-linked oligonucleotides requires that
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methodology is developed that enables all the different nucleoside
building blocks to be synthesised as single stereoisomers.
Synthesis of the vinylphosphonate-linked dinucleotides and then
oligomeric structures can then be carried out.
Using nucleosides in, the Wittig olefination leads to mixtures of E-
and Z-vinyl bromides which cannot be separated and obtained in
stereochemically pure form with the exception of thymidine. It is
the intention of this research to investigate the synthesis of a
generic vinyl bromide building block as a single diastereoisomer
from a simple sugar starting material.
A generic sugar building block can then be elaborated to access the
different diastereomerically pure vinyl bromide nucleosides. Since
the commercially available sugars posses the 2-OH moiety, the
nucleosides produced will be the in the RNA series. This
convergent strategy will then enable access to the 16 different
combinations of 3-5 vinylphosphonate-linked dinucleotides. This
will provide the first examples of vinylphosphonate-linked RNA
which can then be incorporated into RNA oligonucleotides using
solid phase synthesis protocols.
Starting from a generic vinyl bromide gives direct access to the
RNA series of nucleosides. Previous work has shown that the 2-
position can be deoxygenated to allow access to the DNA series.140
If successful, it is hoped that in the future this can be used to
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synthesise both DNA and RNA vinylphosphonate-linked
dinucleotides which can be incorporated into oligonucleotides using
solid phase synthesis.
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2. Results and Discussion
2.1 Synthesis of the Vinyl Bromide Precursor
2.1.1 First Generation Synthesis
In the design and synthesis of the vinyl bromide component, the
initial aim was investigate the installation of the vinyl bromide
moiety prior to addition of the nucleoside base. It was hoped that
this strategy would overcome the problems experienced in the DNA
series where the vinyl bromide could not be isolated as a single
isomer when olefination was performed in the presence of the
nucleoside base (see section 1.6.2.1).129,154
At the start of the project, the commercially available 1,2-
isopropylidene xylofuranose 86 was identified as a good starting
point. Unfortunately, the analogous ribofuranose is not
commercially available so the first steps involved inversion of the
stereochemistry of the 3-OH.
The initial steps of this route followed work developed by R.
Bertram.129 The selective protection of the primary alcohol, 5-OH as
the TBS ether using standard conditions (imidazole, TBS-Cl, DMF),
gave xylofuranose 87 with a pleasing 72% yield (Scheme 38).159
The oxidation with Dess Martin periodinane (DMP) in
dichloromethane160,161 gave the ketone which was then reduced with
NaBH4 (1.2 eq.) in the presence of methanol (20 eq.) in dry ether.
The reduction was entirely selective as the hydride addition occurs
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in an exo fashion, at the more accessible top face, to access
ribofuranose 81 in an excellent 89% yield.
a b-c
O
O
O
HO
HO
O
O
O
HO
TBSO
O
O
O
HO
TBSO
86 87 81
Scheme 38. Reagents & conditions: a. TBSCl, imidazole, DMF, 0 oC (72%); b.
DMP, CH2Cl2, 0
oC (91%); c. NaBH4, MeOH, Et2O, 0
oC (89%).
Previously, Bertram had used the PMB protecting group at the 3-
position,129 however, this proved to be too acid-labile at a later
stage when hydrolysis of the 1,2-isopropylidene was carried out
using acidic conditions. Therefore, at this stage the decision was
made to use the 2-methylnaphthyl protecting group at the 3-OH
position. A protecting group that is both acid and base stable is
necessary for later steps in the synthesis. As first reported by
Spencer et al.,162 Bertram has shown that the 2-methylnaphthyl
could be utilised as an acid stable protecting group in the synthesis
of the vinyl bromide nucleosides. This protecting group can be
cleaved reductively using hydrogenation or oxidatively using DDQ or
CAN.163 Alcohol 81 was protected using the method of Bessodes et
al.:164 thus 2-bromomethyl naphthalene (1.2 eq.) in the presence of
potassium hydroxide (1.8 eq.) and 18-crown-6 (0.04 eq.) in dry THF
afforded 158 in a yield of 70% (Scheme 39). The TBS ether of 158
was then cleaved using TBAF (86%) and the resulting alcohol 88
was cleanly oxidised to aldehyde 89 using hypervalent iodine
oxidising agent DMP in CH2Cl2 (79%).129
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Scheme 39. Reagents & conditions: a. 2-NapCH2Br, KOH, 18-c-6, THF, r.t.
(70%); b. TBAF, THF, r.t. (86%); c. DMP, CH2Cl2, r.t. (79%); d. Ph3P, CBr4,
CH2Cl2, 0
oC (22%); e. (MeO)2P(O)H, Et3N, DMF, 110
oC (84%).
Our next task was to form the E-vinyl bromide, 160; this was
achieved using our previously developed two-step procedure. Work
in the Hayes group has developed a modified Hirao reduction165 of a
dibromo olefin to form the bromo olefin, favouring the trans
geometry.156 Dibromo olefin 159 was generated using the method
of Ramirez et al.; by reaction of the aldehyde 89 with the Ph3P-CBr4
ylid, generated in situ by the reaction of Ph3P (4.0 eq.) and CBr4
(2.0 eq.) in CH2Cl2 at r.t. in a disappointing 22% yield (Scheme
39).153,166,167 Further attempts to optimise this reaction were
unsuccessful.129 The dibromo olefin 159 was then reduced using
dimethyl phosphite and Et3N in DMF at 110 oC to obtain a 3:1
mixture of E- and Z-vinyl bromides isomers in 84% combined yield.
Due to the disappointing yields in the Wittig reaction to form the
aldehyde 89, the decision was made to revert to the benzyl
protecting group previously used by Solesbury in the development
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of a similar route from the 1,2-isopropylidene xylofuranose 86 to an
analogous terminal olefin (Scheme 56).140 Similar to the 2-
methylnaphthyl, the benzyl protecting group is stable in acid and
base environments and can be removed under neutral conditions.
Benzylation of the 3-OH of ribofuranose 81 was achieved using BnBr
(1.3 eq.), TBAI (0.05 eq.) and NaH (1.6 eq.) (Scheme 40).168 This
was followed by deprotection of the TBS ether using TBAF as a
fluoride source to give alcohol 161 in yield of 83% over the two
steps. The intermediate aldehyde was generated by oxidation of the
alcohol 161 using Dess Martin periodinane and this was isolated in
an excellent 96% yield. The dibromo olefin 162 was obtained from
this aldehyde in 69% yield using the protocol of Ramirez et al.153
This shows a marked improvement in yield compared to the 22%
yield when the 2-methylnaphthy protecting group was used
presumably due to reduced steric bulk.
O
O
O
HO
TBSO
O
O
O
BnO
HO
O
O
O
BnO
Br
Bra-b c-d
81 161 162
Scheme 40. Reagents & conditions: a. BnBr, NaH, TBAI, THF, 0 oC; b. TBAF,
THF (83%, 2 steps); c. DMP, CH2Cl2, 0
oC (96%); d. Ph3P, CBr4, CH2Cl2, 0
oC
(69%).
The dibromo olefin 162 was reduced using dimethyl phosphite (4.0
eq.) and Et3N (2.0 eq.) in dry DMF at 110 oC to produce E- and Z-
vinyl bromides 163 and 164 in a 3:1 ratio respectively (Scheme
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41).165,156 The two isomers were separated by column
chromatography and the desired E-vinyl bromide 163 was isolated
in 51% yield. This is an improvement on the previous work in the
DNA series of installing the vinyl bromide with the nucleotide base
already present.
O
O
O
BnO
Br
Br
O
O
O
BnO
O
O
O
BnO
+
Br
Br
162 163 (51%) 164 (17%)
Scheme 41. Reagents & conditions: (MeO)2P(O)H, Et3N, DMF, 110
oC.
Following the generation of E-vinyl bromide 163, the 1,2-acetonide
was hydrolysed in refluxing 60% v/v aqueous acetic acid (Scheme
42). The diol was acetylated to form the bis-acetate 165 using
Ac2O and pyridine as a 10:1 mixture of anomers with a yield of 95%
over the two steps. Using the modified Vorbrüggen glycosylation
conditions of Yang et al.; uracil was added with complete facial
selectivity to form the uridine vinyl bromide 166 in 85% yield.169
O
O
O
BnO
O
BnO OAc
OAc O
BnO OAc
N
NH
O
O
a-b c
Br Br Br
163 165 166
Scheme 42. Reagents & conditions: a. 60% AcOH, reflux; b. Ac2O, pyridine,
r.t. (95%, 2 steps); c. Uracil, BSA, MeCN, 65 oC then TMSOTf (85%).
Although the 2-OAc serves as an adequate protecting group, it was
decided to manipulate this to have the 2-OTBS group as this would
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be required later on, for the solid-phase synthesis of
oligonucleotides. The 2-OAc species 166 was deprotected using
K2CO3 in MeOH to form the alcohol which was then protected to
form TBS ether 167 in 66% yield using TBSCl, and imidazole in dry
DMF (Scheme 43).159
O
BnO OAc
N
NH
O
O
O
BnO OTBS
N
NH
O
O
a, b
Br Br
166 167
Scheme 43. Reagents & conditions: a. K2CO3, MeOH, r.t. (95%); b. TBSCl,
imid., NaH, DMF, 0 oC (66%).
2.1.1.1 Troubleshooting the First Generation Synthesis
The initial synthesis of the vinyl bromide nucleoside from the
isopropylidene starting material contains problems and needs
improvement. In the ten steps it takes to get from the starting
xylofuranose 86 to the 2-OTBS uridine vinyl bromide 167, two
oxidations are performed that require DMP. On its own, Dess Martin
periodinane is a good, clean oxidising agent. However, it is required
in a stoichiometric amount and use of the reagent at such early
stages in the synthesis is not economical. The protecting group
strategy must also be revised to use a protecting group at the 3-
position that can be removed at the desired stage. Parallel work in
the Hayes group showed that the benzyl protecting group could not
be removed without loss of the carbon-carbon double bond moiety
of the vinyl bromide, so a second generation approach was required.
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2.2 Second Generation Synthesis
Taking into consideration the weaker points of the first generation
synthesis, a second generation synthesis was designed. The aim is
to achieve the efficient synthesis of the generic vinyl bromide as a
single stereoisomer. From this key building block, it is the aim of
this project to be able to add the different nucleoside bases so that
all the different vinylphosphonate-linked dinucleotides combinations
can be synthesised by the Pd(0) cross-coupling reaction.
2.2.1 Retrosynthetic Analysis
It was decided to use D-D-glucose 173 as a starting material for the
synthesis of the vinyl halides. Retrosynthetic analysis showed that
although the 3-OH must still be inverted; the 5-aldehyde 170 can
be accessed without the use of Dess Martin periodinane but by the
oxidative cleavage of a 1,2-diol (Scheme 44).
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Scheme 44. Retrosynthetic analysis.
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2.2.2 Synthesis
Using the procedure of Kartha,170 D-D-glucose 173 was stirred
vigorously as a suspension in refluxing acetone in the presence of
iodine (0.2 eq.) for 4.5 hours (Scheme 45). The 1,2:5,6-
diisopropylidene-D-D-glucofuranose 172 was obtained in 66% yield
based on recovered starting material (borsm).
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OHHO
HO
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Oa b-c
173 172 174
Scheme 45. Reagents & conditions: a. acetone, I2, 80
oC (66%); b. PDC,
Ac2O, CH2Cl2, 45
oC; c. NaBH4, MeOH, Et2O, 0
oC (84%, 2 steps).
Once again the inversion of the 3-OH must be carried out in this
approach and based on a survey of the literature, several different
methods for the oxidation of the 3-OH of 172 to ketone 175 were
investigated (Scheme 46, Table 11). There are several examples in
the literature of the use of catalytic ruthenium tetroxide used to
oxidise the alcohol.171 This is generated in situ from RuCl3 or RuO2
and uses biphasic solvent system of chloroform and water.
Sharpless reported that the three-solvent system of CCl4-MeCN-H2O
gave improved yields in ruthenium tetroxide catalysed oxidations.172
Morris and Kiely also reported the use of the phase transfer catalyst
benzyltriethylammonium chloride (BTEAC) to improve yields and
rates of reaction times alcohols with low water solubility.173 Despite
literature examples of this, we failed to get the reaction to perform
effectively. Similarly, the mild reaction conditions of Ley et al. using
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TPAP were unsuccessful.174 The use of the Swern reaction was not
investigated since previous work in the Hayes group had found this
to give unacceptably low yields.
O
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O
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O O
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O
172 175
Scheme 46. Oxidation of the 3-OH of the glucofuranose.
Method
Yield / %
Ref.
172 175
RuCl3 (2 mol%.), K2CO3 (0.27 eq.), NaIO4
(1.5 eq.), 1:1 v/v CHCl3:H2O, 20 h
19 55 171
RuO2 (2 mol%), K2CO3 (0.27 eq.), NaIO4
(1.5 eq.), 1:1 v/v CHCl3:H2O, 19½ h
71 0 171
RuCl3 (2.2 mol%), NaIO4 (4.1 eq.), 2:2:3
v/v CCl4:MeCN:H2O, 72 h
60 0 172
RuCl3 (15 mol%), BTEAC (0.01 eq.), NaIO4
(1.2 eq.), 1:1 v/v CHCl3:H2O, 19½ hours
64 0 173
TPAP (5 mol%), NMO (1.5 eq.), 4Å m.s.,
CH2Cl2, 24 h
91 0 174
PDC (0.9 eq.), AcOH (0.45 eq.), 3Å m.s.,
CH2Cl2, 3½ h
2 12 175
PDC (0.6 eq.), Ac2O (3.3 eq.), CH2Cl2, 3½ h 0 84 176
Table 11. Summary of methods investigated in the oxidation of 26.
The best method uncovered for the oxidation of glucofuranose 175
was the use of pyridinium dichromate (0.6 eq.) with acetic
anhydride (3.0 eq.) and Celite® in refluxing CH2Cl2 for 3½ hours.
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The Celite® prevented the formation of a tar-like substance in the
reaction mixture, enabling a cleaner isolation of the ketone 175.175
Following filtration of the reaction slurry through a plug of silica, and
eluting with petrol-EtOAc (2:1 ratio v/v), the ketone was isolated as
the hydrate. In our hands, the oxidation is a somewhat capricious
reaction resulting in incomplete oxidation. However, longer reaction
times lead to a rapid decrease in yield. Unfortunately, the
glucofuranose 172 and allofuranose 174 are difficult to purify by
chromatography due to poor separation. Following the oxidation,
the reduction was carried out in a stereoselective manner using
NaBH4 and MeOH to allofuranose 174 in a yield of 84% over the two
steps.
Persevering with the allofuranose, the 3-OH of 174 was protected
as the 2-methylnaphthyl ether using the previously used method.164
The 2-methylnaphthyl ether 176 was obtained as a white solid in
75% yield (Scheme 47). Despite the poor yields previously
obtained in the key Wittig reaction, this was the obvious choice
while investigating the feasibility of this route due to the fact that it
can be removed under neutral conditions and it is not vulnerable to
acidic conditions.
O
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Nap
18-c-6, THF
NapCH2Br, KOH,
Scheme 47. Addition of 2-methylnaphthyl protecting group.
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To obtain the aldehyde, hydrolysis of the 5,6-acetonide followed by
oxidative cleavage of the diol was required. The oxidative cleavage
is advantageous over the first generation synthesis where the
stoichiometric use of Dess Martin periodinane was necessary due to
the fact that it uses a cheaper reagent, NaIO4.
It is known that acid hydrolysis of the 5,6-acetonide of the
hexofuranose sugar 176 occurs preferentially over the 1,2-
acetonide.177,178,179,180, Initially, hydrolysis using 80% v/v aqueous
acetic acid at room temperature was attempted (Scheme 48). This
reaction was very slow but unfortunately promotion by gentle
heating resulted in several different products (presumably from
hydrolysis of the 1,2-acetonide). Stirring the mixture at r.t. for up
to 3 days was necessary to obtain reasonable yields without
formation of the tetraol. Purification of diol 177 was problematic
due to its viscous, syrupy nature and difficulties in removing acetic
acid. Following column chromatography, diol 177 was obtained in a
poor 33% yield. Traces of the acetic acid remained despite co-
evaporation with copious quantities of toluene. The reaction was
difficult to follow by TLC, since the acetonide 176 and diol 177 were
co-polar.
O
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O HO
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Scheme 48. Reagents & conditions: a. 80% AcOH, r.t. (33%).
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Several other methods of hydrolysis were also attempted but they
also led to very slow reactions or hydrolysis of 1,2-acetonide 176
(Table 11). Once again the purification and handling of the reaction
mixtures was challenging.
Conditions Observations*
80% v/v AcOH aq., r.t., 3 d.181,182,183 Recovered 176 (33%)
H2SO4 (0.08 M)/MeOH 1:1 v/v, r.t., 4
d.184
Recovered 176 (98%)
NaHSO4.SiO2, 8:3 v/v CH2Cl2-
iPrOH,
r.t., 6 d.185,186
Recovered 176 (97%)
80% v/v HCO2H aq., r.t., 90 mins
Complex mixture of products,
hydrolysis of both acetonides
80% v/v ClCH2CO2H aq., r.t., 90 mins
Complex mixture of products,
hydrolysis of both acetonides
0.1 eq. ClCH2CO2H, 9:1 v/v MeCN-H2O,
r.t., 19 h.
Recovered 176 (81%)
0.1 eq. HCO2H, 9:1 v/v MeCN-H2O,
r.t., 19 h.
Recovered 176 (83%)
Table 12. Summary of attempted hydrolysis conditions.
*All reactions were difficult to purify and obtain dry due to the viscous and
syrup-like nature of the diol.
Unfortunately, synthesis of aldehyde 178 was also problematic; the
reactions were incomplete or yielded a mixture of products. Despite
these challenges, the aldehyde was generated using sodium
periodate (1.05 eq.) in 1:1 v/v CH2Cl2:H2O to achieve the oxidative
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cleavage of diol 177 to attain aldehyde 178 in a 37% yield (Scheme
49).
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CH2Cl2-H2O
r.t
Scheme 49. Oxidative cleavage of the diol.
Although we had reverted to the 2-methylnaphthyl protecting group,
we were aware that the yield from the Wittig reaction of aldehyde
178 was low (22%).129 Since the desired target vinylphosphonate is
formed by the palladium-catalysed cross-coupling of the H-
phosphonate with a vinyl halide there are alternatives to the vinyl
bromide and hence alternative strategies for accessing this coupling
partner were considered. One commonly procedure for preparing E-
vinyl iodides is the Takai reaction.187 An additional advantage of
using the vinyl iodide is that it should undergo the coupling reaction
more efficiently than the vinyl bromide.
2.2.2.1 The Takai Reaction
Chromium(II) chloride (6.0 eq.) and iodoform (2.0 eq.) in dry THF
were used to generate vinyl iodide 179 as a 2:1 mixture of E- and
Z-isomers from aldehyde 178 (Scheme 50).187 Attempted
purification by column chromatography obtained the E-vinyl iodide
179 in 32% yield but impurities from the CrCl2 were still present
and could not be removed.
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Scheme 50. Reagents & conditions: CrCl2, CHI3, THF, 0
oC (E:Z 2:1,
combined 32%).
The 2:1 E:Z ratio, the low yields and purification difficulties of the
vinyl bromide 179 were disappointing and further work using the
Takai reaction was abandoned. Another deleterious factor is that
CrCl2 is used in significant excess. This is an expensive and highly
moisture sensitive reagent. This project would require multi-gram
quantities and large scale handling of such material is not feasible
and the economics of the process is not viable. Although the Wittig
pathway requires an additional step, the chemistry is more robust,
cheaper and offers better yields than Takai chemistry.
Another widely used method of obtaining vinyl halides is through the
use of hydrozirconation.188 However, for the following reasons this
approach was not investigated in the progress of this project.
Currently, the challenging part of this synthesis was the formation of
the aldehyde. Using the hydrozirconation chemistry still requires
formation of aldehyde 178 from which alkyne 181 is synthesised
via the Corey-Fuchs reaction and the intermediate dibromo olefin
180 (Scheme 51). Furthermore, the hydrozirconation requires
stoichiometric use of a zirconocene species e.g. Schwartz reagent,
which is then displaced by the addition of an electrophilic source of
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bromine or iodine (e.g. I2, Br2 or NBS) to obtain the E-vinyl halide
183 as the major product.
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Scheme 51. Synthetic steps required to obtain the vinyl halide using
hydrozirconation methodology.
2.2.2.2 Protecting Group Strategy
The 2-methylnaphthyl group produces significantly lower yields in
the Wittig reaction; however, this route from the D-D-glucose is still
the most viable path for generation of the vinyl bromide. At this
stage in the project it became necessary to investigate a different
protecting group for the 3-OH moiety.
Previous work has shown that the 3-OPMB and the 3-OTBS
protected alcohols 184 and 185 are not appropriate for use at this
stage since they would not survive the acidic conditions required to
hydrolyse the 1,2-isopropylidene moiety. If they were used then
the 1,2,3-triacetate 186 would be generated prior to addition of the
nucleoside base thus making it necessary to be able to discriminate
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between the 2- and the 3-position of the bis-acetate 187 at a later
stage (Scheme 52).
O
AcO
Br
O
O
O
RO
Br
OAc
OAc O
AcO
Br
OAc
Base1. AcOH aq. Base, BSA
184 R= PMB
185 R = TBS
2. Ac2O, pyr. TMSOTf,
MeCN
186 187
Scheme 52. Use of the acid sensitive PMB or TBS protecting group leads to
the bis-acetate nucleoside.
The tert-butyldiphenylsilane (TBDPS) group was the first option to
be considered as it is an acid stable protecting group which can be
removed by treatment with TBAF. Previous work by N. Solesbury
has shown that the TBDPS group cannot be removed from the
vinylphosphonate dimers140 therefore it would be necessary to
deprotect and change the protecting group prior to the formation of
the vinylphosphonate bond. Although this adds two extra steps to
the synthesis, the TBDPS could be used, then cleaved and
reprotected as the 2-methylnaphthyl ether after the vinyl halide has
been installed but prior to the cross-coupling reaction.
Allofuranose 174 was protected using TBDPSCl and imidazole in dry
DMF to form the TBDPS ether 188 in an excellent 94% yield
(Scheme 53).189,190,191 The TBDPS ether is approximately 100 times
more stable to acid hydrolysis than the TBS ether so should remain
intact in the acid hydrolysis at a later stage.192
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imidazole, DMF
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Scheme 53. Addition of the TBDPS protecting group.
Unfortunately, as previously observed with the 2-methylnaphthyl
compound 176 (Scheme 48), acid hydrolysis of the 5,6-
isopropylidene of 188 using the standard aqueous acetic acid (80%
v/v) conditions181,182,183 was very slow so different methods were
investigated. Previous work in the group has shown that if the
reaction mixture was heated or left for too long (four days) then
hydrolysis of the 1,2-isopropylidene would occur.140 Investigating
different methods of hydrolysis led to the use of a catalytic amount
(0.1 eq.) of dichloro-dicyanobenzoquinone (DDQ) in 9:1 v/v
MeCN:H2O at r.t.184 In aqueous media, this is reduced to the bis-
phenol (pKa of 3.42) by the acetone byproduct of the acetal
hydrolysis.193 Hydrolysis did occur however, the reaction was slow
and low yielding. Hydrolysis of the TBDPS acetonide 188 using
acids with a similar pKa to the reduced DDQ was also investigated
but once again the diol, 189 was a viscous syrup and was difficult to
handle and purify by column chromatography or repeated
evaporation with toluene.
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Scheme 54. Acetal hydrolysis.
The hydrolysis was attempted using of 0.1 eq. of chloroacetic acid at
r.t. in 9:1 v/v MeCN:H2O, however, after 19 hours only the
unreacted acetonide 188 was observed. Warming the reaction to
40 oC or increasing the amount of acid (0.2 eq.) led to a complex
mixture of products. Higher levels of the chloroacetic acid (0.5 eq.)
had the undesired effect of cleavage of the TBDPS protecting group.
It is inferred from these results that the large steric bulk of the 2-
methylnaphthyl and the TBDPS protecting groups is responsible for
the very slow rates of hydrolysis of the diols. A solution to this
problem is the use of a smaller protecting group.
Fortunately, a solution to the 3-protection was found with the
acetate group. The 3-OH of the allofuranose 174 was protected
using acetic anhydride (1.56 eq.) in the presence of triethylamine (3
eq.) and a catalytic quantity of DMAP (0.1 eq.), stirring at room
temperature in dry CH2Cl2 to obtain 190 in a 86% yield as a
crystalline solid (Scheme 55).194
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O
O
O
HO
O
O
O
O
O
AcO
O
O
Ac2O, Et3N
190 (86%)174
Scheme 55. Acetate protection of the 3-OH.
The next challenge was the hydrolysis of the 5,6-acetonide 190 to
form diol 191 and oxidative cleavage to access aldehyde 192
(Scheme 56); hydrolysis using a 70% aqueous solution v/v of acetic
acid is a reliable method of cleaving the 5,6-acetonide.182 However,
in the subsequent oxidative cleavage process, it was not desirable to
use sodium periodate which requires an aqueous reaction mixture
(e.g. EtOH:H2O).195 Due to the high polarity of the diol 38, and
aldehyde 39, an aqueous reaction mixture resulted in the significant
loss of product due to its solubility in the aqueous phase and
formation of the aldehyde hydrate.
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190 191 192
Scheme 56. Reagents & conditions: a. 70% AcOH, r.t.; b. NaIO4, 4:1 v/v
EtOH:H2O, r.t.
To reduce the problem of hydrate formation, a single organic phase
could be used instead of the aqueous system. However, this
approach would impede the progress of the NaIO4 mediated
oxidative cleavage of diol 191 due to the poor solubility. The
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presence of silica is often reported to aid such reactions but in this
case, no benefit was seen.196 One-pot procedures for the hydrolysis
and subsequent oxidative cleavage of the diol to the aldehyde 192
have also been published in the literature (Scheme 57).169,196
Different methods were attempted with varying degrees of
conversion (Table 13).
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Scheme 57. One-pot hydrolysis-oxidative cleavage of the 5,6-isopropylidene.
Conditions Observations Ref.
NaIO4.SiO2, CH2Cl2, 4 ½ d. Recovered 190 (50%) 196
NaIO4 (1.0 eq.), H5IO6 (0.5
eq.), EtOAc, 5 d.
Aldehyde 192 and hydrate (92%) 169
H5IO6 (1.1 eq.), EtOAc, 4 h. Aldehyde 192 and hydrate (98%)
176
197
H5IO6 (1.25 eq.), THF, 4 h. Aldehyde 192 and hydrate (71%)
Table 13. Conditions used in the one pot hydrolysis-oxidative cleavage of the
5,6-acetonide of 190.
Using the method of periodic acid in THF, spectroscopic analysis 1H
NMR of the crude product showed a mixture of the aldehyde 192
and the corresponding hydrate. The method of Yang et al. uses a
combination of periodic acid and sodium periodate in dry ethyl
acetate (dried over CaCl2) to obtain the aldehyde 192.169 However,
the most successful results were obtained using a variation of the
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method of Agrofoglio et al. using solely periodic acid (1.2 eq.) in dry
EtOAc.197 Once the aldehyde 192 was obtained, it was used without
further purification; it was found that purification did not increase
the yield of the Wittig reaction and column chromatography often
led to loss of material.
While investigating the formation of aldehyde 192 and the
subsequent olefination and regioselective reduction steps, the
unreliable nature of the earlier PDC oxidation prompted the
exploration of a model system. Using the glucofuranose 172, this
approach would involve the inversion of the 3-OH stereochemistry at
a later stage in the synthesis; removing the capricious PDC
oxidation of the 1,2:5,6-diisopropylidene-D-D-glucofuranose
(Scheme 10). Glucofuranose 172 was protected as the acetate 193
using the same conditions in an excellent 93% yield (Scheme 58).194
Aldehyde 194 was then produced using the one-pot hydrolysis-
oxidative cleavage procedure using 1:1 v/v EtOAc-THF as the
solvent.
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Scheme 58. Reagents & conditions: a. Ac2O, Et3N, DMAP, CH2Cl2, r.t. (93%);
b. H5IO6, EtOAc-THF, r.t. (83%).
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Conditions Observations
NaIO4.SiO2, CH2Cl2, 7 d.
196 Recovered 193 (34%)
NaIO4 (1.0 eq.), H5IO6 (0.5 eq.), EtOAc, 3 d.
169 Aldehyde 194 (73%)
H5IO6 (1.5 eq.), EtOAc, 3 h. Aldehyde 194 (75%)
H5IO6 (1.25 eq.), 1:1 v/v EtOAc-THF, 2½ h. Aldehyde 194 (83%)
Table 14. Conditions used in the one pot hydrolysis-oxidative cleavage of the
5,6-acetonide of 193.
2.2.2.3 Wittig Olefination
After identifying the acetate as a good protecting group at the 3-OH
the olefination reaction was then explored. Previous synthesis of
the gem-dibromo olefin found using the Wittig reaction and
generating the ylid in situ was the most successful method.
Triphenylphosphine (4.0 eq.) and carbon tetrabromide (2.0 eq.)
were combined and stirred at 0 oC for 1 hour 15 minutes. The ylid
was then added to a solution of aldehyde 192 in dry CH2Cl2
(Scheme 59). It was essential that the hygroscopic CBr4 was dried
prior to use in order to obtain respectable yields in the olefination.
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a b
Scheme 59. Reagents & conditions: a. H5IO6, EtOAc, r.t.; b. Ph3P, CBr4,
CH2Cl2, 0
oC (36%, 2 steps).
Following purification, dibromo olefin 195 was obtained as a white
solid in 36% yield (over 2 steps from 190). A potential solution to
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the low yields of this reaction was the synthesis and isolation of the
ylid phosphonium salt Ph3P+CHBr2Br- according to the procedure of
Dolhem et al.198 However, using the isolated phosphonium salt did
not increase the yield of the Wittig reaction and so was not pursued
further.
Investigating the model system, the aldehyde 194 obtained directly
from the glucofuranose acetate 193 was also found to readily form
the hydrate. In order to minimise formation of the undesired gem-
diol it was desirable to use aldehyde 194 immediately after the
hydrolysis-oxidative cleavage. It was hoped that further drying the
aldehyde using freshly activated molecular sieves would push the
aldehyde-hydrate equilibrium towards a higher percentage of the
aldehyde 194, thus increasing the yield of the Wittig reaction
(Scheme 60). Although this failed to increase the yield of the Wittig
reaction, a yield of 45% over the two steps from glucofuranose 193
to dibromo olefin 196 was considered acceptable and enabled us to
pursue the synthetic path further.
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Br
Scheme 60. Reagents & conditions: Ph3P, CBr4, CH2Cl2, 0
oC (45%, 2 steps
from glucofuranose acetate 190).
The low yields of the Wittig reaction are partially due to the
tendency of the aldehyde to form the hydrate. Although the use of
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4Å molecular sieves was unsuccessful at dehydrating the hydrate of
aldehyde 194, it was found that improved yields in the Wittig
reaction were observed when the aldehyde hydrate was dehydrated
using calcium hydride.199 The aldehyde was stirred as a solution in
dichloromethane with CaH2 until evolution of H2 had ceased. Due to
its insoluble nature Ca(OH)2 could be removed by filtration while the
acetate protecting group was left intact. The difference in quality of
the aldehyde 194 was obvious from observing the 1H NMR spectra
before and after the addition of the CaH2 (Figure 16).
Figure 16. Comparison of aldehyde 194 1H NMR before and after the addition
of CaH2.
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A solution of the aldehyde was stirred over CaH2 then transferred
via canula into the Ph3P-CBr4 solution leaving the solid behind.
Alternatively the Ph3P-CBr4 solution could be transferred via canula
to the flask containing the aldehyde and the calcium hydride. Both
strategies were investigated but the yield did not seem to be
adversely affected by the presence of the CaH2 in the reaction
mixture. Using the CaH2 to dry aldehyde 194 and dehydrate the
gem-diol 197 led to a very pleasing increase in the yield of the
Wittig reaction, obtaining the dibromo olefin 196 with yields
consistently over 60% for the two step process of forming the
aldehyde and the olefination.
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Scheme 61. Reagents & conditions: a. H5IO6, EtOAc-THF, r.t., then CaH2,
CH2Cl2, r.t.,; b. Ph3P, CBr4, CH2Cl2, 0
oC (45%, over the 2 steps).
It has also been reported by Kerr et al. that the prolonged exposure
of a ketal functionality to the Ph3P-CBr4 reaction media can result in
poor yields due to the loss of the 1,2-isopropylidene protecting
group.200,201 The standard Ramirez procedure to generate the
dibromo olefin uses four equivalents of the Ph3P and two equivalents
of CBr4. Kerr slightly reduced the quantity of reagents, using Ph3P
(3.6 eq.) and CBr4 (1.7 eq.). In addition, the aldehyde and
phosphine were combined in solution and the carbon tetrabromide
was added slowly while constantly monitoring the reaction.
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Similarly we were able to reduce the relative quantities of phosphine
and carbon tetrabromide used, however, no improvement in yield
was observed using the strategy of the slow addition of carbon
tetrabromide.
2.2.2.4 Investigating the Hirao Reduction
The conditions used for the Hirao reduction used in the first
generation synthesis (Scheme 41) were based on the reduction of
the dibromo olefin of the DNA nucleotides used by Abbas in previous
work and were never fully optimised.156,158 At this stage it was
opportune to investigate and optimise this reaction. Both the
ribofuranose and the xylofuranose vinyl bromides were also
investigated to determine if the stereochemistry of the 3-OH had
any effect on the selectivity of the reaction.
Although the mechanism of the Hirao reduction is not fully known,
studies widely support the theory is that it proceeds via a vinyl
anion intermediate 200 (Scheme 62).156,202 The phosphoryl bromide
species 201 that forms as a product of the halophilic attack is very
reactive. To push the equilibrium to the right hand side, it is
necessary to remove this from the reaction media; this can be
achieved by the reaction with a secondary amine, forming the stable
phosphoramide 204.
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Scheme 62. Proposed mechanism of the Hirao reduction and possible side
products.
Initial studies showed that unlike the first generation synthesis, the
reduction could be carried out at r.t. over a shorter reaction time.
The reduction reactions were carried out at three different
temperatures using the reaction conditions previously optimised
within the group; dimethyl phosphite (4.0 eq.) and an amine (2.0
eq.) in dry DMF for 16 hours (Scheme 63, Scheme 64).156 Following
on from some work in the Hayes group by C. Gonzalez-Rodriguez a
different amine was also tried.203 In agreement with the suggested
mechanism (Scheme 62), it was found that secondary amines led to
faster rates of reaction than tertiary amines, diisopropylamine was
found to be particularly effective. In the case of both dibromo olefin
isomers 195 and 196, the rate of reaction was increased but there
was no increase in the E:Z ratio (Table 15, Table 16).
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Scheme 63. Reagents & conditions: (MeO)2P(O)H, Et3N OR
iPr2NH, DMF.
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Base Temp / oC
Ratio*
195:205:206
Combined yield
/ % **
Et3N -60 70:24:6 95
Et3N r.t. 0:81:19 84
Et3N 70 0:82:18 68
HNiPr2 -60 30:40:14 72
HNiPr2 r.t. 0:76:24 85
HNiPr2 70 0:84:16 76
Table 15. Hirao reduction conditions for the reduction of ribofuranose 195.
* Ratios based on 1H NMR spectra of crude reaction mixture.
** Combined yield after purification by column chromatography.
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Scheme 64. Reagents & conditions: (MeO)2P(O)H, Et3N OR
iPr2NH, DMF.
Base Temp / oC
Ratio*
196:207:208
Combined yield
/ %
Et3N -60 70:24:6 77
Et3N r.t. 2:71:27 60
Et3N 70 5:63:32 75
HNiPr2 -60 12:70:18 43
HNiPr2 r.t. 0:72:28 72
HNiPr2 70 5:66:29 81
Table 16. Hirao reduction conditions for the reduction of xylofuranose 196.
* Ratios based on 1H NMR spectra of crude reaction mixture
** Combined yield after purification by column chromatography.
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These results show that the temperature and the nature of the
amine base had no effect on the selectivity of the reaction.
However, the shorter reaction time required when using
diisopropylamine was advantageous so this was used in place of the
triethylamine in all subsequent reactions.
Further optimisation of the reaction involved altering the quantities
of the dimethyl phosphite and the amine used. It was found that
dimethyl phosphite (2.0 eq.) and diisopropylamine (2.0 eq.) were
sufficient to allow the reaction to proceed to completion.
Although this reaction provided us with a mixture of E- and Z-
isomers, the efficiency of the synthetic route could be further
increased by isomerism of the Z-vinyl bromide 208 to the desired E-
vinyl bromide 207 under radical conditions. Initially thiophenol and
2,2-azobisisobutyronitrile (AIBN) in refluxing carbon tetrachloride
was used, however the reaction was slow and after 48 hours the E:Z
ratio was still 1:4. Similarly, benzoyl peroxide (0.1 eq.) and N-
bromosuccinimde (NBS, 1.1 eq.) in refluxing carbon tetrachloride for
22 hours led to a 2:1 ratio of E- and Z-isomers 207 and 208
respectively.204 The most successful conditions were NBS (1.1 eq.),
AIBN (0.1 eq.), in gently refluxing CCl4 for 2 hours, longer reaction
times led to lower yields (Scheme 65). Subjecting the pure Z-vinyl
bromide 207, to the optimised conditions of NBS (1.0 eq.), AIBN
(0.1 eq.), in CCl4 at 80 oC for two hours led to a 2:1 ratio of E- and
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Z-isomers 207 (62%) and 208 (31%) respectively in a combined
93% yield.
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Scheme 65. Reagents & conditions: NBS (1.1 eq.), AIBN (0.1 eq.), CCl4, 78
oC
(combined: 93%; 207 62%, 208 31%)
2.2.2.5 Inversion of the 3-OH
Following optimisation of the Hirao reduction, it was then necessary
to investigate whether the 3-OH could be inverted. The acetate
protecting group on 207 was removed by base hydrolysis using
K2CO3 (0.5 eq.) in MeOH to produce alcohol 209 in an excellent
93% yield (Scheme 66). Dess Martin periodinane oxidation of
alcohol 209 provided the corresponding C3 ketone. The ketone was
then reduced with complete selectivity using NaBH4 (1.2 eq.) and
MeOH in Et2O at 0 oC to afford the desired ribofuranose 210 in a
yield of 73% over the two steps.
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Scheme 66. Reagents & conditions: a. K2CO3 (0.5 eq.), MeOH, r.t. (93%); b.
DMP (1.2 eq.), CH2Cl2, r.t.; NaBH4 (1.2 eq.), MeOH, Et2O, 0
oC, (73%, 2 steps).
The relative and absolute stereochemistry of 210 was confirmed by
X-ray crystallography (Figure 17 and Appendix 1).
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Figure 17. Structure of 59 obtained by X-ray crystallography.
2.2.2.6 Addition of Nucleoside Base
With the successful inversion of the 3-OH, the 1,2-isopropylidene of
furanose 210 was hydrolysed and acetylated to form triacetate 186
in a 3:1 mixture of anomers (Scheme 67). Using the same
glycosylation conditions as used in the first generation synthesis
(Scheme 42), uracil was then added with complete facial selectivity
to form uridine 211 in 99% yield.169
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Scheme 67. Reagents & conditions: a. 70% AcOH reflux; b. Ac2O (30 eq.),
pyridine (33 eq.), r.t. (82%, 2 steps); c. Uracil (3.0 eq.), BSA (3.0 eq.), MeCN,
then TMSOTf (1.48 eq.), 65 oC (99%).
Although the formation of the uridine vinyl bromide 211 was a
pleasing result, it is, however, not the ideal building block; it is
desirable to be able to discriminate between the 2-OH and the 3-
OH at a later stage. In order to achieve this from uridine 211 the
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bis-acetate would need to be deprotected and then selectively
protected as the TBS ether at the 2-OH. There is literature
precedent for this to be possible; the 2-OH is more acidic than the
3-OH.205,206 However, these literature examples are of nucleotides
containing a bulky 5-ODMT group which may exert a steric
influence.207,208,209 For the purposes of the palladium-catalysed
cross-coupling reaction, it is thought that the free 3-OH will not
affect the coupling reaction.
2.2.2.7 Accessing the desired building blocks
To enable the discrimination between the 2-OH and 3-OH, we
resorted to using a protecting group following the inversion of the
3-OH. Thus alcohol 210 was protected using TBDPSCl, imidazole in
DMF at r.t. to form the TBDPS ether in 99% yield (Scheme 68).189,190
Once again the 1,2-isopropylidene was hydrolysed and then
acetylated to obtain the bis-acetate 212 in an 86% yield over the
two steps. The TBDPS uridine 213 was then formed using standard
conditions of uracil, BSA and TMSOTf in MeCN in 84% yield.
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Scheme 68. Reagents & conditions: a. TBDPSCl, imidazole, DMF, r.t. (99%);
b. 70% AcOH, reflux; c. Ac2O, pyr., r.t., (86%, 2 steps); d. uracil, BSA, MeCN
then TMSOTf, 65 oC (84%).
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Following successful addition of the nucleoside base, it was desirable
to manipulate the functionality at the 2-position. The base
hydrolysis of the uridine acetate 213 using K2CO3 in MeOH and an
acid work up (1N HCl) resulted in a 1:1 mixture of products.
Chromatography was used to separate the products, however during
this process the two isomers re-equilibrated to a 7:3 ratio. The
products were identified by 1H COSY NMR spectrocopy as the 2-OH
214 and 3-OH 215 isomers respectively in a combined yield of
21% (Scheme 69). This mixture of products was caused by the base
mediated migration of the TBDPS group following the hydrolysis of
the acetate.192 The procedure was repeated using K2CO3 and MeOH
hydrolysis but the reaction mixture was dry loaded onto silica and
purified without an aqueous work up. This also led to a 1:2 ratio of
the 2-OH 214 and 3-OH 215 isomers respectively in a combined
yield of 76%, indicating a base-promoted process.
O
Br
TBDPSO OAc
N
NH
O
O
O
Br
TBDPSO OH
N
NH
O
O
O
Br
HO OTBDPS
N
NH
O
O
213 214 215
conditions
Scheme 69. Deprotection of the 2-OAc.
An alternative method of hydrolysis using NaOMe in CH2Cl2 at r.t.
also led to the same problems. After 6 hours a 1:1:1 ratio of
starting material acetate 213 and the two different TBDPS isomers
214 and 215 were observed. Further attempts to remove the
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acetate selectively using DIBAL-H and methanolic ammonia also
resulted in the migration of the silyl group (Table 17).
Conditions
Ratio 213:214:215
(combined yield)
K2CO3 (0.5 eq.), MeOH, r.t., SiO2 dry loaded 0:1:2 (21%)
K2CO3 (0.5 eq.), MeOH, r.t., 21 h., aq. work up 0:7:3 (76%)
K2CO3 (0.5 eq.), MeOH, r.t., 3 h., aq. work up 4:1:1 (96%)
NaOMe, CH2Cl2, r.t., 6 h. 1:1:1 (54%)
DIBAL-H (2.5 eq.), CH2Cl2, -78
oC, 2 ¼ h. 0:1:1 (83%)
2M NH3-MeOH, r.t., 23 h. 5:1:1 (54%)
Table 17. Summary of reagents and conditions used to deprotect 2-position.
Due to the problems encountered, the acetate can be kept in place if
necessary since it can be removed at a later stage in
oligonucleotides synthesis by the global deprotection conditions at
the end of oligonucleotide synthesis. With this in mind, the selective
deprotection of the 3-OTBDPS ether 213 was also attempted.
Since the acetate is base sensitive, the standard conditions to
remove a silyl group using TBAF were modified and the reaction
mixture was buffered with 2.4 equivalents of glacial acetic acid
(Scheme 70, Table 18). The reaction mixture was concentrated and
directly loaded onto silica and purified by chromatography. A
mixture of products, the 2-OAc 216 and 3-OAc products 217 were
co-eluted in a 1:2 ratio respectively (94% combined yield).
Repeating the reaction and using an aqueous work up procedure led
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to the same 1:2 ratio of acetates 216 and 217 respectively in a
combined 63% yield.
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Scheme 70. Reagents & conditions: TBAF (1.2 eq.), AcOH (2.4 eq.), THF, r.t.
Conditions Ratio 216:217 (Combined yield)
dry loaded onto SiO2 1:2 (94%)
aqueous work up 1:2 (63%)
Table 18. Summary of methods used to deprotect 3-TBDPS ether 213.
This lack of success led to the route using the TBDPS ether 212
being abandoned. A suitable protecting group still had to withstand
the acid hydrolysis however with the vinyl bromide installed, the
previous problem of the 2-methylnaphthyl protecting group having
very poor yields in the Wittig reaction were no longer relevant.
Vinyl bromide 210 was protected as the 2-methylnaphthyl ether
using the previous conditions164 to obtain vinyl bromide 160 in an
excellent 98% yield (Scheme 71). Hydrolysis and peracetylation of
the 1,2-isopropylidene 160 generated the bis-acetate 218 as a
mixture of theD and E-anomers in an 85% yield over the two steps.
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Scheme 71. Reagents & conditions: a. BrCH2Nap, KOH, 18-c-6, THF, r.t.
(98%); b. 70% AcOH, reflux; c. Ac2O, pyr., r.t. (85%, 2 steps).
2.3 Vinyl bromide nucleosides
2.3.1 Uridine vinyl bromides
With the bis-acetate 218 in hand, the task of generating the
different vinyl bromide nucleosides was near to being achieved.
Initially we investigated the uridine vinyl bromide since this was
vital for our primary target of the uridine dinucleotide. Using the
modified Vörbruggen conditions of Shi et al.,169 the nucleoside base
was added with excellent 93% yield to obtain the uridine vinyl
bromide 219 (Scheme 72).
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Scheme 72. Reagents & conditions: uracil, BSA, MeCN, 70 oC then TMSOTf.
2.3.2 Adenosine Vinyl Bromides
To date there has been no synthesis of the purine vinyl bromides in
a stereochemically pure form. Synthesis of the adenosine vinyl
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bromide also gives us the chance to explore the Pd(0) cross-
coupling of the RNA purine nucleosides for the first time.
A review of the literature indicated that the different Lewis acids
used in the Vörbruggen glycosylation can affect the ratio of N-7 and
N-9 isomers of purine nucleosides.210,211,212 The desired N-9 isomer
is the kinetic product whereas the N-7 isomer is the thermodynamic
product.213,214 It is reported that the weaker Lewis acid SnCl4 gives
more favourable yields of the desired N-9 isomer. To participate in
the Pd(0) coupling reaction it may be necessary to block the primary
amine to avoid competing reactions. The most commonly used
protecting group on the purine is the benzoyl moiety. There are two
possible routes to the adenosine vinyl bromides; one is to
synthesise the adenosine then protect the amine prior to the Pd(0)
cross-coupling. Initially the adenosine vinyl bromide 220 was
obtained in a 25% yield using adenine (1.5 eq.) and SnCl4 (2.5 eq.)
in MeCN at room temperature (Scheme 73).215 Upon work up, the
tin salts formed an emulsion and after chromatography the yield
was disappointing even though only a single isomer was observed.
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Scheme 73. Two step route to the adenosine vinyl bromide: a. SnCl4, MeCN,
r.t. (25%); b. benzoylation.
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Although the literature has examples of the formation of the
adenosine using Vörbruggen conditions used SnCl4 it was decided to
investigate the use of the TMSOTf to try and improve the
yield.211,212,213
The alternative strategy, avoiding the second step necessary to
protect the amine, utilised benzoyl adenine 223. More recently,
ultra mild protecting groups have been developed using the
phenoxyacetyl group which can be removed under milder
conditions.216,217,218
Taking this into consideration, N-6-benzoyl adenine was selected to
be used instead of the unprotected adenine. The N-6-benzoyl
adenine 223 was prepared by a modified procedure of Bullock et
al.219 using benzoyl chloride (2.5 eq.) and pyridine under reflux
conditions for six hours. The product was cooled, triturated with
NaHCO3 solution then recrystallised from EtOH-H2O (9:1 v/v) to
obtain the desired product 223 in a 76% yield (Scheme 74).
N
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222 223
Scheme 74. Reagents & conditions: BzCl, pyridine, reflux (76%).
The desired N-9-benzoyl adenosine vinyl bromide 221 was obtained
in an excellent 94% yield with no evidence of the N-7 isomer
observed. Although this strategy involved heating the reaction to
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80 oC to solubilise the 6-benzoyl adenine allowing it to be silylated
by the BSA. A cleaner, higher yielding reaction was also attained by
using toluene as the solvent instead of MeCN (Scheme 75).169
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Scheme 75. Reagents & conditions: N-6-benzoyl adenine, BSA, toluene, 80 oC
then TMSOTf (94%).
2.3.3 Cytidine Vinyl Bromides
As with the adenosine, it was also necessary to protect the primary
amine of the cytidine in order to carry out the Pd(0) coupling. The
cytosine base 224 was protected using benzoyl chloride (3.75 eq.)
in pyridine at r.t. to obtain benzoyl cytosine 225 in a 83% yield
(Scheme 76).220
HN N
NH2
O
HN N
NHBz
O
224 225 (83%)
BzCl, pyridine
r.t
Scheme 76. Synthesis of benzoyl cytidine.
The Vörbruggen glycosylation was carried out using the bis-acetate
218, N-4-benzoyl cytosine 225 and BSA in MeCN with TMSOTf as
the Lewis acid (Scheme 77).169 The desired cytidine vinyl bromide
226 was obtained in a 30% yield from the bis-acetate 218.
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Regrettably, due to time constraints within the project this was not
further investigated or optimised.
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Scheme 77. Reagents & conditions: N-4-benzoyl cytosine, BSA, MeCN, 70 oC
then TMSOTf (30%).
2.3.4 Guanosine Vinyl Bromides
Synthesis of the vinyl bromide guanosine presents similar problems
to that of the adenosine; there is the possibility of synthesising both
the N-7 and the N-9 isomers.210,221,222,223,224,225 A literature survey
shows that the amine of guanine 227 is most often protected as the
2-N-acetyl222 or the 2-N-isobutyryl221 or the 2-N-
dimethylformamidine (DMF) derivative. The isobutyryl amide 228
was formed using isobutyric anhydride (2.0 eq.) in DMF at 160 oC in
a 88% yield (Scheme 78).234 The carbonyl of the guanine was then
also protected using the diphenylcarbamyl protecting group
developed by Robins et al. (Scheme 78).222,225 Following the
procedure of Milecki et al., transient acetylation using Ac2O (2.25
eq.) in DMF at 100 oC was followed by treatment with
diphenycarbamoyl chloride (1.05 eq.) and DIPEA (1.75 eq.) in
pyridine to obtain guanine 229 in 57% yield (43% over the two
steps). The diphenylcarbamyl protecting group offers steric bulk to
reduce the formation of the undesired N-7 isomer. Shaughnessy et
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al. have also shown that it is possible for the oxygen of the
guanosine to coordinate irreversibly with palladium species during
Pd(0) coupling reactions.226 The use of the diphenylcarbamyl group
also prevents coordination of the purine oxygen with the palladium
during the Pd(0) cross-coupling formation of the vinylphosphonate.
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Scheme 78. Reagents & conditions: a. (iPrCO)2O, DMF, 160
oC (79%); b.
Ac2O, DMF, 100
oC then Ph2NCOCl, DIPEA, pyridine, r.t. (54%).
The 2-N-isobutyryl-6-O-diphenylcarbamoyl guanine 229 was
silylated in situ with BSA in toluene and reacted with the bis acetate
218 using TMSOTf to obtain the desired vinyl bromide guanosine
230 in a 76% yield (Scheme 79).
O
Br
O OAc
OAc
Nap
O
Br
O OAc
Nap
N
NN
N
O
N
H
O
NPh2
O
218 230 (76%)
Scheme 79. Reagents & conditions: 229, BSA, toluene, 80 oC then TMSOTf.
2.3.5 Manipulation of the 2- and 3-blocking groups
Following successful addition of the four different nucleoside bases,
it was advantageous to manipulate the protecting group at the 2-
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position. Standard oligonucleotide synthesis protocols utilise the 2-
OTBS protecting group which can be cleaved in the global
deprotection after oligomer synthesis. The alternative, widely used
strategy is the use of 2-OMe blocking group.
2.3.5.1 Uridine nucleosides
The acetate of uridine 219 was easily hydrolysed using K2CO3 and
MeOH to obtain the alcohol 231 which could then be elaborated. At
this stage we were interested in investigating the 2-OTBS and the
2-OMe nucleosides. Firstly the 2-OTBS vinyl bromide uridine 232
could be obtained using the standard conditions of TBSCl and
imidazole in DMF in a 98% yield (Scheme 80). The methylated
uridine vinyl bromide 233 was achieved using the protocol of
Wengel et al. of NaH (4 eq.), and MeI (2 eq.) in THF at 4 oC.227
During the course of this reaction, a small amount (<5%) of the bis-
methylated uridine 234 was obtained and this was readily separated
from the desired compound by chromatography.
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Scheme 80. Reagents & conditions: a. K2CO3, MeOH, r.t. (92%); b. TBSCl,
imidazole, DMF, r.t. (98%); c. NaH, MeI, THF, 4 oC (59%).
Coupling of these vinyl bromide uridines showed that the Pd(0)
cross-coupling worked well (see section 2.4). We were interested in
investigating the Pd(0) cross-coupling with a free alcohol at the 3-
OH. This would enable further derivitisation at the 3-OH of the
vinylphosphonate dimer as the phosphoramidite, necessary for
oligonucleotide synthesis. The 2-methylnaphthyl protecting group of
uridines 232 and 234 could be removed using DDQ (3.0 eq.) in 4:1
v/v CH2Cl2-MeOH at a gentle reflux (Scheme 81). These conditions
were suitably mild so that the TBS protecting group was left intact
to obtain the alcohol 235 in an excellent 96% yield. The analogous
2-OMe alcohol 236 was obtained using the same conditions in a
similarly pleasing 81% yield.
Results and Discussion
- 109 -
O
Br
O OR
Nap
N
NH
O
O
O
Br
HO OR
N
NH
O
O
232 R = TBS
233 R = Me
235 R = TBS (96%)
236 R = Me (81%)
Scheme 81. Reagents & conditions: DDQ, 4:1 v/v CH2Cl2:MeOH, reflux.
2.3.5.2 Adenosine nucleosides
As with the uridine vinyl bromide, the acetate on the 2-position of
the adenosine vinyl bromide 221 was exchanged for a methyl
group. Alternative conditions were required to selectively hydrolyse
the acetate of 221 leaving the benzoyl amide intact. Using
potassium carbonate in methanol at 0 oC for two hours led to a
mixture of products. However, sodium methoxide (0.2 eq.) in
methanol at r.t. for 90 minutes led to recovered acetate starting
material 221;228 longer reaction times (13 hours) led to mixtures of
starting material acetate 221, the desired 2-OH 237 and the
debenzoylated adenosine byproduct 238. Methanolic ammonia (1.0
eq.) at 0 oC did not result in any deprotection, however, at r.t. for 2
hours led to a 1.7:1 mixture of acetate starting material 221 and
alcohol 237 respectively.229 The best conditions were found to be a
short reaction time using ethanolic sodium hydroxide with which the
desired N-6-benzoyl adenosine alcohol 237 was obtained in 74%
yield (Scheme 82).230,231 Minimising the reaction time (less than 15
minutes) reduced the amount of the debenzoylated product 238.
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Scheme 82. Reagents & conditions: EtOH, 2M NaOH, r.t.
Using carefully anhydrous conditions, the 2-OH of 237 could be
methylated using the same conditions as for the uridine (NaH (5.0
eq.) followed by MeI (3.0 eq.) in THF at 4 oC) (Scheme 82).227 The
methylated adenosine 239 was obtained in 73% yield.
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Scheme 83. Methylation of 2-OH.
Unfortunately attempts to deprotect the 2-methynaphthyl of 237 to
obtain the 3-OH adenosine 240 were unsuccessful (Scheme 84).
The use of DDQ resulted in a very messy reaction where unreacted
starting material and a complex mixture of products were observed.
Similarly using CAN as an alternative single electron oxidant, was
also unsuccessful. One possible problem is the depurination caused
by the acidic environment of the DDQ in the reaction mixture.232
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Scheme 84. Attempted deprotection of the 3-OCH2Nap protecting group.
It is known that benzyl protecting groups can be reductively cleaved
using hydrogenation conditions and by dissolving metal reductions.
Applying this knowledge to the 2-methylnapthyl group using lithium
metal solely was unsuccessful. Using the conditions of Donohoe et
al. of lithium di tert-butylbiphenyl (LiDBB) and
bis(methoxyethyl)amine in THF at -78 oC resulted in a trace of the
desired compound being observed but attempts to isolate it were
unsuccessful.233
The reasons for the lack of success of the deprotection were
unknown. It was considered that the aromatic nature of the purine
may affect the system thus hindering the one electron oxidation.
However, parallel work in the guanosine series (see section 2.2.5.4)
showed that this was not necessarily the case. Another possibility
was the aromatic benzoyl protecting group of the amine affecting
the system. This was investigated using an alternative group to
protect the amine of the purine.
The N-6-isobutyryl adenine 241 was investigated due to its steric
bulk theoretically leading to a more favourable ratio of the N-9
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isomer. Following the procedure of Shevlin et al,234 the N-6-
isobutyryl adenine 241 was prepared from adenine 222 using
isobutyric anhydride (3.0 eq.) in DMF heating at 160 oC and was
obtained in a pleasing 75% yield (Scheme 85).235 Using the same
conditions as previous, the nucleoside was prepared using BSA and
TMSOTf in toluene obtained the isobutyryl adenosine 242 in an
unoptimised 24% yield. Remaining with the acetate protecting
group to minimise the number of steps, the DDQ mediated
deprotection of the 2-methylnaphthyl of 242 to obtain the 3-OH
adenosine vinyl bromide 243 was investigated however this was
unsuccessful.
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Scheme 85. Reagents & conditions: a. iBu2O, DMF, 160
oC (75%); b. 241,
BSA, toluene, 80 oC then TMSOTf (24%); c. DDQ, 4:1 CH2Cl2:MeOH, reflux.
2.3.5.3 Cytidine nucleosides
A small scale test reaction also showed that the acetate 226 could
be hydrolysed to alcohol 244 using sodium hydroxide in ethanol and
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then the 2-OH methylated to form uridine 245 using the same
reagents and conditions as used for the adenosine series (Scheme
86) although this was not further pursued.
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Scheme 86. Reagents & conditions: a. EtOH, 2N NaOH, r.t. (74%), b. NaH,
MeI, THF, 4 oC (73%).
2.3.5.4 Guanosine nucleosides
With the guanosine vinyl bromide 230 formed, the manipulation of
protecting groups at the 2-position was attempted. The acetate
was removed using a similar method to that of the adenosine and
cytidine (Scheme 87). Deprotection of the 2-OAc of guanosine 230
was achieved using 2M NaOH in a 5:4:1 v/v mixture of
THF:MeOH:H2O at 0 oC for ten minutes, obtaining the 2-OH
guanosine 246 in a 98% yield.236 Unfortunately it was not possible
to form the 2-OTBS ether 247 using the standard TBSCl or TBSOTf
procedures.
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Scheme 87. Reagents & conditions: a. 2N NaOH, 5:4:1 THF-MeOH-H2O, 0
oC
(98%); b. Imidazole (2.4 eq.), TBSCl (1.2 eq.), DMF, r.t.; c. TBSOTf (1.25
eq.), pyridine (1.75 eq.), DMF; d. NaH (5.0 eq.), MeI (3.0 eq.), THF, 5 oC; e.
MeO+BF4
- (1.0 eq.), proton sponge (1.17 eq.), CH2Cl2; f. DBU (2.5 eq.), MeI
(5.0 eq.), MeCN.
Similarly, attempts to methylate the 2-postion to form guanosine
248 using the previously used methyl iodide and sodium hydride
conditions were also unsuccessful. Using the Meerweins salt as an
alternative electrophile237 and the use of MeI and DBU (a non-
nucleophilic base) were also unsuccessful at alkylating the 2-OH of
guanosine 246 (Scheme 87). Due to time limitations, a solution to
this problem has not currently been identified.
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On a more encouraging note, it was possible to oxidatively remove
the 2-methylnaphthyl protecting group of the vinyl bromide
guanosine 230 using DDQ (3.0 eq.) in 4:1 CH2Cl2:MeOH v/v at
reflux over 5 hours (Scheme 88). Unfortunately, due to the acidic
nature of the reaction media, a degree of acid mediated acyl
migration was observed, leading to a 3:2 mixture of inseparable 2-
OAc 249 and 3-OAc 250 products in a combined yield of 93%.
Acylation of this mixture of isomers using Ac2O (1.5 eq.), Et3N (2.5
eq.) and DMAP (0.2 eq.) in CH2Cl2 generated the bis-acetate 251 in
a 55% yield.
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Scheme 88. Reagents & conditions: a. DDQ, 4:1 CH2Cl2:MeOH, reflux (93%);
b. Ac2O, Et3N, DMAP, CH2Cl2, r.t. (55%).
2.4 Synthesis of H-Phosphonates
Previous work in the related DNA series has shown that the H-
phosphonates could be accessed in a single step from the
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commercially available phosphoramidites.129,158 Tetrazoles are the
most commonly used reagents for this process, being mildly acidic
(1H-tetrazole, pKa 4.9). These serve as good activating agents
without interfering with the dimethoxytrityl protecting group
(routinely cleaved from nucleosides by 80% AcOH in about 15
minutes).
Hydrolysis of phosphoramidite 252 using 2 equivalents of 1H-
tetrazole in aqueous acetonitrile at room temperature obtained
the uridine H-phosphonate 253 as a 3:2 mixture of
diastereoisomers in 93% yield. The diastereomeric mixture
(referred to as A and B, with GP 8.26 and 7.61 ppm
respectively) was used as attained, without further purification
or separation of the diastereoisomers (Scheme 89). This is
advantageous since chromatography results in significantly
reduced yields.
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Scheme 89. Synthesis of the uridine H-phosphonate.
During the later stage of this research, we were unable to obtain
1H-tetrazole in its solid form (subsequently it was only available as
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an acetonitrile solution). At this stage, crystalline 5-methyl-1H-
tetrazole was used as an alternative.
When this reaction was repeated, different ratios of the two H-
phosphonate diastereoisomers were observed. The length of
reaction time does not have a correlation with the differing ratios. It
can be speculated that reaction microconditions within the reaction
vessel played a part. The 1H-tetrazole and 5-methyl 1H-tetrazole
gave comparable yields and ratios, thus indicating that the
additional methyl group did not have any effect on the reaction.
Since our aim was to apply the vinylphosphonate modification to a
variety of systems, the 2-OMe uridine H-phosphonate 256 and the
purine N-6-benzoyl adenosine H-phosphonate 257 were also
prepared in excellent yields from the respective phosphoramidites
254 and 255 (Scheme 90).
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Scheme 90. Reagents & conditions: 5-Methyl 1H-tetrazole, MeCN, H2O, r.t.
2.5 Palladium(0) Cross-Couplings
Due to the base sensitive nature of the cyanoethyl group it is
necessary to find an alternative HBr scavenger to the traditionally
used amine base. Propylene oxide has been found to be a suitable
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alternative to this; however, its volatile nature means that it is
necessary to carry out the reaction in a sealed tube. The reaction
vessel used was either a small reactivial or a carousel tube from the
Radleys carousel®.
After completion of the first generation synthesis, the uridine vinyl
bromide was used to test the Pd(0) cross-coupling reaction since
this had previously not been carried out using RNA nucleosides.
Using the methodology previously developed in the group for the
cross-coupling reactions, Pd(OAc)2 was used to generate the active
catalytic Pd(0) species in situ.155,238,157
The H-phosphonate 253 was coupled to the first generation uridine
vinyl bromide 167 using the standard coupling procedures
optimised during work on the DNA series (Scheme 91).129,154 The H-
phosphonate was present in excess (1.3 eq.), along with Pd(OAc)2
(0.2 eq.), 1,1-bis(diphenylphosphino)ferrocene (0.4 eq.) and
propylene oxide (20 eq.) in THF (scheme 46).155,158,239 We were
pleased to be able to form the U*U dimer 258 as a 2:1 mixture of
diastereoisomers in a pleasing 67% yield. Purification by column
chromatography and reverse phase HPLC was unsuccessful at
removing a minor impurity of the oxidised 1,1-
bis(diphenylphosphino)ferrocene ligand [dppf(O)2] and separating
the diastereoisomers. At this stage the reaction was not further
optimised.
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Scheme 91. Reagents & conditions: Pd(OAc)2, dppf, propylene oxide, THF.
A proof of concept study was also obtained by carrying out the Pd(0)
cross-coupling of 2-OTBS H-phosphonate 253 and the bis-acetate
uridine vinyl bromide 211 first obtained in the second generation
synthesis prior to the final route being developed. Once again this
gave pleasing results of 61% yield of the U*U dimer 259 (Scheme
92).
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Scheme 92. Reagents & conditions: Pd(OAc)2, dppf, propylene oxide, THF.
Initial investigations of the Pd(0) coupling with the second
generation RNA vinyl bromides the Pd(0) couplings were carried out
using the vinyl bromides products from the nucleoside base
addition. Using the standard conditions the set of the four different
vinyl bromides were coupled with the 2-OMe uridine H-phosphonate
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254 (1.3 eq.). The pleasing results obtained the four different
vinylphosphonate dimers, U*U 260, U*A(Bz) 261, U*C(Bz) 262 and
U*G(DPC,iBu) 263 in yields of 93%, 77%, 53% and 66% respectively
(Scheme 38).
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Scheme 93. Reagents & conditions: Pd(OAc)2, dppf, propylene oxide, THF.
The results with the U*G(DPC,iBu) dimer 263 were particularly pleasing
since this is the first time we were able to achieve a complete
reaction without having to use sub-stoichiometric quantity of the
palladium catalyst.129 Bertram found that even after 24 hours the
coupling of a thymidine H-phosphonate 79 with the
deoxyribonucleotide G vinyl bromide failed to go to completion.
After 7 hours reaction time, the formation of the T*G dimer (67%
borsm) was observed, however, 46% of the unreacted vinyl bromide
starting material was recovered.129 In this case the only the amine
of the guanine was protected and not the carbonyl group.
Until this stage, the Pd(0) cross-coupling reactions have focussed on
pyrimidine dimers or mixed purine-pyrimidine dimers. With the
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success of forming the U*A(Bz) 261 and U*G(DPC,iBu) 263 dimers in
such good yields it was desirable to investigate purine-purine
dimers. The adenosine 238 and guanosine vinyl bromides 249,
these were coupled to the adenosine H-phosphonate 255 in pleasing
yields to obtain the A(Bz)*A(Bz) 264 and A(Bz)*G(DPC,iBu) 265 dimers in
excellent 99% and 91% yields respectively (Scheme 94, Scheme
95).
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Scheme 94. Reagents & conditions: Pd(OAc)2, dppf, propylene oxide, THF.
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Scheme 95. Reagents & conditions: Pd(OAc)2, dppf, propylene oxide, THF.
For the synthesis of the RNA oligomers, the 3-OH U*U dimers with
both the 2-OMe and the 3-OTBS groups were also synthesised.
The two dimers U*U (2-OTBS) 266 and U*U (2-OMe) 267 were
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obtained in 55% and 78% yields respectively as mixtures of
diastereoisomers (Scheme 96).
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Scheme 96. Reagents & conditions: Pd(OAc)2, dppf, propylene oxide, THF.
To utilise the vinylphosphonate-linked dinucleotides in solid-phase
oligonucleotide synthesis, it was necessary to elaborate the 3-OH
position of the U*U dimers as the phosphoramidite. This was
achieved using 2-cyanoethyl N,N-diisopropylchlorophosphoramidite
(1.1 eq.), DIPEA (4 eq.) and DMAP (0.2 eq.) in CH2Cl2 in the
presence of freshly activated 3Å molecular sieves and under a
protective atmosphere (Scheme 97). The 2-OTBS phosphoramidite
dimer 268 was obtained in a 74% yield and the 2-OMe
phosphoramidite dimer 269 in a 41% yield from the corresponding
3-OH U*U dimers 266 and 267 respectively (Scheme 97).
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Scheme 97. Reagents & conditions: 2-cyanoethyl N,N-diisopropylchlorophos-
phoramidite, DIPEA, DMAP, CH2Cl2.
With limited material and time constraints this reaction has not yet
been optimised. Due to the two chiral phosphorus centres, these
phosphoramidites were obtained as a mixture of the four possible
diastereoisomers. The quality of the phosphoramidite reagent was
key to the success of this reaction and was distilled under reduced
pressure prior to use, to minimise the contamination with the
decomposition product H-phosphonate (usually observed as an
insoluble white solid). Unfortunately, despite investigating several
different solvent systems the phosphoramidites were found to be co-
polar with the H-phosphonate byproduct generated.
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3. Conclusions and Future Work
3.1 Conclusions
Based on the aims set out at the start of this research, we have
been very successful in developing a synthesis of the generic vinyl
bromide from D-D-glucose. The desired E-vinyl bromide was
obtained in stereochemically pure form and gave direct access to
the four different vinyl bromide nucleosides as single
stereoisomers. This is the first time that the four vinyl bromide
nucleosides have been obtained as single stereoisomers and it is
the first time that RNA nucleosides have been synthesised.
After obtaining the four different vinyl bromide nucleosides, the
functionality of the 2-positions were modified to be analogous to
the 2-blocking groups of the phosphoramidites used in solid phase
oligonucleotide synthesis. Deprotection of the 2-methylnaphthyl
protecting group at the 3-position was also achieved for the
pyrimidine nucleosides, although, regrettably due to time
constraints this was not achieved in the purine nucleosides.
The palladium-catalysed cross-coupling reaction was successfully
carried out between the vinyl bromide nucleosides of all four
different bases and the uridine and adenosine H-phosphonates.
These provide the first examples of vinylphosphonate-linked RNA
dinucleotides and the first examples of purine-purine
vinylphosphonate-linked dinucleotides. In addition to this, this was
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the first time that the guanosine nucleoside had been successfully
applied to the palladium-catalysed cross-coupling.
3.2 Future Work
After obtaining the vinylphosphonate-linked dinucleotide 3-
phosphoramidites, these could be incorporated into RNA
oligonucleotides. This has previously been achieved with the
vinylphosphonate-linked DNA phosphoramidites by Abbas and
Bertram.129,154
With two interesting targets we attempted the synthesis of the
oligonucleotides using an Applied Biosystems RNA/DNA synthesiser
(Model 594). Standard RNA synthesis protocols were used apart
from the coupling time on the occasions that the
vinylphosphonate-linked U*U phosphoramidite was added. Using
the same strategy as when vinylphosphonate-linked DNA oligomers
were synthesised, the coupling time was increased by the addition
of a 900 second waiting period after the solid support column had
been flushed with the vinylphosphonate phosphoramidite and
tetrazole solution (Figure 18). Although the phosphoramidites
synthesised are obtained as mixtures of diastereoisomers the
oligomers undergo a global deprotection at the end of the
synthesis which removes the cyanoethyl protecting group and
leaves the phosphorus centres achiral.
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Unfortunately, the oligomer synthesis was not successful and there
was poor coupling of the vinylphosphonate-linked dinucleotide.
The conditions used were not optimised to the synthesis of RNA
oligomers; typically, RNA oligonucleotide synthesis requires longer
coupling times than DNA synthesis. Due to lack of time and
material, it was unfortunate that we were not able to optimise the
oligomer synthesis procedures; however this is a process that can
be developed in the future.
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Figure 18. Synthesis cycle for the automated synthesis of oligonucleotides.
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4. Experimental
4.1 General Considerations
The starting materials used in the syntheses were obtained from
commercial suppliers and were used without further purification.
All reactions were carried out in oven dried glassware and were
carried out under a protective argon atmosphere at room
temperature unless otherwise stated. Dry Et2O was obtained from
solvent purification towers containing activated alumina. Early on
in this project, the dry THF used was also obtained from towers
containing activated alumina, however, in the second generation
synthesis, the THF drying process was changed to using a still and
freshly distilling the THF over potassium and using
benzophenone.240 Dry methanol was distilled over Mg/I2241 and
CH2Cl2 over CaH2 according to literature procedures.242 Thin layer
chromatography (tlc) was carried out using Merck silica gel
precoated glass plates as the stationary phase. The tlc plate was
then visualized under a UV lamp then stained with either basic
potassium permanganate solution or acidic vanillin solution. The
flash column chromatography was carried out using Merck silica gel
60, 35-70 Pm as the stationary phase according to the procedure
of Still et al.243 The solvents used were all analytical grade
reagents. The term petrol refers to petroleum ether (40-60 oC
fraction) and ether refers to diethyl ether solvent. All water used
was deionised water.
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Microanalysis data was obtained using an Exeter Analytical CE-440
elemental analyzer. Infra-red spectra were obtained using either a
Perkin Elmer 1600 FTIR spectrometer, a Bruker Tensor 27 or a
Nicolet Avatar 360 FTIR. Spectra were acquired as dilute sample
solutions in CHCl3 or as thin films on a NaCl disc, or solid phase FT-
IR (Nicolet Avatar 360 FTIR). Mass spectra were obtained using a
Micromass AutoSpec or Micromass LCT spectrometers using
electrospray (ES), fast atom bombardment (FAB), electron
ionisation (EI) or chemical ionisation (CI). Optical rotations were
measured using a JASCO Polarimeter DIP-370 (Na lamp, O 589
nm) using a path length of 5 cm or 10 cm and concentrations are
expressed in g/100 mL. In some instances, where a very low
optical rotation was observed using the Na lamp an Optical Activity
AA-100 Dual Wavelength polarimeter was used with a mercury
lamp (O 546 nm) and a 1 cm or 2 cm path length cell. Melting
points were measured using a Gallenkamp variable heater melting
point apparatus.
NMR spectra were obtained at 298 K unless otherwise stated at the
stated frequency using a Bruker DRX500, Bruker AV400, Bruker
AM400, Bruker DMX300 or a JEOL EX270 spectrometer. The
samples were acquired using dilute solutions in CDCl3 unless
otherwise stated. The samples were referenced to a residual
solvent peak (CHCl3 GH 7.27 ppm, GC 77.1 ppm, d4-MeOD GH 3.35
ppm, GC 49.0 ppm). The 31P NMR spectra are recorded with H3PO4
as an external standard. All coupling constants are reported in
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Hertz (Hz), and the multiplicities of the signals labelled are
abbreviated as singlet (s), doublet (d), double doublet (dd), dt
(doublet of triplets) and t (triplet), br (broad), m (multiplet) and
sometimes apparent (app) or obscured (obs). The protons of the
furanose ring of the sugars are labelled 1-H, 2-H, 3-H etc. In the
case of the nucleosides, the nomenclature used for describing the
protons of the furanose ring uses a superscript prime i.e. 1-H, 2-
H, 3-H etc. to distinguish them from the protons of the heterocycle
nucleobases (5-H, 6-H etc.). The nucleoside bases of the
vinylphosphonate dimers are numbered sequentially in the 3-O o
5-C direction. Assignments were made using 2-dimensional NMR
spectroscopy techniques of 1H COSY, 1H-13C HMQC and 1H-13C
HMBC. In the cases of the vinylphosphonate-linked dinucleotides,
1H TOCSY was also used.
The phosphoramidite reagents were purchased from Link
Technologies and were used without further purification.
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4.2 Synthesis of the Generic Vinyl Bromide
4.2.1 First Generation Synthesis
6-Dibromo-(5-deoxy-5-methylidene)-3-O-benzyloxy-1,2-O-
isopropylidene-D-D-ribofuranose 162
Triphenyl phosphine (11.8 g, 45.0 mmol) and
carbon tetrabromide (7.46 g, 22.5 mmol) were
combined in CH2Cl2 (25 mL) at 0 oC for 30
minutes. The resulting solution was then transferred via canula
into a flask containing the 3-OBn 5-aldehyde (3.13 g, 11.3 mmol)
eluting with an additional portion of CH2Cl2 (25 mL). Stirring was
maintained at 0 oC for 6 hours then saturated aqueous NH4Cl
solution (100 mL) was added. The aqueous layer was extracted
with CH2Cl2 (3 x 100 mL) then the combined organic phases were
washed with brine (175 mL), dried (MgSO4) and concentrated in
vacuo. Purification of the crude product was performed using
column chromatography (2:1 Petrol/Et2O eluant) to produce the
dibromo olefin 162 (3.37 g, 69%) as a colourless oil. Rf 0.36 (2:1
Petrol/Et2O); [D]D29 +4.63 (c 0.73, CHCl3); found C, 44.42%; H,
4.14% (C16H18Br2O4 requires C, 44.27%; H, 4.14%); Qmax/cm-1
(CHCl3) 2985 (C-H), 2934 (C-H), 2872 (C-H), 1629 (C=C), 1498
(C=C), 1455 (C=C), 1384, 1376; GH (400 MHz, CDCl3) 7.42-7.30
(5H, m, Ar-H), 6.30 (1H, d, J 8.6, 5-H), 5.70 (1H, d, J 3.6, 1-H),
4.77 (1H, app d, J ~8.6, 4-H), 4.75 (1H, d, J 12.5, CHH), 4.65
(1H, d, J 12.5, CHH), 4.57 (1H, dd, J 4.2 and 3.6, 2-H), 3.60 (1H,
dd, J 8.9 and 4.2, 3-H), 1.56 (3H, s, CH3), 1.37 (3H, s, CH3); GC
(100 MHz, CDCl3) 148.6 (6-CBr2), 137.3 (Ar-C), 135.2 (5-CH),
O
O
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128.6 (2 x Ar-CH), 128.2 (Ar-CH), 127.9 (2 x Ar-CH), 113.5
(C(CH3)2), 103.8 (1-CH), 80.9 (3-CH), 78.1 (4-CH), 77.6 (2-CH),
72.3 (CH2), 26.9 (CH3), 26.6 (CH3); m/z (ES+) 454.9466 (37)
(M+Na, C16H1879Br79BrO4Na+ requires 454.9470), 456.9450 (100)
(M+Na, C16H1879Br81BrO4Na+ requires 456.9449), 458.9453 (30)
(M+Na, C16H1881Br81BrO4Na+ requires 458.9429).
6-E-bromo-(5-deoxy-5-methylidene)-3-O-benzyloxy-1,2-O-
isopropylidene-D-D-ribofuranose 163
Dimethyl phosphite (7.80 mL, 85.3 mmol) and
Et3N (5.90 mL, 42.6 mmol) were added to a
stirred solution of dibromo olefin 162 (9.26 g,
21.3 mmol) in dry DMF (110 mL). The reaction mixture was
heated at 110 oC for 17 hours then cooled, diluted with water (200
mL) and extracted with Et2O (4 x 120 mL). The combined organics
were washed with water (150 mL) then brine (150 mL), dried
(MgSO4) and evaporated to give the crude products as a 3:1
mixture of E- and Z- isomers respectively. Column
chromatography (2:1 Petrol/Et2O eluant) isolated the desired
trans-vinyl bromide 163 (3.40 g, 45%) as a colourless oil. Rf 0.42
(2:1 Petrol:Et2O); [D]D27 +41.1 (c 0.42 in CHCl3); Qmax/cm-1 (CHCl3)
2985 (C-H), 2936 (C-H), 2899 (C-H), 2872 (w), 1627 (C=C), 1455
(C=C), 1384, 1376; GH (400 MHz, CDCl3) 7.40-7.32 (5H, m, ArH),
6.49 (1H, dd, J 13.7, 1.0, 6-H), 6.15 (1H, dd, J 13.7, 6.8, 5-H),
5.73 (1H, d, J 3.9, 1-H), 4.76 (1H, d, J 12.2, CHH), 4.60 (1H, d, J
12.2, CHH), 4.57 (1H, dd, J 4.1 and 3.9, 2-H), 4.46 (1H, ddd, J
O
O
O
BnO
Br
Experimental
- 134 -
8.6, 6.8, 1.0, 4-H), 3.52 (1H, dd, J 8.6, 4.1, 3-H); GC (100 MHz,
CDCl3) 137.1 (Ar-C), 134.1 (5-CH), 128.6 (2 x Ar-CH), 128.2 (Ar-
CH), 128.1 (Ar-CH), 113.2 (C(CH3)2), 110.0 (6-CH), 103.7 (1-CH),
81.4 (3-CH), 78.2 (4-CH), 77.2 (2-CH), 72.4 (CH2), 26.7 (CH3),
26.4 (CH3); m/z (ES+) 377.0365 (M+Na, C16H1979BrO4Na+ requires
377.0364), 379.0362 (M+Na, C16H1981BrO4Na+ requires 379.0344).
6-Z-bromo-(5-deoxy-5-methylidene)-3-O-benzyloxy-1,2-O-
isopropylidene-D-D-ribofuranose 164
From the above procedure, further elution
obtained cis-vinyl bromide 164 as a colourless
oil, (484 mg, 18%). Rf 0.26 (2:1 Petrol:Et2O);
[D]D27 +27.3 (c 0.95 in CHCl3); found C, 54.03%; H, 5.26%
(C16H19BrO4 requires C, 54.08%; H, 5.26%); Qmax/cm-1 (CHCl3)
2985 (C-H), 2964 (C-H), 2935 (C-H), 2871 (C-H), 1630 (C=C),
1600 (C=C), 1495 (C=C), 1458 (C=C), 1384, 1375; GH (400 MHz,
CDCl3) 7.38-7.29 (1H, m, Ar-H), 6.49 (1H, dd, J 7.4, 0.9, 6-H),
6.05 (1H, dd, J 8.5, 7.4, 5-H), 5.74 (1H, d, J 3.9, 1-H), 5.04 (1H,
app t, J ~8.5, 4-H), 4.73 (1H, d, J 12.5, CHH), 4.66 (1H, d, J 12.5,
CHH,), 4.58 (1H, app t, J ~3.9, 2-H), 3.61 (1H, dd, J 8.6, 3.9, 3-
H), 1.67 (3H, s, CH3), 1.38 (3H, s, CH3); GC (100 MHz, CDCl3)
137.5 (Ar-C), 131.9 (5-CH), 128.5 (2 x Ar-CH), 128.0 (Ar-CH),
127.9 (2 x Ar-CH), 113.4 (C(CH3)2), 113.1 (6-CH), 103.8 (1-CH),
81.3 (3-CH), 77.9 (2-CH), 75.8 (4-CH), 72.2 (CH2), 26.9 (CH3),
26.6 (CH3); m/z (ES+) 377.0355 (M+Na, C16H1979BrO4Na+ requires
377.0364), 379.0366 (M+Na, C16H1981BrO4Na+ requires 377.0364).
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6-E-bromo-(5-deoxy-5-methylidene)-3-O-benzyloxy-1,2-
bis-acetate-DE-D-ribofuranose 165DE
Vinyl bromide 163 (1.23 g, 3.47 mmol) was
stirred in 60% v/v AcOH (55 mL) at reflux for 4
hours. The solvent was evaporated and the
acetic acid was co-evaporated with toluene (2 x 30 mL). Dry
pyridine (10 mL) and acetic anhydride (10 mL) were added to the
residue which was then stirred at room temperature for 23 hours.
H2O (40 mL) was added and the aqueous layer extracted with Et2O
(3 x 30 mL). The combined organics were washed with brine (2 x
25 mL), CuSO4 (20% w/v) solution (20 mL), dried (MgSO4) and
reduced in vacuo. The residue was co-evaporated with toluene (2
x 10 mL) to obtain bis-acetate 165 in 9:1 mixture of
diastereoisomers (1.17 g, 85%) as a foam. Rf 0.42 and 0.21 (1:1
Petrol:Et2O); for the mixture of anomers: found C, 51.40%; H,
4.73% (C17H19BrO6 requires C, 51.14%; H, 4.80%); Major E
isomer: Rf 0.42 (1:1 Petrol:Et2O); [D]D27 +14.4 (c 1.31, CHCl3);
Qmax/cm-1 (CHCl3) 2874 (C-H), 1746 (C=O), 1626 (C=C), 1455 (C-
H), 1372; GH (400 MHz, CDCl3) 7.40-7.29 (5H, m, Ar-H), 6.42 (1H,
dd, J 13.6 and 1.0, 6-H), 6.16 (1H, dd, J 13.6 and 7.2, 5-H), 6.14
(1H, app s, 1-H), 5.30 (1H, app d, J ~4.4, 4-H), 4.64 (1H, d, J
11.6, CHH), 4.49 (1H, d, J 11.6, CHH), 4.46 (1H, app t, J 7.8, 2-
H), 4.02 (1H, dd, J 7.8 and 4.4, 3-H), 2.15 (3H, s, 2-COCH3), 2.08
(3H, s, 1-COCH3)); GC (100 MHz, CDCl3) 169.9 (2-CO), 169.1 (1-
CO), 137.0 (Ar-C), 135.5 (5-CH), 128.7 (2 x Ar-CH), 128.3 (Ar-
CH), 128.1 (2 x Ar-CH), 110.1 (6-CH), 98.5 (1-CH), 82.0 (2-CH),
O
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80.2 (3-CH), 73.5 (CH2), 73.4 (4-CH), 21.2 (2-COCH3), 20.9 (1-
COCH3). Minor D isomer: Rf 0.21 (1:1 Petrol:Et2O); GH (270 MHz,
CDCl3) 7.37-7.30 (5H, m, Ar-H), 6.38 (1H, d, J 4.7, 1-H), 6.37
(1H, dd, J 13.6 and 1.2, 6-H), 6.04 (1H, dd, J 13.6 and 6.8, 5-H),
5.19 (1H, dd, J 6.3 and 4.7, 2-H), 4.67 (1H, d, J 11.9, CHH), 6.49
(1H, d, J 11.9, CHH), 4.54 (1H, ddd, J 6.8, 5.7 and 1.2, 4-H), 3.88
(1H, dd, J 6.3 and 5.7, 3-H), 2.15 (3H, s, COCH3), 2.14 (3H, s,
COCH3); m/z (ES+) for the mixture of anomers: 421.0279 (M+Na,
C17H1979BrO6Na+ requires 421.0263), 423.0237 (M+Na,
C17H1979BrO6Na+ requires 423.0242).

4.2.2 Second Generation Synthesis
1,2:5,6-Diisopropylidene-D-D-glucofuranose 172
Following a modified literature procedure,170
iodine (7.16 g, 56.4 mmol), was added to a
stirring suspension of D-D-glucose 173 (50.8 g,
282 mmol) in acetone (2.5 L). The reaction mixture was then
heated at reflux for 4 ½ hours then cooled, filtered and the filtrate
quenched with saturated Na2SO3 solution (750 mL). The acetone
was removed in vacuo and the remaining solution was extracted
with Et2O (3 x 500 mL). The combined organics were dried
(Na2SO4) then concentrated in vacuo and the pale yellow solid was
recrystallised from petrol to a obtain glucofuranose 172 as a white
solid 53.1 g (72%). m.p. 108110 oC (Lit. 108-109 oC, aq.
MeOH)244; Rf 0.46 (4:1 Et2O:Petrol); [D]D23 -10.3 (c 0.73, CHCl3),
(Lit. [D]D -13.51, CHCl3);170 found C, 55.38%; H, 7.69% (C12H20O6
O
O
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requires C 55.37%, H 7.74%); Qmax/cm-1 (CHCl3) 3607 (O-H), 3474
(O-H), 2988 (C-H), 2938 (C-H), 2892 (C-H), 1455 (C-H), 1384,
1374; GH (400 MHz, CDCl3) 5.95 (1H, d, J 3.6, 1-H), 4.54 (1H, app
d, J ~3.6, 2-H), 4.35 (2H, m, 3-H and 5-H), 4.18 (1H, dd, J 8.8
and 5.7, 6-Ha), 4.08 (1H, dd, J 7.6 and 3.2, 4-H), 3.99 (1H, dd, J
8.8 and 5.7, 6-Hb), 2.55 (1H, d, J 4.0, OH), 1.51 (3H, s, CH3),
1.45 (3H, s, CH3), 1.37 (3H, s, CH3), 1.33 (3H, s, CH3); GC (100
MHz, CDCl3) 111.8 (C), 109.7 (C), 105.3 (1-CH), 85.1 (2-CH), 81.1
(4-CH), 75.3 (3-CH), 73.5 (5-CH), 67.7 (CH2), 26.9 (CH3), 26.8
(CH3), 26.2 (CH3), 25.1 (CH3); m/z (ES+) 261.1333 (M+H,
C12H21O6+ requires 261.1338), 283.1153 (M+Na, C12H20O6Na+
requires 283.1152).
1,2:5,6-Diisopropylidene-D-D-allofuranose 174
Using a modified procedure of Saito et al.176 PDC
(908 mg, 2.41 mmol) and Celite® (3.10 g) were
added to a stirred solution of glucofuranose 172
(9.37 g, 36.0 mmol) in CH2Cl2 (70 mL) and stirred at room
temperature. After ten minutes, Ac2O (11.2 mL, 11.9 mmol) was
added and the reaction mixture was heated at reflux for 3 hours.
The solvent was removed in vacuo to obtain a crude residue.
Water (5 mL) was added and the acetic acid was co-evaporated
with toluene (3 x 30 mL). The residue was then taken up in EtOAc
(20 mL) and filtered through a pad of silica and eluted with
EtOAc/CH2Cl2 (9:1 v/v) (3 x 100 mL). The combined filtrates were
O
O
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reduced to a crude white solid of ketone (10.0 g, quantitative
yield), Rf 0.72 and 0.31 (Et2O).
The crude ketone (10.0 g, 36.0 mmol) was taken up in anhydrous
Et2O (195 mL) and stirred at 0 oC. NaBH4 (1.76 g, 46.6 mmol) was
added and after a further 10 minutes MeOH (50 mL) was added
and the reaction mixture was stirred for 17 hours (0 oC o r.t.).
The reaction mixture was quenched with H2O (100 mL) and the
aqueous layer was extracted with Et2O (3 x 80 mL). The combined
organics were dried (MgSO4), filtered and reduced to obtain
allofuranose 174 a white solid (7.92 g, 84% over 2 steps). m.p.
7678 oC (Lit. 75-76 oC, petrol)179; Rf (3:2 Et2O:Petrol) 0.19; [D]D23
+41.9 (c 0.73, CHCl3) (Lit. [D]D22 +38.0, CHCl3);179 Qmax/cm-1
(CHCl3) 3556 (O-H), 2988 (C-H), 2937 (C-H), 2896 (C-H), 1455
(C-H), 1384, 1375; GH (400 MHz, CDCl3) 5.82 (1H, d, J 3.8, 1-H),
4.62 (1H, dd, J 5.2 and 3.8, 2-H), 4.31 (1H, app d, J 6.6 and 4.7,
4-H), 4.09 (1H, dd, J 8.5 and 6.6, 6-Ha), 4.04 (1H, dd, J 8.4, 6.6
and 5.2, 3-H), 4.02 (1H, dd, J 8.5 and 6.6, 6-Hb), 3.82 (1H, dd, J
8.5 and 4.7, 5-H), 2.55 (1H, d, J 8.4, OH), 1.59 (3H, s, CH3), 1.47
(3H, s, CH3), 1.39 (3H, s, CH3), 1.38 (3H, s, CH3); GC (100 MHz,
CDCl3) 112.9 (1,2-C(CH3)2), 109.9 (5,6-C(CH3)2), 104.0 (1-CH),
79.8 (4-CH), 79.0 (2-CH), 75.7 (5-CH), 72.6 (3-CH), 66.0 (6-CH2),
26.7 (CH3), 26.6 (CH3), 26.4 (CH3) and 25.4 (CH3); m/z (ES+)
283.1146 (M+Na, C12H21O6Na+ requires 283.1152).
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3-O-Acetyl-1,2:5,6-diisopropylidene-D-D-allofuranose 190
Neat Et3N (8.30 mL, 59.4 mmol), Ac2O (2.90
mL, 30.9 mmol) and DMAP (242 mg, 1.98
mmol) were added sequentially to a stirring
solution of allofuranose 174 (5.15 g, 19.8 mmol) in CH2Cl2 (100
mL) at r.t. Stirring was maintained under N2 (g) atmosphere for
19 hours then the reaction mixture was quenched with saturated
aqueous NH4Cl solution (80 mL). Phases were separated and the
aqueous phase was re-extracted with Et2O (3 x 50 mL). The
combined organics were washed with brine (100 mL), dried
(MgSO4) and concentrated in vacuo to crystalline white solid of
acetate 190 (5.67 g, 95%). m.p. 73-75 oC; Rf 0.13 (2:1
Petrol:Et2O); [D]D23 +94.9 (c 1.02, CHCl3); Qmax/cm-1 (CHCl3) 2986
(C-H), 2937 (C-H), 2892 (C-H), 1742 (C=O), 1455 (C-H, C-O),
1385, 1374; GH (400 MHz, CDCl3) 5.82 (1H, d, J 3.8, 1-H), 4.88
(1H, dd, J 8.6 and 5.0, 3-H), 4.82 (1H, dd, J 5.0 and 3.8, 2-H),
4.30 (1H, ddd, J 6.9, 5.6 and 4.3, 5-H), 4.16 (1H, dd, J 8.6 and
4.3, 4-H), 4.07 (1H, dd, J 8.6 and 6.9, 6-Ha), 3.91 (1H, dd, J 8.6
and 5.6, 6-Hb), 2.13 (3H, s, COCH3), 1.56 (3H, s, CH3), 1.43 (3H,
s, CH3), 1.35 (3H, s, CH3) and 1.34 (3H, s, CH3); GC (100 MHz,
CDCl3) 170.0 (COCH3), 113.1 (C), 110.0 (C), 104.1 (1-CH), 77.7
(2-CH), 77.5 4-CH), 75.0 (5-CH), 72.6 (3-CH), 65.6 (6-CH2), 26.7
(CH3), 26.6 (CH3), 26.2 (CH3), 25.0 (CH3), 20.7 (COCH3); m/z
(ES+) 303.1443 (M+H, C14H23O7 requires 303.1438), 325.1260
(M+Na, C14H22O7Na+ requires 325.1258).
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6-Dibromo-(5-deoxy-5-methylidene)-3-O-acetyloxy-1,2-O-
isopropylidene-D-D-ribofuranose 195
Method 1. Periodic acid (1.34 g, 5.87 mmol)
was added to a stirring solution of allofuranose
190 in dry THF (9.5 mL). Stirring was
maintained for 6 hours then NaIO4 (1.17 g, 2.35 mmol) was
added. After a further 18 hours the reaction mixture was filtered
and concentrated in vacuo. The residue was diluted with CH2Cl2
(10 mL) and was washed with Na2S2O3 solution (10 mL). The
organic phase was dried (Na2SO4) and concentrated in vacuo to a
pale yellow oil aldehyde 192 (1.06 g).
Solid CBr4 (3.05 g, 9.21 mmol) was added to a stirred solution of
Ph3P (4.83 g, 18.4 mmol) in dry CH2Cl2 (9 mL) at 0 oC under an
argon atmosphere. Stirring was maintained for 1 hr then a
solution of the crude aldehyde 192 (1.06 g) in dry CH2Cl2 (9 mL)
was added. The reaction mixture was stirred for 18 hours
gradually warming to r.t. and was then quenched with water (25
mL), separated and the aqueous phase re-extracted with Et2O (3 x
10 mL). Combined organic extracts were washed with brine (20
mL), dried (MgSO4) and reduced in vacuo to crude yellow solid
(4.50 g). Purification by column chromatography (2:1 petrol/Et2O)
gave dibromo olefin 195 as a colourless oil (662 mg, 37% over 2
steps).
Method 2. A solution of KHMDS (26.3 mL, 0.5 M in toluene, 13.8
mmol) was added to a stirried solution of Ph3P+CHBr2.Br- (6.71 g,
13.0 mmol) in dry CH2Cl2 (7 mL) at -10 oC over 75 minutes. A
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solution of crude aldehyde 92 (1.63 g, 7.08 mmol) in dry CH2Cl2
(25 mL) was then added dropwise over 15 minutes. The reaction
mixture was gradually warmed to r.t. over 3 hours then quenched
with water (30 mL). The phases were separated and the aqueous
layer was re-extracted with Et2O (3 x 15 mL). Combined organic
portions were dried (MgSO4), filtered and reduced in vacuo to a
brown residue. Purification by column chromatography (2:1
Petrol:Et2O) produced dibromo olefin 195 as a pale orange oil
(1.05 g, 38% over 2 steps). Rf 0.25 (2:1 Pet/Et2O); [D]D29 +27.9
(c 0.22, CHCl3); found C, 34.37%; H, 3.59% (C11H14Br2O5 requires
C, 34.22%; H, 3.66%); Qmax/cm-1 (CHCl3) 3025 (C-H), 1743
(C=O), 1602 (C=C), 1518 (C=C), 1424, 1376; GH (400 MHz,
CDCl3) 6.44 (1H, dd, J 8.3, 5-H), 5.82 (1H, dd, J 3.7, 1-H), 4.81
(1H, dd, J 9.2 and 8.3, 4-H), 4.79 (1H, dd, J 4.5 and 3.7, 2-H),
4.68 (1H, dd, J 9.2 and 4.5, 3-H), 2.17 (3H, s, COCH3), 1.61 (3H,
s, CH3), 1.36 (3H, s, CH3); GC (100 MHz, CDCl3) 170.2 (CO), 134.2
(5-CH), 113.6 (C(CH3)2), 104.0 (1-CH), 95.8 (6-CBr2), 77.1 (2-
CH), 77.0 (4-CH), 75.4 (3-CH), 26.7 (CH3), 26.4 (CH3), 20.7
(COCH3).
6-E-bromo-(5-deoxy-5-methylidene)-3-O-acetyloxy-1,2-O-
isopropylidene-D-D-ribofuranose 205
Dimethylphosphite (102 PL, 1.11 mmol) and
diisopropylamine (78 PL, 554 Pmol) were added
to a stirred solution of dibromo olefin 195 (107
mg, 277 Pmol) in dry DMF (1.38 mL) at r.t. under an Argon
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atmosphere. Stirring was maintained for 16 hours then the
reaction mixture was quenched with H2O (2 mL) and extracted with
Et2O (2 x 2 mL). The combined organics were washed with brine
(2 mL), dried (Na2SO4), filtered and concentrated in vacuo to a 3:1
mixture of E- and Z-isomers 205 and 206 respectively.
Purification by column chromatography yielded the trans-vinyl
bromide 205 as a white solid (34 mg, 40%). m.p. 68-69 oC; Rf
0.28 (3:1 Petrol:Et2O); [D]D22 +80.0 (c 1.40, CHCl3); Qmax/cm-1
(CHCl3) 2984 (C-H), 2939 (C-H), 2903 (C-H), 1742 (C=O), 1628
(C=C), 1376; GH (400 MHz, CDCl3) 6.51 (1H, dd, J 13.7 and 0.8, 6-
H), 6.19 (1H, dd, J 13.7 and 6.4, 5-H), 5.81 (1H, d, J 3.8, 1-H),
4.81 (1H, dd, J 4.0 and 3.8, 2-H), 4.51 (1H, dd, J 9.0 and 4.0, 3-
H), 4.47 (1H, ddd, J 9.0, 6.4 and 0.8, 4-H), 2.13 (3H, s, COCH3),
1.55 (3H, s, CH3), 1.32 (3H, s, CH3); GC (100 MHz, CDCl3) 170.2
(COCH3), 133.2 (5-CH), 113.2 (C(CH3)2), 110.9 (6-CH) 103.9 (1-
CH), 77.3 (2-CH), 77.0 (4-CH), 75.7 (3-CH), 26.6 (CH3), 26.5
(CH3), 20.7 (COCH3); m/z (ES+) 328.9980 (M+Na,
C11H1579BrO5Na+ requires 329.0001), 331.0010 (M+Na,
C11H1581BrO5Na+ requires 330.9980).
6-Z-bromo-(5-deoxy-5-methylidene)-3-O-acetyloxy-1,2-O-
isopropylidene-D-D-ribofuranose 206
In the above procedure, further elution during
chromatography led to isolation of cis-vinyl
bromide 206 as a colourless oil (5 mg, 6%). Rf
0.18 (3:1 Petrol:Et2O); [D]D29 +10.3 (c 0.40, CHCl3); Qmax/cm-1
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(CHCl3) 2975 (C-H), 2937 (C-H), 1742 (C=O), 1632 (C=C), 1454,
1376; GH (400 MHz, CDCl3) 6.48 (1H, dd, J 7.4 and 1.0, 6-H), 6.14
(1H, dd, J 8.2 and 7.4, 5-H), 5.85 (1H, d, J 3.7, 1-H), 5.08 (1H,
ddd, J 9.2, 8.2 and 1.0, 4-H), 4.79 (1H, dd, J 4.6 and 3.7, 2-H),
4.73 (1H, dd, J 9.2 and 4.6, 3-H), 2.15 (3H, s, COCH3), 1.64 (3H,
s, C(CH3)), 1.37 (3H, s, C(CH3)); GC (100 MHz, CDCl3) 170.5 (CO),
131.1 (5-CH), 113.6 (C(CH3)), 113.2 (6-CH), 104.2 (1-CH), 77.4
(2-CH), 75.7 (3-CH), 75.0 (4-CH), 26.8 (CH3), 26.7 (CH3), 20.8
(COCH3); m/z (ES+) 329.0020 (M+Na, C11H1579BrO5Na+ requires
329.0001), 330.9987 (M+Na, C11H1581BrO5Na+ requires 330.9980).
3-O-Acetyl-1,2:5,6-diisopropylidene-D-D-allofuranose 193
Neat Et3N (45.5 mL, 327 mmol), DMAP (1.33 g,
10.9 mmol) and Ac2O (15.4 mL, 164 mmol)
were successively added to a stirred solution of
glucofuranose 172 28.5 g, 109 mmol) in CH2Cl2
(550 mL). Stirring at r.t. was maintained for 3 hours until tlc
indicated no residual starting material. The reaction was quenched
with saturated NH4Cl solution (200 mL), and stirred for 5 minutes
then separated and the aqueous phase re-extracted with Et2O (2 x
100 mL). The combined organics were washed with brine (200
mL), dried (Na2SO4), filtered and concentrated in vacuo to a pale
brown solid. The acetate 193 was obtained as pale yellow crystals
31.8 g (96%) following recrystallisation from petrol. m.p. 60-62 oC
(lit. 62.0-62.5 oC, aq. MeOH);194 Rf 0.65 (4:1 Et2O:Petrol); [D]D25 -
31.1 (c 0.41, CHCl3), (Lit. [D]D22 -27.9, CHCl3);194Qmax/cm-1 (CHCl3)
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2988 (C-H), 2938 (C-H), 2903 (C-H), 1746 (C=O), 1455, 1374; GH
(400 MHz, CDCl3) 5.86 (1H, d, J 3.7, 1-H), 5.24 (1H, app d, J
~2.4, 3-H), 4.48 (1H, app d, J ~3.7, 2-H), 4.21 (2H, m, 4-H and
5-H), 4.06 (1H, dd, J 8.4 and 5.4, 6-Ha), 4.01 (1H, dd, J 5.4 and
3.6, 6-Hb), 2.09 (3H, s, COCH3), 1.50 (3H, s, CH3), 1.39 (3H, s,
CH3), 1.31 (3H, s, CH3) and 1.29 (3H, s, CH3); GC (100 MHz, CDCl3)
169.6 (COCH3), 112.3 (C) 109.3 (C), 105.1 (1-CH), 83.4 (2-CH),
79.7 (5-CH), 76.2 (3-CH), 72.5 (4-CH), 67.2 (6-CH2), 26.9 (CH3),
26.8 (CH3), 26.2 (CH3), 25.3 (CH3) and 20.9 (COCH3); m/z (ES+)
303.1446 (M+H, C15H23O7+ requires 303.1438), 325.1261 (M+Na,
C15H22O7Na+ requires 325.1328).
6-Dibromo-(5-deoxy-5-methylidene)-3-O-acetyloxy-1,2-O-
isopropylidene-D-D-xylofuranose 196
Periodic acid (9.25 g, 40.6 mmol) was added to
a stirred solution of acetate 193 (9.82 g, 32.5
mmol) in 1:1 v/v dry EtOAc:THF (65 mL) (EtOAc
dried with CaCl2, THF with Na wire). Stirring at r.t. was maintained
for 5 hours then the reaction mixture was filtered under vacuum.
The filtrate was washed with saturated aqueous Na2S2O3 solution
(3 x 60 mL), then dried (MgSO4) and concentrated in vacuo to
obtain the crude aldehyde 194 as a yellow syrup (5.60 g).
Solid Ph3P (29.5 g, 93.7 mmol) was added to a stirring solution of
CBr4 (16.1 g, 48.6 mmol) in dry CH2Cl2 at 0oC under an Argon
atmosphere and the resulting solution was stirred for 80 mins. To
this mixture was then added a solution of crude aldehyde 194
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(5.60g, ~24.3 mmol crude material) in dry CH2Cl2 (49 mL).
Stirring was maintained for a further 17 ½ hours (0 oC to r.t.) and
the reaction mixture was then quenched with saturated NH4Cl
solution (100 mL). The phases were separated and the aqueous
phase was re-extracted with Et2O (3 x 50 mL). The combined
organics were washed with brine (2 x 100 mL), dried (MgSO4) then
concentrated in vacuo to a brown residue (42.7 g). Following
purification by column chromatography (2:1 Petrol:Et2O) the
dibromo olefin 196 was obtained as a white solid (5.55 g, 59%).
Rf 0.34 (2:1 Petrol:Et2O); m.p. 118-120 oC; [D]D25 -48.7 (c 0.42,
CHCl3); found C, 34.62%; H, 3.67% (C11H14Br2O5 requires C,
34.22%; H, 3.66%); Qmax/cm-1 (CHCl3) 2978 (C-H), 2936 (C-H),
2875 (C-H), 1747 (C=O), 1633 (C=C), 1455, 1376; GH (400 MHz,
CDCl3) 6.50 (1H, d, J 7.6, 5-H), 5.93 (1H, d, J 3.7, 1-H), 5.31 (1H,
dd, J 3.7 and 3.1, 3-H), 4.92 (1H, dd, J 7.6 and 3.1, 4-H), 4.54
(1H, d, J 3.7, 2-H), 2.12 (3H, s, COCH3), 1.55 (3H, s, CH3), 1.33
(3H, s, CH3); GC (100 MHz, CDCl3) 169.5 (CO), 131.8 (5-CH), 112.5
(6-CBr2), 104.5 (1-CH), 94.4 (C(CH3)2), 83.3 (3-CH), 79.3 (2-CH),
77.2 (4-CH), 26.8 (C(CH3)), 26.3 (C(CH3)), 20.7 (COCH3); m/z
(EI+) 383.9234 (M+, C11H1479Br79BrO5+ requires 383.9208),
385.9193 (M+, C11H1479Br81BrO5+ requires 385.9188), 387.9154
(M+,C11H1481Br81BrO5+ requires 397.9167).
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6-E-Bromo-(5-deoxy-5-methylidene)-3-O-acetyloxy-1,2-O-
isopropylidene-D-D-xylofuranose 207
Neat (MeO)2P(O)H (1.60 mL, 17.4 mmol) and
iPr2NH (2.45 mL, 17.4 mmol) were added
sequentially to a stirring solution of dibromo
olefin 196 (3.37 g, 8.73 mmol) in dry DMF (45 mL) and the
resulting solution was stirred at r.t. for 22 hours. The reaction was
then quenched with water (50 mL) and extracted with Et2O (3 x 30
mL). The combined organics were washed with brine (30 mL),
dried (MgSO4) and concentrated in vacuo to obtain a mixture of E-
and Z-isomers as a pale yellow oil (4.10 g, E:Z 65:35). Separation
of the E and Z isomers using column chromatography (2:1 Petrol:
Et2O) gave the trans-vinyl bromide 207 (1.97 g, 74%) as a
colourless oil. Rf 0.55 (2:1 Petrol: Et2O) [D]D29 -17.5 (c 0.83,
CHCl3); found C, 42.85%; H, 4.82% (C11H15BrO5 requires C,
43.02%; H, 4.92%); Qmax/cm-1 (thin film) 2989 (C-H), 2940 (C-H),
1746 (C=O), 1627 (C=C), 1611 (C=C), 1454, 1375; GH (270 MHz,
CDCl3) 6.51 (1H, dd, J 13.7 and 1.3, 6-H); 6.15 (1H, dd, J 13.7
and 6.1, 5-H), 5.93 (1H, d, J 3.7, 1-H), 5.20 (1H, dd, J 3.7 and
3.0, 3-H), 4.73 (1H, ddd, J 6.1, 3.0 and 1.3, 4-H), 4.56 (1H, dd, J
3.7 and 3.0, 2-H), 2.08 (3H, s, COCH3), 1.52 (3H, s, CH3), 1.32
(3H, s, CH3); GC (68 MHz, CDCl3) 169.7 (COCH3), 130.1 (5-CH),
112.3 (C(CH3)2), 110.8 (6-CH), 104.5 (1-CH), 83.4 (2-CH), 79.2
(4-CH), 76.8 (3-CH), 26.8 (CH3), 26.2 (CH3), 20.8 (COCH3).
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6-Z-Bromo-(5-deoxy-5-methylidene)-3-O-acetyloxy-1,2-O-
isopropylidene-D-D-xylofuranose 208
In the above procedure, further elution during
chromatography isolated cis-vinyl bromide 208
as a colourless solid (614 mg, 24%). Rf 0.43 (2:1 Petrol: Et2O);
m.p. 74-75 oC; [D]D26 -106 (c 1.02, CHCl3); Qmax/cm-1 (CHCl3) 2984
(C-H), 2938 (C-H), 1747 (C=O), 1631 (C=C), 1455, 1384, 1375;
GH (270 MHz, CDCl3) 6.42 (1H, dd, J 7.4 and 1.3, 6-H), 6.20 (1H,
dd, J 7.4 and 7.2, 5-H), 5.95 (1H, d, J 3.7, 1-H), 5.34 (1H, d, J 3.2
and 3.0, 3-H), 5.16 (1H, ddd, J 7.2, 3.2 and 1.3, 4-H), 4.55 (1H,
dd, J 3.7 and 3.2, 2-H), 2.07 (3H, s, COCH3), 1.52 (3H, s, CH3),
1.33 (3H, s, CH3); GC (68 MHz, CDCl3) 169.6 (COCH3), 128.8 (5-
CH), 112.4 (C(CH3)2), 111.8 (6-CH), 104.7 (1-CH), 83.6 (2-CH),
77.5 (4-CH), 77.0 (3-CH), 26.8 (CH3), 26.4 (CH3), 20.8 (COCH3);
m/z (ES+) 329.0003 (M+Na, C11H1579BrO5Na+ requires 329.0001),
330.9975 (M+Na, C11H1581BrO5Na+ requires 330.9980).
6-E-Bromo-(5-deoxy-5-methylidene)-3-O-acetyloxy-1,2-O-
isopropylidene-D-D-xylofuranose 207
Isomerism of Z-alkene 208. A solution of cis-
vinyl bromide 208 (2.95 g, 9.60 mmol) in CCl4
(100 mL) was degassed using a steady stream of
argon for 30 mins. Neat AIBN (158 mg, 960 Pmol) and NBS (1.70
g, 9.60 mmol) were then added and the reaction mixture was
heated to 80 oC for 2 hours. The solution was then cooled, filtered
through a sinter, eluting with further CCl4 (50 mL). The combined
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filtrates were washed sequentially with H2O (50 mL), saturated
NaHCO3 solution (50 mL) and brine (100 mL) then dried (MgSO4),
filtered and concentrated in vacuo to a yellow oil (E:Z ratio 11:7).
The isomers were separated by column chromatography (3:1
Petrol:Et2O) to obtain E-vinyl bromide 207 as a colourless oil (1.63
g, 55 %) and Z-vinyl bromide 208 as a white solid (37%).
Combined yield: 2.73 g (93%). Spectroscopic properties of the
product were identical to alkenes obtained from the Wittig reaction.
6-E-Bromo-(5-deoxy-5-methylidene)-1,2-O-isopropylidene-
D-D-xylofuranose 209
Solid K2CO3 (420 mg, 3.04 mmol) was added to
a stirred solution of acetate 207 (1.87g, 6.09
mmol) in dry MeOH (60 mL) and stirring was
maintained for 14 h. The solvent was evaporated in vacuo and the
residue extracted with CH2Cl2 (30 mL), dried (MgSO4) and the
extracts concentrated to give the alcohol 209 (1.44 g, 87%) as a
white solid. Rf 0.18 (2:1 Petrol: Et2O); m.p. 119-122 oC; [D]D29 -
69.7 (c 0.66, CHCl3); found C, 40.61%; H, 4.89% (C9H13BrO4
requires C, 40.78%; H, 4.94%); Qmax/cm-1 (solution, CHCl3) 3610
(O-H), 3578 (O-H), 2982 (C-H), 2937 (C-H), 2882 (C-H), 1626
(C=C), 1454, 1385, 1376; GH (400 MHz, CDCl3) 6.59 (1H, dd, J
13.7 and 1.5, 6-H), 6.29 (1H, dd, J 13.7 and 5.7, 5-H), 5.96 (1H,
d, J 3.7, 1-H), 4.68 (1H, ddd, J 5.7, 2.6 and 1.5, 4-H), 4.57 (1H,
d, J 3.7 and 3.2, 2-H), 4.15 (1H, app t, J 4.6, 3.2 and 2.6 3-H),
1.67 (1H, d, J 4.6, OH), 1.51 (3H, s, CH3), 1.33 (3H, s, CH3); GC
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(100 MHz, CDCl3) 130.5 (5-CH), 112.0 (C(CH3)2); 111.0 (6-CH),
104.5 (1-CH), 84.8 (2-CH), 80.4 (4-CH), 75.7 (3-CH), 26.7 (CH3),
26.1 (CH3).
6-E-Bromo-(5-deoxy-5-methylidene)-1,2-O-isopropylidene-
D-D-ribofuranose 210
Dess Martin periodinane160,161 (4.61 g, 10.9
mmol) was added to a stirred solution of alcohol
209 (1.44 g, 5.43 mmol) in dry CH2Cl2 (20 mL)
at r.t. under an argon atmosphere and stirring was maintained for
5 ¼ h then the reaction mixture was quenched with Na2S2O3
solution (10 mL) and saturated NaHCO3 (10 mL). After a further
15 minutes of stirring, the emulsion was extracted with Et2O (3 x
15 mL). The combined organics were dried (MgSO4) and
concentrated in vacuo to the ketone (1.69 g) as a white solid. The
crude ketone was dissolved in dry CH2Cl2 (25 mL) and dry MeOH
(7.0 mL) and cooled to 0 oC under an argon atmosphere. Solid
NaBH4 (1.31 g, 4.98 mmol) was added and the resulting solution
was stirred for 19 h before quenching with water (25 mL). The
aqueous phase was separated and re-extracted with Et2O (3 x 20
mL). The combined organics were washed with brine (2 x 20 mL),
dried (MgSO4) then concentrated to alcohol 210 (1.04 g, 79% over
2 steps) as a crystalline white solid. Rf 0.48 (1:3 Petrol: Et2O).
m.p. 118-121 oC; [D]D28 +39.5 (c 0.26, CHCl3); found C, 40.71%;
H, 4.91% (C9H13BrO4 requires C, 40.78%; H, 43.94); Qmax/cm-1
(CHCl3) 2985 (O-H), 2939 (O-H), 2872 (C-H), 1629 (C=C), 1456,
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1396, 1385, 1377; GH (400 MHz, CDCl3) 6.51 (1H, dd, J 13.7 and
1.1, 6-H), 6.28 (1H, dd, J 13.7 and 6.3, 5-H), 5.83 (1H, d, J 4.0,
1-H), 4.59 (1H, dd, J 5.0 and 4.0, 2-H), 4.15 (1H, ddd, J 8.5, 6.3
and 1.1, 4-H), 3.75 (1H, app dd, J ~8.5 and ~5.0, 3-H), 2.39 (1H,
br d, J 9.8, OH), 1.58 (3H, s, CH3), 1.38 (3H, s, CH3); GC (100 MHz,
CDCl3) 133.6 (5-CH), 112.9 (C(CH3)2), 109.7 (6-CH), 103.7 (1-
CH), 80.2 (4-CH), 78.2 (2-CH), 75.7 (3-CH), 26.5 (CH3), 26.4
(CH3).
6-E-Bromo-(5-deoxy-5-methylidene)-3-O-acetyloxy-1,2,3-
tri-O-acetyl-DE-D-ribofuranose 186D/E
A solution of alcohol 210 1.02 g, 3.85 mmol) in
70% (v/v) aqueous AcOH (64 mL) was heated at
reflux for 3 h then the solvent was removed by
co-evaporation with toluene (2 x 30 mL). The residue was
dissolved in dry pyridine (10 mL) then Ac2O (10.9 mL) was added
the resulting solution was stirred under an argon atmosphere at
r.t. for 3 h. The solvent was removed by co-evaporation with
toluene (3 x 25 mL) to orange oil (1.48 g, 3:1 mixture of
anomers). Purification by column chromatography yielded tri-
acetate 186 (1.11 g, 82%) as a colourless oil containing an
unseparated mixture of anomers. As a mixture of anomers: [D]D29
+5.1 (c 0.59, CHCl3); as a mixture of anomers: found C, 41.04%;
H, 4.28% (C12H15BrO7 requires C, 41.04%; H, 4.31%); Qmax/cm-1
(CHCl3) 2926 (C-H), 1751 (C=O), 1626 (C=C), 1451 (C-H, C-O),
1372 (C-H, C-O). Major anomer: Rf 0.30 (1:1 Pentane:Et2O); GH
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(400 MHz, CDCl3) 6.47 (1H, dd, J 13.6 and 1.1, 6-H), 6.25 (1H, dd,
J 13.6 and 7.0, 5-H), 6.16 (1H, d, J 1.0, 1-H), 5.33 (1H, dd, J 4.7
and 1.0, 2-H), 5.24 (1H, dd, J 7.0 and 4.7, 3-H), 4.57 (1H, app t, J
~7.0 and 1.1, 4-H), 2.13 (3H, s, COCH3), 2.12 (3H, s, COCH3),
2.09 (3H, s, COCH3); GC (100 MHz, CDCl3) 169.7 (2-CO), 169.4 (1-
CO), 169.1 (3-CO), 134.3 (5-CH), 110.8 (6-CH), 98.0 (1-CH), 81.3
(4-CH), 73.9 (2-CH), 73.3 (3-CH), 21.0 (3-COCH3), 20.5 (1-COCH3
and 2-COCH3). Minor anomer: Rf 0.18 (1:1 Pentane:Et2O); GH
(400 MHz, CDCl3) 6.50 (1H, dd, J 13.6 and 1.4, 6-H), 6.42 (1H, d,
J 4.6, 1-H), 6.27 (1H, dd, J 13.6 and 5.7, 5-H), 5.22 (1H, dd, J 6.6
and 4.6, 2-H), 5.08 (1H, dd, J 6.6 and 3.7, 3-H), 4.63 (1H, ddd, J
5.7, 3.7 and 1.4, 4-H), 2.12 (3H, s, COCH3), 2.10 (3H, s, COCH3),
2.07 (3H, s, COCH3); GC (100 MHz, CDCl3) 170.0 (2-CO), 169.5 (1-
CO), 169.3 (3-CO), 132.9 (5-CH), 110.4 (6-CH), 93.6 (1-CH), 82.8
(4-CH), 72.0 (3-CH), 69.3 (2-CH), 20.9 (3-COCH3), 20.5 (1-
COCH3) 20.2 (2-COCH3); as a mixture of anomers: m/z (ES+)
372.9897 (M+Na, C12H1579BrO7Na+ requires 372.9899), 374.9877
(M+Na, C12H1581BrO7Na+ requires 374.9878).
6-E-Bromo-(5-deoxy-5-methylidene)-3-(tert-butyldiphenyl-
silyl)-1,2-O-isopropylidene-D-D-xylofuranose 270
Imidazole (740 mg, 10.8 mmol) then TBDPSCl
(1.41 mL, 5.43 mmol) were added to a stirred
solution of alcohol 210 (1.20 g, 4.52 mmol) in
dry DMF (15 mL) under argon. The reaction mixture was stirred
for 23 ½ hours then quenched with water (15 mL) and extracted
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with Et2O (3 x 15 mL). The combined organics were washed with
brine (15 mL), dried (Na2SO4) the concentrated in vacuo to a
yellow solid. Following purification by column chromatography
(4:1 Petrol:Et2O), silyl ether 270 (2.27 g, 99%) was obtained as a
pale yellow syrup. Rf 0.63 (1:1 Petrol:Et2O); [D]D17 -7.75 (c 0.52,
CHCl3); Qmax/cm-1 (CHCl3) 2961 (C-H), 2932 (C-H), 2896 (C-H),
2859 (C-H), 1627 (C=C), 1463, 1384, 1375; GH (400 MHz, CDCl3)
7.50-7.36 (10H, m, ArH), 6.48 (1H, dd, J 13.6 and 0.9, 6-H), 6.00
(1H, dd, J 13.6 and 7.5, 5-H), 5.54 (1H, d, J 3.7, 1-H), 4.42 (1H,
ddd, J 8.7, 7.5 and 0.9, 4-H), 4.08 (1H, dd, J 4.4 and 3.7, 2-H),
3.62 (1H, dd, J 8.7 and 4.4, 3-H), 1.61 (3H, s, CH3), 1.29 (3H, s,
CH3), 1.10 (6H, s, 2 x CH3), 1.09 (3H, s, CH3); GC (100 MHz, CDCl3)
136.1 (Ar-CH), 136.0 (Ar-CH), 134.9 (5-CH), 134.7 (Ar-CH), 133.4
(Ar-C), 132.7 (Ar-C), 130.1 (Ar-CH), 130.0 (Ar-CH), 129.7 (Ar-
CH), 127.9 (Ar-CH), 127.8 (Ar-CH), 127.7 (Ar-CH), 127.6 (Ar-CH),
112.7 (C(CH3)2), 110.3 (6-CH), 103.6 (1-CH), 79.9 (4-CH), 78.6
(2-CH), 76.8 (3-CH), 26.8 (C(CH3)), 26.6 (C(CH3)), 26.4 (C(CH3)),
19.3 (SiC); m/z (ES+) 525.1073 (M+Na, C25H3179BrNaO4Si+
requires 525.1067), 527.1049 (M+Na, C25H3181BrNaO4Si+ requires
527.1052).
6-E-Bromo-(5-deoxy-5-methylidene)-3-(tert-butyldiphenyl-
silyl)-1,2 -bis-O-acetyl-DE-D-ribofuranose 212
A solution of 270 (925 mg, 1.84 mmol) in 70%
AcOH aq. v/v (30 mL) was heated at reflux for
2 ½ hours. The reaction mixture was then
O
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cooled to r.t. and co-evaporated with toluene (3 x 25 mL). The
residue was then dissolved in dry pyridine (50 mL), Ac2O (5.20 mL)
added and the reaction mixture was stirred at r.t. for 15 hours.
The reaction mixture was then concentrated in vacuo, co-
evaporating with toluene (5 x 10 mL) to yellow oil (4:1 mixture of
anomers). The residue was purified by column chromatography
(3:1 Petrol:Et2O) to obtain a 4:1 mixture of anomers the bis-
acetate 212 which were not separated as a pale yellow oil (857
mg, 86%). Rf 0.35 and 0.32 (3:1 Petrol:Et2O); as a 4:1 mixture of
anomers: [D]D21 -12.5 (c 1.33, CHCl3); as a mixture of anomers:
Qmax/cm-1 (CHCl3) 2957 (C-H), 2932 (C-H), 2895 (C-H), 2859 (C-
H), 1746 (C=O), 1626 (C=C), 1462, 1372; Major isomer: GH (400
MHz, CDCl3) 7.76-7.72 (2H, m, Ar-H), 7.76-7.65 (4H, m, Ar-H),
7.53-7.35 (6H, m, Ar-H), 6.23 (1H, dd, J 13.5 and 0.8, 6-H), 6.04
(1H, d, J 0.7, 1-H), 5.75 (1H, dd, J 13.5 and 5.6, 5-H), 4.86 (1H,
dd, J 4.6 and 0.7, 2-H), 4.46 (1H, ddd, J 6.8, 5.6 and 0.8, 4-H),
4.30 (1H, dd, J 6.8 and 4.6, 3-H), 2.16 (3H, s, COCH3), 2.00 (3H,
s, COCH3) 1.10 (9H, s, C(CH3)3); GC (100 MHz, CDCl3); 169.7 (CO),
169.1 (CO), 135.9 (Ar-CH), 135.8 (2 x Ar-CH), 135.2 (5-CH),
132.6 (Ar-C), 132.3 (Ar-C), 130.4 (Ar-CH), 129.7 (Ar-CH), 128.0
(Ar-CH), 127.9 (Ar-CH), 127.7 (Ar-CH), 110.4 (6-CH), 97.8 (1-
CH), 84.0 (4-CH), 75.3 (2-CH), 74.6 (3-CH), 34.2, 26.9 (CCH3),
26.8 (CCH3), 26.6 (CCH3), 21.1 (COCH3), 21.0 (COCH3), 19.2
(SiC(CH3)); Minor isomer: GH (400 MHz, CDCl3) 7.76-7.72 (2H, m,
Ar-H), 7.76-7.65 (4H, m, Ar-H), 7.53-7.35 (6H, m, Ar-H), 6.37
(1H, d, J 4.5, 1-H), 6.07 (1H, dd, J 13.6 and 1.3, 6-H), 5.68 (1H,
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dd, J 13.6 and 6.6, 5-H), 4.91 (1H, dd, J 5.6 and 4.5, 2-H), 4.53
(1H, ddd, J 6.6, 3.5 and 1.3, 4-H), 4.20 (1H, dd, J 5.6 and 3.5, 3-
H), 2.17 (3H, s, COCH3), 2.07 (3H, s, COCH3), 1.13 (9H, s,
C(CH3)3); GC (100 MHz, CDCl3) 169.7 (CO), 169.1 (CO), 135.9 (Ar-
CH), 135.8 (Ar-CH), 135.3 (Ar-CH), 132.6 (Ar-CH), 132.3 (Ar-CH),
128.0 (2 x Ar-CH), 134.8 (5-CH), 133.6 (Ar-C), 133.0 (Ar-C),
127.9 (Ar-CH), 109.9 (6-CH), 93.9 (1-CH), 85.7 (4-CH), 73.4 (3-
CH), 71.2 (2-CH), 26.9 (CCH3), 26.8 (CCH3), 26.6 (CCH3), 20.8
(COCH3), 20.5 (COCH3), 19.0 (SiC(CH3)); m/z (ES+) 569.0941
(M+Na, C26H3179BrNaO6Si+ requires 569.0965), 571.0915 (M+Na,
C26H3181BrNaO6Si+ requires 571.0951).
6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaphthyl)-
1,2-O-isopropylidene-D-D-xylofuranose 160
Solid 2-(Bromomethyl)naphthalene (1.05 g,
4.75 mmol), KOH (400 mg, 7.13 mmol) and
18-crown-6 (42 mg, 158 Pmol) were added to
a stirring solution of 210 (1.05 g, 3.96 mmol) in dry THF (7.9 mL)
at r.t. under an argon atmosphere. Stirring was maintained for 16
hours, then water (10 mL) was added and the mixture was
extracted with Et2O (3 x 6 mL). The combined organics were
washed with brine (10 mL), dried (Na2SO4), and concentrated to
yellow syrup. Purification by column chromatography (3:1
Petrol:Et2O) yielded the naphthyl ether 160 (1.57 g, 98%) as a
colourless oil. Rf 0.30 (3:1 Petrol:Et2O); [D]D23 +10.6 (c 1.23,
CHCl3); Qmax/cm-1 (thin film) 2986 (C-H), 2936 (C-H), 2899 (C-H),
O
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2973 (C-H), 1627 (C=C), 1497 (C=C), 1455, 1381, 1372; GH (400
MHz, CDCl3) 7.89-7.85 (3H, m, Ar-H), 7.82 (1H, s, 1-Ar-H), 7.52-
7.48 (3H, m, Ar-H), 6.52 (1H, dd, J 13.7 and 1.1), 6.18 (1H, dd, J
13.7 and 6.8, 5-H), 5.72 (1H, d, J 3.7, 1-H), 4.93 (1H, d, J 12.4,
CHH), 4.78 (1H, J 12.4, CHH), 4.58 (1H, dd, J 4.2 and 3.7, 2-H),
4.50 (1H, ddd, J 8.9, 6.8 and 1.1, 4-H), 3.56 (1H, dd, J 8.9 and
4.2, 3-H), 1.63 (3H, s, CH3), 1.37 (3H, s, CH3); GC (100 MHz,
CDCl3) 134.9 (2-Ar-C), 134.5 (5-CH), 133.5 (Ar-C), 133.4 (Ar-C),
128.8 (Ar-CH), 128.3 (Ar-CH), 128.1 (Ar-CH), 127.3 (1-Ar-CH),
126.6 (Ar-CH), 126.5 (Ar-CH), 126.1 (Ar-CH), 113.5 (C(CH3)2),
110.4 (6-CH), 104.1 (1-CH), 81.6 (3-CH), 78.5 (4-CH), 77.6 (2-
CH), 72.0 (CH2), 27.1 (CH3), 26.8 (CH3); m/z (ES+) 427.0502
(M+Na, C20H2179BrNaO4+ requires 427.0521), 429.0483 (M+Na,
C20H2181BrNaO4+ requires 429.0500.
6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaphthyl)-
1,2-bis-O-acetyl-DE-D-ribofuranose 218
A solution of acetonide 160 (1.51 g, 3.73
mmol) in 70% v/v AcOH (60 mL) was heated at
reflux for 4 ½ hours then cooled and co-
evaporated with toluene (3 x 25 mL). The resulting residue was
dissolved in dry pyridine (12.2 mL, 123 mmol) and stirred at r.t.
under an argon atmosphere. Neat Ac2O (10.6 mL, 112 mmol) was
added and stirring maintained for 16 hours. The reaction mixture
was then diluted with water (15 mL) and extracted with Et2O (3 x
15 mL). The combined organics were washed sequentially with
O
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aqueous CuSO4 (20% w/v) solution (2 x 15 mL), brine (2 x 15
mL), dried (Na2SO4) and concentrated in vacuo. Purification by
column chromatography gave bis-acetate 218 (1.42 g, 85%) as a
colourless oil as a 9:1 mixture of anomers. Major anomer: Rf
0.20 (3:1 Petrol:Et2O); [D]D29 +34.5 (c 0.95, CHCl3); Qmax/cm-1
(CHCl3) 2977 (C-H), 2923 (C-H), 2875 (C-H), 1746 (C=O), 1626
(C=C), 1455, 1372; GH (400 MHz, CDCl3) 7.88-7.85 (3H, m, Ar-H),
7.66 (1H, s, 1-Ar-H), 7.52-7.50 (2H, m, Ar-H), 7.41 (1H, dd, J 8.4
and 1.4, Ar-H), 6.46 (1H, dd, J 13.6 and 0.7, 6-H), 6.18 (1H, dd, J
13.6 and 7.4, 5-H), 6.16 (1H, app s, 1-H), 5.35 (1H, app d, J
~4.4, 2-H), 4.82 (1H, d, J 12.0, CHH), 4.66 (1H, d, J 12.0, CHH),
4.51 (1H, dd, J 7.9, 7.4 and 0.7, 4-H), 4.07 (1H, dd J 7.9 and 4.4,
3-H), 2.17 (3H, s, 2-COCH3), 2.07 (3H, s, COCH3); GC (100 MHz,
CDCl3) 169.9 (2-CO), 169.0 (1-CO), 135.4 (5-CH), 134.5 (Ar-C),
133.2 (2-Ar-C), 128.5 (Ar-CH), 128.0 (Ar-CH), 127.9 (Ar-C), 127.8
(Ar-CH), 126.8 (Ar-CH), 126.4 (Ar-CH), 126.3 (Ar-CH), 125.6 (Ar-
CH), 110.2 (6-CH), 98.4 (1-CH), 81.9 (4-CH), 79.9 (3-CH), 73.3
(2-CH), 73.3 (CH2), 21.1 (1-COCH3), 20.8 (2-COCH3); Minor
anomer: Rf (3:1 Petrol:Et2O) 0.11; [D]D29 +59.4 (c 0.94, CHCl3);
Qmax/cm-1 (CHCl3) 2985 (C-H), 2923 (C-H), 2873 (C-H), 1747
(C=O), 1627 (C=C), 1602 (C=C), 1455, 1374; GH (400 MHz,
CDCl3) 7.88 -7.83 (3H, m, Ar-H), 7.76 (1H, s, 1-Ar-H), 7.52-7.49
(2H, m, Ar-H), 7.43 (1H, dd, J 8.4 and 1.6, Ar-H), 6.38 (1H, dd, J
13.6 and 1.1, 6-H), 6.39 (1H, d, J 4.6, 1-H), 6.06 (1H, dd, J 13.6
and 6.8, 5-H), 5.23 (1H, dd, J 6.2 and 4.6, 2-H), 4.82 (1H, d, J
12.1, CHH), 4.67 (1H, d, J 12.1, CHH), 4.58 (1H, ddd, J 6.8, 6.3
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and 1.1, 4-H), 3.93 (1H, app dd, J 6.3 and 6.2, 3-H), 2.16 (3H, s,
COCH3), 2.15 (3H, s, COCH3); GC (100 MHz, CDCl3) 170.0 (CO),
169.7 (CO), 135.5 (5-CH), 134.6 (Ar-C), 133.2 (Ar-C), 128.5 (Ar-
CH), 127.9 (Ar-CH), 127.8 (Ar-CH), 126.8 (Ar-CH), 126.4 (Ar-CH),
126.3 (Ar-CH), 125.7 (Ar-CH), 110.6 (6-CH), 94.2 (1-CH), 82.7
(4-CH), 78.5 (3-CH), 73.5 (CH2), 70.3 (2-CH), 21.1 (1-COCH3),
20.6 (2-COCH3); as a mixture of anomers: m/z (ES+) 471.0419
(M+Na, C21H2179BrNaO6+ requires 471.0414), 473.0390 (M+Na,
C21H2181BrNaO6+ requires 473.0399).
4.3 Vinyl Bromide Nucleosides
4.3.1 First Generation Nucleosides
6-E-bromo-(5-deoxy-5-methylidene)-3-O-benzyloxy-2-
acetoxy uridine 166
Neat BSA (2.17 mL, 8.79 mmol) was added to a
stirred suspension of the mixture of anomers of
bis-acetate 165 (1.17 g, 2.93 mmol) and uracil
(985 mg, 8.79 mmol) in dry MeCN (50 mL). The
reaction mixture was heated at 65 oC for 90 minutes then TMSOTf
(670 PL, 4.34 mmol) was added. Stirring was maintained for a
further 16 hours, the mixture was then cooled, diluted with CH2Cl2
(30 mL) and extracted with saturated NaHCO3 (20 mL). The
organic portion was separated and dried (MgSO4) and evaporated
to a crude oil. Flash column chromatography (3:2 EtOAc/Petrol)
yielded uridine 166 as a white solid (1.16 g, 85%). Rf 0.24 (3:2
EtOAc:Petrol); m.p. 76-78 oC; [D]D27 +71.9 (c 0.52 in CHCl3);
O
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found C, 50.28%; H, 4.14%; N, 5.94%; (C19H19BrN2O6 requires C
50.57%, H 4.14%, N 5.94%); Qmax/cm-1 (CHCl3) 3694 (N-H), 3399
(N-H), 1744 (C=O), 1722 (C=O), 1716 (C=O), 1697 (C=O), 1629
(N-H), 1603 (N-H), 1455 (C=C), 1375; GH (400 MHz, CDCl3) 9.28
(1H, br s, NH), 7.39-7.29 (5H, m, ArH), 7.18 (1H, d, J 8.1, 6-H),
6.49 (1H, dd, J 13.6 and 0.9, 6-H), 6.22 (1H, dd, J 13.6 and 7.1,
5-H), 5.77 (1H, dd, J 8.1 and 2.1, 5-H), 5.68 (1H, d, J 2.7, 1-H),
5.45 (1H, dd, J 5.8 and 2.7, 2-H), 4.62 (1H, d, J 11.5, CHH), 4.49
(1H, d, J 11.5, CHH), 4.38 (1H, ddd, J 7.1, 1.6 and 1.0, 4-H), 4.13
(1H, dd, J 5.8 and 1.6, 3-H), 2.14 (3H, s, COCH3); GC (100 MHz,
CDCl3) 170.0 (2-COCH3), 163.6 (2-CO), 149.9 (4-CO), 141.1 (6-
CH), 136.9 (Ar-C), 133.5 (5-CH), 128.8 (2 x Ar-CH), 128.5 (Ar-
CH), 128.3 (2 x Ar-CH), 111.4 (6-CH), 103.0 (5-CH), 91.6 (1-
CH), 81.9 (4-CH), 79.1 (3-CH), 73.9 (CH2), 73.6 (2-CH), 20.9
(2-COCH3); m/z (ES+) 473.0345 (M+Na, C19H1979BrN2O6Na+
requires 473.0324), 475.0292 (M+Na, C19H1981BrN2O6Na+ requires
475.0304).
6-E-bromo-(5-deoxy-5-methylidene)-3-O-benzyloxy uridine
271
Solid K2CO3 (1.12 g, 2.40 mmol) was added to a
stirred solution of uridine 166 (347 mg, 2.52
mmol) in MeOH (24 mL) at r.t. Stirring was
maintained for 90 minutes then MeOH was
removed by evaporation and the residue was taken up in CH2Cl2
(10 mL) and washed with water (10 mL). The organic portion was
O
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dried (Na2SO4) and evaporated to the crude alcohol 271 as white
foam (930 mg, 95%). The alcohol 217 was used directly without
further purification. Rf 0.10 (neat Et2O); m.p. 76-78 oC; [D]D31 -
66.0 (c 0.67, CHCl3); Qmax/cm-1 (CHCl3) 3390 (O-H), 2925 (C-H),
1727 (C=O), 1698 (C=O), 1634 (N-H, C=C), 1611 (C-N, N-H),
1455 (C=C), 1381, 1093 (O-H); GH (270 MHz, CDCl3) 9.97 (1H, br
s, NH), 7.38-7.31 (5H, m, Ar-H), 7.24 (1H, d, J 8.0, 6-CH), 6.46
(1H, dd, J 13.6 and 0.8, 6-H), 6.24 (1H, dd, J 13.6 and 6.6, 5-H),
5.74 (1H, d, J 8.0, 5-CH), 5.67 (1H, d, J 3.2, 1-H), 4.72 (1H, d, J
11.8, CHH), 4.63 (1H, d, J 11.8, CHH), 4.45 (1H, app t, J 6.9 and
6.6, 4-H), 4.38 (1H, ddd, J 6.5, 4.7 and 3.2, 2-H), 4.05 (1H, dd, J
6.9 and 6.5, 3-H), 3.78 (1H, d, J 4.7, 2-OH); GC (100 MHz, d4-
MeOD) 178.6 (4-CO), 161.3 (2-CO), 141.5 (6-CH), 140.0 (Ar-C),
137.3 (5-CH), 130.3 (2 x Ar-CH), 130.1 (2 x Ar-CH), 129.8 (Ar-
CH), 111.9 (6-CH), 104.6 (5-CH), 94.0 (1-CH), 83.5 (4-CH), 82.4
(3-CH), 74.9 (2-CH), 74.4 (CH2); m/z (ES+) 431.0182 (M+Na,
C17H1779BrN2O5Na+ requires 431.0219), 433.0188 (M+Na,
C17H1781BrN2O5Na+ requires 433.0198).
E-6-Bromo-(5-deoxy-5-methylidene)-3-O-benzyl-2-(tert-
butyldimethylsilyl)uridine 167
Imidazole (72 mg) and TBSCl (83 mg) were
added to a stirred solution of alcohol 271 (180
mg) in dry DMF (1.7 mL) at r.t. under an argon
atmosphere for 18 hours. The reaction mixture
was quenched with saturated aqueous NaHCO3 solution (5 mL) and
O
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was extracted with Et2O (3 x 3 mL). The ethereal extracts were
washed with water (5 mL), dried (Na2SO4) and evaporated to a
crude white solid. Uridine 167 was triturated in Et2O, filtered and
dried to a white powder (146 mg, 66%). Rf 0.52 (3:2
EtOAc:Petrol); m.p. 128-130 oC; [D]D29 +91.1 (c 0.25, CHCl3);
found C, 52.55%; H, 5.88%; N, 5.21% (C23H31BrN2O5Si requires C
52.77%, H 5.97%, N 5.35%); Qmax/cm-1 (CHCl3) 3390 (N-H), 2954
(C-H), 2931 (C-H), 2859 (C-H), 1694 (C=O), 1627 (N-H, C=C),
1455 (C=C), 1390, 1362; GH (400 MHz, CDCl3) 7.40-7.30 (5H, m,
Ar-CH), 7.27 (1H, d, J 8.1, 6-H), 6.53 (1H, dd, J 13.6, 1.0, 6-H),
6.27 (1H, dd, J 13.6, 7.2, 5-H), 5.76 (1H, d, J 8.1, 5-H), 5.67 (1H,
d, J 2.7, 1-H), 4.72 (1H, d, J 11.8, CHH), 4.60 (1H, ddd, J 7.2, 7.0
and 1.0, 4-H), 4.48 (1H, d, J 11.8, CHH), 4.43 (1H, dd, J 4.4, 2.7,
2-H), 3.65 (1H, dd, J 7.0, 4.4, 3-H), 0.92 (9H, s, C(CH3)3), 0.15
(3H, s, Si(CH3)), 0.12 (3H, s, Si(CH3)); GC (100 MHz, CDCl3) 163.2
(4-CO), 149.9 (2-CO), 139.8 (6-CH), 138.1 (Ar-C), 137.0 (5-CH),
128.6 (2 x Ar-CH), 128.2 (Ar-CH), 127.7 (2 x Ar-CH), 111.2 (6-
CH), 102.4 (5-CH), 92.6 (1-CH), 81.6 (4-CH), 80.1 (3-CH), 73.7
(2-CH), 72.7 (CH2), 25.66 (C(CH3)3), 18.1 (SiC), -4.7 (SiCH3), -
5.0 (SiCH3); m/z (ES+) 523.1267 (M+H, C23H3279BrN2O5Si+
requires 523.1264), 525.1178 (M+H, C23H3281BrN2O5Si+ requires
525.1243), 545.1079 (M+Na, C23H3179BrN2O5SiNa+ requires
545.1083), 547.0923 (M+Na, C23H3181BrN2O5SiNa+ requires
547.1063).
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4.3.2 Second Generation Nucleosides
4.3.2.1 Vinyl Bromide Uridines
6-E-Bromo-(5-deoxy-5-methylidene)-3-O-acetyl-2-O-
acetyl uridine 211
Uracil (747 mg, 6.66 mmol) was added to a
stirring solution of triacetate 186 (780 mg, 2.22
mmol) in dry MeCN (37 mL) at r.t. under an
argon atmosphere. Neat BSA (1.65 mL, 6.66
mmol) was added and the reaction mixture was heated at 60-65 oC
for 40 minutes then TMSOTf (508 PL, 3.29 mmol) was added and
stirring was maintained for 3 ½ h. The reaction mixture was
cooled to r.t. then diluted with CH2Cl2 (40 mL) then washed with
NaHCO3 solution (20 mL). The organic phase was dried (Na2SO4)
then concentrated in vacuo to a yellow glass (1.21 g). Uridine 211
was obtained as a colourless syrupy foam (892 mg, 99%) following
column chromatography (3:2 EtOAc:Petrol). Rf 0.16 (3:2
EtOAc:Petrol). [D]D31 +4.05 (c 0.59, CHCl3); found C, 40.92; H,
3.65; N 6.66% (C15H16N2BrO6 requires C, 41.71; H, 3.75; N,
6.95%); Qmax/cm-1 (CHCl3) 3610 (N-H), 3385 (N-H), 2923 (C-H),
2851 (C-H), 1749 (C=O), 1723 (C=O), 1698 (C=O), 1631 (N-H,
C=C), 1602 (C=C), 1456, 1376; GH (400 MHz, CDCl3) 9.27 (1H, br
s, NH), 7.23 (1H, d, J 8.1, 6-H), 6.57 (1H, dd, J 13.7 and 1.1, 6-
H), 6.36 (1H, dd, J 13.7 and 6.9, 5-H), 5.85 (1H, d, J 4.5, 1-H),
5.82 (1H, dd, J 8.1 and 2.0, 5-H), 5.41 (1H, dd, J 6.0 and 4.5, 2-
H), 5.26 (1H, app t, J 6.0, 3-H), 4.51 (1H, ddd, J 6.9, 6.0 and 1.1,
4-H), 2.13 (3H, s, COCH3), 2.12 (3H, s, COCH3); GC (100 MHz,
O N
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CDCl3) 169.7 (2-CO), 169.6 (3-CO), 162.9 (4-CO), 150.1 (2-CO),
140.3 (6-CH), 132.7 (5-CH), 112.0 (6-CH), 103.5 (5-CH), 89.4
(1-CH), 81.4 (4-CH), 72.7 (2-CH), 72.6 (3-CH) 20.6 (2-COCH3),
20.5 (3-COCH3); m/z (ES+) 424.9980 (M+Na, C15H16N279BrO6Na+
requires 424.9955), 426.9961 (M+Na, C15H16N281BrO6Na+ requires
426.9940).
6-E-Bromo-(5-deoxy-5-methylidene)-3-(tert-
butyldiphenyl-silyl)-2-O-acetyl uridine 213
Uracil (491 mg, 4.38 mmol) then BSA (1.08
mL, 4.38 mmol) were added to a stirred
solution of bis-actate 212 (800 mg, 1.46
mmol) in dry MeCN (25 mL) under an argon
atmosphere. The resulting suspension was heated at 65 oC for 1 ½
hours then TMSOTf (0.33 mL) was added and stirring maintained
for a further 19 hours. The reaction mixture was cooled to r.t.,
diluted with CH2Cl2 (25 mL) and washed with saturated NaHCO3
solution (25 mL) then brine (25 mL). The organic phase was dried
(Na2SO4) and concentrated in vacuo to white syrupy foam 213
(732 mg, 84%). Rf 0.38 (8:1 Et2O:Petrol); [D]D20 +5.76 (c 0.63,
CHCl3); Qmax/cm-1 (CHCl3) 3389 (N-H), 2960 (C-H), 2933 (C-H),
2898 (C-H), 2860 (C-H), 1743 (C=O), 1722 (C=O), 1697 (C=O),
1633 (N-H, C=C), 1456, 1375; GH (400 MHz, CDCl3) 7.67-7.62 (4H,
m, Ar-H), 7.49-7.38 (6H, m, Ar-H), 7.02 (1H, d, J 8.0, 6-CH), 6.19
(1H, dd, J 13.6 and 0.5, 6-H), 5.89 (1H, dd, J 13.6 and 7.3, 5-H),
5.79 (1H, d, J 4.4, 1-H), 5.71 (1H, d, J 8.0, 5-CH), 4.89 (1H, app
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ddd, J 4.4, ~2.6 and ~2.1, 2-H), 4.34 (2H, m, 3-H and 4-H),
2.07 (3H, s, COCH3), 1.11 (9H, s, C(CH3)3); GC (100 MHz, CDCl3)
170.1 (COCH3), 162.9 (4-CO), 149.8 (2-CO), 140.5 (6-CH), 135.9
(2 x Ar-CH), 135.8 (2 x Ar-CH), 133.4 (5-CH), 132.6 (Ar-C), 132.4
(Ar-C), 130.5 (Ar-CH), 130.4 (Ar-CH), 128.1 (2 x Ar-CH), 128.0 (2
x Ar-CH), 111.6 (6-CH), 103.1 (5-CH), 89.9 (1-CH), 84.2 (4-CH),
77.3 (3-CH), 74.0 (2-CH), 26.8 (3 x SiC(CH3)3), 20.8 (2-COCH3)
19.3 (SiC(CH3)3); m/z (ES+) 599.1195 (M+H, C28H3279BrN2O6Si+
requires 599.1213), 601.1163 (M+H, C28H3281BrN2O6Si+ requires
601.1193).
6-E-Bromo-(5-deoxy-5-methylidene)-3-(tert-
butyldiphenylsilyl) uridine 214
Method A. Solid K2CO3 (8 mg, 60 Pmol) was
added to a stirred solution of 213 (72 mg, 120
Pmol) in MeOH (1.2 mL). The reaction
mixture was stirred at r.t. for 21 hours then
neutralised with 1N HCl, diluted with CH2Cl2 then concentrated in
vacuo to give a 1:1 mixture of regioisomers 214 and 215.
Purification by column chromatography (98:2 CHCl3:MeOH) was
then used to separate the two isomers which re-equilibrated to a
7:3 ratio of 2-OH and 3-OH isomers 214 and 215 respectively.
The alcohol 214 co-elutes with the residual starting material
acetate 213 if any is present.
Method B: To a solution of acetate 213 (200 mg, 333 Pmol) in dry
methanol (1.60 mL) was added NaOMe (17.5 mg, 324 Pmol). The
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resulting suspension was stirred at r.t. for 6 hours and was then
neutralised by the addition of saturated NH4Cl solution (1 mL).
The aqueous layer was re-extracted with CH2Cl2 (3 x 1 mL) and the
The combined organics were then washed with brine (1 mL), dried
(Na2SO4), filtered and evaporated to a white solid (171 mg) of a
1:1:1 ratio of acetate 213 starting material, and the 2-OH 214
and 3-OH 215 products. Purification by column chromatography
(98:2 CHCl3:MeOH) allowed partial separation of products. Alcohol
214, the major isomer, was obtained as a 1:1 mixture of 214 and
starting material 213 (79 mg, 29 20%, 30 20% (26% borsm) as a
white solid), m.p. 83-85 oC. Rf 0.50 (9:1 CHCl3:MeOH); Mixture of
isomers [D]D23 +23.9 (c 0.54, CHCl3); Qmax/cm-1 (CHCl3) 3386 (N-
H), 2949 (C-H), 2932 (C-H), 2859 (C-H), 1745 (C=O), 1718
(C=O), 1697 (C=O), 1631 (C=C), 1457, 1388, 1365, 1349; GH
(400 MHz, CDCl3) 9.27 (1H, br s, NH), 7.10 (1H, d, J 8.1, 6-CH),
6.11 (1H, d, J 13.6, 6-H), 5.74 (1H, dd, J 13.6 and 7.8, 5-H),
5.70 (2H, m, 1-H and 5-CH), 4.29 (1H, dd, J 7.8 and 5.5, 4-H),
4.22 (1H, dd, J 5.5 and 5.3, 3-H), 4.03 (1H, ddd, J 5.3, 4.5 and
3.9, 2-H), 3.24 (1H, br s, 2-OH), 1.14 (9H, s, C(CH3)3); GC (100
MHz, CDCl3) 163.1 (4-CO), 150.1 (2-CO), 140.6 (6-CH), 136.0 (Ar-
CH), 135.9 (Ar-CH), 135.7 (Ar-CH), 133.3 (5-CH), 132.1 (Ar-C),
131.8 (Ar-C), 130.8 (Ar-CH), 130.7 (Ar-CH), 130.6 (Ar-CH), 128.3
(2 x Ar-CH), 128.2 (2 x Ar-CH), 111.4 (6-CH), 102.8 (5-CH), 92.1
(1-CH), 83.9 (4-CH), 76.5 (3-CH), 75.0 (2-CH), 27.0 (3 x
SiC(CH3)), 19.2 (SiC(CH3)3); m/z (ES+) 579.0926 (M+Na,
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C26H2979BrN2NaO5Si+ requires 579.0921), 581.0894 (M+Na,
C26H2981BrN2NaO5Si+ requires 581.0906).
6-E-Bromo-(5-deoxy-5-methylidene)-2-(tert-
butyldiphenylsilyl) uridine 215
Method B: Using the above method B, alcohol
215, the minor isomer was obtained as white
solid (36.4 mg, 20%), m.p. 100-102 oC. Rf
0.59 (9:1 CHCl3:MeOH); [D]D25 32.4 (c 0.98,
CHCl3); Qmax/cm-1 (CHCl3) 3538 (N-H), 3390 (N-H), 2953 (C-H),
2932 (C-H), 2887 (C-H), 2860 (C-H), 1721 (C=O), 1697 (C=O),
1632 (C=C), 1456, 1391, 1382, 1364; GH (400 MHz, CDCl3) 9.05
(1H, br s, NH), 7.74-7.35 (10H, m, 10 x ArH), 6.46 (1H, dd, J 13.7
and 1.0, 6-H), 6.40 (1H, d, J 8.0, 6-CH), 6.29 (1H, dd, J 13.7 and
6.0, 5-H), 5.48 (1H, d, J 4.4, 1-H), 5.38 (1H, dd, J 8.0 and 2.1,
5-CH), 4.55 (1H, dd, J 5.8 and 4.4, 2-H), 4.34 (1H, ddd, J 6.0,
5.9, and 1.0, 4-H), 4.15 (1H, dd J 6.2, 5.9 and 5.8, 3-H), 2.99
(1H, d, J 6.2, 3-OH), 1.12 (9H, s, C(CH3)3); GC (125 MHz, CDCl3)
162.4 (4-CO), 149.2 (2-CO), 141.0 (6-CH), 135.8 (2 x Ar-CH),
135.6 (2 x Ar-CH), 133.9 (5-CH), 131.9 (Ar-C), 131.5 (Ar-C),
130.8 (Ar-CH), 130.7 (Ar-CH), 129.7 (Ar-CH), 128.4 (Ar-CH),
128.3 (Ar-CH), 127.8 (Ar-CH), 127.7 (Ar-CH), 110.4 (6-CH),
102.7 (5-CH), 92.7 (1-CH), 84.2 (4-CH), 74.0 (3-CH), 73.6 (2-
CH), 27.0 (3 x SiC(CH3)), 19.3 (SiC(CH3)3); m/z (ES+) 557.1079
(M+H, C26H3079BrN2O5Si+ requires 557.1107), 579.0911 (M+Na,
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C26H2979BrN2NaO5Si+ requires 579.0921), 581.0905 (M+Na,
C26H2981BrN2NaO5Si+ requires 581.0906).
6-E-Bromo-(5-deoxy-5-methylidene)-3-O-acetyl uridine
216
6-E-Bromo-(5-deoxy-5-methylidene)-2-O-acetyl uridine
217
Method 1. Glacial AcOH
(21 PL, 368 Pmol) and 1M
TBAF in THF (184 PL, 184
Pmol) were added to a
stirred solution of 213 (92 mg, 153 Pmol) in dry THF (770 PL).
The reaction mixture was stirred under an argon atmosphere for 1
¼ hour and was then quenched with water (1 mL) then extracted
with Et2O (3 x 1 mL). The combined organics were washed with
brine (1 mL), dried (Na2SO4) and evaporated to yellow oil which
was purified by column chromatography (9:1 CHCl3:Petrol Æ
18:1:1 CHCl3:Petrol:MeOH) to a yellow syrup containing an
inseparable 2:1 mixture of 216 and 217 respectively (30.6
mg, 55%).
Method 2: Glacial AcOH (18.5 PL, 320 Pmol) and 1M TBAF in THF
(160 PL, 160Pmol) were added to a stirred solution of 213 (80
mg, 133 Pmol) in dry THF (650 PL) under an argon atmsphere.
Stirring at r.t. was maintained for 1 ½ hours then SiO2 was added
and the reaction mixture evaporated and purified by column
chromatography (9:1 CHCl3:Petrol then 18:1:1
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CHCl3:Petrol:MeOH). Acetates 216 and 217 were obtained in a
2:1 ratio respectively as a white solid (45.4 mg, 94%), as a
mixture of isomers: m.p. 80-82 oC. Rf 0.05 (8:1 Et2O:Petrol); as a
mixture of isomers: [D]D23 +31.8 (c 0.36, CHCl3); as a mixture of
isomers: Qmax/cm-1 (CHCl3) 3588 (N-H), 3389 (N-H), 2938 (C-O),
1742 (C=O), 1716 (C=O), 1697 (C=O), 1628 (C=C), 1456, 1377;
Major Isomer (3-OAc, 217): GH (400 MHz, CDCl3) 10.22 (1H, br
s, NH), 7.38 (1H, d, J 8.1, 6-H), 6.58 (1H, dd, J 13.7 and 0.9, 6-
H), 6.34 (1H, dd, J 13.7 and 7.1, 5-H), 5.82(1H, d, J 4.4, 1-H),
5.80 (1H, d, J 8.1, 5-H), 4.93 (1H, dd, J 5.7 and 5.3, 3-H), 4.60
(1H, ddd, J 7.1, 5.7 and 0.9, 4-H), 4.52 (1H, app dd, J ~5.7 and
~4.4, 2-H), 2.17 (3H, s, COCH3); GC (100 MHz, CDCl3) 170.6
(COCH3), 163.9 (NCO), 151.0 (CHCO), 140.0 (6-CH), 133.9 (5-H),
111.8 (6-CH), 103.1 (5-CH), 91.1 (1-CH), 81.3 (4-CH), 74.5 (3-
CH), 72.7 (2-CH), 20.8 (COCH3); Minor Isomer (2-OAc, 216): GH
(400 MHz, CDCl3) 9.94 (1H, br s, NH), 7.29 (1H, d, J 8.1, 6-CH),
6.56 (1H, dd, J 13.7 and 0.8, 6-H), 6.37 (1H, dd, J 13.7 and 7.7,
5-H), 5.78 (1H, d, J 8.1, 5-CH), 5.72 (1H, d, J 2.8, 1-H), 5.35
(1H, dd, J 5.7 and 2.8, 2-H), 4.39 (1H, app dd, J ~7.2 and ~5.7,
3-H), 4.33 (1H, ddd, J 7.7, 7.2 and 0.8, 4-H), 2.16 (3H, s,
COCH3); GC (100 MHz, CDCl3) 170.8 (COCH3), 163.9 (4-CO), 150.3
(2-CO), 141.3 (6-CH), 133.6 (5-CH), 111.3 (6-CH), 103.0 (5-CH),
90.6 (1-CH), 83.0 (4-CH), 75.3 (2-CH), 72.4 (3-CH), 20.8
(COCH3); as a mixture of isomers: m/z (ES+) 361.0035 (M+H,
C12H1479BrN2O6+ requires 361.0035), 363.0020 (M+H,
C12H1481BrN2O6+ requires 363.0015), 382.9854 (M+Na,
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C12H1379BrN2O6Na+ requires 382.9848), 384.9834 (M+Na,
C12H1381BrN2O6Na+ requires 384.9834.
6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaph-
thyl)-2-O-acetyl uridine 219
Uracil (920 mg, 8.21 mmol) and BSA (2.03
mL, 8.21 mmol) were added to a stirred
solution of bis-acetate 218 (1.23 g, 2.74
mmol) in dry MeCN (45 mL). The resulting
suspension was heated to 65 oC and maintained at this
temperature with stirring for 17 hours. The reaction mixture was
then cooled to r.t., diluted with CH2Cl2 (40 mL) and quenched with
a saturated solution of NaHCO3 (45 mL). The organic phase was
separated, washed with brine (45 mL), dried (Na2SO4) then filtered
and concentrated to a yellow foam. Purification by column
chromatography (9:1:1 CHCl3:MeOH:Petrol) produced 219 as a
white foam (1.10 g, 83%). m.p. 84-86 oC, Rf 0.24 (98:2
CH2Cl2:MeOH); [D]D25 +84.1 (c 1.36, CHCl3); Qmax/cm-1 (CHCl3)
3387 (N-H), 3182 (N-H), 3118 (C-H), 2933 (C-H), 2879 (C-H),
1744 (C=O), 1723 (C=O), 1713 (C=O), 1694 (C=O), 1631 (C=C),
1455, 1375; GH (400 MHz, CDCl3) 8.74 (1H, br s, NH), 7.87-7.84
(3H, m, Ar-H), 7.75 (1H, s, 1-Ar-H), 7.52-7.49 (2H, m, Ar-H), 7.40
(1H, dd, J 8.5 and 1.6, Ar-H), 7.16 (1H, d, J 8.1, 6-H), 6.51 (1H,
dd, J 13.7 and 0.9, 6-H), 6.23 (1H, dd, J 13.7 and 7.3, 5-H), 5.75
(1H, d, J 8.1 and 2.2, 5-H), 5.71 (1H, d, J 2.7, 1-H), 5.48 (1H, dd,
J 5.8 and 2.7, 2-H), 4.79 (1H, d, J 11.7, CHH), 4.65 (1H, d, J
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11.7, CHH), 4.42 (1H, ddd, J 7.7, 7.3 and 0.9, 4-H), 4.15 (1H, dd,
J 7.7 and 5.8, 3-H), 2.16 (3H, s, 2-COCH3); GC (100 MHz, CDCl3)
170.1 (COCH3), 162.7 (4-CO), 140.8 (6-CH), 134.3 (Ar-C), 133.4
(5-CH), 133.3 (Ar-C), 128.5 (Ar-C), 128.1 (Ar-C), 127.8 (Ar-C),
127.1 (1-Ar-CH), 126.5 (Ar-C), 126.4 (Ar-C), 125.8 (Ar-C), 111.5
(6-CH), 103.1 (5-CH), 91.4 (1-CH), 82.0 (4-CH), 79.0 (3-CH),
73.9 (CH2), 73.6 (2-CH), 20.8 (COCH3); m/z (ES+) 523.0521
(M+Na, C23H2179BrN2NaO6+ requires 523.0475), 525.0498 (M+Na,
C23H2181BrN2NaO6+ requires 525.0460).
6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaph-
thyl) uridine 231
Solid K2CO3 (281 mg, 2.03 mmol) was added
to a stirred solution of 219 in MeOH (8 mL)
and stirring was maintained at r.t. for 4 hours.
The reaction mixture was then quenched with
concentrated HCl (168 PL) and stirred for a further 10 minutes
then concentrated in vacuo to a white solid. Purification by column
chromatography (195:5 CH2Cl2:MeOH) produced 231 white solid
(856 mg, 92%); m.p. 85-86 oC. Rf 0.42 (95:5 CH2Cl2:MeOH);
[D]D27 +54.8 (c 1.20, CHCl3); Qmax/cm-1 (CHCl3) 3696 (O-H), 3689
(O-H), 3532 (N-H), 3388 (N-H), 2974 (C-H), 2874 (C-H), 1713
(C=O), 1694 (C=O), 1627 (C=C), 1603 (C=C), 1456, 1385, 1363,
1322; GH (400 MHz, CDCl3) 9.08 (1H, br s, NH), 7.89-7.84 (3H, m,
Ar-H), 7.79 (1H, s, Ar-H), 7.54-7.50 (2H, m, Ar-H), 7.45 (1H, dd, J
8.4 and 2.0, Ar-H), 7.20 (1H, d, J 8.0, 6-H), 6.45 (1H, dd, J 13.6
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and 1.0, 6-H), 6.24 (1H, dd, J 13.6 and 7.2, 5-H), 5.72 (1H, dd, J
8.0 and 3.2, 5-H), 5.61 (1H, d, J 3.2, 1-H), 4.86 (1H, d, J 12.0,
CHH), 4.80 (1H, d, J 12.0, CHH), 4.44 (1H, ddd, J 7.2, 6.4 and
1.0, 4-H), 4.36 (1H, ddd, J 6.0, 4.4 and 3.2, 2-H), 4.13 (1H, dd J
6.4 and 6.0, 3-H), 3.37 (1H, d, J 4.4, 2-OH); GC (100 MHz, CDCl3)
163.0 (4-CO), 150.2 (2-CO), 141.2 (6-CH), 134.0 (Ar-C), 133.9
(5-CH), 133.4 (Ar-C), 128.8 (Ar-CH), 128.1 (Ar-CH), 127.9 (Ar-
CH), 127.3 (Ar-CH), 126.6 (Ar-CH), 126.6 (Ar-C), 125.7 (Ar-CH),
125.6 (Ar-CH), 111.2 (6-CH), 102.8 (5-CH), 93.7 (1-CH), 82.2
(4-CH), 80.2 (3-CH), 73.6 (CH2), 73.0 (2-CH); m/z (ES+)
359.0547 (M+H, C21H2079BrN2O5+ requires 359.0556), 361.0522
(M+H, C21H2081BrN2O5+ requires 361.0535), 481.0370 (M+Na,
C21H1979BrN2O5Na+ requires 481.0370), 483.0357 (M+Na,
C21H1981BrN2O5Na+ requires 483.0355).
6-E-Bromo-(5-deoxy-5-methylidene)-2-(tert-
butyldimethylsilyl)-3-(2-methylnaphthyl) uridine 232
Imidazole (445 mg, 6.53 mmol) then TBSCl
(492 mg, 3.26 mmol) were added to a stirred
solution of 231 (1.00 g, 2.18 mmol) in dry
DMF (11 mL). Stirring was maintained under
argon at r.t. for 26 hours then H2O (15 mL) was added and the
reaction mixture was extracted with CHCl3 (3 x 10 mL). The
combined organics were washed with brine (2 x 10 mL), dried
(Na2SO4), filtered and evaporated to a pale yellow foam. The TBS
ether 232 was obtained by trituration with pentane as a white solid
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(1.23 g, 98%) m.p. 74-76 oC. Rf 0.16 (95:5 CHCl3:MeOH); [D]D25
+90.7 (c 0.73, CHCl3); Qmax/cm-1 (CHCl3) 3390 (N-H), 2953 (C-H),
2930 (C-H), 2886 (C-H), 2858 (C-H), 1711 (C=O), 1694 (C=O),
1626 (C=C), 1603 (C=C), 1456, 1390, 1362; CHN: found C,
44.50%; H, 5.65%; N 6.07% (C16H25BrN2O5Si requires C, 44.34%;
H, 5.81%; N, 6.46%); GH (400 MHz, CDCl3) 9.20 (1H, br s, NH),
7.87-7.83 (3H, m, Ar-H), 7.76 (1H, s, 1-Ar-H), 7.52-7.49 (2H, m,
Ar-H), 7.44-7.41 (1H, dd, J 8.5 and 1.5, Ar-H), 7.26 (1H, d, J 8.2,
6-H), 6.56 (1H, dd, J 13.6 and 0.9, 6-CH), 6.28 (1H, dd, J 13.6
and 7.3, 5-H), 5.74 (1H, dd, J 8.2 and 2.0, 5-H), 5.68 (1H, d, J
2.4, 1-H), 4.89 (1H, d, J 12.1, CHH), 4.65 (1H, m, J 7.3, 7.2 and
0.9, 4-H), 4.64 (1H, d, J 12.1, CHH), 4.48 (1H, dd, J 4.4 and 2.4,
2-H), 3.71 (1H, dd, 7.2 and 4.4, 3-H), 0.94 (9H, s, C(CH3)3), 0.18
(3H, s, CH3), and 0.16 (3H, s, CH3); GC (100 MHz, CDCl3) 163.2 (4-
CO), 149.9 (2-CO), 139.8 (6-CH), 134.6 (Ar-C), 134.1 (5-CH),
133.2 (Ar-C), 133.1 (Ar-C), 128.5 (Ar-CH), 128.0 (Ar-CH), 127.9
(Ar-CH), 126.5 (Ar-CH), 126.4 (Ar-CH), 126.3 (Ar-CH), 125.5 (Ar-
CH), 111.4 (6-CH), 102.5 (5-CH), 92.8 (1-CH), 81.6 (4-CH), 80.2
(3-CH), 73.8 (2-CH), 72.8 (CH2), 25.7 (SiC(CH3)3), 18.2
(SiC(CH3)3), -4.6 (Si(CH3)), -4.9 (Si(CH3)); m/z (ES+) 573.1400
(M+H, C27H3479BrN2O5Si+ requires 573.1420), 575.1387 (M+H,
C27H3481BrN2O5Si+ requires 575.1400), 595.1214 (M+Na,
C27H3379BrN2O5SiNa+ requires 595.1234), 597.1198 (M+Na,
C27H3381BrN2O5SiNa+ requires 597.1219).
Experimental
- 172 -
6-E-Bromo-(5-deoxy-5-methylidene)-2-(tert-
butyldimethylsilyl) uridine 235
Neat DDQ (715 mg, 3.15 mmol) was added to a
stirred solution of 232 (602 mg, 1.05 mmol) in
4:1 v/v CH2Cl2:MeOH (10.5 mL) under an argon
atmosphere. The solution was heated to reflux
for 22 hours then the reaction mixture was quenched with
saturated solution of NaHCO3 (10 mL). The phases were separated
and the aqueous phase was re-extracted with CH2Cl2 (3 x 10 mL).
The combined organics were washed with brine (2 x 10 mL), dried
(Na2SO4), filtered and evaporated to an orange solid. Column
chromatography (95:5 CHCl3:MeOH) followed by recrystallisation
(CHCl3) produced uridine 235 as a white solid (437 mg, 96%);
m.p. 195-196oC. Rf 0.38 (95:5 CH2Cl2:MeOH); [D]D23 +54.3 (c
0.73, CHCl3); Qmax/cm-1 (CHCl3) 3538 (O-H, N-H), 3387 (N-H),
3178 (N-H), 2954 (C-H), 2931 (C-H), 2897 (C-H), 2885 (C-H),
2859 (C-H), 1713 (C=O), 1694 (C=O), 1626 (C=O), 1455, 1390,
1363; GH (400 MHz, CDCl3) 8.81 (1H, br s, NH), 7.24 (1H, d, J 8.1,
6-H), 6.57 (1H, dd, J 13.7 and 1.1, 6-H), 6.38 (1H, dd, J 13.7 and
6.6, 5-H), 5.80 (1H, dd, J 8.1 and 2.8, 5-H), 5.69 (1H, d, J 2.8,
1-H), 4.35-4.32 (2H, m, 2-H and 4-H), 3.94 (1H, ddd, J 8.1, 6.6
and 4.8, 3-H), 2.59 (1H, d, J 8.1, 3-OH), 0.94 (9H, s, C(CH3)3),
0.18 (3H, s, SiCH3), 0.15 (3H, s, SiCH3); GC (100 MHz, CDCl3)
162.8 (4-CO), 149.8 (2-CO), 139.9 (6-CH), 133.7 (5-CH), 110.7
(6-CH), 103.0 (5-CH), 91.8 (1-CH), 83.6 (4-CH), 75.0 (2-CH),
73.6 (3-CH), 25.7 (SiC(CH3)3), 18.1 (SiC(CH3)3), -4.5 (SiCH3), -
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5.1 (SiCH3); m/z (ES+) 433.0793 (M+H, C16H2679BrN2O5Si+
requires 433.0794), 435.0769 (M+H, C16H2681BrN2O5Si+ requires
435.0774), 455.0603 (M+Na, C16H2579BrN2O5SiNa+ requires
455.0608), 457.0584 (M+Na, C16H2581BrN2O5SiNa+ requires
457.0593).
6-E-Bromo-(5-deoxy-5-methylidene)-2-O-methyl-3-(2-
methylnaphthyl) uridine 233
A solution of alcohol 231 (670 mg, 1.46
mmol) in dry THF (14.6 mL) under an argon
atmosphere was cooled to 0 oC. Solid NaH
(60% w/w dispersion on mineral oil, 175 mg,
4.38 mmol) was added and stirring was maintained for 30 minutes
then MeI (454 PL, 7.29 mmol) was added. Stirring was maintained
at 4 oC for a further 21 hours then ice cold H2O (6 mL) was added
followed by EtOAc (20 mL). The organic phase was separated then
washed with saturated NaHCO3 solution (3 x 6 mL), dried (Na2SO4)
then filtered and concentrated in vacuo to a pale yellow foam (630
mg). Purification by column chromatography (98:2 CH2Cl2:MeOH)
enabled separation of the mono- and bis-methylated compounds.
The mono-methylated uridine, 233 was obtained as a white foam
(406 mg, 59%), m.p. 83-84 oC. Rf 0.10 (3:1 Et2O:Petrol); [D]D22
+66.5 (c 0.24, CHCl3); Qmax/cm-1 (CHCl3) 3389 (N-H), 3003 (C-H),
1714 (C=O), 1694 (C=O), 1627 (C=C), 1454, 1361; GH (400 MHz,
CDCl3) 8.93 (1H, br s, NH), 7.88-7.84 (3H, m, Ar-H), 7.78 (1H, s,
Ar-H), 7.52-7.50 (2H, m, Ar-H), 7.46 (1H, dd, J 8.4 and 1.6, Ar-
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H), 7.22 (1H, d, J 8.1, 6-H), 6.55 (1H, dd, J 13.6 and 0.9, 6-H),
6.28 (1H, dd, J 13.6 and 7.0, 5-H), 5.81 (1H, d, J 2.0, 1-H), 5.74
(1H, d, J 8.1, 5-H), 4.84 (1H, d, J 12.2, CHH), 4.74 (1H, d, J 12.2,
CHH), 4.59 (1H, ddd, J 7.8, 7.0 and 0.9, 4-H), 3.91 (1H, dd, J 4.8
and 2.0, 2-H), 3.81 (1H, dd, J 7.8 and 4.8, 3-H), 3.56 (3H, s,
OCH3); GC (100 MHz, CDCl3) 162.9 (4-CO), 149.8 (2-CO), 139.7 (6-
CH), 134.3 (Ar-C), 133.8 (5-CH), 133.3 (Ar-C), 133.2 (Ar-C),
128.6 (Ar-CH), 128.0 (Ar-CH), 127.9 (Ar-CH), 126.9 (Ar-CH),
126.5 (Ar-CH), 126.4 (Ar-CH), 125.7 (Ar-CH), 111.4 (6-CH),
102.8 (5-CH), 90.3 (1-CH), 81.5 (4-CH), 81.4 (2-CH), 79.3 (3-
CH), 73.1 (CH2), 58.8 (CH3); m/z (ES+) 473.0720 (M+H,
C22H2279BrN2O5+ requires 473.0712), 475.0708 (M+H,
C22H2281BrN2O5+ requires 475.0692), 495.0537 (M+Na,
C22H2179BrN2NaO5+ requires 495.0532), 497.0524 (M+Na,
C22H2181BrN2NaO5+ requires 497.0511).
6-E-Bromo-(5-deoxy-5-methylidene)-2-O-methyl-3-(2-
methylnaphthyl) 5-methyluridine 234
From the above procedure, further elution
obtained the bis-methylated uridine 234
(137 mg, 20%) as a white foam; m.p. 54-56
oC. Rf 0.22 (3:1 Et2O:Petrol); [D]D22 +74.2
(c 0.79, CHCl3); Qmax/cm-1 (CHCl3) 2995 (C-H), 2930 (C-H), 2872
(C-H), 1709 (C=O), 1666 (C=O), 1628 (C=C), 1461, 1372; GH
(400 MHz, CDCl3) 7.88-7.83 (3H, m, Ar-H), 7.78 (1H, s, Ar-H),
7.52-7.50 (2H, m, Ar-H), 7.46 (1H, dd, J 8.4 and 1.5, Ar-H), 7.20
O
O
Br
OMe
N
N
OMe
O
Nap
Experimental
- 175 -
(1H, d, J 8.1, 6-H), 6.56 (1H, dd, J 13.7 and 1.0, 6-H), 6.29 (1H,
dd, J 13.7 and 7.2, 5-H), 5.82 (1H, d, J 1.5, 1-H), 5.79 (1H, d, J
8.1, 5-H), 4.84 (1H, d, J 12.1, CHH), 4.74 (1H, d, J 12.1, CHH),
4.60 (1H, ddd, J 8.1, 7.2 and 1.0, 4-H), 3.88 (1H, dd, J 5.0 and
1.5, 2-H), 3.80 (1H, dd, J 8.1 and 5.0, 3-H), 3.59 (3H, s, COCH3),
3.32 (3H, s, 2-COCH3); GC (100 MHz, CDCl3) 162.5 (4-C), 150.7
(2-C), 137.1 (6-CH), 134.4 (Ar-C), 133.8 (5-CH), 133.3 (Ar-C),
133.2 (Ar-C), 128.6 (Ar-CH), 128.0 (Ar-CH), 127.9 (Ar-CH), 126.9
(Ar-CH), 126.5 (Ar-CH), 126.4 (Ar-CH), 125.7 (Ar-CH), 111.5 (6-
CH), 102.1 (5-CH), 90.8 (1-CH), 81.5 (4-CH), 81.4 (2-CH), 79.4
(3-CH), 73.2 (CH2), 58.8 (COCH3), 27.6 (2-OCH3); m/z (ES+)
487.0877 (M+H, C23H2479BrN2O5+ requires 487.0869), 489.0858
(M+H, C23H2481BrN2O5+ requires 489.0848), 509.0693 (M+Na,
C23H2379BrN2O5Na+, requires 509.0688), 511.0676 (M+Na,
C23H2381BrN2O5Na+, requires 511.0668).
6-E-Bromo-(5-deoxy-5-methylidene)-2-O-methyl uridine
236
Neat DDQ (309 mg, 1.36 mmol) was added to a
stirring solution of uridine 233 (215 mg, 454
mmol) in 4:1 v/v dry CH2Cl2:MeOH (4.5 mL)
under an argon atmosphere. The solution was
then heated at reflux for 10 hours then cooled to r.t. and quenched
with saturated NaHCO3 solution (4 mL) and then extracted with
EtOAc (4 x 4 mL). The combined organic extracts were washed
with brine (4 mL), dried (Na2SO4), filtered and concentrated in
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vacuo to a red residue. Purification by column chromatography
(195:5 CH2Cl2:MeOH) followed by recrystallisation (1:1 v/v
toluene:CHCl3) produced uridine 236 as off-white crystalline
needles (123 mg, 81%); m.p. 141-143 oC. Rf 0.25 (98:2
CH2Cl2:MeOH); [D]D27 +106 (c 0.62, CHCl3); Qmax/cm-1 (CHCl3) 3534
(O-H, N-H), 3389 (O-H, N-H), 2940 (C-H), 2841 (C-H), 1714
(C=O), 1694 (C=O), 1628 (C=C), 1456, 1392, 1362; GH (400 MHz,
d4-MeOD) 7.58 (1H, d, J 8.5, 6-H), 6.65 (1H, dd, J 13.5 and 1.0,
6-H), 6.44 (1H, dd, J 13.5 and 7.5, 5-H), 5.83 (1H, d, J 2.5, 1-
H), 5.72 (1H, d, J 8.5, 5-H), 4.29 (1H, ddd, J 7.5, 7.5 and 1.0, 4-
H), 4.05 (1H, dd, J 7.5 and 5.5, 3-H), 3.87 (1H, dd, J 5.5 and 2.5,
2-H), 3.52 (3H, s, CH3); GC (126 MHz, d4-MeOD) 166.9 (4-CO),
152.7 (2-CO), 143.0 (6-CH), 136.8 (5-CH), 112.2 (6-CH), 103.8
(5-CH), 91.1 (1-CH), 85.3 (4-CH), 84.8 (2-CH), 74.8 (3-CH),
49.1 (CH3); m/z (ES+) 333.0087 (M+H, C11H1479BrN2O5+ requires
333.0086), 335.0071 (M+H, C11H1481BrN2O5+ requires 335.0066),
354.9902 (M+Na, C11H1379BrN2O5Na+ requires 354.9900), 356.9885
(M+Na, C11H1381BrN2O5Na+ requires 356.9885).
4.3.2.2 Vinyl Bromide Adenosines
6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaph-
thyl)-2-O-acetyl adenosine 220
To a stirred suspension of bis-acetate 210
(170 mg, 378 Pmol) and adenine (77 mg,
567 Pmol) in dry acetonitrile (2.5 mL) at r.t.
under an argon atmosphere was added
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SnCl4 (111 PL, 946 Pmol). After 15 hours, the reaction mixture
was concentrated in vacuo and the residue then partitioned
between saturated NaHCO3 solution (20 mL) and CHCl3 (20 mL).
The organic layer was washed with brine (20 mL), dried (Na2SO4),
filtered and concentrated in vacuo to a pale yellow solid (107 mg).
Purification by column chromatography (98:2 CHCl3:MeOH)
obtained adenosine 220 as a white solid (48.8 mg, 25%), m.p. 69-
71 oC. Rf 0.27 (98:2 CH2Cl2:MeOH); [D]D22 +29.7 (c 0.70, CHCl3);
Qmax/cm-1 (CHCl3) 3686 (N-H), 3524 (N-H), 3413 (N-H), 2985 (C-
H), 1748 (C=O), 1631 (C=O), 1588 (C=C), 1470 (C=C), 1372,
1329, 1295; GH (400 MHz, CDCl3) 8.22 (1H, s, 2-H), 7.88-7.80 (5H,
m, 8-H and 4 x Ar-H), 7.52-7.50 (2H, m, Ar-H), 7.45 (1H, dd, J
8.4 and 1.6, Ar-H), 6.49 (1H, dd, J 13.7 and 0.8, 6-H), 6.29 (1H,
dd, J 13.7 and 7.4, 5-H), 6.04 (1H, d, J 2.8, 1-H), 5.99 (2H, br s,
NH2), 5.96 (1H, dd, J 5.3 and 2.8, 2-H), 4.84 (1H, d, J 11.8,
CHH), 4.74 (1H, dd, J 7.3 and 5.3, 3-H), 4.73 (1H, d, J 11.8,
CHH), 4.53 (1H, ddd, J 7.4, 7.3 and 0.8, 4-H), 2.17 (3H, s,
COCH3); GC (100 MHz, CDCl3) 169.9 (COCH3), 155.7 (6-C), 153.2
(2-CH), 149.3 (4-C), 139.7 (8-CH), 134.4 (Ar-C(CH2)), 133.9 (5-
CH), 133.3 (Ar-C), 133.2 (Ar-C), 128.5 (Ar-CH), 128.0 (Ar-CH),
127.8 (Ar-CH), 127.3 (Ar-CH), 126.4 (Ar-CH), 126.3 (Ar-CH),
125.9 (Ar-CH), 120.4 (5-C), 111.2 (6-CH), 88.0 (1-CH), 82.2 (4-
CH), 79.0 (3-CH), 73.7 (CH2), 73.6 (2-CH), 20.8 (COCH3); m/z
(ES+) 524.0928 (M+H, C24H2379BrN5O4+ requires 524.0928),
526.0920 (M+H, C24H2381BrN5O4+ requires 524.0928).
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6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaph-
thyl)-2-O-acetyl N-benzoyladenosine 221
Benzoyl adenine (998 mg, 4.17 mmol) and
BSA (1.24 mL, 5.01 mmol) were added to
a stirring solution of bis-acetate 218 (750
mg, 1.67 mmol) in dry toluene (16.7 mL)
at r.t. under an argon atmosphere. The reaction mixture was then
heated to 80 oC for 3 hours then TMSOTf (380 PL, 2.47 mmol) was
added. Stirring at 80 oC maintained for a further 3 ½ hours then
the reaction mixture was cooled to r.t., diluted with EtOAc (20 mL),
washed with a saturated NaHCO3 solution (25 mL), dried (Na2SO4),
filtered and concentrated in vacuo to a pale yellow foam.
Purification by column chromatography produced benzoyladenosine
221 as a white foam (995 mg, 94%), m.p. 96-97 oC. Rf 0.45 (9:1
CH2Cl2:MeOH); [D]D28 +17.6 (c 1.51, CHCl3); Qmax/cm-1 (CHCl3)
3405 (N-H), 2992 (C-H), 2933 (C-H), 2882 (C-H), 1748 (C=O),
1710 (C=O), 1613 (C=C), 1588 (C=C), 1457, 1438, 1372, 1328;
GH (400 MHz, CDCl3) 9.01 (1H, br s, NH), 8.70 (1H, s, 2-CH), 8.03-
8.01 (3H, m, 2 x Ar-CH and 8-CH), 7.89-7.85 (3H, m, 3 x Ar-CH),
7.81 (1H, s, Ar-H), 7.61 (1H, d, J 7.0, Ar-CH), 7.55-7.51 (4H, m,
Ar-CH), 7.46 (1H, dd, J 7.0 and 1.2, Ar-CH), 6.49 (1H, d, J 13.7,
6-H), 6.28 (1H, dd, J 13.7 and 7.4, 5-H), 6.10 (1H, d, J 2.8, 1-
H), 5.96 (1H, dd, J 5.3 and 2.8, 2-H), 4.86 (1H, d, J 11.5, CHH),
4.75 (1H, d, J 11.5, CHH), 4.72 (1H, dd, J 7.1 and 5.3, 3-H), 4.55
(1H, dd, J 7.4 and 7.1, 4-H), 2.18 (3H, s, COCH3); GC (100 MHz,
CDCl3) 169.9 (COCH3), 164.6 (NCOPh), 152.9 (2-CH), 151.2 (6-C),
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149.8 (4-CH), 142.1 (8-CH), 134.3 (Ar-C), 133.7 (5-CH), 133.6
(Ar-C), 133.2 (Ar-C), 133.1 (NCO-Ar-C), 132.9 (Ar-CH), 129.0 (2 x
Ar-CH), 128.6 (Ar-CH), 128.0 (Ar-CH), 127.9 (2 x Ar-CH), 127.8
(Ar-CH), 127.4 (Ar-CH), 126.5 (Ar-CH), 126.4 (Ar-CH), 125.9 (Ar-
CH), 123.8 (5-C), 111.4 (6-CH), 88.2 (1-CH), 82.4 (4-CH), 78.9
(3-CH), 73.8 (CH2), 73.6 (2-CH), 20.8 (COCH3); m/z (ES+)
628.1128 (M+H, C31H2779BrN5O5 requires 628.1190), 630.1154
(M+H, C31H2781BrN5O5 requires 630.1175), 650.0984 (M+Na,
C31H2679BrN5O5Na+ requires 650.1005), 652.0982 (M+Na,
C31H2681BrN5O5Na+ requires 652.0995).
6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaph-
thyl)-N-benzoyladenosine 237
A 1:1 v/v solution of EtOH-2N NaOH (22.5
mL) was added to a stirred solution of
acetate 221 (1.70 g, 2.70 mmol). The
reaction mixture was stirred for 10 minutes
at r.t. and was then neutralised with saturated NH4Cl solution (40
mL) and extracted with CH2Cl2 (3 x 25 mL). The combined
organics were washed with brine (25 mL), dried (Na2SO4), filtered
and evaporarted in vacuo to a pale brown oil (2.20 g). Purification
by column chromatography (97:3 CH2Cl2:MeOH) obtained alcohol
237 as a pale yellow foam (1.17 g, 74%), m.p. 100-102 oC. Rf
0.21 (97:3 CH2Cl2:MeOH); [D]D23 -16.3 (c 0.65, CHCl3); Qmax/cm-1
(CHCl3) 3528 (O-H), 3399 (N-H), 2991 (C-H), 2933 (C-H), 2872
(C-H), 1709 (C=O), 1613 (C=C), 1586 (C=C), 1483, 1455, 1400,
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1359, 1327; GH (500 MHz, CDCl3) 9.05 (1H, br s, NH), 8.71 (1H, s,
2-CH), 8.02-8.01 (2H, m, Ar-H), 7.99 (1H, s, 8-CH), 7.90 (1H, d, J
8.0, Ar-H), 7.88-7.85 (2H, m, Ar-H), 7.84 (1H, s, Ar-H), 7.62-7.59
(1H, m, Ar-H), 7.54-7.49 (5H, m, Ar-H), 6.46 (1H, dd, J 14.0 and
1.0, 6-H), 6.31 (1H, dd, J 14.0 and 7.0, 5-H), 5.95 (1H, d, J 3.5,
1-H), 4.93 (1H, d, J 11.3, CHH), 4.90 (1H, d, J 11.3, CHH), 4.83
(1H, dd, J 4.5 and 3.5, 2-H), 4.58 (1H, ddd, J 7.0, 5.5 and 1.0, 4-
H), 4.54 (1H, dd, J 5.5 and 4.5, 3-H), 3.72 (1H, br s, OH); GC (126
MHz, CDCl3) 164.7 (NCOPh), 152.7 (2-CH), 151.2 (6-C), 149.7 (4-
C), 142.2 (8-CH), 134.0 (5-CH), 133.9 (Ar-CH), 133.6 (Ar-C),
133.5 (Ar-C), 133.3 (Ar-C), 133.2 (Ar-C), 132.9 (Ar-CH), 128.9 (2
x Ar-CH), 128.8 (Ar-CH), 128.7 (Ar-CH), 128.0 (Ar-CH), 127.9 (Ar-
CH), 127.8 (Ar-CH), 127.5 (Ar-CH), 126.6 (Ar-CH), 125.8 (Ar-CH),
123.6 (5-CH), 110.9 (6-CH), 90.2 (1-CH), 82.5 (4-CH), 80.5 (3-
CH), 73.6 (CH2), 73.1 (2-CH); m/z (ES+) 586.1076 (M+H,
C29H2579BrN5O4+ requires 586.1084), 588.1078 (M+H,
C29H2581BrN5O4+ requires 588.1069), 608.0903 (M+Na,
C29H2479BrN5O4Na+ requires 608.0909), 610.0887 (M+Na,
C29H2479BrN5O4Na+ requires 610.0889).
6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaph-
thyl) adenosine 238
In the above procedure, alcohol 238 was
obtained as a colourless glass (20 mg, 1%),
m.p. 90-92 oC. Rf 0.13 (97:3
CH2Cl2:MeOH); [D]D27 -2.56 (c 0.56, CHCl3);
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Qmax/cm-1 (CHCl3) 3697 (O-H), 3632 (O-H), 3535 (O-H, N-H), 3413
(N-H), 2980 (C-H), 2944 (C-H), 2841 (C-H), 1631 (N-H, C=C),
1587 (N-H, C=C), 1469 (C-H, C=C), 1369, 1339; GH (500 MHz,
CDCl3) 8.25 (1H, s, 2-CH), 7.89-7.80 (4H, m, Ar-H), 7.83 (1H, s,
8-CH), 7.53-7.49 (3H, m, Ar-H), 6.45 (1H, dd, J 13.5 and 1.0, 6-
H), 6.31 (1H, dd, J 13.5 and 7.0, 5-H), 5.92 (1H, d, J 4.0, 1-H),
5.90 (1H, br s, NH2), 5.79 (1H, br s, NH2), 4.94 (1H, d, J 12.0,
CHH), 4.89 (1H, d, J 12.0, CHH), 4.82 (1H, dd, J 4.5 and 4.0, 2-
H), 4.60 (1H, ddd, J 7.0, 5.5 and 1.0, 4-H), 4.48 (1H, dd, J 5.5
and 4.5, 3-H), 4.39 (1H, br s, OH); GC (126 MHz, CDCl3) 155.6 (6-
C), 153.0 (2-CH), 149.9 (4-C), 139.8 (8-CH), 134.3 (5-CH), 134.2
(Ar-C), 133.4 (Ar-C), 133.3 (Ar-C), 128.8 (Ar-CH), 128.0 (Ar-CH),
127.9 (Ar-CH), 127.5 (Ar-CH), 126.6 (Ar-CH), 126.5 (Ar-CH),
125.8 (Ar-CH), 120.4 (5-C), 110.7 (6-CH), 90.3 (1-CH), 82.8 (4-
CH), 80.6 (3-CH), 73.6 (CH2), 73.4 (2-CH); m/z (ES+) 482.0820
(M+H, C22H2379BrN5O3+ requires 482.0822), 484.0813 (M+H,
C22H2381BrN5O3+ requires 484.0807).
6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaph-
thyl)-2-O-methyl N-benzoyladenosine 239
A stirred solution of alcohol 237 (1.10 g,
1.87 mmol) in dry THF (20 mL) under
argon was cooled to 4 oC in a cold room.
Solid NaH (60% w/w dispersion, 375 mg,
9.38 mmol) was added and followed by MeI (350 PL, 5.63 mmol).
Stirring was maintained at 4 oC for 13 ½ hours then saturated
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NH4Cl solution (20 mL) was added and the mixture was extracted
with CH2Cl2 (3 x 20 mL). The combined organic extracts were
washed with brine (50 mL), dried (Na2SO4), filtered and
evaporated to a yellow solid (1.27 g). Purification by column
chromatography obtained the methylated adenosine 239 as a pale
yellow foam (822 mg, 73%); Rf 0.19 (98:2 CH2Cl2:MeOH); [D]D26
+2.06 (c 1.03, CHCl3); Qmax/cm-1 (CHCl3) 3664 (O-H), 3406 (N-H),
2992 (C-H), 2933 (C-H), 2885 (C-H), 2834 (C-H), 1744 (C=N),
1724 (C=N), 1673 (C=C), 1650 (C=C), 1614 (C=O), 1585 (C=C),
1499 (C-C), 1498 (C=C), 1484 (C=C), 1398 (C-O), 1356, 1329; GH
(500 MHz, CDCl3) 9.00 (1H, s, NH), 8.73 (1H, s, 2-CH), 8.05 (1H,
s, 8-CH), 8.00 (2H, d, J 7.5, Ar-H), 7.89-7.81 (5H, m, Ar-H), 7.63-
7.58 (1H, m, Ar-H), 7.54-7.49 (6H, m, Ar-H), 7.41-7.40 (1H, m,
Ar-H), 6.52 (1H, dd, J 13.5 and 1.0, 6-H), 6.38 (1H, dd, J 13.5
and 6.8, 5-H), 6.11 (1H, d, J 3.7, 1-H), 4.90 (1H, d, J 12.0, CHH),
4.86 (1H, d, J 12.0, CHH), 4.67 (1H, ddd, J 6.8, 6.2 and 1.0, 4-H),
4.62 (1H, dd, J 5.0 and 3.7, 2-H), 4.30 (1H, dd, J 6.2 and 5.0, 3-
H), 3.50 (3H, s, CH3); GC (126 MHz, CDCl3) 164.6 (COPh), 152.8
(2-CH), 151.3 (6-C), 149.8 (4-C), 142.2 (8-CH), 134.5 (Ar-C),
134.2 (5-CH), 134.0 (Ar-C), 133.2 (Ar-C), 133.1 (Ar-C), 132.9
(Ar-CH), 129.0 (2 x Ar-CH), 128.6 (Ar-CH), 128.0 (Ar-CH), 127.9
(2 x Ar-CH), 127.8 (Ar-CH), 127.2 (Ar-CH), 126.5 (Ar-CH), 126.4
(Ar-CH), 125.9 (Ar-CH), 124.0 (5-C), 110.9 (6-CH), 88.2 (1-CH),
82.3 (4-CH), 80.9 (3-CH), 79.4 (2-CH), 73.2 (CH2), 58.9 (CH3);
m/z (ES+) 600.1243 (M+H, C30H2779BrN5O4+ requires 600.1241),
602.1219 (M+H, C30H2781BrN5O4+ requires 602.1226), 622.1067
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(M+Na, C30H2679BrN5O4Na+ requires 622.1060), 624.1060 (M+Na,
C30H2681BrN5O4Na+ requires 624.1045).
4.3.2.3 Vinyl Bromide Cytidines
6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaph-
thyl)-2-O-acetyl N-benzoylcytidine 226
To a stirred solution of bis-acetate 218
(1.45 g, 3.23 mmol) in dry MeCN (15 mL)
under an inert atmosphere was added BSA
(2.00 mL, 8.07 mmol) and benzoyl cytosine
225 (729 mg, 3.39 mmol). The resulting suspension was heated
to 70 oC for 90 minutes, the solution was then removed from heat,
cooled for 5 minutes then TMSOTf was added (1.50 mL, 9.68
mmol). The reaction mixture was then heated at 70 oC for a
further 75 minutes then cooled to r.t. The reaction mixture was
diluted with EtOAc (50 mL), washed with saturated NaHCO3
solution (30 mL), dried (NaSO4), filtered and evaporated to a
brown foam. Purification by column chromatography (98:2
CH2Cl2:MeOH) followed by trituration with EtOAc produced the
cytidine 226 as an off-white solid (593 mg, 30%); m.p. 93-94 oC;
Rf 0.25 (98:2 CH2Cl2:MeOH); [D]D28 +144 (c 0.85, CHCl3); Qmax/cm-
1 (CHCl3) 3404 (N-H), 2880 (C-H), 1746 (C=O), 1672 (C=O), 1628
(C=C), 1556, 1483, 1370; GH (500 MHz, DMSO) 11.33 (1H, NH),
8.16 (1H, d, J 7.0, 6-H), 8.01 (2H, d, J 7.9, Ar-H), 7.91 (3H, m,
Ar-H), 7.80 (1H, s, Ar-H), 7.63 (1H, dd, J 7.3 and 6.9, Ar-H), 7.51
(4H, m, Ar-H), 7.40 (2H, m, Ar-H and 5-H), 6.96 (1H, d, J 13.3,
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6-H), 6.58 (1H, dd, J 13.3 and 8.5, 5-H), 5.89 (1H, d, J 2.0, 1-
H), 5.61 (1H, dd, J 5.4 and 2.0, 2-H), 4.72 (1H, d, J 12.1, CHH),
4.67 (1H, d, J 12.1, CHH), 4.54 (1H, dd, J 8.5 and 8.0, 4-H), 4.27
(1H, dd, J 8.0 and 5.4, 3-H), 2.14 (3H, s, COCH3); GC (100 MHz,
CDCl3) 170.2 (COPh), 147.2 (2-C), 136.3 (Ar-C), 135.5 (5-CH),
133.8 (Ar-C), 133.7 (Ar-C), 133.6 (Ar-C), 133.5 (6-CH), 129.4 (2
x Ar-CH), 129.4 (2 x Ar-CH), 128.8 (Ar-CH), 128.7 (Ar-CH), 128.5
(Ar-CH), 127.2 (Ar-CH), 127.0 (Ar-CH), 126.9 (Ar-CH), 126.6 (Ar-
CH), 113.6 (6-CH), 97.5 (5-CH), 90.8 (1-CH), 82.3 (4-CH), 79.5
(3-CH), 74.2 (2-CH), 73.1 (CH2), 21.6 (COCH3); m/z (ES+)
604.1063 (M+H, C30H2779BrN3O6+ requires 604.1078), 606.1074
(M+H, C30H2781BrN3O6+ requires 606.1063).
4.3.2.4 Vinyl Bromide Guanosines
6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaphth-
yl)-2-O-acetyl 2-N-isobutyryl-6-O-diphenylcarbamoyl
guanosine 230
Neat BSA (742 mL, 3.00 Pmol) and
2-N-isobutyryl-6-O-diphenylcarba-
moyl guanosine 229 (1.04 g, 2.50
mmol) were added to a stirred
solution of bis-acetate 218 (450
mg, 1.00 mmol) in dry toluene (10 mL). The reaction mixture was
heated to 80 oC and maintained at this temperature for 90 minutes
in which time the suspension became a clear solution. Neat
TMSOTf (229 PL, 1.48 mmol) was added and stirring was
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maintained for a further 2 ½ hours. The reaction mixture was then
removed from the heat, cooled and diluted with EtOAc (15 mL)
then washed sequentially with saturated NaHCO3 solution (10 mL)
and brine (10 mL). The organic phase was separated, dried
(Na2SO4), filtered and concentrated to a grey foam. Following
purification by column chromatography obtained guanosine 230
(610 mg, 76%) as a white foam, m.p. 107-108 oC. Rf 0.53 (98:2
CH2Cl2:MeOH); [D]D28 +59.4 (c 0.72, CHCl3); Qmax/cm-1 (CHCl3)
3427 (N-H), 2974 (C-H), 1746 (C=O), 1622 (C=C), 1588, 1491,
1452, 1406, 1372, 1322, 1303; GH (400 MHz, CDCl3) 8.01 (1H, br
s, NH), 7.93 (1H, s, 8-CH), 7.85-7.82 (4H, m, Ar-H), 7.51-7.32
(12H, m, Ar-H), 7.26 (1H, m, Ar-H), 6.52 (1H, d, J 13.6, 6-H),
6.48 (1H, dd, J 13.6 and 4.9, 5-H), 5.95 (1H, d, J 2.4, 1-H), 5.82
(1H, dd, J 5.5 and 2.4, 2-H), 5.38 (1H, dd, J 7.3 and 5.5, 3-H),
4.95 (1H, d, J 11.6, CHH), 4.87 (1H, d, J 11.6, CHH), 4.51 (1H,
app ddd, J 7.3, 4.9 and ~2.1, 4-H), 2.70 (1H, sept, J 6.9,
CH(CH3)2), 2.12 (3H, s, 2-COCH3), 1.29 (3H, d, J 6.9, CH(CH3)),
1.26 (3H, d, J 6.9, CH(CH3)); GC (126 MHz, CDCl3) 172.3
(COCH(CH3)2), 170.0 (COCH3), 156.4 (6-C), 154.1 (2-C), 152.0 (4-
C and CONPh2), 150.3 (2 x Ar-C), 143.2 (Ar-CH), 135.3 (Ar-C),
134.1 (5-CH), 133.3 (Ar-C), 133.2 (Ar-C), 129.3 (Ar-CH), 128.3
(2 x Ar-CH), 127.8 (2 x Ar-CH), 127.7 (2 x Ar-CH), 127.2 (2 x Ar-
CH), 127.1 (2 x Ar-CH), 126.2 (2 x Ar-CH), 126.1 (2 x Ar-CH),
126.1 (2 x Ar-CH), 122.0 (5-C), 111.3 (6-CH), 88.7 (1-CH), 82.9
(4-CH), 79.3 (3-CH), 74.4 (2-CH), 73.9 (CH2), 36.6
(COCH(CH3)2), 20.8 (2-COCH3), 19.5 (CH(CH3)2), 19.3 (CH(CH3)2);
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m/z (ES+) 805.1966 (M+H, C41H3879BrN6O7+ requires 805.1985),
807.1970 (M+H, C41H3881BrN6O7+ requires 807.1965), 827.1769
(M+Na, C41H3779BrN6NaO7+ requires 827.1799), 829.1773 (M+Na,
C41H3781BrN6NaO7+ requires 829.1784).
6-E-Bromo-(5-deoxy-5-methylidene)-3-(2-methylnaphth-
yl) 2-N-iso-butyryl-6-O-diphenylcarbamoyl guanosine 246
A stirred solution of 230 (200 mg,
248 Pmol) in 5:4:1 v/v
THF:MeOH:H2O (14 mL) was cooled
to 0 oC in an ice bath. A solution of
NaOH (2N, 990 PL, 1.99 mmol) was
added and stirring was maintained for 10 mins. Solid NH4Cl (114
mg, 2.13 mmol) was added and stirring was continued for a further
30 mins. The solvent was removed in vacuo and the remaining
residue was taken up in CH2Cl2 (10 mL) and filtered through a plug
of silica, eluting with 5:1 v/v CH2Cl2:MeOH (10 mL). The filtrate
was evaporated to give guanosine 246 (186 mg, 98%) as a white
foam; m.p. 112-114 oC. Rf 0.40 (98:2 CH2Cl2:MeOH); [D]D26 +48.4
(c 0.43, CHCl3); Qmax/cm-1 (CHCl3) 3425 (O-H), 3377 (N-H), 2974
(C-H), 2936 (C-H), 2877 (C-H), 1746 (C=O), 1717 (C=O), 1621
(C=O), 1588 (C=C, C-N, N-H), 1492 (C=C), 1452 (C=C), 1407,
1386, 1365, 1323, 1301; GH (500 MHz, CDCl3) 8.11 (1H, br s, NH),
8.07 (1H, s, 8-CH), 7.87-7.83 (4H, m, Ar-H), 7.56 (1H, dd, J 8.5
and 1.5, Ar-H), 7.51-7.48 (2H, m, Ar-H), 7.47-7.42 (4H, m, Ar-H),
7.39-7.36 (4H, m, Ar-H), 7.26 (2H, m, Ar-H), 6.34 (1H, dd, J 13.5
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and 0.5, 6-H), 6.29 (1H, dd, J 13.5 and 6.8, 5-H), 5.92 (1H, d, J
4.5, 1-H), 5.16 (1H, d, J 11.5, CHH), 5.11 (1H, br s, 2-OH), 4.98
(1H, d, J 11.5, CHH), 4.81 (1H, app ddd, J 4.7, 4.5 and ~1.5, 2-
H), 4.74 (1H, dd, J 4.7 and 4.0, 3-H), 4.63 (1H, dd, J 6.8, 4.0 and
0.5, 4-H), 2.61 (1H, dq, J 7.0 and 6.5, CH(CH3)2), 1.29 (3H, d, J
7.0, CH(CH3)), 1.28 (3H, d, J 6.5, CH(CH3)); GC (126 MHz, CDCl3)
174.6 (COCH(CH3)2), 156.4 (6-C), 153.8 (2-C), 151.6 (4-C), 150.4
(CONPh2), 143.3 (8-CH), 141.7 (2 x Ar-C), 135.3 (Ar-C), 134.4
(5-CH), 133.3 (Ar-C), 133.2 (Ar-C), 129.3 (5 x Ar-CH), 128.5 (2 x
Ar-CH), 128.0 (2 x Ar-CH), 127.8 (2 x Ar-CH), 127.1 (2 x Ar-CH),
126.3 (2 x Ar-CH), 126.2 (2 x Ar-CH), 126.0 (2 x Ar-CH), 121.8
(5-C), 110.4 (6-CH), 90.9 (1-CH), 84.2 (4-CH), 81.2 (3-CH),
74.9 (2-CH), 73.8 (CH2), 37.1 (CH(CH3)2), 19.5 (CH(CH3)2), 19.4
(CH(CH3)2); m/z (ES+) 763.1825 (M+H, C39H3679BrN6O6+ requires
763.1874), 765.1844 (M+H, C39H3681BrN6O6+ requires 765.1859),
785.1670 (M+Na, C39H3579BrN6NaO6+ requires 785.1694),
787.1673 (M+Na, C39H3581BrN6NaO6+ requires 787.1679).
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6-E-Bromo-(5-deoxy-5-methylidene)-2-O-acetyl-2-N-iso-
butyryl-6-O-diphenylcarbamoyl guanosine 249
6-E-Bromo-(5-deoxy-5-methylidene)-3-O-acetyl-2-N-iso-
butyryl-6-O-diphenylcarbamoyl guanosine 250
Solid DDQ (28 mg, 124 Pmol) was
added to a stirred solution of 246
(100 mg, 124 Pmol) in 4:1 v/v
CH2Cl2:MeOH (distilled) (2.5 mL)
under an argon atmosphere. The
reaction mixture was heated to a
gentle reflux at 40 oC for 11 hours
then cooled and quenched with
saturated NaHCO3 solution (2 mL).
The aqueous phase was re-extracted with CH2Cl2 (3 x 2 mL) and
then the combined organics were then washed with brine (2 mL),
dried (Na2SO4) and evaporated to an off-white solid. Repeated
trituration with warm hexane (3 x 1 mL) generated a 3:2 mixture
of 249 and 250 isomers (77 mg, 93%) as an off-white solid.
Column chromatography was unsuccessful at separating the
individual components and the mixture was taken on without
further purification. Rf 0.34, 0.29 (96:4 CH2Cl2:MeOH); as a
mixture of isomers: [D]D25 +31.1 (c 1.85, CHCl3); as a mixture of
isomers: Qmax/cm-1 (CHCl3) 3424 (O-H), 3391 (N-H), 3304 (N-H),
2969 (C-H), 2935 (C-H), 2908 (C-H), 2832 (C-H), 1746 (C=O),
1716 (C=O), 1694 (C=N), 1622 (C=C), 1589 (C=C), 1491 (C=C),
1454, 1372, 1342, 1322, 1303; as a mixture of isomers: m/z
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(ES+) 665.1372 (M+H, C30H3079BrN6O9+ requires 665.1359),
667.1366 (M+H, C30H3081BrN6O9+ requires 667.1339), 687.1154
(M+Na, C30H3079BrN6O9Na+ requires 687.1179), 689.1158 (M+Na,
C30H3081BrN6O9Na+ requires 689.1148).
6-E-Bromo-(5-deoxy-5-methylidene)- 2-O-acetyl, 3-O-
acetyl-2-N-iso-butyryl-6-O-diphenylcarbamoyl guanosine
251
Dry Et3N (100 PL, 715 Pmol), DMAP (7
mg, 57.2 Pmol) then Ac2O (40 PL, 429
Pmol) were added to a stirred solution
of the mixture of acetates 49 and 50
(190 mg, 286 Pmol) in dry CH2Cl2 (3
mL) at r.t. under an argon atmosphere. The solution was stirred
for 20 hours and was then diluted with water (2 mL) and the
aqueous phase re-extracted with CH2Cl2 (2 x 2 mL). The combined
organics were washed with brine (2 mL), dried (Na2SO4) and
concentrated to a brown residue. Purification by column
chromatography obtained the guanosine bis-acetate 251 (110 mg,
55%) as a pale yellow foam. Rf 0.38 (97:3 CH2Cl2:MeOH); [D]D22
+29.4 (c 0.70, CHCl3); Qmax/cm-1 (CHCl3) 3672 (N-H), 3602 (N-H),
2974 (C-H), 2935 (C-H), 2876 (C-H), 1748 (C=O), 1697 (C=N),
1622 (C=C), 1590 (C=C), 1491 (C=C), 1453 (C=C), 1405, 1386,
1372; GH (500 MHz, CDCl3) 8.08 (1H, br s, NH), 7.99 (1H, s, 8-CH),
7.86-7.82 (2H, m, Ar-H), 7.49-7.43 (4H, m, Ar-H), 7.38-7.35 (4H,
m, Ar-H), 6.66 (1H, dd, J 13.7 and 7.0, 5-H), 6.55 (1H, d, J 13.7,
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6-H), 6.04 (2H, m, 1-H and 2-H), 5.81 (1H, dd, J 4.7 and 4.6, 3-
H), 4.62 (1H, dd, J 7.0 and 4.6, 4-H), 2.86 (1H, app sept, J 0.5,
COCH), 2.16 (3H, s, COCH3), 2.08 (3H, s, COCH3), 1.28 (3H, d, J
1.5, CH(CH3)2), 1.27 (3H, d, J 1.5 CH(CH3)2); GC (100 MHz, CDCl3)
174.6 (COCH(CH3)2), 169.6 (COCH3), 169.5 (COCH3), 156.5 (6-C),
154.4 (2-C), 152.3 (4-C), 150.3 (CONPh2), 142.8 (8-CH), 148.8
(Ar-C), 148.7 (Ar-C), 133.1 (5-CH), 129.4 (Ar-CH), 129.31 (Ar-
CH), 129.26 (2 x Ar-CH), 128.3 (Ar-CH), 128.0 (Ar-CH), 127.8
(Ar-CH), 127.1 (Ar-CH), 126.2 (Ar-CH), 126.1 (Ar-CH), 118.0 (5-
C), 111.8 (6-CH), 87.1 (1-CH), 82.6 (4-CH), 73.2 (3-CH), 72.6
(2-CH), 36.4 (CH(CH3)2), 20.6 (COCH3), 20.5 (COCH3), 19.4
(CH(CH3)2), 19.3 (CH(CH3)2); m/z (ES+) 707.1471 (M+H,
C32H3279BrN6O8+ requires 707.1465), 709.1449 (M+H,
C32H3281BrN6O8+ requires 709.1445), 729.1289 (M+Na,
C32H3179BrN6O8Na+ requires 729.1284), 731.1258 (M+Na,
C32H3181BrN6O8Na+ requires 731.1264).
4.4 H-Phosphonates
2-O-(tert-butyldimethylsilyl)-3-O-(2-cyanoethyl)-H-
phosphonate-5-O-(4,4-dimethoxytrityl) uridine 253
Solid 1H-tetrazole (28 mg, 546 Pmol) was
added to a stirred solution to
phosphoramidite 252 (235 mg, 273 Pmol)
in dry MeCN (2.3 mL) at r.t. under an
argon atmosphere. After 10 minutes
water (0.4 mL) was added and the stirring maintained for 1 hour.
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CH2Cl2 (20 mL) was added, the organic portion was washed with
brine (20 mL), dried (MgSO4) and evaporated under reduced
pressure to obtain H-phosphonate 253 as a white foam (198 mg,
93%) as a 3:2 mixture of diastereoisomers. The H-phosphonate
253 was used in the Pd-coupling reaction without further
purification. Data is reported for the 3:2 mixture of
diastereoisomers which were not separated. Rf 0.36 (98:2
CH2Cl2:MeOH); [D]D32 +12.7 (c 0.51, CHCl3); Qmax/cm-1 (CHCl3)
3391 (N-H), 2955 (C-H), 2932 (C-H), 2859 (C-H), 1716 (C=O),
1695 (C=O), 1636 (C=C), 1609 (C=C, N-H), 1582 (C=C), 1508,
1458, 1389, 1363; GH (400 MHz, CDCl3) 8.32 (4H, br s, NH major
and minor), 7.90 (1H, d, J 8.1, 6-H major), 7.80 (1H, d, J 8.1, 6-H
minor), 7.38-20 (9H, m, ArH), 7.13 (1H, d, J 740, PH), 6.92 (1H,
d, J 724, PH), 6.87 (4H, dd, J 11.7 and 2.9, ArH), 6.20 (0.5H, s,
PH), 6.08 (1H, d, J 6.2, 1-H major), 6.01 (0.5H, s, PH), 5.97 (1H,
d, J 4.5, 1-H minor), 5.31 (1H, d, J 8.1, 5-H major), 5.27 (1H, d, J
8.1, 5-H minor), 5.11 (1H, ddd, J 7.7, 4.4 and 2.5, 3-H major),
4.99 (1H, app dt, J 9.7 and 4.7, 3-H minor), 4.57 (1H, dd, J 5.9
and 4.7, 2-H major), 4.51 (1H, t, J 4.5, 2-H minor), 4.37-4.34
(1H, m, 4-H minor), 4.32-4.14 (5H, m, 4-major and CH2CH2CN
major and minor), 3.82 (6H, s, 2 x Ar-OCH3 minor), 3.81 (3H, s,
Ar-OCH3 major), 3.81 (3H, s, Ar-OCH3 major), 3.66 (1H, dd, J 11.2
and 2.5, 5-Ha minor), 3.60 (1H, dd, J 11.1 and 2.5, 5-Ha major),
3.49 (1H, dd, J 11.1 and 2.0, 5-Hb major), 3.46 (1H, dd, J 11.2
and 2.1, 5-Hb minor), 2.74 (2H, ddd, J 11.0, 6.2 and 6.1,
CH2CH2CN minor), 2.71 (1H, ddd, J 10.4, 5.9 and 5.1, CH2CH2CN
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major), 2.67 (1H, ddd, J 10.4, 5.9 and 4.4, CH2CH2CN major), 0.91
(18H, s, SiC(CH3)3 major and minor), 0.19 (3H, s, SiCH3 minor),
0.15 (3H, s, SiCH3 major), 0.14 (3H, s, SiCH3 major), 0.10 (3H, s,
SiCH3 minor); GC (100 MHz, CDCl3) 162.7 (4-C), 162.5 (4-CO),
159.0 (4 x Ar-COCH3, major and minor), 150.2 (2-CO), 150.1 (2-
CO), 144.1 (2 x ArC, major and minor), 140.1 (6-CH), 139.9 (6-
CH), 134.6 (2 x ArC, major and minor), 134.5 (2 x Ar-C, major
and minor), 130.3 (2 x ArCH), 130.2 (2 x ArCH), 130.1 (2 x
ArCH), 128.3 (4 x ArCH), 127.6 (ArCH), 127.5 (ArCH), 116.3 (CN),
116.2 (CN), 113.5 (ArCH), 113.4 (ArCH), 102.8 (5-CH minor),
102.4 (5-CH major), 88.6 (CPh(4-OMePh)2), 87.7 (4-CH, major),
87.6 (CPh(4-OMePh)2), 87.2 (4-CH, minor), 82.1 (1-CH minor),
81.5 (1-CH major), 77.3 (3-CH, major), 75.1 (2-CH, minor), 75.0
(2-CH, major), 74.8 (3-CH, minor), 62.7 (CH2CH2CN), 61.5
(CH2CH2CN), 60.5 (CH2CH2CN), 60.4 (CH2CH2CN), 55.4 (2 x OCH3),
25.7 (SiC(CH3)3), 25.6 (SiC(CH3)3), 20.0 (SiC(CH3)3), 18.0
(SiC(CH3)3), -4.8 (2 x Si(CH3)2) and 4.9 (2 x Si(CH3)2); GP (121
MHz, CDCl3) minor 8.49 and major 7.82; m/z (ES+) 800.2743
(M+Na, C39H48N3O10NaSiP+ requires 800.2744).
2-O-methoxy-3-O-(2-cyanoethyl)-H-phosphonate-5-O-
(4,4-dimethoxytrityl) uridine 256
To a stirred solution of phosphoramidite
254 (973 mg, 1.28 mmol) in MeCN (10.7
mL) was added 5-methyl-1H-tetrazole
(215 mg, 2.56 mmol). The solution was
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stirred for 30 minutes then H2O (1.78 mL) was added and stirring
was maintained for a further 70 minutes. The reaction mixture
was then diluted with CH2Cl2 (12 mL), washed with brine (12 mL),
dried (Na2SO4), filtered and concentrated in vacuo to obtain H-
phosphonate 2 as a 1:1 mixture of diastereoisomers as a
colourless foam (897 mg, 103%). The crude H-phosphonate 256
was used without further purification. Data is reported for the 1:1
mixture of diastereoisomers which were not separated. Rf 0.31
(98:2 CH2Cl2:MeOH); [D]D29 +19.9 (c 0.91, CHCl3); Qmax/cm-1
(CHCl3) 3663 (N-H), 3390 (N-H), 3202 (O-H), 2959 (C-H), 2936
(C-H), 2908 (C-H), 2839 (C-H), 2411 (P-H), 2248 (CʵN), 1720
(C=O), 1694 (C=O), 1632 (C=C), 1609 (C=C) 1582 (C=C), 1507,
1492, 1460, 1389, 1369, 1303, 1272; GH (400 MHz, CDCl3) 8.75
(2H, br s, 2 x NH), 7.84 (1H, d, J 8.2, 6-H), 7.78 (1H, d, J 8.2, 6-
H), 7.40-7.22 (8H, m, Ar-H), 7.31-7.23 (10H, m, Ar-H), 7.11 (1H,
d, J 748, PH), 6.92 (1H, d, J 728, PH), 6.88-6.86 (8H, m, Ar-H),
6.10 (1H, d, J 4.7, 1-H), 6.05 (1H, d, J 3.9, 1-H), 5.33 (1H, d, J
8.2, 5-H), 5.28 (1H, d, J 8.2, 5-H), 5.17 (1H, dd, J 10.3 and 4.9,
3-H), 5.08 (1H, dd, J 7.7 and 5.1, 3-H), 4.36-4.31 (4H, m, 2 x 4-
H and CH2CH2CN), 4.26-4.17 (2H, m, CH2CH2CN), 4.17 (1H, dd, J
4.9 and 4.7, 2-H), 4.10 (1H, dd, J 5.1 and 3.9, 2-H), 3.82 (6H, s,
2 x ArOCH3), 3.81 (6H, s, 2 x ArOCH3), 3.65 (2H, m, 2 x 5-H),
3.61 (3H, s, 2-OCH3), 3.60 (3H, s, 2-OCH3), 3.50 (2H, m, 2 x 5-
H), 2.79 (2H, ddd, J 10.7, 6.5 and 6.3, CH2CH2CN), 2.69 (2H, ddd,
J 10.7, 6.0 and 5.0, CH2CH2CN); GC (100 MHz, CDCl3) 162.9 (4-C),
162.8 (4-C), 158.9 (2-C), 158.8 (2-C), 150.2 (2 X Ar-C), 144.0 (2
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x Ar-C), 143.9 (2 x Ar-C), 139.7 (6-CH), 139.6 (6-CH), 134.8 (Ar-
C), 134.7 (2 x Ar-C), 134.6 (Ar-C), 130.3 (3 x Ar-CH), 130.2 (5 x
Ar-CH), 130.1 (3 x Ar-CH), 128.3 (3 x Ar-CH), 128.2 (6 x Ar-CH),
127.5 (Ar-CH), 127.4 (Ar-CH), 116.3 (CN), 116.2 (CN), 113.5 (4 x
Ar-CH), 102.8 (5-CH), 102.7 (5-CH), 87.7 (CPh(4-OMePh)2), 87.6
(CPh(4-OMePh)2), 86.7 (1-CH), 86.5 (1-CH), 82.7 (2 x 4-CH),
82.0 (2-CH), 81.7 (2-CH), 74.8 (3-CH), 73.2 (3-CH), 61.8 (5-
CH2), 61.2 (5-CH2), 60.1 (CH2CH2CN), 60.0 (CH2CH2CN), 59.6
(CH2CH2CN), 59.5 (CH2CH2CN), 59.2 (2-OCH3), 58.9 (2-OCH3),
55.4 (4 x Ar-OCH3); GP (121 MHz, CDCl3) 8.10 (dd, J 749 and 6)
and 7.19 (dd, J 734 and 8); m/z (ES+) 700.2041 (M+Na,
C34H36NaN3O10P+ requires 700.2036).
2-O-methoxy-3-O-(2-cyanoethyl)-H-phosphonate-5-O-
(4,4-dimethoxytrityl) 6-N-benzoyladenosine 257
To a stirred solution of phosphoramidite
255 (500 mg, 563 mmol) in distilled
MeCN (4.7 mL) at r.t. was added 5-
methyl-1H-tetrazole (94.7 mg, 1.13
mmol). The resulting solution was
stirred for 10 minutes then water (0.8 mL) added and stirring
maintained for a further 50 minutes. The solution was then diluted
with CH2Cl2 (10 mL) then washed with brine (5 mL), dried
(Na2SO4), filtered and concentrated under reduced pressure to
obtain H-phosphonate 257 as a 1:1 mixture of diastereoisomers as
a white foam (449 mg, 99%). Data is reported for the 1:1 mixture
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of diastereoisomers (A and B) which were not separated. Rf 0.20
(98:2 CH2Cl2:MeOH); [D]D20 -20.9 (c 0.43, CHCl3); Qmax/cm-1
(CHCl3) 3662 (O-H), 3413 (N-H), 2992 (C-H), 2959 (C-H), 2936
(C-H), 2913 (C-H), 2839 (C-H), 2476 (P-H), 1708 (C=O), 1612
(C=O), 1587 (C=C), 1457, 1505, 1484, 1457, 1404, 1356, 1327;
GH (500 MHz, CDCl3) 9.11 (2H, app br s, 2 x NH, A and B), 8.73
(2H, s, 2 x 2-H, A and B), 8.18 (2H, d, J 9.5, 8-H, A and B), 8.04
(4H, app d, Ar-H, A and B), 7.63 (2H, app tt, J 8.0, 7.5 and 1.5,
Ar-H, A and B), 7.55 (4H, app t, J 7.5, Ar-H, A and B), 7.45-7.39
(4H, m, Ar-H, A and B), 7.35-7.26 (12H, m, Ar-H, A and B), 7.25
(2H, ddd, J 7.5, 4.6 and 1.5, Ar-H, A and B), 7.02 (1H, d, J 745,
PH, A), 7.02 (1H, d, J 735, PH), 6.83 (4H, m, Ar-H), 6.82 (4H, m,
Ar-H), 6.18 (1H, d, J 6.5, 1-H, A), 6.17 (1H, d, J 7.0, 1-H, B),
5.32-5.29 (1H, m, 3-H, B), 5.28-5.24 (1H, m, 3-H, A), 5.01 (1H,
dd, J 7.0 and 5.0, 2-H, B), 4.97 (1H, dd, J 6.5 and 5.0, 2-H, A),
4.47-4.44 (2H, m, 2 x 4-H, A and B), 4.37 (2H, ddd, J 13.1, 6.5
and 6.0, CH2CH2CN, A), 4.34-4.21 (2H, m, CH2CH2CN, B), 3.79
(12H, s, 4 x ArOCH3), 3.61-3.57 (2H, m, 5-Ha and 5-Hb), 3.51
and 3.50 (6H, s, 2 x 2-OCH3), 3.47 (2H, ddd, J 10.8, 3.5 and 3.0,
5-Ha), 3.44 (2H, ddd, J 10.8, 3.5 and 2.5, 5-Hb), 2.79 (2H, app
dd, J ~6.5 and ~6.0, CH2CH2CN, A), 2.76-71 (2H, ddd, J 10.5, 6.5
and 4.4 CH2CH2CN, B); GC (100 MHz, CDCl3) 164.7 (COPh), 164.8
(COPh), 159.3 (Ar-COCH3), 158.8 (2 x Ar-COCH3), 158.7 (Ar-
COCH3), 152.9 (6-C), 152.4 (6-C), 149.6 (2 x 4-C), 144.3 (Ar-C),
143.4 (Ar-C), 144.2 (2 x 8-CH), 142.3 (2-CH), 142.1 (2-CH),
135.4 (2 x Ar-C), 135.3 (2 x Ar-C), 135.2 (2 x Ar-C), 133.3 (Ar-
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CH), 133.1 (2 x Ar-CH), 131.7 (2 x Ar-CH), 130.2 (3 x Ar-CH),
130.1 (2 x Ar-CH), 129.9 (Ar-CH), 129.2 (Ar-CH), 129.1 (Ar-CH),
129.0 (2 x Ar-CH), 128.2 (3 x Ar-CH), 128.1 (3 x Ar-CH), 127.9 (4
x Ar-CH), 127.8 (Ar-CH), 127.3 (Ar-CH), 127.2 (Ar-CH), 123.6 (5-
C), 123.5 (5-C), 113.4 (4 x Ar-CH), 113.2 (Ar-CH), 113.0 (Ar-CH),
87.2 (CPh(4-OMe-Ph)2), 87.1 (CPh(4-OMe-Ph)2), 86.2 (1-CH),
86.0 (1-CH), 83.2 4-CH), 83.1 (4-CH), 81.8 (2 x 2-CH), 81.2 (2-
CH), 76.2 (3-CH), 74.8 (3-CH), 62.7 (5-CH2), 62.6 (5-CH2), 59.6
(CH2CH2CN), 59.4 (CH2CH2CN), 59.3 (CH2CH2CN), 59.2
(CH2CH2CN), 55.3 (4 x Ar-OCH3), GP (121 MHz, CDCl3) 8.16 and
7.15; m/z (ES+) 805.2765 (M+H, C42H42N6O9P+ requires
805.2751), 827.2533 (M+Na, C42H41N6O9PNa+ requires 827.2565).
4.5 Vinylphosphonate-linked Dinucleotides
5-O-(4,4-dimethoxytrityl)-2-O-(tert-butyldimethylsilyl)-
uridinyl 2-cyanoethylphosphono-[3(O)Æ5(C)]-5-deoxy-5-
methylidene-3-O-benzyl-2-O-(tert-butyldimethylsilyl)
uridine 258
A solution of H-Phosphonate 253 (212
mg, 273 mmol) in dry THF (2.8 mL)
was added to a stirred mixture of
Pd(OAc)2 (9.4 mg, 42 mmol), dppf (46
mg, 84 mmol), vinyl bromide 167 (110
mg, 210 mmol) and propylene oxide
(0.29 mL, 4.22 mmol) in a screw cap reactivial. The reaction
mixture was heated in the sealed vial at 70 oC for 6 hours. The
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reaction mixture was cooled, further propylene oxide (0.29 mL)
was added then stirring continued at r.t. for a further 16 hours.
The solvent was removed in vacuo and the residue (416 mg) was
dissolved in CHCl3 (1 mL) and purification by gradient column
chromatography was attempted (8:1 EtOAc-Petrol o neat EtOAc).
All tlc spots co-eluted but later HPLC (9:1 MeOH-H2O) showed
product present in all fractions. Combined fractions were further
purified by reverse phase HPLC (9:1 MeOH-H2O), peak collected at
17 minutes. Combined fractions were evaporated and the U*U
vinylphosphonate dimer 258 was obtained as a 2:1 mixture of
diastereoisomers as white solid (63 mg, 25%). Rf 0.53 (EtOAc);
[D]D29 -74.1 (c 1.37, CHCl3); Qmax/cm-1 (CHCl3) 3392 (N-H), 2954
(C-H), 2932 (C-H), 2903 (C-H), 2859 (C-H), 2839 (C-H), 1714
(C=O), 1697 (C=O), 1634 (C=O), 1609 (C=C), 1585 (C-H), 1508,
1461, 1456, 1389, 1363; Major diastereoisomer: GH (500 MHz,
CDCl3) 9.18-8.85 (2H, br s, NH), 7.90 (1H, d, J 8.2, U1-6-H), 7.40-
7.26 (15H, m, Ar-H), 7.06-6.95 (2H, m, U2-5-H), 6.90-6.86 (3H,
m, 2 x Ar-H and U2-5-H), 6.90-6.86 (3H, m, 2 x Ar-H and U2-5-H),
6.15-6.03 (2H, m, U2-6-H), 6.01 (1H, d, J 4.7, U1-1-H), 5.79 (1H,
d, J 8.1, U2-5-H), 5.75 (1H, d, J 4.1, U2-1-H), 5.30 (1H, d, J 8.2,
U1-5-H), 4.95 (1H, m, U1-3-H), 4.74 (1H, d, J 11.6, U2-3-
OCH2Ph), 4.69-4.66 (1H, m, U2-4-H), 4.55-4.51 (3H, m, U2-3-
OCH2Ph, U1-2-H, U2-2-H), 4.34 (1H, m, U1-4-H), 4.30-4.16 (1H,
m, CH2CH2CN), 4.10-3.89 (1H, m, CH2CH2CN), 3.83 (3H, s, Ar-
OCH3), 3.81 (3H, s, Ar-OCH3), 3.83-3.78 (1H, obscured multiplet,
U2-3-H), 3.59 (1H, dd, J 11.0 and 1.8, U1-5-H), 3.46 (1H, dd, J
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11.0 and 1.8, U1-5-H), 2.79-2.68 (2H, m, CH2CH2CN), 0.93 (9H, s,
SiC(CH3)3), 0.92 (9H, s, SiC(CH3)3), 0.18 (3H, s, SiCH3), 0.17 (3H,
s, SiCH3), 0.14 (3H, s, SiCH3), 0.11 (3H, s, SiCH3); Minor
diastereoisomer: GH (500 MHz, CDCl3) 9.18-8.85 (2H, br s, NH),
7.93 (1H, d, J 8.2, U1-6-H), 7.40-7.26 (15H, m, Ar-H), 7.06-6.95
(2H, m, U2-5-H), 6.90-6.86 (3H, m, 2 x Ar-H and U2-6-H), 6.15-
6.03 (2H, m, U2-6-H), 5.98 (1H, d, J 3.9, U1-1-H), 5.82 (1H, d, J
8.1, U2-6-H), 5.81 (1H, obscured d, U2-1-H), 5.28 (1H, d, J 8.2,
U1-6-H), 5.02 (1H, m, U1-3-H), 4.79-4.76 (1H, obs m, U2-4-H),
4.76 (1H, d, J 11.6, U2-3-OCH2Ph), 4.55-4.51 (3H, m, U2-3-
OCH2Ph, U1-2-H, U2-2-H), 4.40 (1H, m, U1-4-H), 4.30-4.16 (1H,
m, CH2CH2CN), 4.10-3.89 (1H, m, CH2CH2CN), 3.84 (6H, app s, 2 x
Ar-OCH3), 3.83-3.78 (1H, obscured multiplet, U2-3-H), 3.72 (1H,
dd, J 11.2 and 1.6, U1-5-H), 3.54 (1H, dd J 11.2 and 1.6, U1-5-H),
2.53 (1H, dt, J 17.1 and 5.8, CH2CH2CN), 2.44 (1H, dt, J 17.1 and
5.8, CH2CH2CN), 0.93 (9H, s, SiC(CH3)3), 0.89 (9H, s, SiC(CH3)3),
0.17 (3H, s, SiCH3), 0.15 (3H, s, SiCH3), 0.12 (6H, s, 2 x SiCH3);
Major diastereoisomer: GC (125 MHz, CDCl3) 163.2 (4-C), 163.1
(4-C), 158.83 (Ar-COCH3), 158.81 (Ar-COCH3), 150.4 (U2-5-CH),
150.0 (2-C), 149.8 (2-C), 144.1 (Ar-C), 140.8 (6-CH), 139.9 (6-
CH), 137.1 (2 x Ar-C), 128.6 (3 x Ar-CH), 128.3 (Ar-CH), 128.2 (2
x Ar-CH), 128.1 (Ar-CH), 128.09 (3 x Ar-CH) 127.7 (3 x Ar-CH),
127.3 (Ar-CH), 130.3 (Ar-CH), 130.27 (Ar-CH), 130.2 (Ar-CH),
130.2 (Ar-CH), 118.25 (U2-6-CH), 116.7 (CN), 116.5 (CN), 113.38
(4 x Ar-CH), 102.8 (5-CH), 102.5 (5-CH), 92.6 (U2-1-CH), 88.2
(U1-1-CH), 87.5 (CPh(4-OMe-Ph)2), 82.0 (U1-4-CH), 81.2 (U2-4-
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CH), 80.3 (U2-3-CH), 74.4 (U1-2-CH), 73.5 (U2-2-CH), 73.1
(CH2Ph), 72.8 (U1-3-CH), 61.9 (U1-5-CH2), 60.8 (d, JCP 4.7,
CH2CH2CN), 55.3 (2 x Ar-OCH3), 25.6 (2 x SiC(CH3)3), 19.9 (d, 2JCP
6.5, CH2CH2CN), 18.1 (SiC(CH3)3), 18.05 (SiC(CH3)3), -4.75
(SiCH3), -4.8 (SiCH3), -4.9 (2 x SiCH3); Minor diastereoisomer:
GC (125 MHz, CDCl3) 163.1 (2 x 4-C), 158.89 (Ar-COCH3), 158.86
(Ar-COCH3), 150.3 (U2-5-CH), 150.0 (2-C), 149.7 (2-C), 144.2
(Ar-C), 140.1 (6-CH), 139.8 (6-CH), 137.1 (2 x Ar-C), 134.9 (Ar-
C), 134.8 (Ar-C), 128.6 (2 x Ar-CH), 128.2 (2 x Ar-CH), 128.1 (Ar-
CH), 128.09 (2 x Ar-CH), 127.6 (2 x Ar-CH), 127.4 (Ar-CH), 30.3
(Ar-CH), 130.27 (Ar-CH), 130.2 (Ar-CH), 130.2 (Ar-CH), 118.3
(U2-6-CH), 116.7 (CN), 116.4 (CN), 113.40 (4 x Ar-CH), 102.8 (5-
CH), 102.4 (5-CH), 92.4 (U2-1-CH), 88.7 (U1-1-CH), 87.5 CPh(4-
OMe-Ph)2), 81.6 (U1-4-CH), 81.5 (U2-4-CH), 80.2 (U2-3-CH),
74.8 (U1-2-CH), 74.5 (U2-2-CH), 73.4 (CH2Ph), 72.77 (U1-3-CH),
61.7 (U1-5-CH2), 60.7 (d, JCP 4.1, CH2CH2CN), 55.3 (2 x Ar-OCH3),
25.7 (SiC(CH3)3), 25.6 (SiC(CH3)3), 19.7 (d, 2JCP 6.8, CH2CH2CN),
18.0 (2 x SiC(CH3)3), -4.7 (SiCH3), -4.82 (SiCH3), 4.85 (SiCH3), -
5.0 (SiCH3); GP (121 MHz, CDCl3) minor 19.7 and major 19.4; m/z
(ES+) 1242.4624 (M+Na, C62H78N5NaO15SiP2+ requires 1242.4668).
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5-O-(4,4-dimethoxytrityl)-2-O-(tert-butyldimethylsilyl)
uridinyl 2-cyanoethylphosphono-[3(O)Æ5(C)]-5-deoxy-5-
methylidene-3-O-acetyl-2-O-acetyl uridine 259
Uridine bis-acetate 211 (81 mg, 201
Pmol), dppf (45 mg, Pmol), Pd(OAc)2
(9 mg, Pmol) and propylene oxide (280
PL, 4.02 mmol) were charged to a 5
mL reactivial flushed with argon. To
this mixture was added a solution of H-
phosphonate 253 (203 mg, 261 Pmol)
in dry THF (2.7 mL). The reactivial was sealed and the reaction
mixture was heated at 70 oC for 6 hours, then cooled to r.t. and
concentrated in vacuo to an orange foam (303 mg). Purification by
column chromatography (4:1 CHCl3:EtOAc) produced a pale orange
foam U*U dimer 53 as a 1:1 mixture of diastereoisomers (95 mg,
43%). Rf 0.23 (4:1 CHCl3:EtOAc); [D]D28 -82.4 (c 0.40, CHCl3);
Qmax/cm-1 (CHCl3) 3696 (N-H), 3604 (N-H), 3390 (O-H), 2954 (C-
H), 2932 (C-H), 2858 (C-H), 1748 (C=O), 1698 (C=O), 1634
(C=C), 1608 (C=C), 1508, 1456, 1377; GH (400 MHz, CDCl3) 9.38
(1H, s, NH), 9.36 (1H, s, NH), 9.24 (1H, s, NH), 9.18 (1H, s, NH),
7.90 (1H, d, J 7.8, U1-CH), 7.88 (1H, d, J 7.7, U1-CH), 7.38-7.23
(20H, m, 2 x U2-CH and 18 x Ar-H), 7.00 (1H, ddd, J 11.6, 6.2 and
4.3, U2-5-H), 6.90 (1H, ddd, J 10.7, 6.3 and 4.1, U2-5-H), 6.88-
6.83 (8H, m, Ar-H), 6.10 (1H, app td, J 17.4 and 1.7, U2-6-H),
6.05 (1H, app td, 17.1 and 1.7, U2-6-H), 5.94 (1H, d, J 4.4, U1-1-
H), 5.92 (1H, d, J 3.8, U1-1-H), 5.86 (1H, d, J 4.4, U2-2-H), 5.81
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(1H, dd, J 7.8 and 1.1, U2-CH), 5.80 (1H, d, J 4.4, U2-1-H), 5.78
(1H, dd, J 7.7 and 1.3, U2-CH), 5.43-5.38 (2H, app dd, J 10.6 and
5.9, 2 x U2-2-H), 5.29-5.25 (1H, obs m, U1-CH), 5.27 (2H, app dd,
J 6.2 and 5.5, 2 x U2-3-H), 5.23 (1H, dd, J 8.2 and 1.6, U1-CH),
5.01 (1H, ddd, J 9.5, 9.3 and 4.8, U1-3-H), 4.92 (1H, ddd, J 8.8,
8.6 and 4.0, U1-3-H), 4.65-4.61 (1H, m, U2-4-H), 4.54-4.50 (1H,
m, U2-4-H), 4.48 (1H, dd, J 4.8 and 4.4, U1-2-H), 4.46 (1H, dd, J
4.3 and 4.1, U1-2-H), 4.37 (1H, ddd, J 5.4, 4.8 and 2.7, U1-4-H),
4.33 (1H, ddd, J 4.6, 4.4 and 2.3, U1-4-H), 4.30-4.25 (1H, m,
CH2CH2CN), 4.21-4.15 (1H, m, CH2CH2CN), 3.98-3.88 (2H, m,
CH2CH2CN), 3.81 (6H, s, 2 x ArOCH3), 3.80 (6H, s, 2 x ArOCH3),
3.69 (1H, dd, J 11.2 and 2.0, U1-5-H), 3.61-3.57 (1H, m, U1-5-H),
3.55-3.49 (1H, m, U1-5-H), 3.45 (1H, dd, J 11.2 and 2.0, U1-5-H),
2.73 (1H, app t, J 5.9, CH2CH2CN), 2.59 (1H, app ddd, J 24.3, 12.4
and 6.2, CH2CH2CN), 2.56 (1H, app ddd, J 23.4, 12.0 and 6.0,
CH2CH2CN), 2.45 (1H, app ddd, J 17.1, 7.4 and 5.4, CH2CH2CN),
2.13 (3H, s, 2 x U2-2-COCH3), 2.12 (3H, s, 2 x U2-2-COCH3), 2.11
(6H, s, 2 x U2-2-COCH3), 0.89 (9H, s, SiC(CH3)3), 0.87 (9H, s,
SiC(CH3)3), 0.15 (3H, s, SiCH3), 0.14 (6H, s, 2 x SiCH3) and 0.11
(3H, s, SiCH3); GC (100 MHz, CDCl3) 169.66 (COCH3), 169.65
(COCH3), 169.6 (COCH3), 169.5 (COCH3), 163.1 (2 x U-4-C),
162.85 (2 x U-4-C), 158.9 (2 x Ar-COCH3), 158.8 (Ar-COCH3),
158.7 (Ar-COCH3) 150.45 (U-2-C), 150.01 (U-2-C), 148.2 (U-2-C),
148.0 (U-2-C), 144.2 (4 x Ar-C), 141.0 (U-6-CH), 140.7 (U-6-CH),
139.9 (U-6-CH), 139.8 (U-6-CH), 135.04 (2 x Ar-C), 130.4 (3 x Ar-
CH), 130.3 (3 x Ar-CH), 130.2 (2 x Ar-CH), 129.2 (Ar-CH), 128.6
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(Ar-CH), 128.3 (2 x Ar-CH), 128.2 (2 x Ar-CH), 128.1 (2 x Ar-CH),
127.9 (Ar-CH), 127.5 (Ar-CH), 118.9 (d, J 56.9, U2-5-CH), 117.4
(d, J 52.8, U2-5-CH), 116.9 (CN), 116.6 (CN), 113.5 (3 x Ar-CH),
113.4 (3 x Ar-CH), 113.2 (2 x Ar-CH), 103.8 (U-5-CH), 103.6 (U-
5-CH), 102.5 (U-5-CH), 102.4 (U-5-CH), 90.2 (2 x U2-1-CH), 88.8
(U1-1-CH), 88.5 (U1-1-CH), 87.6 (2 x CPh(4-OMe-Ph)2), 81.8 (U1-
4-CH), 81.5 (U1-4-CH), 81.0 (U2-4-CH), 80.8 (U2-4-CH), 80.9 (d,
J 23.9, U2-6-CH), 80.5 (d, J 23.6, U2-6-CH), 74.9 (2 x U1-2-CH),
74.3 (U1-3-CH), 73.6 (U1-3-CH), 72.7 (2 x U2-2-CH), 72.5 (U2-3-
CH), 72.4 (U2-3-CH), 61.8 (U1-5-CH2), 61.7 (U1-5-CH2), 60.9 (d,
J 3.8, CH2CH2CN), 60.80 (d, J 5.0, CH2CH2CN), 55.4 (2 x Ar-OCH3),
55.3 (2 x Ar-OCH3), 25.7 (SiC(CH3)3), 25.6 (SiC(CH3)3), 20.5 (4 x
COCH3), 20.0 (d, J 7.5, CH2CH2CN), 19.8 (d, J 6.3, CH2CH2CN), -
4.76 (SiCH3), -4.79 (SiCH3), -4.86 (SiCH3), -4.91 (SiCH3); GP (121
MHz, CDCl3) 19.1 and 18.9; m/z (ES+) 1122.3551 (M+Na,
C53H62N5NaO17PSi+ requires 1122.3545).
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5-O-(4,4-dimethoxytrityl)-2-O-methyl uridinyl 2-
cyanoethyl-phosphono-[3(O)Æ5(C)]-5-deoxy-5-
methylidene-3-O-methyl(2-naphthyl)-2-O-acetyl uridine
260
Vinyl bromide 218 (102 mg, 203
Pmol), Pd(OAc)2 (9.1 mg, 40.7 Pmol)
and dppf (45.1 mg, 81.4 Pmol) were
combined in a Radleys® Carousel tube
flushed with argon. A solution of H-
phosphonate 254 (179 mg, 264 Pmol)
in freshly distilled THF (2.71 mL) was
added followed by propylene oxide (285 PL, 4.07 mmol). The tube
was then sealed, placed in the carousel and heated at 70 oC. After
6 hours the tube was removed from the heat, then diluted with
CH2Cl2 (2 x 1.5 mL) to transfer to a flask and concentrated in
vacuo then purified by column chromatography (96:4
CH2Cl2:MeOH) to obtain U*U dimer 260 as a pale yellow foam (120
mg, 54%). Rf 0.04 (96:4 CH2Cl2:MeOH); [D]D24 +588 (c 0.76,
CHCl3); Qmax/cm-1 (CHCl3) 3673 (N-H), 3602 (N-H), 3415 (O-H),
3390 (O-H), 3177 (C-H), 3060 (C-H), 3011 (C-H), 2960 (C-H),
2937 (C-H), 2912 (C-H), 2878 (C-H), 2839 (C-H), 1752 (C=O),
1701 (C=O), 1635 (C=C), 1609 (C=C), 1583 (C=C), 1510, 1459,
1416, 1379, 1335; GH (500 MHz, CDCl3) 9.93 (1H, s, NH), 9.85
(1H, s, NH), 9.76 (1H, s, NH), 9.69 (1H, s, NH), 7.90-7.83 (8H, m,
Ar-H), 7.79 (2H, app d, J 7.5, Ar-H), 7.48-7.45 (4H, m, Ar-H),
7.42 (1H, d, J 8.2, U1-CH), 7.42 (1H, d, J 8.2, U1-CH), 7.37-7.26
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(10H, m, Ar-H), 7.25-7.22 (8H, m, Ar-H), 7.21 (1H, d, J 8.1, U2-
CH), 7.16 (1H, d, J 8.1, U2-CH), 7.00 (1H, ddd, J 17.2, 4.5 and
3.8, U2-5-H), 6.95 (1H, ddd, J 17.2, 4.6 and 3.8, U2-5-H), 6.87
(4H, d, J 8.9, Ar-CH), 6.83 (4H, J 8.9, Ar-CH), 6.14 (1H, ddd, J
17.2, 16.4 and 1.6, U2-6-H), 6.04 (1H, d, J 3.8, U1-1-H), 6.02
(1H, d, J 3.5, U1-1-H), 6.02 (1H, ddd, J 37.6, 17.2 and 1.6, U2-6-
H), 5.77-5.75 (3H, m, 2 x U2-1-H and U2-5-CH), 5.73 (1H, dd, J
8.1 and 1.3, U2-5-CH), 5.51 (1H, dd, J 5.9 and 2.8, U2-2-H), 5.47
(1H, dd, J 5.8 and 3.1, U2-2-H), 5.28 (2H, J 8.2 and 1.6, 2 x U1-5-
CH), 5.13 (1H, ddd, J 10.7, 5.3 and 1.6, U1-3-H), 5.06 (1H, ddd, J
11.6, 6.2 and 5.4, U1-3-H), 4.75 (1H, d, J 11.5, U2-3-OCHH), 4.70
(1H, d, J 11.6, U2-3-OCHH), 4.66 (1H, d, J 11.5, U2-3-OCHH),
4.59 (1H, d, J 11.6, U2-3-OCHH), 4.61-4.58 (1H, m, U2-3-H),
4.44 (1H, m, U2-3-H), 4.30 (1H, ddd, J 5.1, 3.8 and 1.6, U1-4-H),
4.28 (1H, ddd, J 7.6 and 5.9, U2-4-H), 4.24 (1H, ddd, J 4.6, 3.8
and 1.6, U1-4-H), 4.20 (1H, dd, J 7.6 and 5.9, U2-4-H), 4.09 (1H,
dd, J 4.6 and 3.8, U1-2-H), 4.08-3.95 (3H, obs m, CH2CH2CN),
3.90-3.84 (1H, m, CH2CH2CN), 4.02 (1H, app dd, J 4.3 and 4.2,
U1-2-H), 3.80 (3H, s, Ar-OCH3), 3.79 (3H, s, Ar-OCH3), 3.75 (3H,
s, Ar-OCH3), 3.74 (3H, s, Ar-OCH3), 3.64 (1H, dd, J 11.0 and 2.2,
U1-5-H), 3.59 (3H, s, U1-2-OCH3), 3.54 (1H, dd, J 11.0 and 2.2,
U1-5-H), 3.48 (1H, dd, J 11.1 and 2.2, U1-5-H), 3.40 (1H, dd, J
11.1 and 2.2, U1-5-H), 3.40 (3H, s, U1-2-OCH3), 2.53 (1H, ddd, J
10.4, 7.2 and 5.4, OCH2CH2CN), 2.48 (1H, ddd, J 11.0, 6.1 and
5.5, OCH2CH2CN), 2.45 (1H, ddd, J 11.3, 7.2 and 5.4,
OCH2CH2CN), 2.40 (1H, ddd, J 17.0, 6.1 and 5.5, OCH2CH2CN),
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2.12 (3H, s, U2-2-COCH3), 2.11 (3H, s, U2-2-COCH3); GC (121
MHz, CDCl3) 170.04 (U2-2-COCH3), 170.02 (U2-2-COCH3), 163.31
(U-4-C), 163.29 (2 x U-4-C), 163.17 (U-4-C), 158.89 (Ar-COCH3),
158.86 (Ar-COCH3), 158.83 (Ar-COCH3), 158.78 (Ar-COCH3),
150.6 (U-2-C), 150.4 (U-2-C), 150.0 (U-2-C), 149.9 (U-2-C),
148.9 (d, J 6.8, U2-5-CH), 148.2 (d, J 6.0, U2-5-CH), 144.2 (Ar-
C), 144.0 (Ar-C), 141.31 (U-6-CH), 141.28 (U-6-CH), 139.6 (U-6-
CH), 139.5 (U-6-CH), 134.97 (Ar-C), 134.95 (Ar-C), 134.86 (Ar-
C), 134.77 (Ar-C), 134.36 (Ar-C), 134.30 (Ar-C), 133.18 (Ar-C),
133.16 (2 x Ar-C), 133.14 (Ar-C), 130.4 (2 x Ar-CH), 130.3 (2 x
Ar-CH), 130.2 (2 x Ar-CH), 130.1 (2 x Ar-CH), 128.51 (Ar-CH),
128.48 (Ar-CH), 128.4 (2 x Ar-CH), 128.1 (6 x Ar-CH), 128.05 (Ar-
CH), 128.01 (Ar-CH), 127.8 (Ar-CH), 127.7 (Ar-CH), 127.4 (Ar-
CH), 127.33 (Ar-CH), 127.26 (Ar-CH), 127.1 (Ar-CH), 126.37 (Ar-
CH), 126.35 (Ar-CH), 126.30 (Ar-CH), 126.29 (Ar-CH), 125.96 (Ar-
CH), 125.84 (Ar-CH), 118.0 (d, J 140, U2-6-CH), 116.8
(CH2CH2CN), 116.5 (d, J 139, U2-6-CH), 116.5 (CH2CH2CN), 113.4
(8 x Ar-CH), 103.3 (U-5-CH), 103.2 (U-5-CH), 102.7 (U-5-CH),
102.6 (U-5-CH), 91.9 (U2-1-CH), 91.4 (U2-1-CH), 87.5 (CPh(4-
OMePh)2), 87.3 (CPh(4-OMePh)2), 86.8 (U1-1-CH), 86.6 (U1-1-
CH), 82.7 (U1-2-CH), 82.3 (U1-2-CH), 81.7 (U1-4-CH), 81.6 (U1-
4-CH), 81.4 (U2-3-CH), 81.2 (U2-3-CH), 80.8 (U2-3-CH), 80.6
(U2-3-CH), 79.2 (U2-4-CH), 78.9 (U2-4-CH), 73.9 (CH2Nap), 73.7
(CH2Nap), 73.6 (U2-2-CH), 73.5 (U2-2-CH), 72.8 (d, J 5.4, U1-3-
CH), 72.0 (d, J 5.3, U1-3-CH), 61.4 (U1-5-CH2), 61.2 (U1-5-CH2),
60.4 (d, J 5.2, CH2CH2CN), 60.1 (d, J 5.5, CH2CH2CN), 58.8 (U1-2-
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OCH3), 58.6 (U1-2-OCH3), 55.4 (2 x Ar-OCH3), 55.3 (2 x Ar-OCH3),
20.8 (U2-2-COCH3), 20.7 (U2-2-COCH3), 19.7 (d, J 8.0,
CH2CH2CN), 19.6 (d, J 7.0, CH2CH2CN); GP (121 MHz, CDCl3) 19.5
and 19.3; m/z (ES+) 1120.3375 (M+Na, C57H56N5NaO16P+ requires
1120.3357).
5-O-(4,4-dimethoxytrityl)-2-O-methyl uridinyl 2-
cyanoethyl-phosphono-[3(O)Æ5(C)]-5-deoxy-5-
methylidene-3-O-methyl-(2-naphthyl)-2-O-acetyl (N-6-
benzoyl)adenosine 261
Vinyl bromide 220 (81.0 mg, 129
Pmol), dppf (28.6 mg, 51.6 Pmol)
and Pd(OAc)2 (5.8 mg, 25.8 Pmol)
were combined in an oven-dried
carousel tube purged with nitrogen.
A solution of H-phosphonate 254
(130 mg, 167 Pmol) in dry THF
(1.75 mL) was added followed by propylene oxide (180 PL, 2.58
mmol). The tube was sealed and placed in a Radleys® Carousel at
70 oC for 6 hours. The reaction mixture was then removed from
heat, transferred to a flask, diluting with CH2Cl2 (2 mL) and
concentrated in vacuo to a orange foam. Purification by column
chromatography (95:5 CH2Cl2:MeOH) obtained U*A dimer 261 as
an orange foam (155 mg, 92%). Rf 0.11 (95:5 CH2Cl2:MeOH);
[D]D28 +26.5 (c 0.95, CHCl3); Qmax/cm-1 (CHCl3) 3698 (N-H), 3606
(N-H), 3394 (O-H), 2954 (C-H), 2935 (C-H), 2875 (C-H), 2839 (C-
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H), 1747 (C=O), 1711 (C=O), 1694 (C=O), 1636 (C=C), 1610
(C=C), 1587 (C=C), 1487, 1456, 1372, 1303; GH (500 MHz, CDCl3)
9.47 (1H, br s, NH), 9.44 (1H, br s, NH), 8.78 (2H, app d, J 6.9, 2
x A-NH), 8.17 (2H, app d, J 13.5, 2 x Ar-H), 8.12 (1H, s, A-8-H),
8.10 (1H, s, A-8-H), 7.95-7.84 (5H, m, 2 x A-2-H, 3 x Ar-H), 7.68-
7.62 (1H, m, Ar-H), 7.59-7.51 (6H, m, 2 x U-6-CH and Ar-H),
7.49-7.42 (1H, m, Ar-H), 7.40-7.35 (4H, m, Ar-H), 7.34-7.20
(16H, m, Ar-H), 7.11 (2H, m, 2 x A-5-H), 6.93-6.84 (8H, m, Ar-
H), 6.23 (1H, dd, J 25.5 and 3.2, A-1-H), 6.09 (1H, dd, J 20.9 and
3.7, A-6-H), 6.03 (2H, app dd, J 3.9 and 3.7, A-1-H and A-2-H),
6.00 (1H, dd, J 4.6 and 3.2, A-2-H), 6.00-5.95 (1H, m, A-6-H),
5.33-5.29 (2H, m, 2 x U-5-CH), 5.17 (1H, dd, J 11.7 and 5.8, U-1-
H), 5.07 (1H, dd, J 11.7 and 6.6, U-1-H), 4.89 (1H, d, J 11.6, A-
3-OCHH), 4.84-4.78 (2H, m, A-3-OCH2 and A-3-H), 4.77-4.73
(1H, m, A-3-H), 4.63 (1H, m, A-4-H), 4.33 (1H, dd, J 5.7 and 2.6,
U-4-H), 4.25-4.23 (1H, m, U-3-H), 4.11 (1H, dd, J 4.2 and 3.3,
A-4-H), 4.09-3.90 (2H, obs m, CH2CH2CN), 4.03 (2H, dd, J 15.7
and 4.1, 2 x U-2-H), 3.97-3.91 (1H, m, U-3-H), 3.86-3.78 (2H,
obs m, CH2CH2CN), 3.86 (6H, s, (6H, s, 2 x Ar-OCH3), 3.85 (6H, s,
2 x Ar-OCH3), 3.83 (1H obs m, U-3-H), 3.80 (3H, s, U-2-OCH3),
3.79 (3H, s, U-2-OCH3), 3.72-3.69 (1H, m, U-5-Ha), 3.61-3.58
(1H, m, U-5-Ha), 3.53-3.50 (1H, m, U-5-Hb), 3.44-3.40 (1H, m,
U-5-Hb), 2.63 (1H, ddd, J 12.6, 6.2 and 6.0, CH2CH2CN), 2.56
(1H, ddd, J 17.4, 6.0 and 5.8, CH2CH2CN), 2.48 (1H, ddd, J 11.9,
6.2 and 6.0, CH2CH2CN), 2.41 (6H, s, 2 x A-2-COCH3), 2.40 (1H,
obs m, CH2CH2CN); GC (125 MHz, CDCl3) 169.9 (A-2-COCH3),
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169.8 (A-2- COCH3), 165.0 (U-4-C), 164.9 (U-4-C), 163.04 (A-
NCOPh), 163.01 (A-NCOPh), 158.86 (A-6-C), 158.80 (A-6-C),
152.82 (A-2-CH), 152.79 (A-2-CH), 152.74 (U-2-C), 152.73 (U-2-
C), 151.50 (Ar-C), 150.20 (Ar-C), 150.14 (2 x A-4-C), 149.1 (d, J
6.9, A-5-CH), 148.1 (d, J 6.5, A-5-CH), 144.2 (2 x Ar-C), 144.0
(2 x A-C), 142.3 (A-8-CH), 140.0 (A-8-CH), 139.7 (2 x U-NCH),
137.9 (4 x Ar-C), 135.03 (Ar-C), 135.00 (Ar-C), 134.91 (Ar-C),
134.81 (Ar-C), 134.28 (Ar-C), 134.24 (Ar-C), 133.25 (2 x Ar-C),
133.20 (Ar-C), 133.19 (Ar-C), 132.93 (Ar-CH), 132.88 (Ar-CH),
132.5 (Ar-CH), 131.89 (Ar-CH), 130.37 (2 x Ar-CH), 130.34 (3 x
Ar-CH), 130.26 (Ar-CH), 130.21 (2 x Ar-CH), 130.19 (Ar-CH),
130.16 (Ar-CH), 130.08 (2 x Ar-CH), 129.10 (2 x Ar-CH), 128.86
(Ar-CH), 128.83 (Ar-CH), 128.60 (Ar-CH), 128.38 (Ar-CH), 128.29
(2 x Ar-CH), 128.27 (Ar-CH), 128.2 (Ar-CH), 128.16 (4 x Ar-CH),
128.13 (Ar-CH), 128.06 (Ar-CH), 127.84 (Ar-CH), 127.83 (Ar-CH),
127.67 (Ar-CH), 127.48 (Ar-CH), 127.34 (Ar-CH), 127.12 (Ar-CH),
126.51 (Ar-CH), 126.43 (Ar-CH), 126.03 (Ar-CH), 125.9 (A-5-C),
125.36 (Ar-CH), 124.0 (A-5-C), 116.5 (CN), 116.39 (CN), 113.4 (8
x Ar-CH), 113.27 d, J 16.5, A-6-CH), 113.16 (d, J 16.3, A-6-CH),
102.6 (U-5-CH), 102.5 (U-5-CH), 88.1 (A-1-CH), 88.0 (A-1-CH),
87.5 (CPh(4-OMePh)2), 87.3 (CPh(4-OMePh)2), 87.0 (2 x U-1-CH),
84.1 (U-4-CH), 83.3 (U-4-CH), 82.8 (A-4-CH), 82.30 (A-4-CH),
81.7 (U-2-CH), 81.3 (U-2-CH), 79.2 (A-3-CH), 78.8 (A-3-CH),
73.8 (OCH2Nap), 73.6 (OCH2Nap), 73.50 (A-2-CH), 73.47 (A-2-
CH), 72.6 (d, J 6.0, U-3-CH), 71.91 (d, J 5.6, U-3-CH), 61.3 (U-
5-CH2), 61.0 (U-5-CH2), 60.3 (d, J 5.2, CH2CH2CN), 60.0 (d, J 5.4,
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CH2CH2CN), 58.7 (U-2-OCH3), 58.6 (U-2-OCH3), 55.4 (2 x Ar-
OCH3), 55.3 (2 x Ar-OCH3), 21.5 (2 x A-2-COCH3), 19.7 (d, J 7.0,
OCH2CH2CN), 19.6 (d, J 6.3, OCH2CH2CN); GP (121 MHz, CDCl3)
19.7 and 19.3; m/z (ES+) 1225.4026 (M+H, C65H62N8O15P+
1225.4072), (M+Na, C65H61N8NaO15P+ requires 1247.3892).
5-O-(4,4-dimethoxytrityl)-2-O-methyl uridinyl 2-
cyanoethylphosphono-[3(O)Æ5(C)]-5-deoxy-5-
methylidene-3-O-methyl(2-naphthyl)-2-O-acetyl (N-6-
benzoyl)cytidine 262
To an oven dried Carousel tube
purged with argon was added vinyl
bromide 226 (150 mg, 248 Pmol),
dppf (55 mg, 99.3 Pmol), Pd(OAc)2
(11 mg, 49.6 Pmol). A solution of H-
phosphonate 254 (251 mg, 323
Pmol) in dry THF (3.30 mL) was
added, followed by propylene oxide (350 PL, 4.96 mmol). The
tube was sealed and placed in the Radleys® Carousel at 70 oC for 6
hours. The tube was then removed from the heat, cooled to r.t.,
and transferred to a flask, diluting with CH2Cl2 (2 x 1 mL) and
concentrated in vacuo to a pale brown foam. Purification by
column chromatography (95:5 CH2Cl2:MeOH) followed by
trituration (Et2O) produced the U*C dimer 262 (286 mg, 96%) as
a 1:1 mixture of diastereoisomers as a pale yellow solid. Rf 0.17
(95:5 CH2Cl2:MeOH); [D]D28 +64.5 (c 2.05, CHCl3); Qmax/cm-1
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(CHCl3) 3395 (N-H), 2995 (C-H), 2954 (C-H), 2933 (C-H), 2913
(C-H), 2882 (C-H), 2841 (C-H), 1744 (C=O), 1692 (C=O), 1631
(C=C), 1610 (C=C), 1580 (C=C), 1554, 1482, 1462, 1369, 1323,
1303; GH (500 MHz, CDCl3) 9.18-8.72 (2H, obs br s, 2 x NHBz),
9.15 (1H, br s, U-NH), 8.89 (1H, br s, U-NH), 7.96-7.91 (4H, m, 4
x Ar-H), 7.86-7.80 (6H, m, U-6-H and 5 x Ar-H), 7.76 (1H, d, J
8.1, U-6-H), 7.74 (1H, s, Ar-H), 7.70 (1H, s, Ar-CH), 7.68 (1, d, J
7.0, C-6-H), 7.64-7.59 (3H, m, Ar-H), 7.62 (1H, d, J 8.4, C-6-H),
7.53-7.42 (10H, m, Ar-H), 7.40-7.32 (8H, m, Ar-H), 7.31-7.23
(14H, m, Ar-H), 7.02 (1H, ddd, J 1.73, 5.9 and 4.0, C-5-H), 6.98
(1H, ddd, J 17.0, 5.9 and 3.7, C-5-H), 6.88-6.81 (8H, m, Ar-H),
6.16-5.95 (2, m, 2 x C-6-H), 6.08 (1H, d, J 4.3, U-1-H), 6.01
(1H, d, J 2.7, U-1-H), 5.90 (1H, app s, C-5-H), 5.84 (1H, app s, C-
5-H), 5.69 (1H, d, J 4.8, C-1-H), 5.64 (1H, d, J 4.6, C-1-H), 5.28
(1H, d, J 8.1, U-5-CH), 5.27 (1H, d, J 8.3, U-5-CH), 5.17 (1H, dd, J
11.8 and 5.0, U-3-H), 5.05 (1H, dd, J 11.5 and 6.3, U-3-H), 4.76-
4.69 (1H, obs m, C-3-H), 4.75 (1H, d, J 11.4, OCH2Nap), 4.74
(1H, d, J 11.4, OCH2Nap), 4.64-4.48 (1H, obs m, C-3-H), 4.57
(1H, d, J 11.4, OCH2Nap), 4.52 (1H, d, J 11.4, OCH2Nap), 4.32
(1H, app d, J 2.2, U-4-H), 4.25-4.20 (2H, m, U-4-H and C-2-H),
4.17-4.12 (1H, obs m, U-2-H), 4.15 (1H, dd, J 8.5 and 5.4,
OCH2CH2CN), 4.10-4.03 (1H, obs m, U-2-H), 4.09 (1H, app dd, J
3.8 and 3.7, C-4-H), 4.04 (1H, dd, J 4.5 and 4.0, C-2-H), 4.07-
3.97 (3H, obs m, C-4-H and 2 x OCH2CH2CN), 3.96-3.90 (1H, m,
OCH2CH2CN), 3.81 (3H, s, Ar-OCH3), 3.80 (3H, s, Ar-OCH3), 3.75
(3H, s, Ar-OCH3), 3.74 (3H, s, Ar-OCH3), 3.64-3.46 (1H, obs m, U-
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5-H), 3.59 (3H, s, U-2-OCH3), 3.26 (3H, s, U-2-OCH3), 3.39 (1H,
dd, J 13.9 and 4.6, U-5-H), 2.57 (1H, ddd, J 16.7, 7.2 and 6.2,
OCH2CH2CN), 2.57-2.51 (2H, obs m, OCH2CH2CN), 2.47 (1H, d, J
16.8, 6.1 and 5.6, OCH2CH2CN), 2.17 (3H, s, C-2-COCH3), 2.16
(3H, s, C-2-COCH3); GC (125 MHz, CDCl3) 169.9 (COCH3), 169.7
(COCH3), 162.9 (2 x C-4-C), 162.8 (2 x U-4-C), 158.94 (Ar-
COCH3), 158.92 (Ar-COCH3), 158.86 (Ar-COCH3), 158.81 (Ar-
COCH3), 150.7 (Ar-C), 150.6 (Ar-C), 150.2 (2 x C-2-C), 149.0 (d, J
6.7, C-5-CH), 147.8 (d, J 6.0, C-5-CH), 144.9 (C-6-CH), 144.2
(Ar-C), 144.1 (Ar-C), 139.67 (2 x U-6-CH), 139.42 (C-6-CH),
134.98 (2 x Ar-C), 134.84 (Ar-C), 134.35 (Ar-C), 134.28 (Ar-C),
133.4 (Ar-CH), 133.3 (Ar-CH), 133.2 (3 x Ar-C), 130.4 (2 x Ar-
CH), 130.3 (2 x Ar-CH), 130.2 (2 x Ar-CH), 130.1 (2 x Ar-CH),
129.1 (2 x Ar-CH), 129.0 (2 x Ar-CH), 128.5 (2 x Ar-CH), 128.4 (2
x Ar-CH), 128.19 (6 x Ar-CH), 128.15 (2 x Ar-CH), 128.13 (Ar-
CH), 128.07 (Ar-CH), 127.96 (Ar-CH), 127.78 (2 x Ar-CH), 127.72
(Ar-CH), 127.5 (Ar-CH), 127.38 (Ar-CH), 127.36 (Ar-CH), 127.2
(Ar-CH), 126.36 (Ar-CH), 126.34 (Ar-CH), 126.31 (2 x Ar-CH),
126.1 (Ar-CH), 125.9 (Ar-CH), 118.1 (d, J 171, C-6-CH), 116.6 (d,
J 171, C-6-CH), 116.7 (OCH2CH2CN), 116.5 (OCH2CH2CN), 113.5
(4 x Ar-CH), 113.4 (4 x Ar-CH), 103.0 (U-5-CH), 102.5 (U-5-CH),
93.1 (C-5-CH), 92.9 (C-5-CH), 87.5 (CPh(4-OMePh)2, 87.4 (CPh(4-
OMePh)2, 87.03 (U-1-CH), 86.28 (U-1-CH), 82.8 (U-2-CH), 82.4
(U-2-CH), 82.0 (d, J 6.8, C-4-CH), 81.6 (d, J 8.4, C-4-CH), 81.3
(U-4-CH), 81.1 (U-4-CH), 80.9 (C-1-CH), 80.7 (C-1-CH), 78.9 (2
x C-2-CH), 73.8 (C-3-CH), 73.7 (2 x OCH2Nap), 73.4 (C-3-CH),
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72.0 (U-3-CH), 71.9 (U-3-CH), 61.7 (U-5-CH2), 61.1 (U-5-CH2),
60.4 (d, J 5.3, OCH2CH2CN), 60.1 (d, J 5.3, OCH2CH2CN), 58.8 (U-
2-OCH3), 58.6 (U-2-OCH3), 55.4 (2 x Ar-OCH3), 55.3 (2 x Ar-
OCH3), 20.9 (C-2-COCH3), 20.8 (C-2-COCH3), 19.8 (d, J 7.1,
OCH2CH2CN), 19.7 (d, J 6.6, OCH2CH2CN), 14.3 (C-2-COCH3),
14.1 (C-2-COCH3); GP (121 MHz, CDCl3) 19.5 and 19.1; m/z (ES+)
1223.3742 (M+Na, C64H61N6NaO16P+ requires 1223.3779).
5-O-(4,4-dimethoxytrityl)-2-O-methyl uridinyl 2-
cyanoethylphosphono-[3(O)Æ5(C)]-5-deoxy-5-
methylidene-3-O-methyl(2-naphthyl)-2-O-acetyl (O-6-
(N,N-diphenylcarbamoyl N-2-iso-butyryl)guanosine 263
Vinyl bromide 230 (104 mg,
129 Pmol), Pd(OAc)2 (5.8
mg, 25.8 Pmol) and dppf
(28.6 mg, 51.6 Pmol) were
combined in a Radleys®
Carousel tube flushed with
argon. A solution of H-
phosphonate 254 (114 mg, 168 Pmol) in freshly distilled THF (1.7
mL) was added followed by propylene oxide (181 PL, 2.58 mmol).
The tube was then sealed, placed in the carousel and heated at 70
oC. After 6 hours the tube was removed from the heat, diluted
with CH2Cl2 (2 x 1 mL) to transfer to a flask then concentrated in
vacuo and purified by column chromatography (96:4 CH2Cl2:MeOH)
to a pale yellow foam of U*G dimer 263 (140 mg, 83%). Rf 0.34
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(97:3 CH2Cl2:MeOH); [D]D28 +271 (c 0.37, CHCl3); Qmax/cm-1
(CHCl3) 3411 (N-H), 3392 (N-H), 2948 (C-H), 2936 (C-H), 2903
(C-H), 2864 (C-H), 1746 (C=O), 1721 (C=O), 1707 (C=O), 1694
(C=O), 1621 (C=C), 1609 (C=C), 1589 (C=C), 1496, 1491, 1455,
1386, 1373, 1342, 1323, 1304; GH (500 MHz, CDCl3) 9.50-9.15
(2H, 2 x br s, 2 x NHCOiPr), 8.76 (1H, br s, U-NH), 8.59 (1H, br s,
U-NH), 7.98 (1H, app d, J 2.8, G-8-H), 7.97 (1H, app d, J 2.7, G-
8-H), 7.86-7.81 (8H, m, 2 x U-6-H and 6 x Ar-H), 7.80 (1H, s, Ar-
H), 7.77 (1H, s, Ar-H), 7.61 (1H, s, Ar-H), 7.60 (1H, s, Ar-H), 7.59
(1H, s, Ar-H), 7.58 (1H, s, Ar-H), 7.51-7.40 (16H, m, 16 x Ar-H),
7.39-7.29 (13H, m, 13 x Ar-H), 7.27-7.20 (11H, m, 11 x Ar-H),
7.21-7.07 (2H, m, G-5-H), 6.88-6.80 (8H, m, 8 x Ar-H), 6.07-5.90
(6H, m, 2 x G-1-H, 2 x G-6-H, 2 x U-1-H), 5.90-5.85 (2H, m, 2 x
G-2-H), 5.28-2.22 (1H, obs dd, G-3-H), 5.26 (1H, d, J 8.5, U-5-
H), 5.24 (1H, d, J 8.7, U-5-H), 5.18 (1H, dd, J 11.6 and 5.4, G-3-
H), 5.12 (1H, dd, J 11.6 and 5.7, U-3-H), 5.05 (1H, dd, J 11.6 and
5.7, U-3-H), 4.70 (1H, dd, J 7.4 and 7.0, G-4-H), 4.59-4.55 (1H,
m, G-4-H), 4.29 (1H, app d, J 5.7, U-2-H), 4.21 (1H, app d, J 5.7,
U-2-H) 4.16-4.07 (3H, m, U-4-H and OCH2CH2CN), 4.03-3.92
(3H, m, U-4-H and OCH2CH2CN), 3.80 (3H, d, J 4.8, Ar-OCH3),
3.79 (3H, d, 5.5, Ar-OCH3), 3.73 (3H, s, Ar-OCH3), 3.72 (3H, s, Ar-
OCH3), 3.58 (3H, s, U-2-OCH3), 3.54-3.44 (4H, m, 2 x U-5-CHH),
3.37 (3H, s, U-2-OCH3), 2.62 (1H, dd, J 6.8 and 5.5, OCH2CH2CN),
2.60 (1H, dd, J 5.8 and 5.2, OCH2CH2CN), 2.44 (1H, dd, J 6.7 and
6.5, OCH2CH2CN), 2.43 (1H, dd, J 6.7 and 6.5, OCH2CH2CN), 2.10
(3H, s, G-2-OCOCH3), 2.09 (3H, s, G-2-OCOCH3), 1.30 (3H, d, J
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6.4, COCH(CH3)2), 1.24 (3H, d, J 6.8, COCH(CH3)2), 1.22 (3H, d, J
6.8, COCH(CH3)2), 1.21 (3H, d, J 6.4, COCH(CH3)2); ฀C (125 MHz,
CDCl3) 175.4 (NHCOiPr), 175.2 (NHCOiPr), 169.93 (G-2-COCH3),
169.88 (G-2-COCH3), 163.2 (U-4-C), 163.1 (U-4-C), 158.91 (Ar-
C), 158.90 (Ar-C), 158.86 (Ar-C), 158.81 (Ar-C), 156.46 (G-2-C),
156.44 (G-2-C), 154.0 (2 x G-NC), 152.34 (U-2-C), 152.32 (U-2-
C), 150.44 (G-4-C), 150.42 (G-4-C), 150.3 (2 x G-6-C), 149.8 (d,
J 6.8, G-5-CH), 149.1 (d, J 5.3, G-5-CH), 144.15 (Ar-C), 143.53
(G-8-CH), 143.45 (G-8-CH), 141.81 (Ar-C), 139.75 (2 x U-6-CH),
137.92 (Ar-C), 135.39 (Ar-C), 135.17 (Ar-C), 135.11 (Ar-C),
135.07 (Ar-C), 135.02 (Ar-C), 135.00 (Ar-C), 134.97 (Ar-C),
134.84 (Ar-C), 134.07 (Ar-C), 133.28 (Ar-C), 133.26 (Ar-C),
133.22 (Ar-C), 133.14 (Ar-C), 131.93 (Ar-CH), 131.8 (2 x Ar-CH),
131.6 (2 x Ar-CH), 131.4 (2 x Ar-CH), 131.3 (2 x Ar-CH), 130.36
(2 x Ar-CH), 130.33 (2 x Ar-CH), 130.28 (2 x Ar-CH), 130.21 (2 x
Ar-CH), 130.09 (2 x Ar-CH), 129.3 (2 x Ar-CH), 129.2 (2 x Ar-CH),
129.10 (2 x Ar-CH), 128.44 (2 x Ar-CH), 128.37 (2 x Ar-CH),
128.36 (2 x Ar-CH), 128.29 (2 x Ar-CH), 128.25 (2 x Ar-CH),
128.19 (2 x Ar-CH), 128.15 (2 x Ar-CH), 128.09 (2 x Ar-CH),
127.98 (2 x Ar-CH), 127.79 (2 x Ar-CH), 127.4 (d, J 11.0,Ar-CH),
127.0 (d, J 3.2, Ar-CH), 126.3 (d, J 2.9, Ar-CH), 126.2 (d, J 4.0,
Ar-CH), 126.0 (d, J 3.3, Ar-CH), 125.4 (2 x Ar-CH), 121.96 (G-5-
C), 121.92 (G-5-C), 118.0 (d, J 179, G-6-CH), 117.5 (d, J 178, G-
6-CH), 116.6 (CN), 116.5 (CN), 113.43 (8 x Ar-CH), 102.6 (U-5-
CH), 102.5 (U-5-CH), 88.6 (d, J 12.6, U-1-CH), 88.5 (d, J 11.3, U-
1-CH), 87.45 (CPh(4-OMePh)2, 87.36 (CPh(4-OMePh)2, 87.0 (G-1-
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CH), 86.9 (G-1-CH), 82.9 (U-4-CH), 82.5 (d, J 15.0, G-4-CH),
82.3 (d, J 9.9, G-4-CH), 82.3 (U-4-CH), 81.75 (d, J 3.1, U-2-CH),
81.67 (d, J 1.7, U-2-CH), 79.6 (G-3-CH), 79.4 (G-3-CH), 74.2
(G-2-CH), 74.1 (G-2-CH), 73.9 (d, J 4.7,U-2-CH), 73.74
(CH2Nap), 73.66 (CH2Nap), 73.56 (d, J 6.3, U-2-CH), 72.6 (d, J
5.6, U-3-CH), 72.0 (d, J 5.2, U-3-CH), 61.4 (U-5-CH2), 61.1 (U-
5-CH2), 60.5 (d, J 5.1, OCH2CH2CN), 60.1 (d, J 4.7, OCH2CH2CN),
58.8 (U-2-OCH3), 58.6 (U-2-OCH3), 55.4 (2 x Ar-OCH3), 55.3 (2 x
Ar-OCH3), 36.0 (COCH(CH3)2), 35.9 (COCH(CH3)2), 21.5 (d, J 3.8,
G-2-COCH3), 20.7 (d, J 3.6, G-2-COCH3), 19.64 (d, J 6.1,
OCH2CH2CN), 19.59 (d, J 5.8, OCH2CH2CN), 19.5 (COCH(CH3)2),
19.41 (COCH(CH3)2), 19.36 (COCH(CH3)2), 19.30 (COCH(CH3)2); GP
(121 MHz, CDCl3) 19.86 and 19.58; m/z (ES+) 1402.4801 (M+H,
C75H73N9O17P+ requires 1402.4857), 1424.4460 (M+Na,
C75H73N9NaO17P+ requires 1424.4676).
5-O-(4,4-dimethoxytrityl)-2-O-methyl (N-6-benzoyl)-
adenosine 2-cyanoethylphosphono-[3(O)Æ5(C)]-5-deoxy-
5-methylidene-3-O-methyl(2-naphthyl)-2-O-acetyl (N-6-
benzoyl)adenosine 264
Vinyl bromide 238 (120 mg, 191
Pmol), Pd(OAc)2 (8.6 mg, 38.2
Pmol), dppf (42.3 mg, 76.4 Pmol)
and H-phosphonate 255 (184 mg,
229 Pmol) were all combined in a
Radleys® Carousel tube purged with
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argon. Freshly distilled THF (2.55 mL) was added followed by
propylene oxide (267 PL, 3.82 mmol), the tube was then sealed
and heated at 70 oC for 6 hours. After this time, the tube was
removed from the heat, cooled to r.t. and transferred to a flask,
diluting with CH2Cl2 (2 mL). The solution was evaporated to
dryness and the residue purified by column chromatography (96:4
CH2Cl2:MeOH) to obtain the pale yellow solid A*A dimer 264 as a
1.66:1.00 mixture of diastereoisomers (260 mg, 99%). Rf 0.11
(96:4 CH2Cl2:MeOH); [D]D25 +3.81 (c 1.20, CHCl3); Qmax/cm-1
(CHCl3) 3668 (N-H), 3626 (N-H), 3403 (N-H), 2990 (C-H), 2936
(C-H), 2838 (C-H), 1748 (C=O), 1709 (C=O), 1612 (C=C), 1587
(C=C), 1504, 1485, 1456, 1401, 1356, 1328, 1301; GH (500 MHz,
CDCl3) 9.21 (1H, br s, NH), 9.12 (3H, br s, 3 x NH), 8.75 (1H, s, A-
H), 8.73 (1H, s, A-2-H), 8.70 (1H, s, A-2-H), 8.66 (1H, s, A-2-H),
8.33 (1H, s, A-2-H), 8.18 (1H, s, A-8-H), 8.17 (1H, s, A-8-H), 8.15
(1H, s, A-8-H), 8.11-8.04 (8H, m, Ar-8-H), 7.96-7.85 (8H, m, Ar-
H), 7.68-7.62 (4H, m, Ar-H), 7.60-7.52 (14H, m, Ar-H), 7.50-7.42
(6H, m, Ar-H), 7.39-7.22 (12H, m, Ar-H), 7.06-6.96 (2H, m, A2-5-
H), 6.88-6.82 (8H, m, Ar-H), 6.30 (1H, d, J 3.5, A1-1-H), 6.23
(1H, d, J 3.1, A1-1-H), 6.16 (1H, d, J 2.7, A2-1-H), 6.15 (1H, d, J
2.5, A2-1-H), 6.16-6.04 (2H, obs m, 2 x A2-6-H), 6.00-5.97 (2H,
m, 2 x A1-2-H), 5.33-5.29 (1H, m, A2-3-H), 5.25-5.22 (1H, m, A2-
3-H), 4.94 (2H, app dd, J 11.5 and 6.5, 2 x A2-2-H), 4.91-4.75
(6H, m, 2 x A1-3-H, 1 x A1-4-H, 2 x A2-3-OCHH), 4.68-4.64 (1H,
m, A1-4-H), 4.48-4.47 (1H, m, A2-4-H), 4.39-4.35 (1H, m, A2-4-
H), 4.18-3.91 (4H, m, 2 x OCH2CH2CN), 3.83 (6H, s, 2 x Ar-OCH3),
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3.79 (6H, s, 2 x Ar-OCH3), 3.65 (1H, dd, J 11.1 and 4.6, A1-5-H),
3.57 (1H, dd, J 13.6 and 8.9, A1-5-H), 3.54-3.48 (1H, m, A1-5-H),
3.52 (3H, s, A1-2-OCH3), 3.38 (1H, dd, J 10.6 and 3.7, A1-5-H),
3.30 (3H, s, A1-2-OCH3), 2.68-2.48 (4H, m, 2 x OCH2CH2CN), 2.22
(3H, s, A2-2-OCOCH3), 2.20 (3H, s, A2-2-OCOCH3); GC (100 MHz,
CDCl3) 169.88 (A2-2-COCH3), 169.85 (A2-2-COCH3), 164.6 (2 x
NHCOPh), 158.74 (Ar-COCH3), 158.71 (Ar-COCH3), 158.69 (Ar-
COCH3), 158.64 (Ar-COCH3), 152.8 (2 x A-2-CH), 152.7 (A-2-CH),
152.6 (A-2-CH), 151.8 (2 x A-6-C), 151.5 (A-6-C), 151.4 (A-6-C),
150.0 (A-4-C), 149.7 (A-4-C), 148.7 (d, J 6.9, A2-5-CH), 147.8 (d,
J 6.7, A2-5-CH), 144.33 (A-4-C), 144.29 (A-4-C), 142.8 (A-8-CH),
142.2 (A-8-CH), 142.1 (2 x A-8-CH), 135.5 (Ar-C), 135.4 (Ar-C),
135.35 (2 x Ar-C), 134.22 (Ar-C), 134.18 (Ar-C), 133.6 (Ar-C),
133.4 (Ar-C), 133.3 (2 x Ar-C), 133.2 (2 x Ar-C), 132.99 (Ar-CH),
132.93 (Ar-CH), 132.88 (Ar-CH), 132.85 (Ar-CH), 132.5 (2 x Ar-
C), 131.9 (2 x Ar-C), 130.20 (Ar-CH), 130.18 (Ar-CH), 130.13 (4 x
Ar-CH), 130.08 (2 x Ar-CH), 128.96 (2 x Ar-CH), 128.93 (3 x Ar-
CH), 128.91 (4 x Ar-CH), 128.63 (2 x Ar-CH), 128.28 (2 x Ar-CH),
128.21 (3 x Ar-CH), 128.09 (2 x Ar-CH), 128.07 (2 x Ar-CH),
127.99 (7 x Ar-CH), 127.95 (5 x Ar-CH), 127.83 (Ar-CH), 127.81
(Ar-CH), 127.5 (Ar-CH), 127.4 (Ar-CH), 127.21 (Ar-CH), 127.16
(Ar-CH), 126.55 (Ar-CH), 126.53 (Ar-CH), 126.47 (Ar-CH), 126.45
(Ar-CH), 126.1 (Ar-CH), 125.9 (Ar-CH), 123.94 (A-5-C), 123.88
(A-5-C), 123.81 (A-5-C), 123.71 (A-5-C), 118.5 (d, J 116, A2-6-
CH), 117.0 (d, J 113, A2-6-CH), 116.5 (OCH2CH2CN), 116.4
(OCH2CH2CN), 113.29 (4 x Ar-CH), 113.27 (4 x Ar-CH), 88.0 (A1-
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1-CH), 87.9 (A1-1-CH), 87.1 (CPh(4-OMePh)2, 87.0 (CPh(4-
OMePh)2, 86.3 (A2-1-CH), 86.3 (A2-1-CH), 83.5 (d, J 5.2, A2-4-
H), 83.3 (d, J 5.0, A2-4-CH), 81.8 (d, J 23.8, A1-4-CH), 81.2 (d, J
22.9, A1-4-CH), 81.0 (d, J 1.5, A2-2-CH), 80.7 (d, J 1.9, A2-2-
CH), 79.0 (A1-3-CH), 78.8 (A1-3-CH), 74.2 (A2-3-CH), 74.1 (A2-
3-CH), 73.63 (d, J 25.3, A1-2-CH), 73.55 (d, J 18.1, A1-2-CH),
62.8 (A1-5-CH2), 62.5 (A1-5-CH2), 60.2 (d, J 5.3, OCH2CH2CN),
60.0 (d, J 5.0, OCH2CH2CN), 58.9 (A1-2-OCH3), 58.8 (A1-2-OCH3),
55.34 (2 x Ar-OCH3), 55.28 (2 x Ar-OCH3), 22.7 (A2-2-COCH3),
20.8 (A2-2-COCH3), 19.8 (d, J 2.0, OCH2CH2CN), 19.7 (d, J 1.8,
OCH2CH2CN); GP (121 MHz, CDCl3) 19.6 (minor) and 19.3 (major);
m/z (ES+) 1353.4558 (M+H, C73H67N11O14P+ requires 1353.4607),
1374.4418 (M+Na, C73H66N11NaO14P+ requires 1374.4421).
5-O-(4,4-dimethoxytrityl)-2-O-methyl (N-6-benzoyl)-
adenosine 2-cyanoethylphosphono-[3(O)Æ5(C)]-5-deoxy-
5-methylidene-3-O-acetyl-2-O-acetyl (O-6-(N,N-
diphenylcarb-amoyl N-2-iso-butyryl)guanosine 265
Vinyl bromide 249 (75 mg,
106 Pmol), H-phosphonate
255 (103 mg, 127 Pmol),
Pd(OAc)2 (4.8 mg, 21.2
Pmol) and dppf (23.5 mg,
42.4 Pmol) were combined in
an oven dried Carousel tube
purged with Argon. Freshly distilled THF (1.4 mL) was added
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followed by propylene oxide (148 PL, 212 Pmol) and the tube was
then sealed and heated at 70 oC for 6 hours. The reaction mixture
was then cooled to r.t., transferred to a flask, diluting with CH2Cl2
(2 mL) and concentrated in vacuo to an orange foam. Purification
by column chromatography (95:5 CH2Cl2:MeOH) obtained A*G
dimer 265 (138 mg, 91%) as a pale yellow foam. Rf 0.32 and
0.32 (95:5 CH2Cl2:MeOH); [D]D22 +0.34 (c 1.27, CHCl3); Qmax/cm-1
(CHCl3) 3697 (N-H), 3605 (N-H), 3414 (O-H), 2961 (C-H), 2935
(C-H), 2910 (C-H), 2874 (C-H), 2838 (C-H), 1749 (C=O), 1713
(C=O), 1611 (C=C), 1588 (C=C), 1490, 1456, 1388, 1373, 1336,
1324, 1303; GH (500 MHz, CDCl3) 9.22 (1H, br s, NH), 9.20 (1H, br
s, NH), 8.87-8.61 (4H, m, 2 x NH and 2 x A-2-H), 8.28-8.14 (2H,
m, 2 x 8-H), 8.04-7.98 (8H, m, 2 x 8-H, 6 x Ar-H), 7.90-7.80 (3H,
m, 2 x Ar-H), 7.60-7.57 (3H, m, 3 x Ar-H), 7.51-7.15 (36H, m, 36
x Ar-H), 7.08-6.91 (2H, m, 2 x G-5-H), 6.82-6.77 (8H, m, Ar-H),
6.26-6.01 (6H, m, 2 x A-1-H, 2 x G-1-H, 2 x G-6-H), 6.00-5.95
(1H, dd, J 5.7 and 5.4, G-2-H), 5.95-5.92 (1H, dd, J 6.1 and 5.4,
G-2-H), 5.88-5.78 (1H, m, G-3-H), 5.67-5.63 (1H, m, G-3-H),
5.32-5.28 (1H, m, A-3-H), 5.25-5.20 (1H, m, A-3-H), 4.99-4.95
(2H, m, 2 x G-4-H), 4.78-4.65 (1H, m, G-4-H), 4.63-4.59 (1H, m,
G-4-H), 4.48-4.44 (1H, m, A-4-H), 4.41-4.38 (1H, m, A-4-H),
4.30-4.25 (2H, m, OCH2CH2CN), 4.24-4.08 (2H, m, OCH2CH2CN),
3.78 (3H, s, Ar-OCH3), 3.77 (3H, s, Ar-OCH3), 3.76 (3H, s, Ar-
OCH3), 3.75 (3H, s, Ar-OCH3), 3.52-3.32 (4H, m, 2 x A-5-CHH),
3.49 (3H, s, A-2-OCH3), 3.33 (3H, s, A-2-OCH3), 3.06-2.94 (2H,
m, COCH(CH3)2), 2.73 (1H, dd, J 6.3 and 6.2, OCH2CH2CN), 2.68-
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2.55 (2H, m, OCH2CH2CN), 2.52-2.47 (1H, m, OCH2CH2CN), 2.18
(3H, s, G-3-COCH3), 2.16 (3H, s, G-3-COCH3), 2.06 (3H, s, G-2-
COCH3), 2.04 (3H, s, G-2-COCH3), 1.27-1.14 (12H, m, 2 x G-
CH(CH3)2); GC (125 MHz, CDCl3) 176.0 (NHCOiPr), 174.6
(NHCOiPr), 169.7 (G-3-COCH3), 169.5 (G-3-COCH3), 169.4 (G-2-
COCH3), 169.3 (G-2-COCH3), 164.8 (2 x A-NHCOPh), 158.74 (2 x
Ar-C), 158.71 (2 x Ar-C), 156.54 (G-4-C), 156.51 (G-4-C), 154.5
(G-6-C), 154.4 (G-6-C), 152.7 (G-2-C), 152.63 (G-2-C), 152.62
(A-2-CH), 152.5 (A-2-CH), 151.9 (A-6-C), 151.8 (A-6-C), 150.44
(CONPh2), 150.41 (CONPh2), 149.8 (2 x A-4-C), 148.1 (d, J 7.2, G-
5-CH), 147.5 (d, J 6.9, G-5-CH), 144.5 (Ar-C), 144.32 (2 X Ar-C),
144.30 (Ar-C), 143.02 (8-CH), 142.94 (8-CH), 142.87 (8-CH),
142.3 (8-CH), 141.8 (2 x Ar-C), 135.5 (Ar-C), 135.44 (Ar-C),
135.40 (2 x Ar-C), 133.7 (Ar-C), 133.6 (Ar-C), 132.84 (2 x Ar-CH),
130.18 (4 x Ar-CH), 138.15 (5 x Ar-CH), 130.10 (4 x Ar-CH),
129.24 (3 x Ar-CH), 129.21 (2 x Ar-CH), 128.86 (6 x Ar-CH),
128.4 (Ar-CH), 128.3 (3 x Ar-CH), 128.2 (3 x Ar-CH), 128.05 (4 x
Ar-CH), 128.01 (3 x Ar-CH), 127.99 (5 x Ar-CH), 127.78 (Ar-CH),
127.19 (Ar-CH), 127.15 (Ar-CH), 123.81 (5-C), 123.78 (5-C),
121.9 (2 x 5-C), 119.6 (d, J 78.5, G-6-CH), 118.0 (d, J 76.7, G-6-
CH), 116.6 (CN), 116.4 (CN), 113.2 (8 x Ar-CH), 86.8 (1-CH),
86.4 (2 x 1-CH), 86.3 (1-CH), 83.42 (d, J 6.5, A-4-CH), 83.36 (d,
J A-4-CH), 82.4 (d, J 2.45, G-4-CH), 81.8 (d, J 23.9, G-4-CH),
80.9 (d, J 2.1, A-2-CH), 80.6 (d, J 1.7, A-2-H), 74.5 (d, J 5.8, A-
3-CH), 74.0 (d, J 6.2, A-3-CH), 73.5 (G-3-CH), 73.1 (G-3-CH),
71.9 (G-2-CH), 71.8 (G-2-CH), 62.7 (A-5-CH2), 62.6 (A-5-CH2),
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60.7 (d, J 5.3, OCH2CH2CN), 60.4 (d, J 5.1, OCH2CH2CN), 59.0 (A-
2-OCH3), 58.9 (A-2-OCH3), 55.33 (2 x Ar-OCH3), 55.29 (2 x Ar-
OCH3), 35.7 (COCH(CH3)2), 35.6 (COCH(CH3)2), 20.7 (G-3-
COCH3), 20.6 (G-3-COCH3), 20.4 (2 x G-2-COCH3), 19.80 (d, J
6.9, OCH2CH2CN), 19.78 (d, J 5.8, OCH2CH2CN), 19.44
(COCH(CH3)2), 19.39 (COCH(CH3)2), 19.34 (COCH(CH3)2), 19.32
(COCH(CH3)2); GP (121 MHz, CDCl3) 19.5 and 19.0; m/z (ES+)
1431.4834 (M+H, C74H72N12O17P+ requires 1431.4876), 1453.4639
(M+Na, C74H71N12NaO17P+ requires 1453.4695)
5-O-(4,4-dimethoxytrityl)-2-O-(tert-butyldimethylsilyl)
uridinyl 2-cyanoethylphosphono-[3(O)Æ5(C)]-5-deoxy-5-
methylidene-2-O-(tert-butyldimethylsilyl) uridine 266
Vinyl bromide 235 (58 mg, 134 Pmol),
dppf (29.7 mg, 53.5 Pmol) and
Pd(OAc)2 (6.0 mg, 26.8 Pmol) were
combined in a Carousel tube. A
solution of H-phosphonate 251 (135
mg, 174 Pmol) in freshly distilled THF
(1.78 mL) was added followed by
propylene oxide (187 mL, 2.68 Pmol). The carousel tube was
sealed and heated at 70 oC for 6 hours, then cooled to r.t. and
evaporated to an orange foam. Purification by column
chromatography (96:4 CH2Cl2:MeOH) obtained a 7:3 mixture of
diastereoisomers of U*U dimer 266 (117 mg, 77%) as a pale
yellow solid. Rf 0.29 and 0.21 (97:3 CH2Cl2:MeOH); [D]D29 -38.7 (c
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0.17, CHCl3); Qmax/cm-1 (CHCl3) 3392 (N-H), 3215 (O-H), 3062 (C-
H), 2976 (C-H), 2959 (C-H), 2932 (C-H), 2859 (C-H), 2714 (C-H),
1697 (C=O), 1636 (C=C), 1608 (C=C), 1485, 1459, 1438, 1389,
1364, 1310; GH (400 MHz, CDCl3) 9.56 (1H, br s, NH), 9.51 (1H, br
s, NH), 9.49 (1H, br s, NH), 9.45 (1H, br s, NH), 7.88 (2H, app d, J
8.2, U1-6-H major and U1-6-H minor), 7.86-7.42 (2H, m, Ar-H
major and Ar-H minor), 7.37-7.33 (4H, m, 2 x Ar-H major and 2 x
Ar-H minor), 7.32-7.22 (14H, m, U2-6-H major, U2-6-H minor, 6 x
Ar-H major and 6 x Ar-H minor), 7.05 (1H, ddd, J 23.6, 17.3 and
4.0, U2-5-H minor), 6.99 (1H, ddd, J 23.4, 17.1 and 4.0, U2-5-H
major), 6.88-6.83 (8H, m, 4 x Ar-H major and 4 x Ar-H minor),
6.10 (1H, ddd, J 20.8, 17.3 and 1.7, U2-6-H minor), 6.03 (1H,
ddd, J 20.6, 17.4 and 1.8, U2-6-H major), 5.97 (1H, d, J 4.6, U1-
1-H major), 5.93 (1H, d, J 3.9, U1-1-H minor), 5.78 (1H, app dd,
J 8.2 and 2.0, U2-5-H minor), 5.77 (1H, app dd, J 8.2 and 2.0, U2-
5-H major), 5.76 (1H, d, J 2.6, U2-1-H minor), 5.72 (1H, d, J 3.4,
U2-1-H major), 5.27 (1H, app dd, J 8.2 and 2.0, U1-5-H major),
5.02 (1H, app ddd, J 9.3, 5.0 and 4.5, U1-3-H minor), 5.01 (1H,
app dd, J 8.2 and 2.0, U1-5-H minor), 4.92 1H, app ddd, J 8.8, 4.5
and 4.3, U1-3-H major), 4.51-4.46 (1H, obs m, U1-2-H minor),
4.48 (1H, app dd, 4.5 and 4.6, U1-2-H major), 4.38-4.36 (2H, m,
U1-4-H major and U2-4-H minor), 4.35-4.30 (4H, m, U1-4-H
minor, U2-4-H major, CH2CH2CN major and CH2CH2CN minor),
4.34-4.31 (2H, m, U2-3-H major and U2-3-H minor), 4.22-4.10
(2H, m, CH2CH2CN major and CH2CH2CN minor), 4.01-3.91 (2H,
U2-2-H major and U2-2-H minor), 3.80 (6H, app s, 2 x Ar-OCH3
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minor), 3.79 (3H, Ar-OCH3, major), 3.78 3H, Ar-OCH3, major),
3.69 (1H, dd, J 11.1 and 2.0, U1-5-H minor), 3.60 (1H, dd, J 11.1
and 2.1, U1-5-H major), 3.53 (1H, dd, J 11.1 and 2.0, U1-5-H
minor), 3.43 (1H, dd, J 11.1 and 1.9, U1-5-H major), 2.82 (1H,
app dddd, J 17.1, 7.7, 7.3 and 1.8, CH2CH2CN major), 2.73 (1H,
app ddd, J 6.5, 5.7 and 4.4, CH2CH2CN major), 2.52 (1H, app
dddd, J 37.9, 12.9, 7.5 and 5.5, CH2CH2CN minor), 2.48 1H, app
dddd, J 38.6, 12.2, 6.2 and 5.7, CH2CH2CN minor), 0.93 (9H, s,
SiC(CH3)3 minor), 0.91 (9H, s, SiC(CH3)3 major), 0.90 (9H, s,
SiC(CH3)3 major), 0.88 (9H, s, SiC(CH3)3 minor), 0.15 (6H, s,
SiCH3 major and SiCH3 minor), 0.14 6H, s, SiCH3 major and SiCH3
minor), 0.13 (6H, 2 x s, 2 x SiCH3 minor), 0.12 (3H, s, SiCH3
major), (3H, s, SiCH3 major); GC (125 MHz, CDCl3) 163.51 (U1-4-C,
minor), 163.47 (U1-4-C, major), 163.43 (U2-4-C, minor), 163.40
(U2-4-C, major), 158.90 (Ar-COCH3, minor), 158.88 (Ar-COCH3,
minor), 158.84 (Ar-COCH3, major), 158.81 (Ar-COCH3, major),
150.7 (U2-2-C, major), 150.6 (U2-2-C, minor), 150.14 (U1-2-C,
major), 150.10 (U1-2-C, minor), 149.8 (d, J 6.8, U2-5-CH, major),
149.7 (d, J 6.7, U2-5-CH, minor), 144.2 (Ar-C major and Ar-C
minor), 140.6 (U2-6-CH, major), 140.2 (U2-6-CH, minor), 139.91
(U1-6-CH, major), 139.89 (U1-6-CH, minor), 134.98 (Ar-C, minor),
134.96 (Ar-C, minor), 134.92 (Ar-C, major), 134.90 (Ar-C, major),
130.34 (2 x Ar-CH, major), 130.31 (4 x Ar-CH, minor), 130.28 (2
x Ar-CH, major), 128.31 (2 x Ar-CH, minor), 128.23 (2 x Ar-CH,
major), 128.2 (2 x Ar-CH, minor), 128.1 (2 x Ar-CH, major),
127.45 (Ar-CH, minor), 127.37 (Ar-CH, major), 117.12 (d, J 190,
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U2-6-CH, major), 117.07 (d, J 191, U2-6-CH, minor), 116.9
(CH2CH2CN, major), 116.7 (CH2CH2CN, minor), 113.37 (4 x Ar-CH
major and 4 x Ar-CH minor), 103.21 (U2-5-CH, minor), 103.17 (U2-
5-CH, major), 102.6 (U1-5-CH, major), 102.4 (U1-5-CH, minor),
91.76 (U2-1-CH, minor), 91.74 (U2-1-CH, major), 88.8 (U1-1-CH,
minor), 88.4 (U1-1-CH, major), 87.5 (CPh(4-OMePh)2, major and
minor), 83.0 (d, J 22.4, U2-4-CH, minor), 82.8 (d, J 22.0, U2-4-
CH, major), 81.9 (d, J 4.4, U1-4-CH, major), 81.5 (d, J 5.3, U1-4-
CH, minor), 74.91 (U1-2-CH, major), 74.88 (U1-2-CH, minor),
74.5 (U2-3-CH, major and minor), 74.3 (d, J 5.1, U1-3-CH,
major), 73.5 (d, J 6.3, U1-3-CH, minor), 73.3 (U2-2-CH, major
and minor), 61.9 (major, U1-5-CH2), 61.6 (minor, U1-5-CH2), 60.9
(major, d, J 4.4, CH2CH2CN), 60.8 (minor, d, J 4.5, CH2CH2CN),
55.4 (Ar-OCH3, 2 x major and 2 x minor), 25.74 (SiC(CH3)3,
minor), 25.73 (SiC(CH3)3, major and minor), 25.64 (SiC(CH3)3,
major), 20.0 (d, J 6.4, CH2CH2CN, major), 19.8 (d, J 6.8,
CH2CH2CN, minor), 18.12 (SiC, major and minor), 18.08
(SiC(CH3)3, major and minor), -4.61 (SiCH3, minor), -4.66 (SiCH3,
major), -4.76 (SiCH3, major), -4.78 (SiCH3, minor), -4.86 (SiCH3,
minor), -4.90 (SiCH3, major), -4.91 (SiCH3, minor), -5.04 (SiCH3,
major); GP (121 MHz, CDCl3) 19.7 and 19.5; m/z (ES+) 1152.4255
(M+Na, C55H73N3NaO15PSi2+ requires 1152.4199).
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5-O-(4,4-dimethoxytrityl)-2-O-(tert-butyldimethylsilyl)
uridinyl 2-cyanoethylphosphono-[3(O)Æ5(C)]-5-deoxy-5-
methylidene-2-O-(tert-butyldimethylsilyl)-3-O-[(2-
cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite uridine
268
A solution of U*U dimer 266 (68 mg,
60.5 Pmol) in dry CH2Cl2 (680 PL) was
added to a flame-dried flask containing
freshly activated 3 Å mol. sieves under
Argon. Neat DIPEA (42 PL, 242 Pmol),
DMAP (1.5 mg, 12.1 Pmol), and 2-
cyanoethyl N,N-diisopropylchloro-
phosphoramidite (14.8 PL, 66.5 Pmol)
were added. Stirring under an argon atmosphere was maintained
for 3 hours then the reaction mixture was filtered, diluted with
CH2Cl2 (2 mL), washed with brine (1 mL), dried (Na2SO4), filtered
and evaporated to a pale yellow foam. Purification by column
chromatography (97:3 CH2Cl2:MeOH) obtained U*U
phosphoramidite 268 (31 mg, 39%) as an off-white solid. Rf 0.30
(97:3 CH2Cl2:MeOH); GH (500 MHz, CDCl3) 9.75-8.98 (8H, app br s,
8 x N-H), 7.90 (1H, d, J 8.1, U1-6-H), 7.87 (2H, app d, J 8.1, U1-6-
H), 7.86 (1H, d, J 8.1, U1-6-H), 7.37-7.34 (9H, m, Ar-H), 7.33-
7.28 (9H, m, Ar-H), 7.28-7.24 (20H, m, 2 x U2-6-H and Ar-H),
7.22 (2H, app d, J 8.0, 2 x U2-6-H), 7.07 (1H, dd, J 17.6 and 4.2,
U2-5-H), 7.02 (1H, dd, J 17.6 and 4.2, U2-5-H), 7.01 (1H, dd, J
17.3 and 4.2, U2-5-H), 6.96 (1H, dd, J 17.3 and 4.2, U2-5-H),
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6.89-6.82 (16H, m, Ar-H), 6.13-6.01 (2H, m, 2 x U2-6-H), 6.03
(2H, ddd, J 20.7, 17.2 and 2.0, 2 x U2-6-H), 5.97-5.95 (2H, d, J
4.7, 2 x U1-1-H), 5.95 (1H, d, J 4.8, U1-1-H), 5.94 (1H, d, J 3.9,
U1-1-H), 5.81 (1H, d, J 8.0, U-5-H), 5.77 (2H, d, J 8.1, U-5-H),
5.76-5.71 (2H, obs m, U-5-H), 5.72 (1H, d, J 8.3, U-5-H), 5.68
(2H, d, J 3.6, U2-1-H), 5.57 (2H, d, J 3.4, U2-1-H), 5.27 (3H, app
d, J 8.1, U-5-H), 5.24 (1H, d, J 8.1, U-5-H), 5.02-4.97 (2H, m, U1-
3-H), 4.93-4.87 (2H, m, U1-3-H), 4.50-4.46 (8H, 4 x U1-2-H, 2 x
U1-4-H, 2 x U2-4-H), 4.38-4.31 (12H, 2 x U1-4-H, 2 x U2-4-H, 8 x
CH2CH2CN), 4.31-4.26 (4H, m, 4 x U2-3-H), 4.25-4.11 (4H, 2 x
CH2CH2CN), 4.10-4.02 (2H, CH2CH2CN), 3.97-3.93 (4H, 4 x U2-2-
H), 3.90-3.81 (2H, m, CH2CH2CN), 3.81 (6H, s, Ar-OCH3), 3.80
(6H, s, Ar-OCH3), 3.80 (6H, s, Ar-OCH3), 3.79 (6H, s, Ar-OCH3),
3.69-3.62 (2H, m, 2 x U1-5-H), 3.60 (2H, dd, J 11.1 and 2.3, 2 x
U1-5-H), 3.58-3.55 (1H, obs m, U1-5-H), 3.55 (2H, app d, J 6.9, 2
x PNCH), 3.55-3.49 (1H, obs m, U1-5-H), 3.52 (2H, app dd, J 6.9
and 2.1, 2 x PNCH), 3.50 (2H, app d, J 6.8, 2 x PNCH), 3.50-3.45
(2H, obs m, 2 x PNCH), 3.44 (2H, app ddd, J 11.2, 2.0 and 1.5, 2 x
U1-5-H), 2.92-2.82 (4H, m, CH2CH2CN), 2.82-2.77 (4H, m,
CH2CH2CN), 2.78-2.71 (8H, m, CH2CH2CN), 1.40-1.30 (6H, m, 2 x
NCH(CH3)2), 1.28 (18H, d, J 6.9, 6 x NCH(CH3)2), 1.27 (18H, d, J
6.9, 6 x NCH(CH3)2), 1.21 (3H, d, J 6.7, NCH(CH3)2), 1.18 (3H, d, J
6.2, NCH(CH3)2), 0.93 (6H, s, SiC(CH3)3), 0.92 (6H, s, SiC(CH3)3),
0.91 (18H, s, SiC(CH3)3), 0.90 (9H, s, SiC(CH3)3), 0.89 (24H, s,
SiC(CH3)3), 0.87 (9H, s, SiC(CH3)3), 0.143 (12H, s, 4 x SiCH3),
0.137 (6H, s, 2 x SiCH3), 0.131 (12H, s, 4 x SiCH3), 0.128 (3H, s,
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SiCH3), 0.118 (3H, s, SiCH3), 0.114 (6H, s, 2 x SiCH3), 0.112 (6H,
s, 2 x SiCH3); GC (126 MHz, CDCl3) 163.3 (U-4-C), 163.2 (U-4-C),
163.13 (3 x U-4-C), 163.11 (U-4-C), 163.04 (2 x U-4-C), 158.93
(Ar-COCH3), 158.91 (Ar-COCH3), 158.88 (2 x Ar-COCH3), 158.87
(Ar-COCH3), 158.85 (2 x Ar-COCH3), 158.81 (Ar-COCH3), 150.57
(U-2-C), 150.54 (3 x U-2-C), 150.49 (U-2-C), 150.0 (3 x U-2-C),
149.8 (2 x U2-5-CH), 149.7 (2 x U2-5-CH), 144.22 (2 x Ar-C),
144.19 (2 x Ar-C), 140.80 (3 x U-6-CH), 140.48 (U-6-CH), 139.91
(3 x U-6-CH), 139.83 (U-6-CH), 135.00 (Ar-C), 134.97 (5 x Ar-C),
134.94 (2 x Ar-C), 130.35 (5 x Ar-CH), 130.31 (4 x Ar-CH),
130.28 (5 x Ar-CH), 130.25 (2 x Ar-CH), 128.32 (2 x Ar-CH),
128.26 (6 x Ar-CH), 128.16 (Ar-CH), 128.13 (7 x Ar-CH), 127.46
(Ar-CH), 127.39 (3 x Ar-CH), 117.1 (d, J 190, 4 x U2-6-CH),
116.96 (2 x CN), 116.82 (4 x CN), 116.77 (CN), 116.63 (CN),
113.45 (16 x Ar-CH), 103.20 (2 x U-5-CH), 103.16 (U-5-CH),
102.94 (U-2-CH), 102.56 (2 x U-5-CH), 102.52 (U-5-CH), 102.49
(U-5-CH), 92.35 (U2-1-CH), 92.23 (3 x U2-1-CH), 88.64 (U1-1-
CH), 88.37 (2 x U1-1-CH), 88.33 (U1-1-CH), 87.58 (4 x CPh(4-
OMePh)2), 83.2 (d, J 23.1, U2-4-CH), 83.1 (d, J 22.9, U2-4-CH),
82.9 (d, J 22.5, 2 x U2-4-CH), 82.0 (d, J 4.6, 3 x U1-4-CH), 81.7
(d, J 4.6, U1-4-CH), 74.9 (app d, J 3.6, 2 x U1-2-CH and 3 x U2-3-
CH), 74.8 (app d, J 3.7, 2 x U1-2-CH and U2-3-CH), 74.44 (U1-3-
CH), 74.39 (3 x U1-3-CH), 73.7 (U2-2-CH), 73.6 (3 x U2-2-CH),
62.0 (3 x U1-5-CH2), 61.8 (U1-5-CH2), 60.9 (d, J 4.5, 3 x
P(O)CH2CH2CN), 60.7 (d, J 4.5, P(O)CH2CH2CN), 58.9 (d, J 5.6,
P(NiPr)CH2CH2CN), 58.3 (d, J 5.3, 3 x P(NiPr)CH2CH2CN), 55.37 (8
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x Ar-OCH3), 47.54 (2 x PNCH), 47.01 (PNCH), 45.45 (3 x PNCH),
45.40 (2 x PNCH), 25.7 (14 x SiC(CH3)3), 25.6 (10 x SiC(CH3)3),
23.05 (4 x PNCHCH3), 23.04 (4 x PNCHCH3), 22.97 (4 x PNCHCH3),
22.95 (4 x PNCHCH3), 20.2 (d, J 6.8, 2 x CH2CH2CN), 20.0 (d, J
6.3, 5 x CH2CH2CN), 19.8 (d, J 6.3, 1 x CH2CH2CN), 8.11 (4 x SiC),
18.09 (3 x SiC), 18.06 (SiC), -4.48 (SiCH3), -4.63 (SiCH3), -4.67
(2 x SiCH3), -4.75 (2 x SiCH3), -4.79 (2 x SiCH3), -4.82 (SiCH3), -
4.83 (SiCH3), -4.87 (4 x SiCH3), -5.02 (2 x SiCH3); GP (121 MHz,
CDCl3) 151.7 (CEPNiPr2), 151.4 (CEPNiPr2), 151.1 (CEPNiPr2), 150.4
(CEPNiPr2), 19.83 (P=O), 19.77 (P=O), 19.6 (P=O), 19.5 (P=O);
m/z (ES+) 1352.5301 (M+Na, C64H89N7NaO16P2Si+ requires
1352.5272).
5-O-(4,4-dimethoxytrityl)-2-O-methyl uridinyl 2-cyano-
ethylphosphono-[3(O)Æ5(C)]-5-deoxy-5-methylidene-2-
O-methyl uridine 267
Vinyl bromide 236 (155 mg, 465
Pmol), Pd(OAc)2 (21 mg, 93 Pmol) and
dppf (103 mg, 186 Pmol) were charged
to a carousel tube purged with Argon.
A solution of H-phosphonate 254 (410
mg, 605 Pmol) in freshly distilled THF
(6.2 mL) was added followed by
propylene oxide (650 PL, 9.30 mmol). The tube was sealed and
heated at 70 oC for 6 hours then cooled and evaporated to an
orange foam. Purification by column chromatography (96:4 ĺ
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90:10 CH2Cl2:MeOH) obtained the 2-OMe *U dimer 267 as yellow
foam (420 mg, 97%). Rf 0.04 (96:4 CH2Cl2:MeOH); [D]D29 +11.6
(c 0.35, CHCl3); Qmax/cm-1 (CHCl3) 3392 (N-H), 2959 (C-H), 2936
(C-H), 2910 (C-H), 2839 (C-H), 1712 (C=O), 1694 (C=O), 1632
(C=C), 1608 (C=C), 1508 (C=C), 1489, 1460, 1456, 1390, 1377,
1364, 1326, 1301; GH (500 MHz, CDCl3) 9.75-9.40 (2H, 2 x br s,
NH), 9.28 (2H, app br s, 2 x NH), 7.84 (1H, d, J 7.9, U1-6-H), 7.82
(1H, d, J 7.9, U1-6-H), 7.53-7.45 (1H, m, Ar-H), 7.44-7.38 (1H, m,
Ar-H), 7.38-7.30 (8H, m, Ar-H), 7.30-7.20 (10H, m, 2 x U2-6-H
and 8 x Ar-H), 7.11-6.96 (2H, m, 2 x U2-5-H), 6.91-6.81 (8H, m,
Ar-H), 6.14 (1H, dd, J 19.6 and 1.11, U2-5-H), 6.05 (1H, obs dd, J
U2-5-H), 6.04 (2H, d, J 3.6, 2 x U1-1-H), 5.87-5.80 (3H, m, 2 x
U2-1-H and U2-5-H), 5.29 (1H, d, J 7.9, U1-5-H), 5.28 (1H, d, J
7.9, U1-5-H), 5.17 (1H, dd, J 10.1 and 6.3, U1-3-H), 5.04 (1H, dd,
J 10.6 and 5.7, U1-3-H), 4.47-4.42 (1H, m, U2-4-H), 4.36-4.31
(2H, m, U1-4-H and OCH2CH2CN), 4.34-4.24 (1H, obs m, U1-4-H),
4.30-4.25 (2H, m, U2-4-H and OCH2CH2CN), 4.15-4.09 (2H, m,
U1-2-H and OCH2CH2CN), 4.08-4.02 (2H, m, U1-2-H and U2-3-H),
4.01-3.94 (2H, m, U2-3-H and OCH2CH2CN), 3.89 (1H, dd, J 4.1
and 3.0, U2-2-H), 3.85 (1H, dd, J 4.8 and 3.5, U2-2-H), 3.67-3.64
(1H, m, U1-5-H), 3.61-3.58 (1H, m, U1-5-H), 3.61 (3H, s, U2-2-
OCH3), 3.60 (3H, s, U2-2-OCH3), 3.57 (3H, s, U1-2-OCH3), 3.53
(3H, s, U1-2-OCH3), 3.42-3.38 (2H, m, 2 x U1-5-H), 2.80-2.78
(2H, m, CH2CH2CN), 2.66-2.53 (2H, m, CH2CH2CN); GC (125 MHz,
CDCl3) 163.3 (U2-4-C), 163.2 (U1-4-C), 163.08 (U1-4-C), 162.9
(U2-4-C), 158.94 (Ar-COCH3), 158.91 (Ar-COCH3), 158.88 (Ar-
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COCH3), 158.82 (Ar-COCH3), 150.6 (U-2-C), 150.4 (U-2-C), 150.0
(U-2-C), 149.9 (U-2-C), 149.5 (d, J 5.9, U2-5-CH), 148.7 (d, J 6.0,
U2-5-CH), 144.1 (Ar-C), 144.0 (Ar-C), 140.0 (U-5-H), 139.9 (U-5-
H), 139.7 (U-5-H), 139.6 (U-5-H), 135.1 (Ar-C), 134.94 (Ar-C),
134.86 (Ar-C), 134.80 (Ar-C), 130.4 (2 x Ar-CH), 130.3 (4 x Ar-
CH), 130.2 (2 x Ar-CH), 128.4 (2 x Ar-CH), 128.21 (2 x Ar-CH),
128.17 (4 x Ar-CH), 127.5 (Ar-CH), 127.4 (Ar-CH), 118.1 (d, J
95.1, U2-6-CH), 116.8 (CH2CH2CN), 116.59 (CH2CH2CN), 116.56
(d, J 93.7, U2-6-CH), 113.5 (8 x Ar-CH), 103.2 (U2-5-CH), 103.1
(U2-5-CH), 102.8 (U1-5-CH), 102.6 (U1-5-CH), 89.8 (U2-1-CH),
89.5 (U2-1-CH), 87.6 (CPh(4-OMePh)2), 87.4 (CPh(4-OMePh)2),
86.9 (U1-1-CH), 86.5 (U1-1-CH), 82.9 (d, J 18.1, U2-4-CH), 82.73
(d, J 19.0, U2-4-CH), 82.76 (d, J 18.0, U2-2-CH), 82.70 (d, J 17.1,
U2-2-CH), 82.52 (d, J 12.2, U1-2-CH), 82.45 (d, J 10.2, U1-2-CH),
81.9 (d, J 7.3, U1-4-CH), 81.8 (d, J 7.38, U1-4-CH), 73.0 (U1-3-
CH), 72.9 (U1-3-CH), 72.4 (U2-3-CH), 72.3 (U2-3-CH), 61.5 (U1-
5-CH2), 61.4 (U1-5-CH2), 60.6 (d, J 5.6, OCH2CH2CN), 60.2 (d, J
4.9, OCH2CH2CN), 59.01 (U2-2-OCH3), 58.98 (U2-2-OCH3), 58.83
(U1-2-OCH3), 58.81 (U1-2-OCH3), 55.4 (4 x Ar-OCH3), 20.0 (d, J
6.4, OCH2CH2CN), 19.8 (d, J 7.0, OCH2CH2CN); GP (121 MHz,
CDCl3) 19.5 and 19.4; m/z (ES+) 952.2793 (M+Na,
C45H48N5NaO15P+ requires 952.2782).
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5-O-(4,4-dimethoxytrityl)-2-O-methyl uridinyl 2-
cyanoethylphosphono-[3(O)Æ5(C)]-5-deoxy-5-
methylidene-2-O-methyl-3-O-[(2-cyanoethyl)-(N,N-
diisopropyl)]-phosphoramidite uridine 269
To a flame dried flask containing
freshly activated 3Å mol. sieves was
added a solution of U*U dimer 267
(160 mg, 172 Pmol) in dry CH2Cl2
(1.60 mL). Freshly distilled DIPEA
(120 PL, 689 Pmol), DMAP (4.2 Pg,
34.4 Pmol) then 2-cyanoethyl N,N-
diisopropylchloro-phosphoramidite (42
PL, 189 Pmol) were added and stirring was maintained for 2 ½
hours. The reaction mixture was then filtered, eluting with CH2Cl2
(2 x 2 mL) and the combined organics were washed with brine (2
mL), dried (Na2SO4), filtered and concentrated to a pale brown
solid. Purification by column chromatography (95:5 CH2Cl2:MeOH)
obtained the U*U CEP 269 as an off-white foam (81 mg, 42%). Rf
0.06 95:5 CH2Cl2:MeOH); GH (400 MHz, CDCl3) 9.95-8.75 (br s, 8 x
NH), 7.86 (1H, d, J 8.2, U1-6-H), 7.85 (1H, d, J 8.1, U1-6-H), 7.83
(1H, d, 8.2, U1-6-H), 7.81 (1H, d, J 8.1, U1-6-H), 7.38-7.30 (16H,
m, Ar-H), 7.30-7.21 (24H, m, 4 x U2-6-H and 20 x Ar-H), 7.22-
6.93 (4H, m, 4 x U2-5-H), 6.89-6.82 (16H, m, Ar-H), 6.17-6.04
(4H, m, 4 x U2-6-H), 6.05 (1H, d, J 4.2, U1-1-H), 6.04 (2H, app d,
J 3.9, 2 x U1-1-H), 6.03 (1H, d, J 3.5, U1-1-H), 5.85 (1H, d, J 3.7,
U2-1-H), 5.84 (1H, d, J 4.0, U2-1-H), 5.83 (1H, d, J 3.7, U2-1-H),
O
O OMe
N
NH
O
O
O
DMTO
O OMe
N
NH
O
O
P O
O
NC
P
O N
iPr
iPr
NC
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5.82 (1H, d, J 3.9, U2-1-H), 5.78 (2H, app d, J 7.5, 2 x U2-5-H),
5.75 (1H, d, J 8.1, U2-5-H), 5.74 (1H, d, J 8.0, U2-5-H), 5.29 (3H,
app d, J 8.2, 3 x U1-5-H), 5.25 (1H, app d, J 8.0, U1-5-H), 5.18-
5.12 (2H, m, 2 x U1-3-H), 5.10-5.05 (2H, m, 2 x U1-3-H), 4.74-
4.69 (1H, m, U2-4-H), 4.68-4.63 (1H, m, U2-4-H), 4.65-4.60 (1H,
m, U2-4-H), 4.60-4.55 (1H, m, U2-4-H), 4.40-4.05 (8H, obs m, 4
x OCH2CH2CN), 4.35-4.31 (2H, obs m, 2 x U1-4-H), 4.32-4.25 (4H,
obs m, 2 x U1-4-H and 2 x U2-3-H), 4.25-4.15 (2H, obs m, 2 x U2-
3-H), 4.15-4.09 (2H, obs m, 2 x U1-2-H), 4.09-4.04 (2H, obs m, 2
x U1-2-H), 4.05-3.92 (4H, obs m, 4 x U2-2-H), 4.05-3.84 (6H, obs
m, 3 x OCH2CH2CN), 3.81 (12H, s, 4 x Ar-OCH3), 3.80 (6H, s, 2 x
Ar-OCH3), 3.79 (6H, s, 2x Ar-OCH3), 3.71-3.60 (12H, obs m, 2 x
U1-5-H, 8 x PNCH, OCH2CH2CN), 3.61 (3H, s, 2-OCH3), 3.60, (3H,
s, 2-OCH3), 3.58-3.42 (6H, m, 6 x U1-5-H), 3.55 (3H, s, 2-OCH3),
3.54 (3H, s, 2-OCH3), 3.53 (6H, 2 x s, 2 x 2-OCH3), 3.52 (3H, s,
2-OCH3), 3.51 (3H, s, 2-OCH3), 2.81-2.77 (4H, app dd, J 12.2 and
6.0, 2 x OCH2CH2CN), 2.78-2.70 (4H, m, 4 x OCH2CH2CN), 2.67-
2.53 (8H, m, 2 x OCH2CH2CN), 1.29 (3H, d, J 6.8, NCH(CH3)2),
1.27 (3H, d, J 7.2, NCH(CH3)2), 1.26 (3H, d, J 8.1, NCH(CH3)2),
1.22 (12H, app d, J 6.7, 4 x NCH(CH3)2), 1.19 (27H, app d, J 6.7, 9
x NCH(CH3)2); GC (125 MHz, CDCl3) 163.12 (U-4-C), 163.09 (U-4-
C), 163.01 (2 x U-4-C), 162.93 (2 x U-4-C), 162.86 (2 x U-4-C),
158.95 (2 x Ar-C), 158.92 (2 x Ar-C), 158.91 (2 x Ar-C), 158.89
(Ar-C), 158.87 (Ar-C), 150.43 (U-2-C), 150.41 (U-2-C), 150.39
(U-2-C), 150.36 (U-2-C), 150.00 (2 x U-2-C), 149.96 (2 x U-2-C),
149.6 (d, J 6.7, U2-5-H), 149.1 (d, J 6.7, U2-5-H), 148.9 (d, J 6.5,
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U2-5-H), 148.5 (d, J 6.3, U2-5-H), 144.2 (Ar-C), 144.1 (Ar-C),
144.04 (Ar-C), 143.99 (Ar-C), 140.8 (U2-6-CH), 140.53 (U2-6-CH),
140.50 (2 x U2-6-CH), 139.8 (U1-6-CH), 139.68 (U1-6-CH), 139.66
(U1-6-CH), 139.57 (U1-6-CH), 134.97 (Ar-C), 134.94 (Ar-C),
134.90 (Ar-C), 134.87 (2 x Ar-C), 134.82 (2 x Ar-C), 134.80 (Ar-
C), 130.41 (4 x Ar-CH), 130.37 (4 x Ar-CH), 130.27 (4 x Ar-CH),
130.17 (4 x Ar-CH), 128.39 (4 x Ar-CH), 128.19 (6 x Ar-CH),
128.16 (6 x Ar-CH), 127.48 (Ar-CH), 127.45 (Ar-CH), 127.41 (Ar-
CH), 127.36 (Ar-CH), 118.6 (d, J 94.6, U2-6-CH), 118.3 (2 x
OCH2CH2CN), 117.9 (2 x OCH2CH2CN), 117.6 (d, J 122.8, U2-6-
CH), 117.1 (d, J 94.4, U2-6-CH), 116.9 (OCH2CH2CN), 116.8
(OCH2CH2CN), 116.6 (OCH2CH2CN), 116.4 (OCH2CH2CN), 116.1 (d,
J 122.3, U2-6-CH), 113.4 (16 x Ar-CH), 103.15 (U1-5-CH), 103.14
(U1-5-CH), 103.05 (2 x U1-5-CH), 102.69 (2 x U2-5-CH), 102.63
(U2-5-CH), 102.58 (U2-5-CH), 90.76 (U2-1-CH), 90.65 (U2-1-CH),
90.3 (U2-1-CH), 90.0 (U2-1-CH), 87.5 (3 x CPh(4-OMePh)2), 87.4
(CPh(4-OMePh)2), 86.92 (U1-1-CH), 86.87 (U1-1-CH), 86.83 (U1-
1-CH), 86.6 (U1-1-CH), 82.7 (d, J 5.1, 2 x U1-2-CH), 82.40 (d, J
3.1, 2 x U2-4-CH), 82.37 (d, J 8.9, U1-2-CH), 82.24 (d, J 3.8, U1-
2-CH), 82.23 (d, J 3.9, U1-2-CH), 82.04 (U1-4-CH), 82.00 (U1-4-
CH), 81.97 (d, J 4.9, U2-2-CH), 81.92 (d, J 5.0, U2-2-CH), 81.8
(app s, 2 x U2-4-CH), 81.76 (U1-4-CH), 81.70 (U1-4-CH), 81.5 (d,
J 4.4, U2-2-CH), 81.4 (d, J 4.5, U2-2-CH), 74.20 (d, J 14.8, U2-3-
CH), 74.16 (d, J 15.4, U2-3-CH), 73.8 (d, J 15.9, U2-3-CH), 73.7
(d, J 14.9, U2-3-CH), 72.6 (d, J 5.4, U1-3-CH), 72.5 (d, J 5.6, U1-
3-CH), 72.40 (d, J 4.2, U1-3-CH), 72.36 (d, J 4.3, U1-3-CH), 61.5
Experimental
- 234 -
(U1-5-CH2), 61.35 (U1-5-CH2), 61.26 (2 x U1-5-CH2), 60.7 (app d,
J 5.4, 2 x P(O)OCH2CH2CN), 60.2 (d, J 5.4, (PO)OCH2CH2CN), 60.1
(d, J 5.1, (PO)OCH2CH2CN), 58.8 (2 x 2-OCH3), 58.82 (2 x 2-
OCH3), 58.77 (2-OCH3), 58.75 (2-OCH3), 58.74 (2-OCH3), 58.70
(2-OCH3), 58.54 (d, J 19.0, P(NiPr2)OCH2CH2CN), 58.53 (d, J 18.9,
P(NiPr2)OCH2CH2CN), 57.9 (d, J 20.2, P(NiPr2)OCH2CH2CN), 57.8
(d, J 20.3, P(NiPr2)OCH2CH2CN), 55.4 (4 x Ar-OCH3), 55.3 (4 x Ar-
OCH3), 43.6 (2 x PNCH), 43.5 (2 x PNCH), 43.5 (2 x PNCH), 43.4
(2 x PNCH), 24.78 (2 x PNCH(CH3)), 24.73 (6 x PNCH(CH3)), 24.69
(6 x PNCH(CH3)), 24.63 (2 x PNCH(CH3)), 20.50 (app d, J 6.1, 2 x
OCH2CH2CN), 20.49 (app d, J 6.3, 2 x OCH2CH2CN), 19.9 (app d, J
6.5, 2 x OCH2CH2CN), 19.8 (app d, J 6.5, 2 x OCH2CH2CN); GP (121
MHz, CDCl3) 151.8 (CEPNiPr2), 151.7 (2 x CEPNiPr2), 150.9
(CEPNiPr2), 19.7 (P=O), 19.5 (P=O), 19.3 (P=O), 18.9 (P=O); m/z
(ES+) 1152.3895 (M+Na, C54H65N7NaO16P2+ requires 1152.3861).
- 235 -
- REFERENCES -
References
- 236 -
5. References
1. Collins, F. S.; Morgan, M.; Patrinos, A.; Science 2003, 300,
286-290.
2. International Human Genome Sequencing Consortium, Nature,
2001, 409, 860-921.
3. Venter, J. C.; Adams, M. D.; Myers, E. W.; Li, P. W.; Mural, R.
J.; Sutton, G. G.; Smith, H. O.; Yandell, M.; Evans, C. A.; Holt, R.
A.; Gocayne, J. D.; Amanatides, P.; Ballew, R. M.; Huson, D. H. et
al. Science, 2001, 291, 1304-1351.
4. Frazier, M. E.; Johnson, G. M.; Thomassen, D. G.; Oliver, C. E.;
Partrinos, A. Science, 2003, 300, 290-293.
5. Krogskaard-Larsen, P.; Liljefors, T.; Madsen, U. Textbook of
Drug Design and Discovery, 3rd Ed., Taylor and Francis, London,
pp. 6-11.
6. Ng, R.; Drugs - from Discovery to Approval, Wiley: New Jersey,
2004.
7. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. J. Health
Economics, 2003, 22, 151-185.
8. Sucheck, S. J.; Wong, C.-H. Current Opinion Chem. Biol., 2000,
4, 678-686.
9. Tor, Y. ChemBioChem, 2003, 4, 998-1007.
10. Hermann, T.; Tor, Y., Expert Opinion Therap. Patents, 2005,
15, 49-62.
11. Gallego, J.; Varani, G., Acc. Chem. Res., 2001, 34, 836-843.
12. Chow, C. S.; Bogdan, F. M., Chem. Rev. 1997, 97, 1489-1513.
References
- 237 -
13. Xavier, K. A.; Eder, P. S.; Giordano, T., Trends Biotech., 2000,
18, 349-356.
14. Denison, C.; Kodadek, T., Chem. Biol., 1998, 5, R129-R145.
15. Ecker, D. J.; Griffey, R. H. Drug Discovery Today, 1999, 9,
420-429.
16. Summerton, J. Biochim. Biophys. Acta, 1999, 1489, 141-158.
17. Boiziau, C.; Kurfurst, R.; Cazenave, C.; Roig, V.; Nguyen, T.
T.; Toulmé, J. J., Nucleic Acids Res., 1991, 19, 1113-1119.
18. Donis-Keller, H., Nucleic Acids Res., 1979, 7, 179-192.
19. Kawasaki, A. M.; Casper, M.D.; Freier, S.M.; Lesnik, E.A.;
Zounes, M. C.; Cummins, L. L.; Gonzalez, C.; Cook, P. D., J. Med.
Chem., 1993, 36, 831-841.
20. Zamaratski, E.; Pradeepkumar, P.I.; Chattopadhyaya J., J.
Biochem. Biophys. Methods, 2001, 48, 189208.
21. Hausen, P.; Stein, H., Eur. J. Biochem., 1970, 14, 278283.
22. Fedoroff, O.-Y.; Salazar, M.; Reid, B. R., J Mol. Biol., 1993,
233, 509523.
23. Salazar, M.; Fedoroff, O. Y.; Miller, J. M.; Ribeiro, N. S.; Reid,
B. R., Biochemistry, 1993, 32, 42074215.
24. Napoli, C.; Lemieux, C.; Jorgensen R. The Plant Cell, 1990, 2,
279-289.
25. Fire, A.; Xu, S. Q.; Montgomery, M. K.; Kostas, S. A.; Driver,
S. E.; Mello, C. C., Nature, 1998, 391, 806-811.
26. Braasch, D. A.; Jensen, S.; Liu, Y.; Kaur, K.; Arar, K.; White,
M. A.; Corey, D. A. Biochemistry, 2003, 42, 7967-7975.
References
- 238 -
27. Elbashir, S. M.; Harbroth, J.; Lendeckel, W.; Yalcin, A.; Weber,
K.; Tuschl, T. Nature, 2001, 411, 494-498.
28. Tuschl, T.; Martinez, J. Genes Dev., 2004, 18, 975-980.
29. Schwarz, D. S.; Tomari, Y.; Zamore, P. D. Curr. Biol., 2004,
14, 787-791.
30. Collins, R. E.; Cheng, X. FEBS Letters, 2005, 579, 5841-5849.
31. Hutvagner, G. FEBS Letters, 2005, 579, 5850-5857.
32. Tang, G. Trends Biochem. Sci., 2005, 30, 106-114.
33. Hammond, S. M. FEBS Letters, 2005, 579, 5822-5829.
34. Sontheimer, E. J. Nat. Rev. Mol. Cell Biol., 2005, 6, 127-138.
35. Hammond, S. M.; Boettcher, S.; Caudy, A.A.; Kobayashi, R.;
Hannon, G. J. Science, 2001, 293, 1146-1150.
36. Meister, G.; Landthaler, M.; Patkaniowska, A.; Dorsett, Y.;
Teng, G.; Tuschl, T. Mol. Cell, 2004, 15, 185-197.
37. Sontheimer, E. J.; Carthew, R. W. Science, 2004, 305, 1409-
1410.
38. Song, J.-J.; Smith, S. K.; Hannon, G. J.; Joshua-Tor L.
Science, 2004, 305, 1434-1437.
39. Parker, J. S.; Roe, S. M.; Barford, D. Nature, 2005, 434, 663-
666.
40. Ma, J. B.; Yuan, Y. R.; Meister, G. ; Pei, Y ; Tuschl, T. ; Patel,
D. J., Nature, 2005, 434, 666-670
41. Ma, J. B.; Ye, K.; Patel, D. J. Nature, 2004, 429, 318-322.
42. Cheng, J. C.; Moore, T. B.; Sakamoto, K. M. Mol. Genet.
Metab., 2003, 80, 121-128.
References
- 239 -
43. Dykxhoorn, D. M.; Novina, C. D.; Sharp, P. A. Nat. Rev. Mol.
Cell Biol., 2003, 4, 457-467.
44. Hall, J. Chimia, 2005, 59, 803-807.
45. De Fougerolles, A.; Vornlocher, H.-P. ; Maraganore, J. ;
Lieberman, J., Nature Rev. Drug Discovery, 2007, 6, 443-453.
46. Dillon, C. P.; Sandy, P.; Nencioni, A.; Kissler, S.; Rubindon, D.
A.; Van Parijs, L. Annu, Rev. Physiol., 2005, 67, 147-173.
47. Antisense Drug Technology: Principles, Strategies and
Applications; Crooke, S. T. Ed.; CRC Press: London, 2006.
48. Casey, J.; Davidson, N., Nucleic Acids Res., 1977, 4, 1539-
1552.
49. Crooke, S. T. Biochim et Biophys. Acta, 1999, 1489, 31-44.
50. Kankia, B. I.; Marky, L. A. J. Phys. Chem. B, 1999, 103, 8759-
8767.
51. Caplen, N. J.; Parrish, S.; Imani, F.; Fire, A.; Morgan, R. A.
Proc. Nat. Acad. Sci. USA, 2001, 97, 9742-9747.
52. Vickers, T. A.; Koo, S.; Bennett, F.; Crooke, S. T.; Dean, N.
M.; Baker, B. F. J. Biol. Chem., 2003, 278, 7108-7118.
53. Achenbach, T. V.; Brunner, B.; Heermeier, K. ChemBioChem,
2003, 4, 928-935.
54. Kurreck, J. Eur. J. Biochem., 2003, 270, 1628-1644.
55. Prakash T.P.; Bhat, B. Curr. Topics Med. Chem., 2004, 7, 641-
649.
56. Micklefield, J. Curr. Med. Chem., 2001, 7, 1157-1179.
References
- 240 -
57. Swayze, E. E.; Bhat, B. In Antisense Drug Technology:
Principles, Strategies and Applications; Crooke, S. T. Ed.; CRC
Press: London, 2006; Ch. 6, pp. 143-182.
58. Iversen, P. L. In Antisense Drug Technology: Principles,
Strategies and Applications; Crooke, S. T. Ed.; CRC Press: London,
2006; Ch. 20, pp. 565-582.
59. Summerton, J.; Weller, D. Antisense Nucleic Acid Drug Dev.,
1997, 7, 187-195.
60 Egholm, M.; Buchardt, O.; Christensen, L.; Behrens, C.; Freier,
S. M.; Driver, D. A.; Berg R. H.; Kim, S. K.; Norden, B.; Nielsen, P.
E. Nature, 1993, 365, 566-568.
61. Shakeel, S.; Karim, S.; Arif A. J. Chem. Technol. Biotechnol.,
2006, 81, 892899.
62 Peptide Nucleic Acids: Protocols and Applications, 2nd Ed.;
Nielsen, P. E. Ed.; Horizon Bioscience: Norfolk, 2004.
63 Nielsen, P. E.; Egholm, M.; Berg, R. H.; Buchardt, O. Science,
1991, 254, 1497-1500.
64. Nielsen, P. E. In Antisense Drug Technology: Principles,
Strategies and Applications; Crooke, S. T. Ed.; CRC Press: London,
2006, Ch. 18, pp. 507-518.
65. Nulf, C. J.; Corey, D. Nucleic Acids Res., 2004, 32, 3792-3798.
66. Doyle, D. F.; Braasch D. A.; Simmons, C. G.; Janowski, B. A.;
Corey, D. R. Biochemistry, 2001, 40, 53-64.
67. Liu, B.; Han, Y.; Ferdous, A.; Corey, D. R.; Kodadek, T. Chem.
Biol., 2003, 10, 909-916.
References
- 241 -
68. Janowski, B. A.; Kaihatsu, K.; Huffman, K. E.; Schwartz, J. C.;
Ram, R.; Hardy, D.; Mendelson, C. R.; Corey, D. R. Nat. Chem.
Biol., 2005, 1, 210-215.
69. Breipohl, G.; Will, D. W.; Peyman A.; Uhlmann, E.
Tetrahedron, 1997, 53, 14671-14686.
70. Koch, T. In Peptide Nucleic Acids: Protocols and Applications,
2nd Ed.; Nielsen, P. E. Ed.; Horizon Bioscience: Norfolk, 2004; Ch.
2, pp. 37-59.
71. Capasso D.; De Napoli L.; Di Fabio G.; Messere A.;
Montesarchio D.; Pedone C.; Piccialli G.; Saviano M. Tetrahedron,
2001, 57, 9481-9486.
72. Casale, R.; Jensen, I. S.; Egholm, M. In Peptide Nucleic Acids:
Protocols and Applications, 2nd Ed.; Nielsen, P. E. Ed.; Horizon
Bioscience: Norfolk, 2004; Ch. 3, p61-76.
73. a) Herdewijn, P. Biochim. Biophys. Acta, 1999, 1489, 167-
179. (b) Herdewijn, P. Liebigs Ann. Chem., 1996, 1337-1348.
74. Eckstein, F. Acc. Chem. Res., 1979, 12, 204-210.
75. Stec, W. J.; Wilk, A.; Angew. Chem. Int. Ed., 1994, 33, 709-
722
76 Lesnikowski, Z. J. Bioorg. Chem., 1993, 21, 127-155.
77. Iyer, R. P.; Egan, W.; Regan, J. B.; Beaucage, S. L., J. Am.
Chem. Soc., 1990, 112, 1253-1254.
78. Oka, N.; Yamamoto, M.; Sato, T.; Wada, T. Nucleic Acids Res.
Symp. Ser., 2006, 50, 123-124.
79. Boczkowskaa, M.; Guga, P.; Stec, W. J., Biochemistry, 2002,
41, 12483-12487.
References
- 242 -
80. Sood, A.; Shaw, R.; Spielvogel, B. F., J. Am. Chem. Soc.,
1990, 112, 9000-9001.
81. Li, H.; Huang F.; Ramsay Shaw, B. Bioorg. Med. Chem., 1997,
5, 787-795.
82. Li, H.; Porter, K.; Huang, F.; Shaw, B. R., Nucleic Acids Res.,
1995, 23, 4495-4501.
83. Zhang, J.; Terhorst, T.; Matteucci, M. D., Tetrahedron, 1997,
38, 4957-4960.
84. Sergueev, D. S.; Ramsay Shaw, B., J. Am. Chem. Soc., 1998,
120, 9417-9427.
85. Sergueeva, Z. A.; Sergueev, D. S.; Ribeiro, A. A.; Summers, J.
S.; Ramsay Shaw, B. R., Helv. Chim. Acta, 2000, 83, 1377-1391.
86.Sergueev, S.; Hasan, A.; Briley, J. D.; Shaw, B. R., Nucleosides
Nucleotides, 1997, 16, 1533-1538.
87. He, K.; Porter, K. W.; Hasan, A.; Ramaswamy, M.; Shaw, B.
R., Nucleic Acids Res., 1999, 27, 1788-1794.
88. Wada, T.; Maizuru, Y.; Shimizu, M.; Oka, N.; Saigo, K., Bioorg.
Med. Chem. Lett., 2006, 16, 3111-3114.
89. Manoharan, M. Curr. Opinion Chem. Biol., 2004, 8, 570-579.
90. Zhang, H.-Y.; Du, Q.; Wahlestedt, C.; Liang, Z. Curr. Topics
Med. Chem., 2006, 6, 893-900.
91. Nawrot, B.; Sipa, K. Curr. Topics Med. Chem., 2006, 6, 913-
925.
92. Manoharan, M.; Rajeev, K. G. In Antisense drug technology:
Principles, strategies, and applications, Ed. Crooke, S. T., 2nd Ed.
London: Taylor & Francis, 2006, Ch 15, pp. 437-443.
References
- 243 -
93. Prakash, T. P.; Kraynack, B.; Baker, B. F.; Swayze, E. E.; Bhat,
B., Bioorg. Med. Chem. Lett., 2006, 16, 3238-3240.
94. Morrissey, D. V.; Blanchard, K.; Shaw, L.; Jensen, K.;
Lockridge, J. A.; Dickinson, B.; McSwiggen, J. A.; Vargeese, C.;
Bowman, K.; Shaffer C. S.; Polisky, B. A.; Zinnen, S., Hepatology,
2005, 41, 1349-1356.
95. Hamada, M.; Ohtsuka, T.; Kawaida, R.; Koizumi, M.; Morita,
K.; Furukawa, H.; Imanishi, T.; Miyagishi, M; Taira, K., Antisense
Nucl. Acid Drug Dev., 2005, 12, 301-309.
96. Xu, Q.; Katkevika, D.; Rozners, E., J. Org. Chem., 2006, 71,
3906-3913.
97. Parrish, S.; Fleenor, J.; Xu, S.-Q.; Mello, C.; Fire, A. Mol. Cell,
2000, 6, 1077-1087.
98. Choung, S.; Kim, Y. J.; Kim, S.; Park, H.-O.; Choi, Y.-C.,
Biochem. Biophys. Res. Commun., 2006, 342, 919-927.
99. Freier, S. M.; Altmann, K.-H., Nucleic Acids Res., 1997, 25,
4429-4443.
100. Ravikumar, V. T.; Andrade, M.; Carty, R. L.; Dan, A.; Barone,
S., Biorg. Med. Chem. Lett., 2006, 16, 2513-2517.
101. Hall, A. H. S.; Wan, J.; Shaughnessy, E. E.; Shaw, B. R.;
Alexander, K. A., Nucleic Acids Res., 2004, 32, 5991-6000.
102. Hall, A. H. S.; Wan, J.; Spesock, A.; Sergueev, Z.; Shaw, B.
R.; Alexander, K. A., Nucleic Acids Res., 2006, 34, 2773-2781.
103. He, K.; Hasan, A.; Krzyzanowska, B.; Ramsay Shaw, B., J.
Org. Chem., 1998, 63, 57695773.
References
- 244 -
104. Summers, J. S.; Shaw, B. R., Curr. Med. Chem., 2001, 8,
1147-1155.
105. Chiu, Y.-L.; Rana, T. M. RNA, 2003, 9, 1034-1048.
106. Prakash, T. P.; Allerson, C. R.; Dande, P.; Vickers, T. A.;
Sioufi, N.; Jarres, R.; Baker, B. F.; Swayze, E. E.; Griffey, R. H.;
Bhat, B. J. Med. Chem., 2005, 48, 4247-4253.
107. Wilson, C.; Keefe, A. D., Curr. Opinion Chem. Biol., 2006, 10,
607-614.
108. Wilds, C. J.; Damha, M. J., Nucleic Acids Res., 2000, 28,
3625-3635.
109. Dowler, T.; Bergeron, D.; Tedeschi, A. L.; Paquet, L.; Ferrari,
N.; Damha, M. J., Nucleic Acids Res., 2006, 34, 1669-1675.
110. Wilds, C. J.; Damha, M. J., Bioconjugate Chem., 1999, 10,
299-305.
111. Whistler, R. L.; Doner, L. W.; Nayak, G. U., J. Org. Chem.,
1966, 31, 813-816.
112. Hoshika, S.; Minakawa, N.; Matsuda, A., Nucleic Acids Res.,
2004, 32, 3815-3825.
113. Haeberli, P.; Berger, I.; Pallan, P. S.; Egli, M., Nucleic Acids
Res., 2005, 33, 3965-3975.
114. Dande, P.; Prakash, T. P.; Sioufi, N.; Gaus, H.; Jarres, R.;
Berdeja, A.; Swayze, E. E.; Griffey, R. H.; Bhat, B., J. Med. Chem.,
2006, 49, 1624-1634.
115. Hoshika, S.; Minakamwa, N.; Kamiya, H.; Harashima, H.;
Matsuda, A., FEBS Letters, 2005, 579, 3115-3118.
References
- 245 -
116. Elman, J.; Thonberg, H.; Ljundberg, K.; Frieden, M;
Westergaard, M.; Xu, Y.; Wahren, B.; Liang, Z.; Orum, H.; Koch,
T.; Wahlestedt, C. Nucleic Acids Res., 2005, 33, 439-447.
117. Jepsen, J. S.; Wengel, J. Curr. Opinion Drug Disc. Dev.,
2004, 7, 188-194.
118. Wengel, J., Acc. Chem. Res., 1999, 32, 301-310.
119. Koshkin, A. A.; Rajwanshi, V. K.; Wengel, J., Tetrahedron
Lett., 1998, 39, 4381-4384.
120. Koshkin, A. A.; Singh, S. K.; Nielsen, P.; Rajwanshi, V. K.;
Kumar,R.; Meldgaard, M.; Olsen C. E.; Wengel J., Tetrahedron,
1998, 54, 3607-3630.
121. Kurnar, R.; Singh, S. K.; Koshkin, A. A.; Rajwanshi, V. K.;
Meldgaard, M.; Wengel, J., Bioorg. Med. Chem. Lett., 1998, 8,
2219-2222.
122. Lauritsen, A.; Dahl, B. M.; Dahl, O.; Vester, B.; Wengel, J.,
Bioorg. Med. Chem. Lett., 2003, 13, 253-256.
123. Zhao, Z. Y.; Caruthers, M. H., Tetrahedron Lett., 1996, 37,
6239-6242.
124. Jones, G. H.; Hamamura, E. K.; Moffatt, G. J., Tetrahedron
Lett., 1968, 5731-5734.
125. Abbas, S.; Hayes, C. J. Synlett, 1999, 1124-1126.
126. Velankar, S. S.; Soultanas, P.; Dillingham, M. S.;
Subramanya, H. S.; Wigley, D. B., Cell, 1999, 97, 75-84.
127. Bird, L. E.; Brannigan, J. A.; Subramanya, H. S.; Wigley, D.
B., Nucleic Acids Res., 1998, 26, 2686-2693.
References
- 246 -
128. Garcia, P. L.; Bradley, G.; Hayes, C. J.; Krintel, S.; Soultanas,
P.; Janscak, P. Nucl. Acids. Res., 2004, 32, 3771-3778.
129. Bertram, R. D., PhD Thesis, The University of Nottingham,
Nottingham, 2004.
130. Doddridge, Z. A.; Bertram, R. D.; Hayes, C. J.; Soultanas, P.;
Biochemistry, 2003, 42, 3239-3246.
131. Minami, T.; Motoyoshiya, J., Synthesis, 1992, 333-349.
132. Dembitsky, V. M.; Al Quntar, A. A. A.; Haj-Yehia, A.; Srebnik,
M., Mini-Rev. Org. Chem., 2005, 2, 91-109.
133. Maffei, M., Current Org. Synth., 2004, 1, 355-375.
134. Agrofoglio, L. A.; Kumamoto, H.; Roy, V., Chimica Oggi,
2006, 24, 16-18.
135. Chatterjee, A. K.; Morgan, J. P.; Scholl, M; Grubbs, R. H., J.
Am. Chem. Soc., 2000, 122, 3783-3784.
136. Hanson, P.; Stoianova, D. S. Tetrahedron Lett., 1999, 40,
3297-3300.
137. Timmer, M. S. M.; Ovaa, H.; Filippov, D. V.; van der Marel, G.
A.; van Boom, J. H., Tetrahedron Lett., 2000, 41, 8635-8638.
138. Chatterjee, A. K.; Choi, T.-L.; Grubbs, R. H. Synlett, 2001,
1034-1037.
139. Lera, M., PhD Thesis, The University of Nottingham,
Nottingham, 2001.
140. Solesbury, N. J., PhD Thesis, The University of Nottingham,
Nottingham, 2005.
141. Tebbe, F. N.; Parshall, G. W.; Reddy, G. S. J. Am. Chem.
Soc., 1978, 100, 3611-3613.
References
- 247 -
142. Petasis, N. A.; Bzowej, E. I. J. Am. Chem. Soc., 1990, 112,
6392-6394.
143. Hirao, T.; Masunaga, T; Yamada, N.; Ohshiro, Y.; Agawa, T.
Bull. Chem. Soc. Jpn., 1982, 55, 909-913.
144. Schwan, A. L., Chem. Soc. Rev., 2004, 218-224.
145. Hirao, T.; Masunaga, T.; Ohsiro, Y.; Agawa, T. Synthesis,
1981, 56-57.
146. Hirao, T.; Masunaga, T.; Ohshiro, Y.; Agawa, T. Tetrahedron
Lett., 1980, 21, 3595-3598.
147. Xu, Y.; Jin, X.; Huang, G.; Huang, Y., Synthesis 1983, 556-
558.
148. Xu, Y.; Wie, H.; Zhang, J.; Huang, G., Tetrahedron Lett.,
1989, 30, 949-952.
149 Kabalka, G. W.; Guchhait, S. K., Org. Lett. 2003, 5, 729-731.
150. Hamamoto, S.; Takaku, H., Chem. Lett., 1986, 8, 1401-
1404.
151. Scaringe, S. A.; Francklyn, C.; Usman, N., Nucl. Acids Res.,
1990, 18, 5433-5441.
152. Beijer, B.; Grotli, M.; Douglas, M. E.; Sproat, B. S.,
Nucleosides Nucleotides, 1994, 13, 1905-1927.
153. Ramirez, F.; Desai, N. B.; McKelvie, N., J. Am. Chem. Soc.,
1962, 84, 1745-1746.
154. Abbas, S., PhD Thesis, The University of Nottingham, 2001.
155. Abbas, S.; Bertram R. D. and Hayes, C. J., Org. Lett., 2001,
3, 3365-3367.
References
- 248 -
156. Abbas, S.; Hayes, C. J.; Worden, S. M., Tetrahedron Lett.,
2000, 41, 3215-3219.
157. Abbas, S.; Hayes, C. J., Tetrahedron Lett., 2000, 41, 4513-
4517.
158. Lera, M.; Hayes, C. J. Org. Lett., 2001, 3, 2765-2768.
159. Corey, E. J.; Venkateswarlu, A., J. Am. Chem. Soc., 1972,
94, 6190-6191.
160. Dess, D. B.; Martin, J. C., J. Org. Chem., 1983, 48, 4155-
4156.
161. Dess D. B.; Martin, J. C., J. Am. Chem. Soc., 1991, 113,
7277-7287
162. Gaunt, M. J.; Yu, J.; Spencer, J. B., J. Org. Chem., 1998, 63,
4172-4173.
163. Wright, J. A.; Yu, J.; Spencer, J. B., Tetrahedron Lett., 2001,
42, 4033-4036.
164. Bessodes, M.; Shamsazar, J.; Antonakis, K., Synthesis, 1988,
560-562.
165. Hirao, T.; Masunaga, T.; Ohshiro, Y.; Agawa, T., J. Org.
Chem., 1981, 46, 3745-3747.
166. Corey, E. J.; Fuchs, P. L., Tetrahedron Lett., 1972, 13, 3769-
3772.
167. Taillefumier, C.; Lakhrissi, Y.; Chretien, F.; Chapleur, Y.,
Tetrahedron Lett., 2001, 42, 7265-7268.
168. Czernecki, S.; Georgoulis, C.; Provelenghiou, C., Tetrahedron
Lett., 1976, 17, 3535-3536.
References
- 249 -
169. Yang, B.-H.; Shi, Z.D.; Wu, Y.-L., Tetrahedron, 2002, 58,
3287-3296.
170. Kartha, K. P. R., Tetrahedron Lett., 1986, 27, 3415-3416.
171. Baker, D. C.; Horton D.; Tindall, C. G., Carb. Res., 1972, 24,
192-197.
172. Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B.;
J. Org. Chem., 1981, 46, 3936-3938.
173. Morris, P. E.; Kiely, D. E., J. Org. Chem., 1987, 52, 1149-
1152.
174. Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P.,
Synthesis, 1994, 639-666.
175. Georgoulis, C.; Czernicki, S.; Stevens, C. L.; Vijayakumaran,
K., Tetrahedron Lett., 1985, 26, 1699-1702.
176. Saito, Y.; Zevaco, T. A.; Agrofoglio, L. A., Tetrahedron, 2002,
58, 9593-9603.
177. Capron, B., Chem. Rev., 1969, 69, 407-498.
178. Clode, D. M., Chem. Rev., 1979, 79, 491-513.
179. Collins, P. M., Tetrahedron, 1965, 21, 1809-1815.
180. Stoddart, J. F., In Stereochemistry of Carbohydrates, Wiley
Interscience, New York, 1971, p195-208.
181. Zamaratski, E.; Milecki, J.; Malteseva, T. V.; Foldesi, A.;
Adamiak, R. W.; Chattopadhyaya, J., Tetrahedron, 1999, 55,
6603-6622.
182. Thomas, E. J.; Chen, A.; Wilson, P. D., J. Chem. Soc. Perkin
Trans. 1, 1999, 3305-3310.
References
- 250 -
183. Venkachalam, T. K.; Goud, P. M.; Uckun, F. M., Synth.
Commun., 2003, 33, 1185-1193.
184. Mellet, C. O.; Fernandez, J. M. G.; Marin, A. M.; Feuntes, J.,
Carb. Res., 1995, 274, 263-268.
185. Breton, G. W., J. Org. Chem., 1997, 62, 8952-8954.
186. Mahender, G.; Das, B.; Ramu, R.; Ramesh, C., Chem. Lett.,
2003, 32, 734-735.
187. Nitta, K.; Takai, K.; Utimoto, K., J. Am. Chem. Soc., 1986,
108, 7408-7410.
188. Hart, D. W.; Blackburn, T. F.; Jeffrey Schwartz, J., J. Am.
Chem. Soc., 1975, 97, 679-680.
189. Hanessian S.; Lavallee. P., Can J. Chem., 1975, 53, 2975-
2977.
190. Hanessian S.; Lavallee. P., Can J. Chem., 1977, 55, 562-565.
191. Knapp, S.; Madduru, M. R.; Lu, Z.; Morriello, G. J.; Emge, T.
J.; Doss, G. A., Org Lett., 2001, 3, 3583-3585.
192. Protective Groups in Organic Synthesis 3rd Ed., Greene, T.
W.; Wuts, P. G. M. Eds.; Wiley: Chichester, 1999.
193. Kocienski, P. J., Protecting Groups: Foundations of Organic
Chemistry, Thieme: Stuttgart, 2003.
194. Paquette, L. A.; Tsui, H.-C., J. Org. Chem., 1998, 63, 9968-
9977.
195. Matulic-Adamic, J.; Haeberli, P.; Usman, N., J. Org. Chem.,
1995, 60, 25632569.
196. Zhong, Y.-L.; Shing, T. K. M., J. Org. Chem., 1997, 62, 2622-
2624.
References
- 251 -
197. Xie, M.; Berges, D. A.; Robins, M. J. J. Org. Chem., 1996, 61,
5178-5179.
198. Lievre, C.; Dolhem, F.; Demailly, G., Tetrahedron, 2003, 59,
155-164.
199. Ball, M; Gaunt, M. J.; Hook, D. F.; Jessiman, A. S.; Kawahara,
S.; Orsini, P; Scolaro A.; Talbot, A. C.; Tanner, H. R.; Yamanoi S.;
Ley, S. V., Angew. Chem., Int. Ed. Engl., 2005, 44, 5433-5438.
200. Donkervoort, J.G.; Gordon, A. R.; Johnstone, C.; Kerr, W.J.;
Lange, U., Tetrahedron, 1996, 52, 7391-7420.
201. Johnstone, C.; Kerr, W. J.; Scott, J. S., Chem. Commun.,
1996, 3, 341-342.
202. Kuang, C.; Senboku, H.; Tokuda, M., Tetrahedron, 2002, 58,
1491-1496.
203. Gonzalez-Rodriguez, C. unpublished results.
204. Baag, M. M.; Kar, A.; Argade, N. P., Tetrahedron, 2003, 59,
6489-6492.
205. Hakimelahi, G. H.; Proba, Z. A.; Ogilvie, K. K., Can. J. Chem.,
1982, 60, 1106-1113.
206. Hamkimelahi, G. H.; Proba, Z. A.; Ogilvie, K. K.; McGee D. P.
C., Tetrahedron Lett., 1982, 23, 1997-2000.
207. Hamkimelahi, G. H.; Proba, Z. A.; Ogilvie, K. K., Tetrahedron
Lett., 1981, 22, 5243-5246.
208. Hamkimelahi, G. H.; Proba, Z. A.; Ogilvie, K. K., Tetrahedron
Lett., 1981, 22, 4775-4778.
209. Hamkimelahi, G. H.; Proba, Z. A. ; Ogilvie, K. K. ; McGee, D.
P. C. ; Boisvert, S. M., Can. J. Chem., 1983, 61, 1204-1212.
References
- 252 -
210. Garner P.; Ramakanth, S., J. Org. Chem., 1988, 53, 1294-
1298.
211. Vörbruggen, H.; Krolikiewicz, K.; Bennua, B., Chem. Ber.,
1981, 114, 1234-1255.
212. Vörbruggen, H.; Krolikiewicz, K., Angew. Chem. Intl. Ed.
Engl., 1975, 14, 421-422
213. Vörbruggen, H.; Höfle, G., Chem. Ber., 1981, 114, 1256-
1268.
214. Robins, M. J.; Zou, R.; Guo, Z.; Wnuk, S. F., J. Org. Chem.,
1996, 61, 9207-9212.
215. Wnuk, S. F.; Ro, B.-O.; Valdez, C. A.; Lewandowska, E.;
Valdez, N. X.; Sacasa, P. R.; Yin, D.; Zhang, J.; Borchardt, R. T.;
De Clercq, E., J. Med. Chem., 2002, 45, 2651-2658.
216. Schulhof, J. C.; Molko, D.; Teoule, R., Nucleic Acids Res.,
1987, 15, 397-416.
217. Singh, R. K.; Misra, K., Ind. J. Chem., 1988, 27B, 409-417.
218. Singh, K. K.; Nahar, P., Synth. Commun., 1995, 25, 1997-
2003.
219. Bullock, M. W.; Hand J. J.; Stokstad, E. L. R., J. Org. Chem.,
1957, 22, 568-569.
220. Lagoja, I. M.; Pochet, S.; Boudou, V.; Little, R.; Lescrinier,
E.; Rozenski, J.; Herdewijn, P., J. Org. Chem., 2003, 68, 1867-
1871.
221. Jenny, T. F.; Benner, S. A., Tetrahedron Lett., 1992, 33,
6619-6620.
222. Zou, R.; Robins, M. J., Can. J. Chem., 1987, 65, 1436-1437.
References
- 253 -
223. Singh, D.; Wani, M. J.; Kumar, A., J. Org. Chem., 1999, 64,
4665-4668.
224. Cheung, A. W.-H.; Sidduri, A.; Garofalo, L. M.; Goodnow Jr.,
R. A., Tetrahedron Lett., 2000, 41, 3303-3307.
225. Zhong, M.; Robins, M. J., Tetrahedron Lett., 2003, 44, 9327-
9330.
226. Western, E. C.; Shaughnessy, K. H., J. Org. Chem., 2005,
70, 3678-3688.
227. Pfundheller, H. M.; Bryld, T.; Olsen, C. E.; Wengel, J., Helv.
Chim. Acta, 2000, 83, 128-151.
228. Gosslein, G.; Bergogne, M.-C.; De Rudder, J.; De Clercq, E.;
Imbach, J.-L., J. Med. Chem., 1987, 30, 982-991.
229. Wnuk, S. F.; Valdez, C. A.; Khan, J.; Moutinho, P.; Robins, M.
J.; Yang, X.; Borchardt, R. T.; Balzarini, J.; De Clercq. E., J. Med.
Chem., 2000, 43, 1180-1186.
230. Saito, Y.; Nyilas, A.; Agrofoglio, L. A., Carb. Res., 2001, 331,
83-90.
231. Terrazas, M.; Ariza, X.; Farràs, J.; Guisado-Yang, J. M.;
Vilarrasa, J., J. Org. Chem., 2004, 69, 54735475.
232. Hotokka, M.; Lönnberg, H., J. Mol. Struct (THEOCHEM),
1996, 363, 191-201.
233. Donohoe, T. J.; House, D. J. Org. Chem., 2002, 67, 5015-
5018.
234. Milecki, J.; Földesi, A.; Fischer, A.; Adamiak, R. W.;
Chattopadhyaya, J., J Labelled Cpd. Radiopharm., 2001, 44, 763-
783.
References
- 254 -
235. Zhou, J.; Bouhadir, K.; Webb, T. R.; Shevlin, P. B.,
Tetrahedron Lett., 1997, 38, 4037-4038.
236. Moroder, H.; Kreutz, C.; Lang, K.; Serganov, A.; Micura, R.,
J. Am. Chem. Soc., 2006, 128, 9909-9918.
237. Diem, M. J.; Burow, D. F.; Fry, J. L., J. Org. Chem., 1977,
42, 1801-1802.
238. Lera, M.; Hayes, C. J., Org. Lett., 2000, 2, 3873-3875.
239. Connon S. J.; Blechert, S., Angew. Chem. Int. Ed., 2003, 42,
1900-1923.
240. Perrin, D. D.; Armarego, W. L. F., Purification of Laboratory
Chemicals, Pergamon Press; New York, 1980.
241. Lund, H.; Bjerrum, J., Chem Ber., 1931, 64, 210-213.
242. Armarego, W. L. F.; Chai, C. L. L.; Purification of Laboratory
Chemicals, 5th Ed.; Butterworth Heinemann, New York; 2003.
243. Stille, W. C.; Kahn, M.; Mitra, A. J. Org. Chem., 1978, 43,
2923-2925.
244. Willard, J. J., Can. J. Chem., 1962, 40, 2035-2040.
- 255 -
- APPENDIX -
Appendix
- 256 -
6. Appendix
X-ray Crystallographic Data
6-Z-bromo-(5-deoxy-5-methylidene)-1,2-O-isopropylidene-D-
D-ribofuranose
O
O
O
HO
Br
Table 1. Crystal data and structure refinement for BRETGL at 150(2)K.
Empirical formula C9 H13 Br O4
Formula weight 265.10
Crystal description colourless plate
Crystal size 0.74 x 0.36 x 0.06 mm
Crystal system Orthorhombic
Space group P 21 21 21
Unit cell dimensions a = 5.5264(10) Å D = 90 deg.
b = 8.611(2) Å E = 90 deg.
c = 22.806(4) Å J = 90 deg.
Volume 1085.3(6) Å3
Reflections for cell refinement 4240
Range in theta 2.5 to 27.0o.
Z 4
Density (calculated) 1.622 Mg/m3
Absorption coefficient 3.775 mm-1
F(000) 536
Diffractometer type Bruker SMART APEX CCD area detector
Wavelength 0.71073 Å
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Scan type omega
Reflections collected 9613
Theta range for data collection 2.53 to 26.33o
Index ranges -7<=h<=7, -11<=k<=11, -28<=l<=29
Independent reflections 2208 [R(int) = 0.055]
Observed reflections 1903 [I>2V(I)]
Absorption correction Semi-empirical from equivalents (Tmin =
0.503, Tmax = 1.000)
Decay correction none
Structure solution by direct and difference Fourier methods
Hydrogen atom location OH from delta-F; others geometrically
placed
Hydrogen atom treatment rigid rotor; riding model
Data / restraints / parameters 2208/0/129 (least-squares on F2)
Final R indices [I>2V(I)] R1 = 0.0446, wR2 = 0.108
Final R indices (all data) R1 = 0.0518, wR2 = 0.111
Goodness-of-fit on F2 1.04
Absolute structure parameter 0.03(2)
Final maximum delta/sigma 0.001
Weighting scheme Calc w=1/[\s2^(Fo^2^)+(0.067P)^2^]
where P=(Fo^2^+2Fc^2^)/3
Largest diff. peak and hole 1.14 and -0.53 e.Å-3
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Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement
parameters (Å2 x 103) for BRETGL. U(eq) is defined as one third of the
trace of the orthogonalized Uij tensor.
x y z U(eq)
O 328(5) 3548(4) 7133(1) 26(1)
C1 522(7) 4001(5) 6570(2) 24(1)
C2 2797(7) 4960(4) 6661(2) 22(1)
O1' 1293(5) 2703(4) 6247(2) 29(1)
C1' 3700(7) 2986(5) 6031(2) 25(1)
O2' 4718(4) 4030(4) 6449(1) 24(1)
C2' 5094(8) 1512(6) 6041(2) 32(1)
C3' 3568(9) 3747(6) 5438(2) 36(1)
C3 3045(7) 5060(5) 7326(2) 24(1)
O3 5453(5) 5162(4) 7529(1) 28(1)
C4 1714(7) 3630(5) 7531(2) 22(1)
C5 820(8) 3698(5) 8144(2) 26(1)
C6 1717(8) 2799(6) 8547(2) 29(1)
Br 803(1) 2897(1) 9346(1) 47(1)
Table 3. Bond lengths [Å], angles and torsions [o] for BRETGL.
O-C1
O-C4
C1-O1'
C1-C2
C1-H1
C2-O2'
C2-C3
C2-H2
O1'-C1'
C1'-O2'
C1'-C2'
1.421(5)
1.450(5)
1.405(5)
1.519(6)
1.0000
1.415(5)
1.525(6)
1.0000
1.439(5)
1.427(5)
1.485(6)
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C1'-C3'
C2'-H2'A
C2'-H2'B
C2'-H2'C
C3'-H3'A
C3'-H3'B
C3'-H3'C
C3-O3
C3-C4
C3-H3
O3-H3O
C4-C5
C4-H4
C5-C6
C5-H5
C6-Br
C6-H6
C1-O-C4
O1'-C1-O
O1'-C1-C2
O-C1-C2
O1'-C1-H1
O-C1-H1
C2-C1-H1
O2'-C2-C1
O2'-C2-C3
C1-C2-C3
O2'-C2-H2
C1-C2-H2
C3-C2-H2
C1-O1'-C1'
O2'-C1'-O1'
O2'-C1'-C2'
O1'-C1'-C2'
O2'-C1'-C3'
O1'-C1'-C3'
C2'-C1'-C3'
C2-O2'-C1'
1.505(6)
0.9800
0.9800
0.9800
0.9800
0.9800
0.9800
1.412(5)
1.508(6)
1.0000
0.8400
1.484(6)
1.0000
1.300(6)
0.9500
1.892(4)
0.9500
107.1(3)
110.8(3)
104.7(3)
107.4(3)
111.2
111.2
111.2
105.4(3)
107.7(3)
103.9(3)
113.0
113.0
113.0
109.0(3)
104.0(3)
108.9(3)
109.3(4)
110.3(4)
109.7(4)
114.3(4)
106.8(3)
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C1'-C2'-H2'A
C1'-C2'-H2'B
H2'A-C2'-H2'B
C1'-C2'-H2'C
H2'A-C2'-H2'C
H2'B-C2'-H2'C
C1'-C3'-H3'A
C1'-C3'-H3'B
H3'A-C3'-H3'B
C1'-C3'-H3'C
H3'A-C3'-H3'C
H3'B-C3'-H3'C
O3-C3-C4
O3-C3-C2
C4-C3-C2
O3-C3-H3
C4-C3-H3
C2-C3-H3
C3-O3-H3O
O-C4-C5
O-C4-C3
C5-C4-C3
O-C4-H4
C5-C4-H4
C3-C4-H4
C6-C5-C4
C6-C5-H5
C4-C5-H5
C5-C6-Br
C5-C6-H6
Br-C6-H6
C4-O-C1-O1'
C4-O-C1-C2
O1'-C1-C2-O2'
O-C1-C2-O2'
O1'-C1-C2-C3
O-C1-C2-C3
O-C1-O1'-C1'
109.5
109.5
109.5
109.5
109.5
109.5
109.5
109.5
109.5
109.5
109.5
109.5
114.2(4)
114.4(3)
102.6(3)
108.4
108.4
108.4
109.5
109.4(3)
103.0(3)
114.9(4)
109.7
109.7
109.7
121.0(4)
119.5
119.5
123.5(4)
118.2
118.2
91.7(4)
-22.1(4)
-7.4(4)
110.4(4)
-120.6(3)
-2.7(4)
-128.1(3)
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C2-C1-O1'-C1'
C1-O1'-C1'-O2'
C1-O1'-C1'-C2'
C1-O1'-C1'-C3'
C1-C2-O2'-C1'
C3-C2-O2'-C1'
O1'-C1'-O2'-C2
C2'-C1'-O2'-C2
C3'-C1'-O2'-C2
O2'-C2-C3-O3
C1-C2-C3-O3
O2'-C2-C3-C4
C1-C2-C3-C4
C1-O-C4-C5
C1-O-C4-C3
O3-C3-C4-O
C2-C3-C4-O
O3-C3-C4-C5
C2-C3-C4-C5
O-C4-C5-C6
C3-C4-C5-C6
C4-C5-C6-Br
-12.6(4)
27.8(4)
144.0(4)
-90.1(4)
24.8(4)
135.3(3)
-32.4(4)
-148.8(3)
85.2(4)
37.7(5)
149.3(3)
-86.5(3)
25.1(4)
161.0(3)
38.2(4)
-162.9(3)
-38.5(4)
78.2(5)
-157.4(3)
131.8(4)
-112.9(5)
176.3(3)
Table 4. Anisotropic displacement parameters (A2 x 103) for BRETGL. The
anisotropic displacement factor exponent takes the form:
-2 S2 [h2 a*2 U11 + ... + 2 h k a* b* U12 ]
U11 U22 U33 U23 U13 U12
O 9(1) 36(2) 33(2) 2(1) -2(1) -2(1)
C1 16(2) 26(2) 29(2) 3(2) -1(2) 1(2)
C2 13(2) 13(2) 41(3) -1(2) 3(2) 1(2)
O1' 12(1) 32(2) 43(2) 6(1) -2(1) -4(1)
C1' 15(2) 34(2) 25(2) -1(2) 2(2) -1(2)
O2' 11(1) 29(2) 33(2) -1(1) 2(1) 1(1)
C2' 26(3) 36(2) 35(3) 0(2) 5(2) 6(2)
C3' 37(3) 37(3) 34(3) 3(2) -5(2) 9(2)
C3 11(2) 23(2) 37(3) -5(2) -2(2) 1(2)
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O3 14(1) 30(2) 39(2) -9(1) -2(1) -2(1)
C4 13(2) 21(2) 32(2) -2(2) -4(2) 1(2)
C5 22(2) 21(2) 36(2) -4(2) 5(2) -1(2)
C6 29(2) 32(2) 28(2) 0(2) -2(2) -5(2)
Br 62(1) 49(1) 30(1) -2(1) 1(1) -16(1)
Table 5. Hydrogen coordinates ( x 104) and isotropic displacement
parameters (Å2 x 103) for BRETGL.
x y z U(eq)
H1 -737 4603 6352 28
H2 2717 6002 6469 27
H2'A 5101 1090 6440 48
H2'B 6761 1712 5915 48
H2'C 4340 762 5774 48
H3'A 2637 4712 5467 54
H3'B 2773 3043 5160 54
H3'C 5207 3980 5299 54
H3 2142 5996 7466 29
H3O 6246 4396 7406 41
H4 2764 2694 7479 26
H5 -426 4411 8244 32
H6 2893 2052 8435 35
